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In the last decade, research processes in Life sciences have evolved at a rapid pace. This 
evolution, mainly due to technological advances, offers more powerful equipment and 
generalizes the digital format of research data. In the data deluge context, we need to 
overcome the current tsunami of data. Making it available raises important challenges in 
terms of scalability, computing needs, or complexity and costs of storage. At the same time, 
privacy and security are important issues to be also taken into account. Hence, the current 
model, consisting to regularly add hardware resources into centralized core facilities 
without global coordination, is no longer sustainable. 
Scientific data management and analysis processes should be enhanced in order to offer 
services and developments corresponding to the new e-Science uses, and infrastructures 
are the vehicles to achieve so. They are defined as the combination of technologies, 
computational resources and support operations that facilitate the collaboration among 
research communities by sharing resources, analysis tools and data. We propose and 
implement our research support infrastructures in line with this new science directives, 
adapting them to the scenarios presented by the divergent use cases. Three different 
domain-specific infrastructures framed in three different scientific projects are assembled 
and introduced in this dissertation. 
The first case is framed in the clinical data management field, and focuses on the data 
platforms build around two epidemiologic case studies on Immune Mediated Inflammatory 
diseases (IMIDs), IMID-clinica and IMID-longitudinal. 
Making the leap to infrastructures more oriented to analysis process support, the 
transPLANT infrastructure represents a first intrusion into the topical cloud computing 
model. It is focused on plant genomics and offers portable, tailored and elastic compute 
services based on virtual machines provisioned on-demand. 
The design became the seed for a more comprehensive and integrative solution, MuG 
Virtual Research Environment (MuGVRE). The web-based framework seamlessly integrates 
cloud-based resources for a selection of data, visualization, and analysis services relevant 
for the 3D/4D genomics community. Designed as an expandable framework, research 
software developers might contribute to the platform by adding their own analysis methods 
in an easy and efficient way. 
Becoming obvious the transversal potential of cloud-based computational infrastructures 
as virtual research environments, openVRE is implemented as an abstraction of MuGVRE. It 
offers a vanilla platform encompassing computation, data and administration services 
ready to be adopted and customized by other scientific communities.  
They all represent an opportunity to establish better research processes through enhanced 
collaboration, data management, analysis practices and resource optimization. 
XII 
The thesis dedicates a separated section at 4. Results chapter for each of these platforms, 
prior introduction to the overall ecosystem of related research practices and technologies 
at 1. Introduction chapter, which are further explored in 3. Software, Data & Methodology 
in case of being directly involved in the work. Finally, in chapter 5. Discussion is gathered a 
global analysis of the exposed  infrastructures with some final remarks and considerations 
in 6. Conclusions. 
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The goal of this introduction is to identify current IT standards that are directly 
relevant in the bioinformatics field, while understanding how they might help 
to enable computational infrastructures. The text does not intend to provide 
an extensive review, but a bird’s view of current tendencies and practices in 
research. 
 Bioinformatics evolution 
The fields of genetics and biology are becoming increasingly dependent on computers and 
specialized software. After 60 years since the first use of computational resources for de 
novo assembly of protein sequences [1], life sciences rely on computer programs on a daily 
basis, they are an essential toolkit for the analysis, information retrieval and visualization of 
life sciences data. Biology is being transformed into a data science. 
Bioinformatics can be defined as the application of computer science, mathematics, and 
engineering to the study of biological data [2]. All over, it intends to: 
I. organize the data in a way that allows researchers to access and contribute new 
data, 
II. develop new tools and resources to analyze such data, and 
III. use the tools to analyze and interpret the data in a biologically meaningful manner  
Born more as a means than an end, bioinformatics discipline has evolved at the pace of 
molecular biology and computer science advances. After the paradigm shift from protein to 
DNA as ‘information carrier’, the evolution of DNA manipulation techniques enhanced the 
emergence of sequencing methods. It resulted in more and more available sequence data, 
which, coupled with the rise of increasingly small and more powerful computers, drove to 
the implementation of specialized software for performing computer-assisted analyses: 
assembling, aligning, pattern matching, tree building, (energy) function minimization, 
diffraction pattern resolution, etc. Then, the promotion of the free software movement 
(GNU manifesto was read in 1985) led to the introduction of scripting languages, which 
would abstract significant areas of computing systems to simplify the process of developing 
a program. The appearance of the World Wide Web communication system in the early 
1990s promoted a rapid proliferation of these bioinformatics tools. The access to 
publications, tools, methods and public databases was simplified, like EMBL [3], GenBank 
[4] or PDB [5]  that went online in that time. 
The draft publication of the human genome in 2001 marked the beginning of the new 
bioinformatics generation [6]. Nowadays, the genomics era permits the technology and the 
resources not only for sequencing whole genomes, but for doing so at feasible costs - since 
2008, Moore’s Law stopped being an accurate predictor of sequencing costs (Figure 1.1). 
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With the arrival of high throughput sequencing and omics techniques, like the massively 
parallel sequencing (the so-called next-generation sequencing - NGS), or the single-cell 
analysis techniques, the challenge is back on the computer engineering field, who ought to 
meaningfully handle a huge amount of data and metadata. With Big Data, more 
computational resources for storage and processing are required, and the need for new and 
consistent ways to generate, access and digest this data are underlined. Scalability, scheme-
less and readiness are requirements that may imply revising present computational 
distribution schemes. 
 
 
 
 
 
 
 
 
Biology and bioinformatics are becoming so interlinked and mutually reinforcing that 
probably, one day there will be no need to distinguish one from the other. Both would be 
simply known as biology [7]. 
 
 The creative chaos 
With the exception of a few big institutes, the bioinformatics community is segregated in 
thousands of independent research groups, typically co-located with diverse related 
disciplines like biology, medicine, biochemistry or biotechnology. Unlike other 
computationally assisted academic communities (i.e., astrophysics, high energy physics, 
climate researchers), bioinformatics has not grown around centralized core facilities (i.e., 
synchrotrons, observatory centers), but rather just the opposite. Because of the intrinsic 
variability of the bio-molecular data, a wide range of bioinformatics domains has emerged, 
each with their own data resources, methods and standards. 
Nowadays, bioinformatics exhibits huge heterogeneity of data types. Based on their 
functions, bioinformatics data sources can be classified into (i) sequence databases, e.g., 
Figure 1.1: Cost per Genome. Extracted from https://www.genome.gov 
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GenBank [4], RefSeq [8]; (ii) functional genomics databases, e.g., ArrayExpress [9], GEO 
(Gene Expression Omnibus) [10]; (iii) protein-protein interaction databases, e.g., BIND 
(Biomolecular Interaction Network Database) [11], MINT (Molecular Interactions Database) 
[12]; (iv) pathway databases, e.g., KEGG (Kyoto Encyclopedia of Genes and Genomes) [13]; 
(v) structure databases, e.g., CATH [14], PDB (Protein Data Bank) [5]; (vi) annotation 
databases, e.g., GO (Gene Ontology) [15], NCBI Taxonomy [16]. Biological data type 
diversity is evolving every day, together with experimental methodologies and their 
analysis. The direct consequence is a fragmentation of bioinformatics resources which is 
neither optimal nor sustainable. Nowadays, a large number of analysis tools, databases and 
Web services are available. The Molecular Biology Database Collection published by the 
Nucleic Acids Research journal currently lists 1737 publicly-available unique databases [17] 
with a linear growth trend of around one hundred databases per year [18] (Figure 1.2).  
 
 
 
 
 
 
 
 
 
In terms of methodology, the initially diverse and loosely defined community, led software 
developers to mostly implement in-house methods as installable applications for their 
personal computers or institutions. Moreover, biologists had traditionally coded their 
specialized software themselves, either because a certain understanding of the biology is 
required prior implementation, or because is only lately that life-sciences research demands 
high-end computational resources. Mostly under free and open-source distribution terms, 
bioinformatics software tools and packages have shown rapid proliferation in number and 
complexity, encapsulating diverse novel algorithms for the processing of the ever-evolving 
biological data types. Currently, the ELIXIR bio.tools registry [19] has up to 14,000 entries 
annotated as Web applications or command-line tools. And the integration of diverse 
software tools, computational resources, services and databases into an analysis workflow 
still adds another tier to the complex bioinformatics “resourceome”. 
Novel techniques have created not only a great variety of data, but also a huge volume of 
them. Methods for rapid genomic and RNA sequencing, mass spectrometry, microarray, 
Figure 1.2: The accumulation of unique databases. 
Plotted are the number of databases debuted in NAR Database Issues between 1991 and 2016  
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yeast two-hybrid assay for protein-protein interactions, X-ray crystallography and NMR for 
protein structures generate an enormous amount of biological data. In fact, to have an idea 
of the volume of data storage that these techniques have to deal with, we can just observe 
that, for the genomics alone, the first 20 of the largest biomedical institutions currently 
consume more than 100 petabytes of storage. Moreover, it is estimated that by 2025 the 
data-storage demands for this application could run to as much as 2–40 Exabyte [20]. It 
raises important challenges in terms of scalability, complexity and costs of big data storage 
infrastructure, but also demands new scientific methodology paradigms. 
This profusion of databases and resources has fueled the scientific knowledge and the 
innovation in bioinformatics for many years, shaping the so-called “creative chaos” [21]. 
Yet, it also has created some significant obstacles. 
The maintenance and hosting of the massive number of bioinformatics tools, databases and 
other services, demands a tremendous effort from the large number of autonomous service 
providers, who confront the consequent challenges in sustainability and long-term 
persistence. Several studies make apparent the number of discontinued published 
resources [18]. As areas of research become more dependent on access to data and method 
collections, more urgent become the need for sorting out the community's capacity to 
maintain them. Redundancy is another undesired side-product of community 
fragmentation that has led to functionally duplicated resources. Additionally, while the 
resources are mainly freely available to the whole community, they are not necessarily easy 
to find, use, compare, evaluate, and integrate with each other in order to find the best and 
most appropriate solution. Discovering and using new resources became one of the major 
issues and bottlenecks in bioinformatics. Gaps exist between the quality of documentation, 
ways of distribution, or degrees of usability. Some computational tools are available with 
various interfaces (i.e. graphical user interface, command-line, web application, plugin, 
programming library), while others offer only one, hence, an additional wrapping effort is 
required if the user is willing to use them in a different way. On top of that, there is a lack 
of standards on bioinformatics software in terms not only of programmatic interfaces, but 
also data formats and types. As a result, input data, output data or data access from distinct 
databases vary hugely in the format in which they are represented. Even when they are 
represented using the same format, the flexibility on some of the formats allow to use them 
in very different ways, greatly complicating tool’s interoperability. Also, the nomenclature 
used inside the data may be meaningful only inside certain domains or databases, or could 
point to not unique data source. And last but not least, the metadata accompanying 
bioinformatics resources is frequently poor, fragmented, domain-specific, outdated, or 
simply absent. A poor qualitative description of the data strongly affects the practical 
reliability and reusability of it, as no knowledge discovery can be applied to that. Efforts in 
standardizing the representation of data, operations, and services is one of the most used 
strategies to achieve portability and interoperability, yet, specifications are numerous and 
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few de facto standards exist, especially in task interoperability, where adoption of common 
strategies is residual. 
The efficiency of research does not rely only on data and software qualities – such as 
heterogeneity, accessibility or usability–, but also on the actual users, as tool end-users, 
data producers, or tool providers. Enabling an efficient collaboration between scientists 
and specialists geographically distributed or of diverse disciplines is the key point to address 
scientific challenges of the largest scale. As a consequence, institutional structures are now 
fostering the adoption of new research practices based on collaboration and supported by 
the development of advanced technological innovations oriented to the adoption of global 
and interconnected solutions for computing models, storage and communication. The 
concept is known as e-Science. 
 e-Science 
The number of research areas becoming reliant on new ways of collaborative and 
multidisciplinary working promoted the emergence of new modes of doing research, all 
they encapsulated under the term “e-Science”. At 2002, John Taylor, the former Director of 
the UK Research Council Oﬃce of Science and Technology (OST) firstly introduced it as 
follows: 
“e-Science is about global collaboration in key areas of science and the next generation 
of infrastructure that will enable it”. (John Taylor [22]) 
The new research practice brings together information technologies (IT) and scientific 
methodologies in order to allow scientific challenges on previously unreachable scales. e-
Science has revolutionized the scientific method: empirical studies relies on big data 
studies across geographically distributed resources, while the scientific theory is now based 
on the use of computer simulation models [23]. e-Science, named by equivalence ‘e-
research’ when applied to other disciplines like social or humanity sciences, is an abstract 
vision, at times misused or even abused, which is sustained by two fundamental concepts: 
I. the enhancement of collaborative research, 
II. the generation of new technologies to enable it. 
Providing computational and data services to tackle large scale challenges is precisely one 
of the pillars of e-Science. e-infrastructures are those hardware and middleware enabling 
the supportive technologies to implement research capabilities. Hardware is wide-ranging 
and may include high-speed networks, large-capacity data storage facilities, 
supercomputers, clusters of workstations, or shared experimental facilities. Meanwhile, 
middleware permits a dynamic interoperability and virtualization of these IT systems, 
implemented as diverse software applications, data management tools, security protocols, 
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algorithms, data transfer protocols, ontologies, and web resources and services. Depending 
on the scope and focus, these infrastructures might be classified: 
- Networking infrastructures: hardware, software, services and facilities that enable 
connectivity, communication, operations and management of devices. 
- Computational infrastructures: software basis for building, configuring, running, and 
analysing on a global network of computational resources and data archives. 
- Data infrastructures: compilation of hardware and software for acquiring, using, 
transporting, storing and securing data for promoting an efficient and adequate data 
consumption and sharing. 
In general terms, all these technologies together with equipment, services, computational 
resources and domain tools make up research infrastructures (RIs).  
 Transversal Infrastructures 
The European Commission (EC) defines, evaluates and invests on strategies and tools to 
provide Europe with sustainable research infrastructures, the key enablers for 
implementing a single and open European space for online research, the so-called European 
Research Area (ERA). In order to support convergent and coherent strategies, several 
coordinated initiatives have been pushed since the emergence of e-Science [24].  
The European Strategy Forum on Research Infrastructure (ESFRI) develops strategic 
roadmaps identifying investment priorities in RIs at long-term. It was firstly established in 
2002 under Framework Program 7, and extended in 2016 under Horizon 2020. ESFRI fosters 
the development of reliable services for networking, computing, data resources, as well as 
standards and procedures for open access to e-Science environments.  In tune with ESFRI 
roadmap, in 2017 the European Open Science Cloud (EOSC) was established for 
coordinating a harmonized contribution of RIs initiatives. Its goal is to assemble a European 
trusted virtual environment to deposit, access, analyze and re-use scientific data. The 
project defined two key enablers, firstly, cloud-based services and data for open and 
multidisciplinary science, and secondly, policy development for global data stewardship and 
long-term funding. 
Following these umbrella initiatives, complementary and very diverse e-infrastructures has 
been funded, covering both, horizontal e-infrastructures providing transversal services, and 
thematic ones, focused on specific disciplines. Also, they include infrastructures based at a 
single location, distributed across several sites, or provided via virtual platforms. A summary 
of the transversal e-infrastructure ecosystem serving life sciences research in Europe is 
following [25]. 
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HPC infrastructures 
The pan-European e-infrastructures for networking, high-performance computing (HPC) 
and high throughput computing (HTC) are already well-established in Europe, and act as a 
supporting layer for other domain-specific e-infrastructures. National Research and 
Education Networks (NRENs) have been connecting universities and research institutes for 
few decades, each country using their technology and access management. GÉANT has 
federated these networks (some 60 NRENs across 43 European countries) providing a high-
performance communication platform that offers private service for IP, multi-domain 
virtual private networks (VPNs), point-to-point connectivity, Wi-Fi access points (Eduroam), 
and also online identities technologies like eduGAIN and eduPKI. The ESFRI initiative PRACE 
(Partnership for Advanced Computing in Europe) is the best-known e-infrastructure in the 
HPC area. It offers world-class HPC facilities access through scientific project proposals, as 
well as educational training (PATC courses) and HPC services to SMEs (small and medium-
sized enterprises). In the HTC area, where clusters are built from more commodity-type 
hardware, EGI (European Grid Infrastructure) is the most well-established e-infrastructure. 
It provides a large-scale HTC data analysis infrastructure, federating a large number of 
national independent organizations and delivering computing resources with high 
scalability. 
Data infrastructures 
Data infrastructures and services are developing fast, evolving along with the open research 
data requirements (see 1.4.4 Data Management). Scientific communities have been 
building their own e-infrastructures for data sharing - formats and metadata - often at the 
international level, (e.g. MIAPPE: Minimum Information About a Plant Phenotyping 
Experiment), taking into account their specific needs. The Research Data Alliance (RDA), a 
global organization started by the European Commission and other American and Australian 
institutions, holds up that community specifics are to be interfaced with generic 
components, such as those provided by EUDAT. EUDAT has started with the aim to store 
researchers’ data at European level and provides services covering the full lifecycle of 
research data: access and deposit of informal data sharing (B2DROP service) and long-term 
archiving (B2SHARE); data identification (B2ACCESS); data discoverability (B2FIND and 
B2HANDLE); and data storage for both long-tail (B2SAVE) and big data (B2STAGE). Other 
European data e-infrastructures are particularly focused on research publication data, like 
OpenAIRE, the European Open Access (OA) infrastructure that enables researchers to 
deposit publications and data into OA repositories such as Zenodo, a research publication 
and archival service hosted by CERN that already houses thousands of datasets and 
software packages. 
Cloud infrastructures 
Unlike networking or HPC/HTC e-infrastructures, pan-European cloud initiatives are not yet 
so well established. EGI offers a federation of cloud infrastructures, and GÉANT a cloud 
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services platform to deploy on-demand IT services. Helix Nebula science cloud has been the 
first European initiative where private cloud service companies have worked with public 
research organizations (e.g. CERN, EMBL and ESA) to offer a federated, multi-tenant and 
multi-supplier hybrid cloud relying on open cloud standards and open-source software. The 
Open Clouds for Research Environments project (OCRE), is the recent initiative that takes 
off after Helix Nebula conclusion with the mission to accelerate cloud adoption in the 
European research community, by bringing together cloud providers and education 
community. Public cloud providers are further discussed in 1.4.3.5 Bioinformatics in the 
cloud. 
Life European e-infrastructures 
ELIXIR [26]  is a ESFRI pan-European distributed infrastructure that brings together life 
science resources from across Europe. It connects national bioinformatics centers, like the 
National Institute of Bioinformatics (INB) [27] in Spain, into a single virtual infrastructure 
for biological research. ELIXIR initiatives include the designation of fundamental data 
resources (Elixir Core Data [28]) to be long-term preserved, the development of transversal 
supportive platforms (e.g. benchmarking or training platforms), or the creation of a 
common Authentication and Authorisation Infrastructure (Elixir-AAI) [29] for single sign-on 
and authorization into ELIXIR services. Importantly, the organization acts as the life science 
interlocutor in Europe to establish collaboration with other international initiatives. 
Examples are the strategic partnership with Global Alliance for Genomics and Health 
(GA4GH) [30] that sets the technical standards to facilitate the responsible sharing of 
genomic data across national borders, or the collaboration with the FAIRsharing, the RDA 
working group dedicated to stablish data and connection standards for bio-data sharing. 
 New science needs 
e-infrastructures are motivated by the promotion and development of the new research 
conducts, characterized by large-scale data-driven simulated analyses undergone on 
geographically scattered laboratories. Such features impose a set of requirements over IT 
systems used to build, configure, run and analyse such data. The following representation 
is proposed [31] to summarize the e-science requirements and its enabling technologies: 
I. Resource sharing 
II. Data-driven science 
III. Collaborative Research 
IV. Reproducible Research 
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Following are presented these four differential features of e-Science that computational 
infrastructures are to promote and preserve. At 1.4 Enabling technologies sections, the 
combination of IT solutions aiming to make possible each of these features is introduced. 
Resource sharing 
Infrastructures are to support Open Science, not a new concept, but definitively pushed 
forward by the emergence of data-driven research. Open access (OA) aims free access to 
data, tools, methods and results in academia, following the rational that scientific 
knowledge is a product of social collaboration and its ownership belongs to the community. 
Indeed, many public funding agencies have data sharing policies and require researchers to 
include compliant data management plans when applying for funding. 
Most academics recognize the vital importance of data sharing and the imperious need of 
distributing it with high-value curated metadata [32] – data about data. Yet, they admit not 
always adopting OA practices [33]. There are a number of barriers to the full-scale adoption 
of data sharing practices, and these are not only technical, like data volume or security, but 
social or funding-related, like the lack of recognition of data providers or the long-term 
sustainability of data infrastructures [34]. Research infrastructures aim to adequately 
handle these limitations, for instance, proposing fine-grained authorization protocols [35], 
adopting open protocols and standards, distributing datasets under digital object identifiers 
(DOIs) for easing being citable, etc. Also, many data repositories have emerged in the last 
years, including pan-European archives like those just above presented. Some initiatives 
[36] [37] keep a registry of the long-term data infrastructures that make available scientific 
records or published data. 
Data-driven science 
Infrastructures are often generators of large volumes of data which have motivated the 
appearance of both, technical and policy solutions in order to properly curate, document, 
process and preserve that data. 
Figure 1.3: Summary of e-Science requirements and key enabling technologies. Source: [31] 
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At the policy level, academia is widely accepting and progressively supporting the definition 
of a minimal set of community-agreed guiding principles and practices for data handling. 
These correspond to the so-called F.A.I.R. principles [38], by which data providers and data 
consumers - both machine and human - could more easily (F)ind, (A)ccess, (I)nteroperate 
and (R)euse the vast quantities of information. Eventually, it would become accessible to 
the new and powerful plethora of semantic and machine learning algorithms. Compiled as 
concise and measurable metrics [39], turning these principles into a reality is proving to be 
challenging as it involve important efforts on data stewardship and data structures – while 
Findable and Accessible principles relay mainly on appropriate metadata, Interoperability 
and Reusability depends on data governance, services and stewardship. In spite of that, the 
principles are being extended to research methods – i.e., F.A.I.R. software. Their key 
requirements are already available: registries, standards, software managers and open 
repositories. Several organizations including the Software Sustainability Institute [40] or the 
ELIXIR itself are participating actively in the discussion. 
Regarding technical specifications, infrastructures have to cope with the needs arising from 
handling Big Data and their five main characteristics: Volume, Velocity, Variety, Value and 
Veracity [41] (known as the “5 Vs”).  Correspondingly, they refer to the huge amount of 
data volume, the fast analysis speed shifting from batch to real-time stream processing, the 
heterogeneous data sources with complex formats and unstructured models, the low 
density of values into the data, and the tolerance of errors within this data. Such features 
oblige the adoption of adequate computing models, processing algorithms and database 
engines into any infrastructure dealing with data-intensive tasks. 
Collaborative Research 
Knowledge diffusion and resource sharing are the cornerstones of multi-center and 
multidisciplinary projects, which nowadays are making possible to tackle large-scale 
scientific analyses otherwise unattainable. Integrative solutions and supporting 
applications are essential to enhance collaboration and personalization, and are especially 
relevant in multi-branched dynamic areas of research like bioinformatics and the omics era 
we are immersed in. Moreover, though collaboration, scientific communities are endorsed 
and better positioned to agree on standards, align scientific goals and practices, etc.  
Additionally, infrastructural resources such as storage, computing facilities, and other 
services are increasingly used and shared by researchers at geographically distributed 
locations. In involves innovative applications for the exchange, selection and aggregation 
of distributed resources. Thus, collaborative research has raised security, trust and privacy 
concerns, along with other technical requirements stressed in data-intensive environments, 
like data transfers. 
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Reproducible Research 
The result of the scientific method must be reproducible in that when carrying out the 
documented procedure, the same result is to be obtained every time. Today, this procedure 
nearly always involves software and digital data, typically known to have short lifespans. 
Because of this alone, traditional results’ documentation, even when good practices are 
adopted – i.e. code and data availability, control version, configuration parameters 
specification, etc. –, might not be sufficient to achieve reproducibility, neither for validation, 
nor reusability. The truth is that inadequate  reproducibility efforts are not the only cause 
of the so called “reproducibility crisis” [42], which indicates for instance, the need of more 
robust experimental designs and better statistics. 
Nevertheless, the global network of infrastructures can play an essential role to foster 
reproducibility by building provenance mechanisms, stateless encapsulations of data and 
workflows, or simply using standard and agreed protocols and technologies. Considering 
computational infrastructures are the software basis for building, configuring, running, and 
analyzing data, these are responsible to encompass these practices, and do so in an 
automatic and deterministic manner in order to achieve reusable and repeatable research 
processes. 
 
 Enabling technologies 
Research infrastructures capabilities are based on various technologies aimed to support 
the new generation of scientific research. The following sections provide introductions of 
relevant methodologies, architectures, tools, systems, services or frameworks that are 
designed to address the new science needs. 
 Distributed computing 
The growing popularity of the Internet and the availability of powerful computers and high-
speed networks as low-cost commodity components have changed the way computing is 
done. Distributed computing has been an essential component of scientific computing for 
decades. It consists on networked independent computer nodes that cooperate to achieve 
a common goal at task level. Several distributed models have appeared along the years 
diverging on the geographical node’s location (sparse or centralized), their interconnection 
(loose or high-speed), their management (centralized or distributed) or their disparity 
(homogeneous or heterogeneous nodes). A classification of them is represented in the 
following figure: 
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 Decentralized systems 
Peer-to-peer (P2P) systems are those where nodes (peers) are simply client computers 
connected to the internet loosely interlinked and with a distributed self-organized 
administrative control that handle the requests to the resources, i.e. peers are both 
resource’s providers and consumers. Rosetta@home [43] and Folding@home [44], for 
protein structure prediction, are examples of P2P volunteer distributed computation 
applied to bioinformatics. Yet, a server-less and self-controlled network involves some 
security challenges that may limit its application in some areas, while enhancing it in others, 
like file-sharing or anonymous network browsing. Lately, blockchain technology has 
promised to ensure security and privacy, enabling projects for rewarding computation (or 
storage) sharing (e.g. CureCoin [45] as Folding@home sequel), but also enabling researcher 
identification systems, or facilitating decentralized genomic data distribution (Nebula 
Genomics [46]) [47]. On top of that, rapid advancement in mobile devices and wireless 
technologies is enabling the use of Personal Digital Assistances (PDAs) and mobile phones 
in several ways (edge computing), including the idea of using such devices to expand P2P-
based systems (ubiquitous computing). 
 High Performance Computing 
Cluster computing is another distributed system that consists of a set of independent but 
local and homogenous computers (nodes) interconnected through a fast local area 
network. Subsystems are supervised by a single administrative domain, integrating the 
system as a single computing resource. Thanks to the availability of low-cost 
Figure 1.4: Subsets of distributed systems 
Classified according its centrality and scalability. HPC: High performance Computing. PHP: Peer-to-peer. Adapted from [256] 
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microprocessors, high-speed networks, and software for high-performance distributed 
computing, these systems have emerged as a cost-efficient parallel computing solution. 
Traditional High Performance Computing (HPC) systems are focused on parallel 
architectures aligned with distributed systems to achieve the petaflop scale. Software 
optimizes the speed-up of multi-core CPUs or graphics processing units (GPUs) using 
(massive) parallel programming techniques - i.e. OpenMP for shared memory machines, 
Message-Passing Interface (MPI) for more loosely connected, or CUDA/OpenCL for GPUs. 
Highly demanding bioinformatics applications have largely benefited from supercomputers 
or GPU clusters, for instance, molecular dynamics (MD), virtual screening software or NGS, 
which even adopted novel algorithms approaches like those inspired by Genetic algorithms 
[48] to better exploit parallel resources. More and more, the tendency of using inexpensive 
general-purpose COTS-based (Commercial Off-The-Shelf) components is being imposed 
over on-purpose designed processors. In 2011, the fastest supercomputer, Tianhe-1A, was 
based on NVIDIA TeslaTM M2050 general-purpose GPUs. Marenostrum 4, placed at the 
Barcelona Supercomputing Center, is composed by Intel Xeon Platinum. Main bottlenecks 
for HPC adoption are its high power consumption, especially for GPUs, the lack of flexibility 
and accessibility, the need of advanced or even on-purpose designed software, and still, 
hardware costs, which indeed are COTS components, albeit with high-end. 
Nowadays, the focus has shifted to programming models like MapReduce, more centered 
on data analysis and manipulation, and not that much on the algorithm optimization. Unlike 
more traditional HPC systems, the data is not stored at a single point but divided and 
replicated across the distributed computer system, and the application only deals with its 
local subset of relevant data (further discussed in 1.4.4.2 Data-storage solutions). These 
new requirements make HPC data systems easy to deliver, even over the cloud. HPC clouds 
tries to address some of the bottlenecks mentioned above offering HPC-as-a-Service. It may 
permit benefiting from multi-tenancy, resources on-demand, and scalability, which 
translates into a better resource utilization. The economic and technological barrier to high 
performance clusters is being lowered, as typically are in-use facilities.  However, other 
challenges have arisen, like network latency, configuration and optimization issues, or 
virtualization overhead, actively researched nowadays. Just in 2016, first commercial HPC 
clouds were launched, offering infrastructures only partially virtualized (e.g. virtualized 
login nodes but bare-metal computing nodes) or with high-speed networking (10 Gbit/s 
Ethernet or InfiniBand)[47][49]. 
 Grid computing 
Cloud computing can be perceived as an evolution of grid computing, with the inclusion of 
virtualization and sharing of resources [50]. The architecture is similar to the clusters, except 
that the computational nodes are spread over the world and connected through a 
combination of local area networks to the Internet [51]. Grid applications implement 
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parallel and distributed computing models where the program can be split into many 
independent pieces and computed independently among the nodes, as communication 
latency among nodes is orders of magnitude higher than in cluster’s backend. Since the late 
90s, distributed and grid computing have been extensively employed in science, and 
particularly for those applications where inter-process latency was not critical, i.e. high 
throughput computing (HTC) (e.g. embarrassingly parallel applications) or many task 
computing (MTC).  
Grid initiatives, like Open Source Grid (OSG) in the USA or the European Grid Infrastructure 
(EGI) have played a crucial role in developing and adopting standards and protocols for grid 
computing, being able to coordinate thousands of processors located in several countries 
into aggregated grids for large-scale scientific computation. The middleware required for 
such distributed executions typically uses a (i) distributed storage system for sharing data 
between application tasks running on different nodes, and (ii) resource managers for 
scheduling tasks to nodes. Both technologies are fundamentals for today’s cloud 
technologies. In deep, these tools and libraries have been updated and adapted to serve 
cloud elasticity and virtualization. Under OSG, it was first developed the Globus grid 
middleware [52], where libraries for remote process management, service discovery, 
monitoring or security are packed. Other middleware appeared afterward [53]. 
Additionally, distributed systems fostered the development of other hardware and 
software stack, like Resource and Job Management Systems (RJMSs), which aim to assign 
jobs upon the available resources in an efficient way. The assignment involves (i) job 
management, (ii) scheduling and allocation, and (iii) remote resource processing. Examples 
for open-source RJMS are TORQUE [54], SLURM [55], CONDOR [56] or Sun Grid Engine (SGE) 
[57], systems widely used in all distributed environments like clusters or HPC. 
OSG also established standards and specifications for enabling interoperability among grid 
components, most part of related software is compliance with: 
- Job Submission Description Language (JSDL) [58]: provides an XML schema to 
describe a single job submission, including pre- and post-staging of data files. 
- Basic Execution Service (BES)[59]: defines an interface to monitor and manage 
remote  computational executions.  
- HPC Basic Profile: coordinates the use of the JSDL and BES, along with an 
interoperable security mechanism in order to compose a batch job. 
With grid technology, computational intensive challenges are accomplished, but the system 
has rigid constraints, since there is only limited access to the servers, with little or no 
interactivity, due to remote batch scheduling of the jobs on the remote clusters. To mitigate 
these problems, the solution might be the creation of flexible virtual environments on top 
of them. Virtualizing resources is critical for making grid computing able to address the 
complex workflow analysis systems that are necessary for Bioinformatics. 
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 Virtualization 
Virtualization is the act of creating logical instances of computing hardware, storage 
resources or network devices on a physical hardware resource (Figure 1.5). The virtualized 
system is called the guest, while the physical system, the host.  
 
 
 
 
 
 
 
 
 
Following sections present the virtualization on each of these four resources. 
 Compute Virtualization 
Virtualization is generally realized by a hypervisor or Virtual Machine Monitor (VMM), a 
piece of specialized software that emulates a hardware by enabling host resource sharing 
with the multiple guest OSs - or virtual machines (VMs). Hence, a VM corresponds to an 
isolated environment with access to a subset of the physical resources. Virtualization 
requires not only powerful processors and fast interconnection with the host hardware, but 
also an architectural control of the shared resources, which affects multiple levels: CPU 
cycles, memory management, storage, I/O operations, communication bandwidth, etc. 
Besides, the hypervisor controls the assignment of resources among VMs, not an easy task 
for some of them – while scheduling for sharing CPU cycles is implemented for most 
hypervisors (virtual CPUs), allocation of cache, memory or I/O bandwidth is more intricate. 
Hypervisor types 
IBM released its VM 370 in the 1970s, yet was VMware who brought virtualization to 
commodity x86 platforms, followed by Xen and a variety of other virtualization platforms, 
each using different underlying techniques. The techniques can be classified based on 
different criteria. Focusing on where the virtualization takes place, a second classification is 
proposed: 
Figure 1.5: Virtualization representation in a cloud system. 
Three main cloud computing resources, i.e., computing, networking, and storage, and applications can be virtualized 
through virtual machines, virtual networks, virtual hard drives, and containers, respectively. Source [257] 
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- Instruction Set Architecture (ISA) level: the ISA of the host processor is fully 
emulated on the guest processor. A virtual ISA requires a processor-specific 
software that translates the instructions issued by the guest OS, which leads to an 
interpretation latency e.g. [60]. 
- Hardware Abstraction Layer (HAL) level: exploits the resemblance between guest 
and host platforms to cut down the interpretation latency. It is performed on top of 
the bare hardware via a kernel extension or from a device driver e.g. [61], [62],[63] 
,[64].  
- OS level: the host OS shares not only the hardware but also the OS to create an OS 
interface instead of a stand-alone guest OS e.g.[65],[66] ,[67];  section 1.4.2.2). 
- Library level: system calls are performed through libraries programmed using a set 
of APIs at user level e.g. [68] for Windows on top of UNIX or [69] for GPU support. 
- User-application level: virtualizes an application as a VM, which executes as a 
process in traditional OS through a high-level language (e.g. Java Virtual Machine). 
Finally, focusing on the type of hypervisor employed, there are two more virtualization 
options presented in Figure 1.6: 
- “bare metal” (or “Type 1”) hypervisors are a thin software sitting directly on top of 
the physical hardware without needing any operating system. Their main advantage 
is performance. Examples: RedHat [70], many Xen variants, VMWare [71] and [72]. 
- “hosted” (or “Type 2”) hypervisors run as an application on the host OS that is 
installed on the physical hardware. Hence, the guest OS calls need to traverse 
through the host OS before reaching the bare metal. Advantages are that the VM is 
easier to build and install, and additionally, they are lighter, as they can use several 
host OS components rather than providing their own. A price to pay is the increased 
overhead because the host OS act as an intermediate, and sharing OS rises 
challenges to support complete isolation of VMs. VirtualBox and QEMU are 
examples of hosted hypervisors. 
 
 
 
 
 
 Figure 1.6: Differences between hosted and bare metal  virtualization. 
(*) KVM is not a clear case as it could be categorized as either one. The KVM kernel module turns Linux kernel into a type 1 
bare-metal hypervisor, while the overall system could be categorized to type 2 because the host OS is still fully functional and 
the VM's are standard Linux processes from its perspective 
VMware ESX, Hyper-V, Xen VMware Workstation, VirtualBox, 
QEMU, KXM (*) 
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Such hypervisors can map resources in two different modes: 
- Full virtualization: the guest OS stays unmodified, so hypervisor needs to fully 
virtualize each guest’s resource petition, a task that entails performance 
consequences. Yet, as the hypervisor is an exact replica of hardware, all system 
functionalities are covered. (e.g. KVM).   
- Paravirtualization: the guest OS is modified to run on the hypervisor, who performs 
the tasks directly on the guest kernel. Is limits support to open source OSs like Linux 
or Solaris, yet, the ability of the kernel to directly communicate with the hypervisor 
results in great performance levels (e.g. Xen).  
 
 
 
 
 
 
 
Benefits 
The important benefits of virtualization make the technology applicable over a wide range 
of areas. Primarily, the virtualization is used to offer configurable and portable computing 
environments, presenting the illusion of an OS fully controlled by the user. In there, the 
environment is controlled, constrained and replicable, what promotes automatic 
application executions and facilitates software development, testing and debugging. The 
environment portability is especially relevant for software migration and sustainability, 
indeed, cloud services allow (live) migration from host to host. Virtual environments are 
isolated from the host system. It presents important security advantages, as the user’s code 
can run sandboxed without risking harm to the OS. Multiple execution environments are 
also supported, with no - or minimal - affectation on the performance of other virtualized 
runs or OS applications. In fact, this last feature, called crosstalk, is an important cloud QoS 
(Quality of Service) as nowadays is still not fully resolved. VMs allow for resource 
optimization and server consolidation by effectively scaling the resources to the user’s real 
needs. Moreover, such flexibility also enables VMs to work as plug-and-play appliances that 
can be easily enabled and disabled, and easily provides disaster-recovery functionalities to 
the system. 
Figure 1.7: Difference between full- and para- virtualization. Adapted from[257] 
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Limitations 
Limitations of virtualization are mainly those derived from the layer of overhead that 
represents being constantly allocating resources to the virtual environment. Hence, the 
performance degradation is more present in hypervisor-based virtualizations than in OS or 
application virtualizations, where the virtual environment does not include their own OS. 
System functions are not all virtualized equally efficiently, critical for the performance of a 
VM are the cache and memory management, and I/O handling. For instance, CPU scheduler 
generally down perform at a 10-20% rate, yet the overhead is much more noticeable as the 
guest workload increases (particularly, in KVM). Memory overhead also fluctuate around 
these values for most of the platforms, yet, the performance variation can be as high as 
140% for network or I/O activities, showing that all techniques outperform others in 
particular operations and conditions. Over-commitment (allocating more resources in the 
guest than the physical host has available) for CPUs is a feature supported for most of the 
hypervisors at a reduced performance cost. However, for memory (RAM) costs are higher 
(e.g. VMware supports it), and other memory management techniques have been 
developed, like memory compression or memory “ballooning”, by which the hypervisor 
dynamically rebalances RAM reallocating idle memory from some VMs to others (e.g. 
VMware, Hyper-V, KVM).  
Cloud platform management 
Cloud platforms make use of different virtualization techniques. For instance, Amazon EC2, 
the largest infrastructure cloud, uses Xen as a hypervisor, but Microsoft Azure uses Hyper-
V and VMware partners use ESX. Recently, Google launched its own IaaS cloud that uses 
KVM as a hypervisor. On the other hand, open-source platforms tend to offer support for 
more than one hypervisor (see section 1.4.3.2 Cloud Management Platforms).  
 Operation System Virtualization 
Hypervisor-based virtualization consumes part of the resources to maintain a separated 
Operating System (OS) for the guest. If guests use the host’s OS, important resource 
consumptions are achieved. Recently, OS-based virtualization – i.e. containers –  captured 
the attention of industry and academy because they accelerate the development process, 
eases distribution, and applications’ deployment. Containers subtract the hypervisor layer 
and rely on namespaces and cgroups in order to provide isolation and resource 
management. Called also lightweight VMs, containers are virtual space instances that field 
like a complete and isolated OS to the user, yet, they run as applications with extended 
chroot permissions into the host. 
Leaders of such development are Docker [73] and Linux Containers (LXC) [74]. Indeed, 
Docker is basically an additional layer on top of LXC exposing additional features such as 
mounted storage, network port redirection, and container catalogue management. 
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Singularity [75] is a container-based approach more focus on application portability than 
on host virtualization. Hence, it only virtualizes what is necessary for achieving a runtime 
application container: user escalation is not supported. Unlike Docker, Singularity inherits 
permissions of the user who runs that container, being able to work within multi-user or 
multi-tenant environments (typically HPC).  
Compared to VMs, OS-level virtualization usually imposes little to no overhead, offers the 
highest performance, specially Singularity, and reach the highest density of virtual 
environments. Memory allocation is more flexible and unused memory in one virtual 
environment can be used by another. Obviously, it implies that the container’s isolation 
degree is lower than in VMs. Another disadvantage is containers’ reduced flexibility, as they 
only support the virtualization of the host OS server, Windows or Linux. Moreover, we have 
mentioned already the security implication that have some of the OS-level 
implementations. 
 Storage Virtualization 
Storage can be virtualized too, and that it is referred to as Software Defined Storage (SDS). 
Storage virtualization means decoupling storage volumes, from the underlying physical 
hardware. Thus, features like caching, snapshotting, high availability, etc. are managed in 
the software layer and are not dependent on a specific hardware brand. Storage systems 
can provide either block accessed (i.e. storage area networks (SANs)) or file accessed (i.e. 
network attached storages (NASs)). 
In block virtualization, multiple physical disks are abstracted into a single logical storage 
resource creating a SAN, typically accessed over Fibre Channel (FC), iSCSI (Internet Small 
Computer Systems Interface) or other protocols. Files are split in chunks into volumes 
known as blocks, which are individually mounted with the underlying file system protocol 
(such as NFS, CIFS, ext3/ext4 and other). In cloud computing, most providers offer virtual 
block storage (e.g.  Amazon Elastic Block Store, Cinder blocks from OpenStack; Datablocks 
from OpenNebula). 
 
 
 
 
 
  
Figure 1.8: Block vs. Object storage. 
Block virtualization provides good I/O performance compared to Object storage virtualized solutions 
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On the other hand, in file virtualization, the abstraction layer is between the file server and 
users accessing these files, typically accessed over NAS protocols like NFS or CIFS. The result 
is that multiple storage devices are grouped together to form a single, logical file mount. 
 Network Virtualization 
Network virtualization (NV) is defined by the ability to create logical, virtual networks that 
are decoupled from the underlying network hardware. From the perspective of any 
application residing on the host, the principal functions of physical networks involve 
switches and routers (at Layers 2 and 3), or load balancers and firewalls (at Layers 4 - Layers 
7). With virtual networks, these functions are accomplished with pieces of software that 
frees physical devices from their one-to-one association with hardened addresses and 
endpoints. This software-based overlay conforms the so-called Software-Defined 
Networking (SDN) technologies. 
 
 
 
 
 
 
Lately, the development of these techniques has come to focus thanks to the popularity of 
distributed computing and storage paradigms. SDNs aims to centralize the management of 
networks to enable a flexible and programmatic network configuration. This strategy 
enables networks to stage multiple workloads, especially micro-services, and scale them 
dynamically on demand. Some other popular SDNs focused on attaching networks to VMs 
or containers are [76], [77] or the Kubernetes propose-solution [78] - all of them compliance 
with the [79] specification. Examples of more general-propose network management 
solutions are [80] or [81]. 
Fast flat and composable networks provide agility and automation, yet, they come with 
their challenges, mainly security considerations. Trust zones frontiers are blurred in virtual 
networks, and current network topologies make difficult to establish the appropriate level 
of trust that is required for each individual system. The dynamic real-time changing 
capability of networks is also raising severe visibility issues, making evident the need for 
new monitoring and tracking tools. Also, as any composable environment, standards and 
compliances are important aspects to consider for SDNs.  
Figure 1.9: Software defined Network (SDN) architecture. 
SDN attempts to centralize network intelligence in one network component by disassociating the forwarding process of 
network packets (data plane) from the routing process (control plane). 
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 Cloud technology 
Technologically speaking, the cloud is more an evolution that a revolution [82], as it has 
emerged as a convergence of several computing trends. It seeks to achieve 
scalability/elasticity, availability and optimal resource utilization, key aspects only partially 
addressed for the individual supporting technologies. Because in fact, cloud computing 
borrows the best of grid computing, virtualization and Service Oriented Architecture (SOA). 
Virtualization is not a requirement to create a cloud environment (e.g. Ironic [83] provisions 
bare-metal machines to OpenStack clouds), but it enables a rapid scaling of resources in a 
way that non-virtualized environments find hard to achieve. 
Computation and storage are delivered as services rather than as resources. Thus, web 
services technologies and SOA are architectural components of cloud (see section 1.5.1 
Service-Oriented Science). 
Distributed computing legacy is also a fundamental part of the new paradigm, where tools 
for remote provisioning, security, compliance, privacy and “pay per use” models are 
inherited from and extended. 
Other IT systems are also part of the new computing model, like metering systems, 
advanced data management system, task orchestrators, etc. 
  Cloud Fundamentals 
A well-accepted definition of cloud computing comes from the National Institute of 
Standards and Technology (NIST) that presents the computing as a utility: 
“Cloud computing is a model for enabling convenient, on-demand network access to a 
shared pool of configurable computing resources (e.g., networks, servers, storage, 
applications, and services) that can be rapidly provisioned and released with minimal 
management effort or service provider interaction” (NIST 800-145 [50]) 
According to this definition, the five key characteristics of cloud services are: 
- on-demand self-service: access to computing power without human intervention. 
- broad network access: access to computing power on the Internet. 
- resource pooling: virtual resources dynamically assigned without having control of 
the exact location of them. 
Introduction 
24 
- rapid elasticity: resources are able to be quickly allocated by increasing/decreasing 
both, the number of virtual appliances deployed (i.e. horizontal) and resources 
dedicated within each (i.e. vertical). 
- measured services: control and optimization of resource use by evaluating storage, 
processing power, bandwidth, active user accounts, etc. These measures are the 
metrics used for achieving a Service Level Agreement (SLA), basic for customer’s 
confidence. 
Cloud computing has developed greatly since 2006 when the Amazon Elastic Cloud 
Compute (EC2) was first launched, and currently, it is reaching its productivity plateau after 
positioning itself beyond a disrupting IT technology, to become the basis for most future IT 
models [84] (Figure 1.10). 
 
 
 
 
 
 
 
 
 
 
 
 
Cloud computing is a large-scale distributed computing model, providing computing, 
storage, networking, and other resources to many users in service mode. The cloud offers 
high scalability (i.e. horizontal, vertical elasticity), high availability and reliability (e.g. 
through replication), while improving resource utilization efficiency (e.g., over virtualization 
techniques like over-commitment or pre-emptible virtual machines). These key capabilities 
is motivating the migration of a large number of companies to cloud computing, but also 
scientists, who point out the new paradigm as a solution for big data storage and large-scale 
analysis in bioinformatics, thanks to the virtualization that may reduce data transference 
and improve computation accessibility to medium or small laboratories, meanwhile 
promoting data sharing and collaborative work. 
Figure 1.10: Hype cycle for cloud and cloud-related technologies. 
The hype cycle [258] graphically represents the maturity and adoption of specific technologies. “Cloud Computing” is 
already in the enlightenment slope and is predicted to be in the productivity plateau in less than 2 years. [84]. 
Computational infrastructures for biomolecular research 
25 
Besides the five essential characteristics, NIST describes three cloud service models, and 
four cloud deployments that are introduced in the following to subsections. 
 
 
 
 
 
 
 
 
〕  Deployment Models  
Clouds can be classified based on their deployment model, that is the architecture and 
purpose of the underlying infrastructure in terms of cloud location and management. NIST 
identifies four different deployment models for cloud computing: private clouds, 
community clouds, public clouds, and hybrid clouds. 
Private Clouds 
They are intended for the exclusive use of a single organization with multiple users and 
emulate cloud computing on private networks, either owned, managed and operated by 
the same organization (on-premises), or by an external cloud provider (off-premises). 
Hence, regarding its physical location, private clouds are classified into “on-site” or 
“outsourced” clouds. “On-site” private clouds are secured and controlled inside the 
organization and clients access it from within the security perimeter or through firewalls 
and a Virtual Private Network (VPN). In “Outsourced” private clouds, the cloud provider 
permits the client access into its premises and separate the private cloud resources from 
the other cloud resources by different mechanisms such as Virtual Local Area Network 
(VLAN), VPN, separate network segments or clusters. As discussed below at 1.4.3.2Cloud 
Management Platforms, several open-source packages are available to install private 
clouds. 
Community Clouds 
They are intended for the exclusive use of a specific community of users from several 
organizations that have shared objectives (e.g., security requirements, compliance 
considerations), who can reduce costs by sharing the infrastructure.  Like in private clouds, 
Figure 1.11: NIST cloud taxonomy. 
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the infrastructure can be owned and managed by a third party, or be operated within the 
community on-premises on-site scenario, where each organization may provide cloud 
infrastructure, consume services, or both. 
Public Clouds 
They correspond to the traditional and mainstream definition of cloud computing, where 
resources are dynamically provisioned on a self-service basis over the Internet. The 
infrastructure, owned, managed and operated by a business, academic or governmental 
organization, is intended for open use by the general public.  Cloud provider is responsible 
for the security management. Compared to private clouds, public cloud services offer a 
lower degree of control and oversight of the physical and logical security perimeters to 
separate computational resources (usually present in the outsourced private cloud model). 
Amazon Web Services (AWS) is the leading company, representing almost 50% of the 
market share in 2018.  Together with the rest of the main public cloud providers, Microsoft 
Azure, Google Cloud, Alibaba Cloud, and IBM, they dominate 80% of the market [85]. 
Hybrid Clouds 
They are a composite of any of the other deployment models. The individual clouds remain 
unique entities and are aggregated by standardized or proprietary technologies that enable 
data and application portability (see also section 1.4.3.3).  Some use cases for this complex 
model are the access to external clouds during periods of high demand (called cloud 
bursting), or to run some applications into public clouds while maintaining sensitive data in 
an on-premises private cloud. 
〕  Service models  
Cloud Computing enables hardware and software to be delivered as services following the 
SOA principles (see also section 1.5.1 Service-Oriented Science). These services are usually 
described on a Something as-a-service (XaaS) taxonomy. In this context, the term service 
not only refers to SOA precepts, but also reflects that the service is provided on-demand as 
a utility - very convenient for cloud vendors. According to NIST and as depicted in Figure 
1.13, these services can be classified into one of three delivery models: Software as a Service 
(SaaS), Platform as a Service (PaaS), and Infrastructure as a Service (IaaS). 
 
 
 
 
 
Figure 1.12 Cloud service models: SaaS, PaaS and IaaS 
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Each model allows the user a different degree of control over the cloud stack:  
 
 
 
 
 
 
 
 
 
 
Software as a Service (SaaS) 
This service mode delivers application services online and facilitates remote access to 
available bioinformatics software tools through the internet. The user typically accesses to 
a web application and is totally unaware of the infrastructure lying behind. A simple and 
widely used SaaS is Google Docs. SaaS is actually the most usual approach to publish 
bioinformatics tools on the cloud. CloudBlast [86] would be an example, but there are many 
others, some introduced at 1.4.3.5 Bioinformatics in the cloud. 
Platform as a Service (PaaS) 
Allows the development, installation and execution of user-developed applications on the 
cloud infrastructure. Applications must be created using specific programming languages, 
API libraries or tools supported by the PaaS provider which constitute the development 
environment. The clients have full access and control over the created tools and the 
developmental languages, yet not over service run times, web server, or storage network. 
Offered services rank from user’s application hosting, development and testing, to 
extensive integrated services with scalability and maintenance. Examples for PaaS generic 
vendors are Heroku [87] or openShift [88], where the user is able to execute in the cloud 
their applications (called “Dynos” or “Gears” respectively) as containers in real time and 
shying away the deployment details of the infrastructure. The main benefits of these 
services include that users can focus on high-value software rather than infrastructure. 
Additionally, to these stand-alone PaaS, if user’s applications are meant to be exposed to 
online through a certain SaaS, the developer’s platform is called “PaaS from SaaS”.  
Figure 1.13:  Stack under user’s control on the different cloud service models. 
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As illustrated in Figure 1.14, in the bioinformatics domain, some platforms have been 
designed following the same philosophy, as a new strategy to outsource infrastructure 
management while keeping control of the scientific code running there. Eventually, such 
code can even be offered as SaaS to researchers. Section 1.4.3.5 Bioinformatics in the cloud 
shows some examples following this approach.  
 
 
 
 
 
 
 
 
 
Infrastructure as a Service (IaaS)  
It refers to the group of high-level APIs that control low-level details of the underlying 
infrastructure, like physical computing resources, data partitioning, scaling, security, 
backup, etc. In this way, the user controls the virtualized servers and the specific 
computational capabilities and storage of the same: VLANs, access to raw block or file 
storage, load balancers, IP addresses, etc. However, he/she has limited control over the 
network settings. The most popular example is Amazon EC2, which allows the user to create 
virtual machines and manage them, or Amazon Storage Service (S3), which allows to store 
and access data through a web-service interface. 
 Cloud Management Platforms 
In the classical cluster-like cloud architecture, a front-end executes the core management 
services (e.g. schedulers, APIs), hypervisor-enabled hosts laying behind provide VMs’ 
resources, and datastores hold VM base images. They all are connected by at least one 
physical network to such support basic services, while VLANs are set for the VMs (). Thus, 
three main components conform a cloud architecture, i.e. storage, networking and 
virtualization, and cloud management platforms (CMPs) provide software solutions to 
administrate them in an integrative way. 
Figure 1.14: PaaS model motivation on research. 
Scientists are not anymore responsible for computing hardware, software installation, yet they only produce and 
consume applications and pipelines. 
PaaS 
Traditional 
implementation 
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CMPs are software products that provide management of cloud infrastructure to facilitate 
organizations the deployment, management, monitoring and control of virtual applications 
in an agile and cost-effective way. Necessary capabilities include: 
- Infrastructure management: resource management across the infrastructure/s to 
allow the user configure and control life-cycle’s virtual appliances (virtual machines 
or containers), storage and networks, always mediating with the local virtualization 
tools.  
- Automation: improve agility and resource utilization with load balancing tools, 
automatic booting and contextualization systems, live migration tools, automatic 
snapshotting or backups, etc. 
- Compliance and security: ensure compatibility with other cloud system adopting 
unified configurations, while protecting the user’s environment. 
- Accounting and cost management: log and monitor activity to not only optimize 
resource consumption, but also costs. 
Depending on which of these features are bold, the platform management is more oriented 
to offer “infrastructure provisioning” clouds (also called “consumer” clouds) or “datacenter 
virtualization” clouds (also called “enterprise or organization clouds”). “Infrastructure 
provisioning” clouds are mostly designed for public clouds offering a simplified view of life-
cycle’s virtual resources and its underlying infrastructure, while “datacenter virtualization” 
clouds are targeting private clouds, with more transparent view of physical resources, and 
easy to adapt into existing infrastructure. Amazon AWS is the reference for “infrastructure 
provisioning”, while VMware vCloud lays on the opposite side. 
〕  Open-source Cloud Management Platform s 
After the success of the public cloud providers based on proprietary CMPs, many open-
source CMP solutions appeared in the market during the last 10 years. They offer other 
deployment models like on-premises or hybrids clouds, motivated by particular enterprise 
or institution computing needs, hypervisor-agnostic requirements or simply wriggling away 
   Front-end 
Figure 1.15: Classical cluster-like cloud architecture 
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from highly-priced advanced cloud services. Following, a brief introduction to some of the 
best known open-source CMP.  Figure 1.16 classifies them according to their cloud model 
and flexibility. 
 
 
 
 
 
 
 
 
 
 
 
- Nimbus (2009) [89]: targets the scientific community by support for instance proxy 
credentials and rich batch schedulers. Also compatible with EC2/S3, it does not 
support VM migration. 
- Eucalyptus (2008) [90]: designed primarily for private cloud, it supports Amazon EBS 
(elastic block storage) and AWS, but not VM migration.  
- Opennebula (2008) [91]: can deal with dynamic resource needs, snapshotting, live 
migration, fault tolerance and load balancing. Besides, features good 
interoperability, supporting different access interfaces, including OCCI service 
interface, REST-based interfaces and emerging cloud API standards. 
- Openstack (2008) [92]: designed for private and public clouds, it provides very good 
scalability, and flexibility. It exploits various open-source projects and manages VM 
migration, load balancing and fault tolerance. 
- Cloudstack (2010) [93]: beside supporting most common hypervisors and operating 
systems, it can deal with snapshotting and supports high availability. However, 
shows reduced flexibility and lacks support for shared access. 
- Abicloud (2009): manage and integrate clouds on virtualized heterogeneous 
environments. However, it does not support VM migration, fault tolerance, nor 
AWS.  
- Xen Cloud Platform (XCP) (2012) [94]: a light platform that concentrates on 
provisioning XEN VMs, but user access is only via CLI. 
Figure 1.16: Classification of open source cloud management platforms  
In terms of flexibility and cloud strategy. Adapted from [95] 
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A number of papers analyze and qualitatively compare each platform [95] [96] [97]. 
However, it is a challenging mission, as the previous figure illustrates, each platform is 
designed to offer certain cloud models, and institutions should decide which is the one that 
better fits their needs. 
 Cloud interoperability and portability 
Portability is the ability of software (application cloud portability) and data (data cloud 
portability) to be transferred from one cloud system to another. Interoperability is the 
ability of two or more cloud infrastructures to exchange information in a common 
model. Addressing cloud interoperability and portability issues surrounding cloud 
infrastructures are one of the major discussions in the field. They have received 
considerable attention as standards are the key enabler for cloud brokering and multi-
cloud architectures. Being able to easily reuse data among different cloud DaaS (Data as a 
service) or use your appliances across clouds, would be the solution to one of the cloud 
computing limitations: the vendor lock-in. If interoperability is achieved, several cloud 
infrastructures could be federated.  
Several European and international research projects (like OASIS, SNIA, VENUS-C) have 
designed and implemented various cloud brokers, - i.e. single point entries to manage 
multiple cloud services, which are based on a number of specifications that [98] summarizes 
in the following table: 
 
 
 
 
 
 
 
 
We cite here the more relevant: 
- Open Cloud Computing Interface (OCCI) [99], Cloud Infrastructure Management 
Interface (CIMI) and Unified Cloud Interface (UCI) offer standard APIs for all kinds of 
IaaS management tasks (e.g. instantiate a VM). 
- mOSAIC and jClouds are complete brokering APIs for resource discovery and usage. 
Table 1.1: Standards for cloud portability and interoperability. 
They define standard operations for managing an infrastructure, image packing files, or application deployment procedures.   
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- Open Virtualization Format (OVF) is a standard platform-independent packaging 
virtual images. 
- Topology and Orchestration Specification for Cloud Applications (TOSCA) [100] 
standardize application description and orchestration to automatize its deployment. 
- Cloud Data Management Interface (CDMI) [101] offer an interface for creation, 
retrieval, update and deletion of data elements from the Cloud 
Unfortunately, none of these ongoing standards is widely adopted. In general, public cloud 
computing providers resist adopting open standards, and in fact, are open source solutions 
that incorporate compliance with them (e.g. via AWS API). Adoption examples are 
VirtualBox and VMware, that support OVF images, or multiple open-source CMPs 
(OpenStack, Microsoft Azure, jClouds, EMOTIVE cloud, Amazon EC2) that support OCCI. In 
fact, OpenNebula supports well open standards (CDMI, CIMI). 
 Cloud software 
Cloud architecture layers as 
shown in Figure 1.17 is a good 
way to classify cloud-related 
software, which grows in 
diversity and number by leaps 
and bounds. Cloud-Native 
Computing Foundation shows in 
a complete diagram the major 
cloud-native technologies of the 
commercial and open-source 
scope [102]. 
 In the following lines, a short 
introduction to some of these well-known pieces of software. They all operate on top of the 
cloud infrastructure, and are here classified according to the layer they run at. 
Provisioning 
Provisioning refers to the allocation of the user’s system into the cloud up to the point of 
having a functional virtual appliance. It implies cloud services such as image repository, 
storage or networking. In case the user’s system is built from several virtualized 
components, provisioning also implies orchestration and interconnection management. 
Provision might be based on manual CLI or GUI processes when directly interacting with 
CMPs; a semi-automatic process based on scripts or APIs, or a fully automated process 
following “Infrastructure as a Code” (IaC) practices. 
Figure 1.17: Cloud stack classification 
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Semi-automatic approaches include the use of cloud-vendor provisioning tools, for 
instance, OpenStack Nova scripts [103] for VM scheduling or load balancing, or OpenNebula 
OneFlow [104] for self-provisioning in front of conditional triggers like workload, or 
OpenStack Heat for orchestration deployment and scalability. In any case, they are 
dependent on the underlying CMP, so other cloud-agnostic tools are developed based on 
open cloud standards. For instance, the Barcelona Supercomputing Center developed a 
programming model enactment service (PMES) [105] that permits the programmatic 
deployment of VMs on OCCI compliant CMPs in an elastic manner. 
Good examples of automatic provisioning of infrastructures are Packer and Terraform. 
Packer automatically builds from a coded recipes VM images for several platforms (e.g. 
OpenStack, Amazon). Terraform composes from recipes VM instances or sets of them – i.e. 
virtual clusters. The mature and widely-used implementation supports the majority of cloud 
vendors, including OpenNebula and OpenStack. Additionally, it interacts with software 
provisioning tools, discussed hereafter, to further configure the virtual instance.  
Contextualization 
Contextualization refers to the cloud context information passed to newly created VMs that 
enables a first customization of the virtual instances – e.g. the network configuration of the 
VM, user credentials, initialization scripts, or some free form data. Contextualization 
packages are installed as part of the VM stack and are executed upon boot time on different 
“runlevels”. Cloud providers pass the information to the virtual environment using different 
strategies, like ISO file systems attached to the VM, file injection into the VM, or through a 
metadata server at a known location. 
Nowadays, de-facto standard for VM contextualization is Cloud-init [106], available for 
many popular operating systems and supported by a good number of open-source CMPs. It 
enables advanced options like configuration of trusted CA certificates, creation partitions 
and file systems, configuration of cloud data stores, or execution of user-defined scripts. 
There exist other implementation-specific tools like One-context [107] for OpenNebula, or 
Amiconfig [108] for Amazon EC2. 
Typically, contextualization is useful for setting configurations not known until instantiation, 
like DNS, hostname, private information like user’s SSH keys or personal data volumes, or 
software that changes frequently with discrete user-defined commands.  
Software provisioning 
The philosophy of Development Operations (DevOps) is pushing towards the full 
automation of provisioning, deployment and configuration of software. In this context, 
runtime environments are build starting with vanilla hosts and dynamically installing in 
there all the necessary software required to run the applications at scale. Under such 
interest, lots of configuration management tools have arisen. Differences aside, they all 
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model specific actions on a local or remote machine in order to prepare and fully configure 
their applications according a given recipe. As such, developers and administrator tasks are 
considerably reduced. Popular examples are Ansible [109], Chef [110], Saltstack [111] or 
Puppet [112], each with their pros and their cons [113]. 
Orchestration & Management 
Orchestration tools automate the deployment, management, scaling and networking of 
coordinated applications. Such tools, are everyday more used in the cloud environment 
because of the rise of microservices architectures, frequently implemented as container-
based applications. Some examples would be Apache Mesos [114] or Nomad [115], 
workload orchestrators for distributed environments, or Docker Swarm [116] and 
Kubernetes [117], more focused on container-based clusters.  
 Bioinformatics in the cloud 
Over the last 10 years, there have been numerous efforts in developing cloud-based tools 
to support very diverse bioinformatics tasks, including new processing algorithms ready to 
exploit horizontal scalability, portable compute infrastructures to outsource computing or 
exploit data/compute colocation, and secure remote data frameworks with flexible 
computing backend. These are approaches well positioned to exploit cloud differential 
benefits respect to other distributed computational infrastructures, such as its intrinsic 
availability, portability and elasticity. Following are mentioned several of cloud-based 
efforts, yet, it is a fast-moving field and as diverse as the bioinformatics field itself [118]. 
Cloud infrastructures 
During recent years, an increasing number of commercial and academic cloud vendors are 
offering services for science. Although cloud computing has not been initially designed for 
science but for business, the model has grown increasingly popular among scientists, and 
commercial providers offer not only general-propose IaaS (e.g. Amazon EC2 or Microsoft 
Azure), but on-purpose infrastructures specialized or with particular high-end services, for 
instance, GENESIS [119], a cloud-based on GPU accelerated nodes, or HPC Google cloud 
[120]. Meanwhile, the number of public providers is increasing. Table 1.2 lists the most 
representative for life sciences domain, some with co-located public databases like the 
Embassy Cloud [121] hosted at the EMBL-EBI, other production clouds developed for 
university- or institute-based projects. Resource services are provided free of charge, 
although under their own access policy, usually bound to scientific projects, collaborations, 
or institutional agreements. 
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Rodeo www.tacc.utexas.edu/systems/rodeo  
Part of Texas Advanced Computing Center (TACC), 
allocating the central Galaxy public server. Comprises 256 
processing cores and 2 TB of memory  
Corral www.tacc.utexas.edu/systems/corral  
Part of TACC and also allocating Galaxy public servers. 
Comprises 20 PB of storage 
XSEDE xsede.org  Supported by NSF 
Jetstream jetstream-cloud.org  
Science cloud in XSEDE located at TACC and Indiana 
University's Pervasive Technology Institute 
Bionimbus 
Protected 
Data Cloud 
bionimbus-pdc.opensciencedatacloud.org  
Science cloud associated with Open Source Data Center 
(OSDC) that permits secure analysis of protected health 
information 
Compute 
Canada 
computecanada.ca  
High-performance Canadian computing network spanning 
ACENET, Calcul Québec, Compute Ontario and WestGrid 
de.NBI www.denbi.de  
Bioinformatics service provider in Germany spanning 
education, consulting, computing and storage, as well as 
databases 
Embassy 
Cloud 
embassycloud.org  
Science cloud for EMBL–EBI affiliates including direct access 
to public genomics data sets 
Helix 
Nebula 
helix-nebula.eu  
European open science partnership across industry and 
academia to provide cloud computing infrastructure 
Nectar 
Cloud 
nectar.org.au  Self-service Australian science cloud 
Broad 
FireCloud 
software.broadinstitute.org/firecloud  
Part of Cancer Genomics Cloud (CGC) by the NCI. Offers 
collocated genomic data and analysis tools in the cloud 
ISB-CGC http://cgc.systemsbiology.net/  Part of Cancer Genomics Cloud (CGC) by  the NCI 
Seven 
Bridges 
CGC 
cancergenomicscloud.org  Part of Cancer Genomics Cloud (CGC) by  the NCI 
Table 1.2: Public cloud providers. 
Adapted from  [122] 
 
In such a way, the execution of bioinformatics applications and pipelines is moving from the 
traditional "download and analyse" paradigm to the “compute on-demand” model. Some 
IaaS are delivered as pre-build infrastructures. A classic example would be CloVR [123], a  
publicly available VM with a desktop interface and a CLI with configured pipelines for 
microbial analysis. CloVR runs on Amazon EC2 the pre-packed applications as a cluster of 
VMs, where data is transferred via SSH. Similarly, Cloud BioLinux [124] is another popular 
distributed virtual machine for bioinformatics computing on Amazon EC2. There exist other 
domain-specific workbenches, like BioVLab [125] for sequence mapping, ProteoCloud [126] 
for proteomics, or BioVLAB-MMIA [127] for transcriptomic. Most of them are compatible 
with Amazon EC2, some even feature GUIs or include workflow orchestrators, and all of 
them are delivered as deployable infrastructures.  
Cloud Platforms 
Another delivery model would be that of serving customizable platforms on the cloud 
(PaaS). Here, the most popular solution is Galaxy [128], an online user-friendly workbench 
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for bioinformatics tools, where such tools are plug in and out to achieve a tailored 
framework. With thousands of users, Galaxy was first born as a centralized analysis platform 
with a cluster-based backend behind. Nowadays, Galaxy interface can run atop different 
computing infrastructures, and the community has set up over 80 public servers besides the 
main server. Moreover, users can also install Galaxy on cloud clusters using CloudMan 
[129], and Galaxy containerization made possible a Kubernetes-based deployment to 
outsource jobs from public servers towards other clouds [130]. 
Alternative include stand-alone PaaS, like Eoulsan [131], a package developed to easily set 
up a cloud with a Hadoop implementation of the MapReduce algorithm. It includes a 
number of NGS tools. Another platform offering tailored research environments, in this case 
for metabolomics analysis, is Phenomenal [132]. Applications are presented to the 
researcher through a Galaxy server, or, in case of advanced users, a Jupyter Notebook [133] 
– i.e. an interactive development environment. Interestingly, the whole infrastructure 
deployment is customizable and automatically provisioned: Terraform deploys a virtual 
cluster with Kubernetes or Mesos, who in turn installs the chosen containerized 
metabolomics applications and launch the corresponding front-end and auxiliary services. 
Finally,  Indigo Data cloud [134] does not offer virtual workbenches in particular, but any 
type of application the user might configure Indigo to compose. Indigo is a set of PaaS 
components (including authentication, data or orchestration modules) that automates the 
deployment and configuration of virtualized services given a tool configuration recipe – 
specified using TOSCA standard. The resulting virtual environment could be any, a Galaxy 
server, or simply a web application with a MySQL database. 
Cloud Software 
Regarding standalone cloud-native applications in bioinformatics, most solutions are 
focused on large-scale sequence processing, mainly exploiting the benefits of the Hadoop 
implementation of MapReduce. Examples are CloudBurst [135] for short sequence 
alignment, CloudAligner [135] for long reads, or Balaur [136]  for mapping on hybrid clouds 
while preserving data privacy, Crossbow [137] for single nucleotide identification (SNP) 
identification, PeakRanger [138] for ChIP-seq peak calling, or Myrna [139] for RNA 
expression analysis, or Falco [140] for single-cell RNA-seq processing, amongst others. 
Additionally, a number of programming libraries that facilitate sequence manipulation and 
processing have arisen, such minimizes Genome Analysis Toolkit (GATK) [141] and Hadoop-
BAM [142]. Hadoop implementation is also present in other areas, yet more residual. Works 
in other areas like molecular dynamics (MD) or medical imaging are in their infancy. There 
are few examples of cloud-native developments like AutoDockCloud [143], a workﬂow 
system that enables distributed screening. Some clustering methods [144] or search 
engines for proteomics [145] are also being explored.   
Applications or frameworks may not be distributed but directly offered as SaaS, each bound 
to a particular IaaS. The list of commercial products is long, mostly targeting the genomics 
Computational infrastructures for biomolecular research 
37 
sector, but telemedicine and medical imaging are increasingly popular fields. By way of 
example, DNAnexus [146] is an NGS analysis framework used by ENCODE and running on 
Amazon EC2, Globus Genomics [147] includes Globus toolkit with its GridFTP backend, and 
CycleCloud [148] runs on Azure a virtualize Gromacs and NAMD on GPUs for MD. Publicly 
available platforms are not that abundant. FireCloud [149] makes the perfect example of a 
SaaS offering an analysis platform. Hosted at the Broad Institute, FireCloud runs on a Google 
powered cloud and offers cancer genome pipelines while hosting public datasets (e.g. The 
Cancer Genome Atlas (TCGA) data). Similarly, other infrastructures dealing with data-
intensive tasks like imaging data, either from electronic microscopy [150]  or biomedical 
images [151] could well benefit from this computing model 
Data services 
Cloud data services have also been developed to approach researchers’ requirements. 
Public funded scientific datasets are being made available in commercial clouds, like 
Amazon Web services (e.g. Ensembl, GenBank) [152]. Repositories with sensitive data are 
also exploring how to securely access and distribute it on the cloud. For instance, the 
European Genome-phenome Archive (EGA) is providing a local-EGA [153] implementation 
by which a private repository is stored on-premises installations, though it is findable 
through the central EGA and accessible upon the right credentials. Beacon [35] is a platform 
for global discovery and sharing of genetic variants on distributed and private clinical 
repositories. 
 Cloud open challenges 
Despite the many benefits associated with cloud computing, it currently presents some 
issues and open challenges that prevent research institutions and companies from the 
systematic adoption of the popular model, particularly in those case dealing with sensitive 
data. 
Security is probably one of the most important issues that providers must confront. 
Biomedical research, with omics data extracted from patient’s samples, as in 
pharmacogenomics studies, as well as other clinical and epidemiologic studies, are imposing 
specific constraints in terms of privacy and security. Risks are mainly related to the failure 
of mechanisms for separating storage, memory, and routing between different tenants in a 
shared infrastructure. Centralized storage solutions and shared tenancies of physical 
storage space mean that the cloud users are at a higher risk of disclosure of their sensitive 
data to unwanted parties. Other threats on transferring data to third-party platforms 
include user’s identity spoofing, data malicious alterations or information disclosure to 
authorized parties. Lately, there is considerable work aiming to adopt secure protection 
schemes and cryptographic techniques to protect the data. Even so, there are some legal-
related issues in open discussion. The usual lack of transparency and visibility on IaaS, 
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especially in public clouds, prevents a user from controlling the actual data location, which 
might entail contractual issues, particularly if cross-border transfers occur, as data privacy 
laws are different in each country. Discussions over legal agreements for multi-cloud or 
federated strategies at European level are taking place [154]. Indeed, the first step has been 
the General Data Protection Regulation (GDPR) that came into force in 2018 and set a 
uniform data protection law for European members. Meanwhile, international certificate 
agencies like ISO (e.g. IEC27018, IEC27017) are auditing infrastructures and establishing 
standards to grant data protection as much as possible. At the same time, however, the 
possibility of deploying virtualized tools in private clouds running under controlled 
conditions provides a seamless solution for such concerns. 
Another point to consider is reliability and performance. Data is to be accessible anytime 
and anywhere, thus, high-availability cloud strategies like load balancing cluster services or 
live migrations from host to host are every day more optimized and automatized. 
Performance is mostly bounded to virtualization or networking latency issues, but as 
mentioned, specialized cloud providers are working to offer HPC clouds [83]. 
Issues on interchanging data and cloud APIs standardization are also becoming relevant. 
Common standards are still immature and lead to vendor lock‐in [155], as most cloud 
providers still use proprietary APIs, for both application development and data storage. The 
community is working in pushing vendor‐agnostic applications relying on open standards to 
recover portability and flexibility among cloud providers.  
Finally, computing's pay-as-you-go model of public clouds is proving to be a barrier to 
adoption of cloud computing in research [149], especially for publicly funded research. This 
is a quickly evolving field and with rapid reductions in cost, but in parallel, agencies are 
adapting requirements, more and more public providers are available, and resource 
consumption is also being optimized.   
 Data Management 
Data is undoubtedly the cornerstone of new scientific research. In the last years, data stack 
has suffered structural changes, mainly driven by virtualization and its dynamicity, which 
has driven storage systems from static COTS hardware into software delivered. As discussed 
above, computing and applications rapidly adopted the new paradigm, which means that 
users can compute anywhere, rapidly accessing huge resources, while data could be 
fragmented over different infrastructures. However, data management shows important 
difficulties in this paradigm, and these are only stressed by big data. From the data policies 
to novel storage systems or strategies, data management has responded to the new 
scientific research. 
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 Data governance 
Until recent years, a focused and centralized strategy for the annotation, storage, and 
curation of research data is something that has not been widely considered within academic 
communities. The majority of research data sits, fragmented, on a variety of disk structures 
and is usually managed locally. In front of new research practices, data policies governing 
how data is backed up, disseminated and organized for short or long term reuse are gaining 
relevance.  
Infrastructures intend to assist researchers with the 
digital data cycle. It implies (i) acquitting the data, (ii) 
validating it for the analysis, (iii) transforming it into 
understandable results, (iv) and preserving them in 
long-standing conditions, (v) to enable share and 
reuse. 
With new technologies, the implementation of these 
stages has not come without challenges, and 
infrastructures need to include a set of services, quite 
interconnected with FAIR principles, that aim to 
maximize resource interoperability: 
- the use of services for assigning permanent identifiers to datasets and accessing 
data using these IDs. In such a way, stored data is more easily findable and 
accessible. 
- metadata services for assigning metadata to a digital object identified by identifiers 
and accessing the metadata. Good quality of data annotation ease reusability and 
interoperability, especially if controlled vocabulary or data models are used. 
- authentication services for identifying researchers and authorization services for 
determining which datasets researchers can access. As such, platforms can support 
controlled access data. 
- standardization, encapsulation, and versioning of processing services for executing 
bioinformatics tools so that data can be traced and harmonized. 
 Data-storage solutions 
The number of data-access solutions increases as much as the diversity of scenarios where 
they are intended to be implemented: easy anytime/anywhere data access, simplicity for 
data sharing or for making it public, efficient access to large volumes of data, long and 
secure archiving, strict and granular access, changeable data, etc. Hence, according to the 
system’s purposes, we could define data-access solutions as one of the following: 
Figure 1.18: Research data life cycle 
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Typical grid and cloud lower level data-access tools 
Lustre (Intel) and GPFS (IBM) are parallel file systems often used as high-performance 
scratch systems for computational clusters. They can only be shared within the local cluster 
and has not transparency, although they show high efficiency, high availability and low 
metadata-access latency. GlusterFS is an interesting alternative that does not need 
metadata servers to locate data across nodes, which ensures good performance scaling, yet 
affects elasticity and reconfiguration. Block storages, either as NAS or SAN, can be built on 
top of any of them. SAN keeps high performances, yet NAS provide shared access with 
limited scalability. Alternatively, scalability can be maximized using object storages that 
manage data as objects, but there is no hierarchical structure nor block access like in 
traditional file systems, and no file edition is permitted. OpenStack Object Store (known as 
Swift) and Amazon S3 are the most popular object storages.  
Tools for any time/anyplace data access 
They focus on the ease of access. Widely known examples are Dropbox and Google Drive. 
Most popular OS have clients for transparently mounting them and as virtual file systems, 
letting the user to manually handle discrepancies in case of desynchronization. 
Furthermore, they impose rigorous limits on the storage size and transfer speed, which 
become an obstacle for conducting research in a geographically distributed manner. 
ownCloud, or his successor NextCloud, offer a more flexible solution, transferring data over 
HTTP via WebDAV, allowing users to maintain full control over their data location, and 
providing file sharing using public URLs. However, it might not be sufficient for data-
intensive applications. 
Tools for distributed data processing 
One of the most prominent tools for remote data access is Globus Connect, built on the 
GridFTP protocol to provide fast data movement and data-sharing capabilities inside an 
organization. Another possibility is the use of parallel file systems like those typically set for 
grid nodes, mentioned above. Solutions built on top of object storage systems are equally 
valid. For instance, CephFS shows good performance and features simple POSIX-compliant 
file systems instead of object storage delivery. Alternatively, on another direction, map-
reduce paradigm effectively process distributed data, and Hadoop Distributed File System 
(HDFS) is designed to support it, as it permits to stream large data sets at high bandwidth 
for the user’s processes. 
Tools for a unified view of multi-organizational data 
They aim at providing an abstraction layer on top of the storage resources across multiple 
organizations – i.e. across multiple clouds. Files have a unique namespace across data 
servers and data-management rules can be configured to control the data location policy 
across servers. An exemplary tool is iRODS, used in EUDAT project. Data can be simply 
stored at designated folders on any data server and its metadata is centralized in a 
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database. POSIX interface is available upon FUSE mount, and several storage systems are 
supported and integrated as plug-ins (GridFTP, Amazon S3). Importantly, multiple iRODS 
installations can be federated into a “Zone”. OneData represents an IRODS alternative, as it 
features very similar characteristics. Yet, oneData [156] provides location transparency for 
data stored across federated servers, and importantly, it offers as build-in “copy-on-read” 
policy that transfers data among Zones only when at the moment it is required and 
transparently. Indigo data cloud is using oneData. Another slightly different perspective is 
given by CernVM file system (CVMFS) [157] originally designed for efficient software 
distribution. It provides a FUSE-based POSIX interface for local users, but all writes occur at 
a central repository server, whose data is distributed with an efficient caching system 
around nodes. Additionally, CVMFS has no data privacy mechanisms at the metadata level, 
so the system is more used for multi-organizational data distribution than for data 
exchange. 
  Databases 
Relational database management systems (RDBMSs) has been the primary database 
technology used since the beginning of data warehousing. They are well-matched to client-
server programming and today they are the predominant technology for storing structured 
data in Web. RDBMS stores data values in fixed tables and logical relationships among them, 
and ensures data integrity using a strict transaction model called ACID (Atomic, Consistent, 
Isolated and Durable) by which once a transaction is complete, its data remains consistent 
and stable in disk and memory. Moreover, most relational engines adopt Structured Query 
Language (SQL) as their querying language, a very powerful and flexible standard. When 
considering the CAP theorem [158], which states that a distributed system cannot 
simultaneously provide (C)onsistency – all reads get last write –, (A)vailability – clients 
always can read and write – and (P)artition Tolerance  – system up despite network drops), 
RDBMS falls into the CA category (Figure 1.19), with a poor scalability with vast volume of 
data. Popular implementations are MySQL (currently owned by Oracle), MariaDB or 
PostgresSQL. 
 
 
 
 
 
 
 
Figure 1.19: Database technologies into the CAP theorem 
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However, there are various types of data that may not require a fixed schema, avoid some 
form of join operations, and typically scale horizontally – these are known as unstructured 
data and RDBMS fails to handle so. New omics technologies and biomedical machinery are 
massive producers of such type of data. NoSQL encompasses a wide variety of different 
database technologies developed in response to that complex data and the big data 
requirements (the “5 Vs”). There are several categories of NoSQL databases, each with their 
own specific attributes and limitations, as they are designed to solve specific problems: 
- Key-value stores: are the simplest NoSQL database type, storing attribute names (the 
"key") with values.  They are good for anything requiring in-memory computing, in-
memory analytics, real-time communications, and large amounts of streaming data 
(e.g. Redis). 
- Document databases: store documents, which can be structured or unstructured, 
making them ideal for unstructured and semi-structured data (e.g. Mongodb). 
- Column family stores: are optimized for querying large datasets, storing data as 
columns, not rows, in tables that can have millions or billions of columns (e.g. 
Cassandra, HBase (Hadoop DB)). 
- Graph databases: store information on objects and their relations to one 
another.  Social networks are built on graph databases (e.g. Neo4j). 
Other NoSQL strategies consist on optimizing the search engines, usually supporting 
complex search statements, streaming, and full-text search (e.g. Elasticsearch), or 
optimizing the handling of certain data types, for instance, time-series databases (e.g. 
InfluxDB), or RDF databases for storing subject-object-predicate triples (e.g. MarkLogic). 
NoSQL systems are designed for specific scenarios with different prioritizations, although 
generally speaking, they properly manage fault tolerance, scalability, and availability, in 
exchange of not immediate read and write consistency (AP category from CAP theorem). 
NewSQL is a new branch of relational databases that aims to regain this consistency 
returning to ACID transactions while preserving good scalability capabilities typical from 
NoSQL systems. NewSQL systems can be loosely grouped into: 
- In-memory databases: stores data in RAM with durability and infrequent in-disk storage 
(e.g. VoltDB) 
- Optimized storage engines for SQL: data is partitioned ‘shards’, capable of running on 
a large number of nodes without suffering bottlenecks (e.g. Spanner). 
Computational infrastructures for biomolecular research 
43 
 Science on the Web 
The take-up of Web technologies in bioinformatics is ubiquitous. Since its creation, the 
World Wide Web (WWW) has established itself as a de-facto standard for information 
sharing changing the way users and developers disseminate, discover information, 
collaborate, and distribute data and computation. The Web is the biggest, most successful, 
and most programmable distributed system architecture ever [159]. Its decentralization 
avoids social and technical bottlenecks, and its openness permits information reuse and 
fairness [160]. Such features made the Web the natural gateway for science since the very 
beginning. And resource digitization did not only change how we do research but also who 
does so. e-infrastructures are meant to bring together those high-end researchers used to 
work in high-performance environments, with the long tail of researchers using the Web. 
Several strategies are employed for exploiting the Web potential in online research. 
 Service-Oriented Science 
Service Oriented Architecture (SOA) is a model that looks for efficient and productive coding 
by splitting application architecture into single-purpose reusable units, rather than building 
them within each individual application. SOA is typically implemented through web 
services, that communicate among each other and with clients using standard protocols 
[161]. In life sciences, web services, originally designed to support machine-to-machine 
interaction over the network, have become a road for systematically standardizing the 
multitude of bioinformatics tools available [162]. Three standards recommended by 
international consortiums (W3C [163], OASIS [164]) define the most basic framework for 
representing web services: XML (Extensible Markup Language) as the format used to 
contain the data and provide metadata around it; SOAP (Simple Object Access Protocol) is 
used to transfer the data; WSDL (Web Services Description Language) is used for describing 
the services available; and UDDI  (Universal Discovery, Description, and Integration) lists 
what services are available. 
 
 
 
 
However, services on the web are not limited to these recommendations. Some emerging 
standards are widely used, like JSON (JavaScript Object Notation) for data structure, and 
RESTful web services are very popular. These are implemented directly on the HTTP 
protocol and follow the principles of Representational State Transfer (REST), where a 
Figure 1.20: Web services architecture (a) versus REST services (b) 
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unique URL is a representation of a unique object. Other data transfer protocols still in use 
include RPC (Remote Procedure Call), again XML-based (XML-RCP) and with a similar SOAP 
request-response, but supporting only a subset of his functionalities (only over HTTP(S), 
with basic AUTH, and with no support for WSDL specification). Other protocols like WebDAV 
(Web Distributed Authoring and Versioning) enables the use of web services as generic file 
servers. WebDAV is an HTTP extension that implements extra methods like COPY and 
MOVE. 
Web services are widely used in the context of the life sciences applications, and several 
registries and repositories have appeared along the years, for instance, BioMOBY [165], 
EMBRACE [166], BioSWR [167] or  BioCatalogue [168]. However, ELIXIR bio.tools [19] is 
positioning itself as the most promising repository for bioinformatics tools with more than 
14,000 services annotated from more than 7,000 providers. And web services approach is 
an up and coming model whose benefits are every day best exploited by the scientific 
community. The architecture enables cross-domain expertise integration, by establishing a 
common information framework between different bioinformatics areas, also allows data 
access in a systematic and standardized manner regardless of the underlying data retrieval 
mechanism, and by design and as discussed above, the native interoperability of web 
services make them very suitable for composing scientific workflows. 
Lately and particularly after the emergence of cloud technologies in research, the most 
important principles of SOA - service-oriented, autonomy, reusability, composability, 
discoverability and statelessness - have been extended and applied to heterogeneous 
storage and compute virtualized components able to interoperate with each other at the 
web service level by following the standards and protocols. These cloud-delivered services 
are popularly described under the term ‘as-a-service’ (platform as a service, workflow as a 
service, container as a service, etc), and the “servicification” is reaching infrastructure 
devices as these become more powerful and complex (security as a service, network as a 
service, authentication as a service, etc.).  
Modern e-infrastructures and middleware use a SOA approach on a cloud-based 
infrastructure, i.e., combine web services interoperability and virtualization technologies 
[159]. This computing paradigm frees the researchers from dealing with the maintenance 
of the physical infrastructure and provides many potential benefits, including scalable IT 
infrastructures, QoS (Quality of Service) assured services and customizable computing 
environment. Yet, as discussed previously, the dynamic service composition needs to 
comfort data format compatibility and other standing integration challenges. 
 Web applications 
A web application enables information processing functions to be initiated remotely from a 
browser and executed partly on a web server, application server and/or database server.  
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Through the use of a set of standard languages governed by the World Wide Web 
Consortium [163] - primarily Hypertext Mark-up Language (HTML), but also CSS, JavaScript 
- web applications ensure the interoperability with web browsers, as well as top-level tools 
like multimodal devices (e.g., voice browsers) or semantic web models. 
Although a number of web application architectures are proposed, bioinformatics 
applications typically adopt the classic thin client-server architecture, (Figure 1.21) with a 
client part communicating via the request-response HTTP cycle (HyperText Transmission 
Protocol), with a server web application on the other side, with access to the computational 
and data resources. WWW technologies like Common Gateway Interface (CGI) and FastCGI 
support the execution of scripts (i.e. in Python or Perl) on the web server, as well as Java 
Servlets and other programming environments. But as the complexity of the operations or 
the web frontend grows, the application quickly gets heavy and requires a complete 
implementation on the backend of the server-side for managing high-end computations or 
interacting with the data tier (Database Management System (DBMS)). Some common 
backend languages are Ruby, PHP, Java and Python, although often are run on frameworks 
that simplify the web development process mostly providing templates, data structures and 
component repositories inspired by the Model-View-Controller (MVC) UI pattern (e.g. Ruby 
on Rails [169] for Ruby; Django [170], Flask [171] or Web2py [172] for Python; Laravel [173], 
Symfony [174] or Slim [175] for PHP). Frontend development is based on W3C1 standard 
languages, but there are also frameworks like Bootstrap [176] or Angular [177], as well as 
JavaScript libraries like JQuery [178] or React [179] and CSS extensions like Sass [180] and 
Less [181].  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.21: Web applications architectures. 
Out of the three application layers (presentation, logic and data), thin clients reserve only the presentation tier for the 
client side, while thick clients implement also the logics in them. 
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Now, and increasingly, those web applications where the client-side performs most of the 
operations are becoming much more common, i.e. they run within the web browser on 
increasingly powerful user’s devices with less or no support at all from a remote server. 
These thick clients (or Fat clients) might be even installed and administered locally on the 
user’s computer, but run in a web browser in order to achieve independence from hardware 
platforms and operating systems. In other models, applications are automatically 
downloaded from a web server when a user starts them but do not communicate with the 
server while running. Another type of thick clients is “server-agnostic”, i.e. serverless 
architectures able to connect to multiple (cloud-based) remote servers and data stores, 
which offer great flexibility and scalability. Such applications are often connected to the so-
called web services or microservices (section 1.5.1 Service-Oriented Science). Other 
graphical tools are also available as Java applets, which are usually server-less and can be 
embedded inside web applications. For security reasons, and for avoiding the plugin 
installation required for Java Applets or Flash, rich web applications are today being totally 
developed with the web frontend languages mentioned above, taking profit of the web 
standards like HTML5 and JavaScript and supplemented with CSS, SVG and Ajax 
(Asynchronous JavaScript and XML). These methodologies enable Single-Page Applications 
(SPAs), which allows a dynamic content update to the current page instead of loading 
completely new pages.  
New features in browsers allow for clients to move beyond the client-server pattern. For 
instance, web sockets provide direct communication between a client and some other 
server -  no longer relying on browser’s HTTP requests [182], and there examples of libraries 
allowing browsers to execute peer-to-peer file sharing protocols [183], or turning browsers 
into nodes of a distributed data store [184]. In other words, web application clients seem 
to be evolving into something more like a node of a distributed system, following the trend 
of the distributed data and computing paradigms. 
 Data Portals 
Web portals were among the first type of bioinformatics web applications and nowadays 
are broadly implemented. They are specially designed to serve as information aggregators. 
As the number of distributed data resources available on the Web increases, more 
imperative becomes the development of central web portals imposing an integrative view 
over third party resources.  Research portals aim a one-stop-shop feel for researchers with 
easy navigation and seamless access to information and authentication for underlying 
research e-resources.  
Shortly after WWW was created, ExPASy [185] was released as the first web server in life 
sciences offering data access to multi-databases in an integrated way, a model still up-to-
date today. Others like Entrez [186] or SRS [187] appeared shortly after. Although the use 
of the web standards in the recent web applications hardly resembles that from the 1990s, 
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the conceptual remain unaltered. They do contain more than hyperlinks to other related 
sites, as to some extent, they integrate the resources per se, either consuming them from 
data providers, primarily using APIs (Application Programming Interfaces), or elaborating 
processed cross-linked data to offer a seamless aggregation exploiting, for instance, web 
semantic strategies. Shortly after WWW is created, ExPASy [185] is released as the first web 
server in life sciences offering data access to multi-databases in an integrated, a model still 
up-to-date today. Others like Entrez [186] or SRS [187] appeared shortly after. Although the 
use of the web standards in the recent web applications hardly resembles that from the 
1990s, the conceptual remain unaltered. They do contain more than hyperlinks to other 
related sites, as to some extent, they integrate the resources per se, either consuming them 
from data providers via APIs (Application Programming Interfaces), or elaborating 
processed cross-linked data generated, for instance, using web semantic strategies – an 
approach every day more relevant with the huge among of unstructured e-resources that 
digitalization has brought to the surface. 
 Workbenches 
A natural evolution of web portals is going from promoting resource accessibility over the 
Internet, to actually utilizing them. Firstly, it appeared applications dedicated to executing 
particular programs on the Web, and the plethora of bioinformatics tools quickly made 
obvious the need for integrated analysis platforms. With the primary objective to enable a 
convenient data analysis that minimizes user’s effort, workbenches might include not only 
access to computational tools and data, but also and to a certain extent, visualization, 
storage, automated workflow design, and execution, or data management services. In this 
manner, data process transparency and reproducibility are promoted from the 
infrastructure. Modern workbenches are expandable and multi-functional rather than 
narrowly specialized for a certain research domain. The computational infrastructure 
hidden behind the web application might correspond to any of the computational models 
above presented or simply be a local installation. 
Popular web-based workbench frameworks have already been implemented. Examples are 
Chipster [188], Omics Pipe [189], GeneProf [190], GenePattern [191] or Galaxy [192]. They 
all let users run individual steps or entire pipelines on a remote computing system with the 
framework keeping track of the executed analysis. They all offer graphical user interfaces 
for making the tools accessible to scientists without extensive skills in programming. Yet, 
Galaxy is the solution more widely adopted, as many of these frameworks are exclusively 
focused on specific NGS analyses, or are simply are not designed in an expansible and 
modular way to support the plug in and out the new analysis tools. Omics Pipe would be 
another modular workbench, and both are implemented as to run on top of several 
distributed computational back-ends. Table 1.3 summaries the features of some of these 
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workbenches, including those focused on scripting frameworks, like Snakemake [193]  or 
Nextflow [194] 
 
 
 
 
 
 
 
 
 
 
 
 Virtual Research Environments 
Virtual research environments (VREs) represent a step beyond workbenches. The term is 
born together with the e-science concept, as part of the technologies seeking to support a 
vision of large-scale collaboration. Capable of doing any of the tasks usually assigned to 
workbenches, VREs are presented as the interface of a infrastructure that allows access to 
data and services in an environment focused on a particular research activity [195].  Thus, 
VREs are part of an infrastructure more than a free-standing product as workbenches. In 
line with current research practices, VREs usually integrate community-building 
components, like forums, comprehensive views of data and information or other support 
tools. The ultimate goal is be able to enroll researchers from any discipline that seek to bring 
together despair expertise to collaboratively work on a multidisciplinary problem. 
Multiple and very variated are the interpretations and implementations of VREs in 
bioinformatics.  In the context of LifeWatch [196] project, the European e-infrastructure 
focused on biodiversity, a full catalogue [197] of VREs dedicated to diverse subjects (e.g. 
marine metabolomics, eco-diversity, etc.) has been developed, each with their own 
logistics, interface, datasets, etc., but all operated on LifeWatch grid resources. Another 
approach is that of Workflow4Metabolomics [198] and Phenomenal [132], both dedicated 
to comprehensive metabolomics data processing. 
Table 1.3 Analysis data platforms. Source [259] 
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2 . Objectives 
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In line with the evolution of computational research infrastructures in the field of 
bioinformatics the following main questions arise:  
- Which are the most appropriate technological solutions to fulfill user needs in 
modern bioinformatics 
- How that technology can be abstracted in a way that researchers can 
concentrate on scientific questions. 
To focus on specific objectives for this doctoral work we benefit from a serial of 
bioinformatics projects that will provide the appropriate use cases. Following such projects, 
the specific objectives of the work are: 
1. The development of a clinical data management system appropriate for a multi-
centric biomedical research project. Such a system should provide secure and 
efficient data storage and management, based on data capture approaches 
accepted at the clinical side.  
2. The development of cloud-based solutions for the establishment of production-level 
virtual research environments, adaptable to a series of scientific use cases. Such 
infrastructures should combine state-of-the-art technical solutions, and the 
appropriate interfaces to data management, and to final users and developers.  
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3 . Software, Data & 
Methodology  
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The present chapter includes a selection of IT solutions and methodologies used 
during the implementation of the infrastructures presented in the dissertation. 
 Software components 
 Databases technologies 
The data tier of the web applications developed in the present work is mainly based on 
databases, which vary in architecture and model depending on the nature and architecture 
of the data they are mean to store. Two different technologies have been used, MySQL and 
Mongodb, and they are compared in the following table, that summarize engines’ features: 
 Relational databases, MySQL 
MySQL[199] is the most popular open-source database. Presently owned by Oracle, the 
relational database management system (RDBMS) employs the concept of storing data in 
rows and tables, thus, a rigid structure is to be clearly defined in advance and kept 
essentially unaltered. Changes in data model usually imply the database schema 
modification, yet, data consistency is easily granted. 
MySQL’s limitations are common to most relational databases: millions of read/write highly 
affects the performance and hence horizontal scaling is not quite easy. The constrain 
inherits from the strict transaction model in use, ACID. “Write consistency” is quite suitable 
for applications which can’t bear data loss or inconsistency. Under the CAP theorem, MySQL 
opts for Consistency and Availability (i.e. CA), so data will be consistent between all nodes 
as long as nodes are online. 
Even with relational design limitations, replication and clustering are available for MySQL 
to some extent. Replication, either master-slave or master-master replication, quite easily 
add reading scalability, and multi-master replication writing scalability, yet, the latter only 
for separate applications, each using its master. MySQL Fabric and Cluster [200] are not 
standard implementations that support data sharding for MySQL. 
For the present work, the MySQL server corresponds to a standard installation hosted at 
the (BSC) Life Cluster front-end providing service to several projects. Here, it is being used 
to store phenotypical data: up to 200,000 records of clinical variables in a key-value pair 
pattern, together with well-structured data of clinical cases and donations. Although clinical 
fields feature a very changing nature, for legacy and technology maturity reasons, MySQL is 
the chosen system. MySQL is around the block for a long time and supported by a wide 
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community. Flexibility is achieved using a particular database design further discussed at 4 
. Results. Furthermore, clinical studies have a very clear structure easily to be defined in 
advance. Apart from offering strong security, MySQL servers have easy and low-
maintenance implementations. 
 Mongodb 
Mongodb [201] is one of the most popular document-oriented databases under the banner 
of NoSQL databases. It was first released in 2010 and employs the format of key-value pairs, 
here called document store, in collections as BSON files (binary version of JSON files) which 
facilitates data exchange between web applications and servers in a human-readable 
format. 
Moreover, Mongodb offers great efficiency and reliability while meeting high storage 
capacity and speed demands thanks to the adoption of the BASE consistency model (Basic 
Availability, Soft-state and Eventual consistency), popular among NoSQL databases, which 
generally have loosened their requirements for immediate consistency, data freshness and 
accuracy in order to gain other benefits, like scale and resilience. The database does not 
guarantee consistency of replicated data at write time, but it does eventually, for instance, 
at read time. In this way, Mongodb supports atomic updates on a single document level. In 
summary, Mongodb system has opted to provide Consistency & Partition tolerance 
sacrificing availability so that users of one node will have to wait for any other nodes to 
come to an agreement before being able to read or write to the database. 
Mongodb provides also high scalability and service availability as it supports auto-sharding 
and on-board replication. Its sharding breaks up a collection into subsets of data and 
distributes it, with redundancy and automatic failure recover, and transparently to the 
application. Data replication is also supported, only in a master-slave model. 
But on top of all that, the schema-free implementation is one of the best Mongodb features. 
It eliminates the prerequisites of defining a fixed structure which provides high flexibility 
and facilitates the ability to change the structure of a record. However, due to the absence 
of joins and transactions, the user needs to frequently optimize the schema based on how 
the application will be accessing the data. Moreover, schema-less documents might cause 
problems with data consistency, which should be resolved by the application. These are 
reasons might motivate the use of JSON schemas ($jsonSchema) for validating document 
collections, an option appeared in Mongo 3.6. 
Mongodb results in a good solution for handling unstructured data in a cost-effective way. 
In the present work, stored data corresponding to: 
- Metadata (operational and functional) accompanying file system entries. 
- Tools registry repository (software developers’ applications and visualizers) 
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- Application’s management data (job registry, user administration, etc) 
It is convenient to loosely define such data at the database level, in particular for the two 
first cases, as they are very changing data models, with complex, nested content, and 
hierarchical data. Furthermore, they are easily abstracted as programming objects at the 
application’s library, and the JSON format is very handy to directly map them into the 
database model. Even offering such flexibility, Mongodb is not comparable to other NoSQL 
systems more target for big data, but still. 
Furthermore, the in-built sharding solution of Mongodb offers good horizontal scalability 
very suitable for cloud-based services as ours, as it aligns with the horizontal elasticity and 
agility provided by cloud resource pooling. The expansion might be flexible, easily achieved 
by adding more machines and RAM to the system.  
 Cloud-related software 
 Cloud management platforms 
Cloud management platforms (CMP) are the suite of integrative software tools used to 
monitor and control cloud computing resources. They incorporate interfaces for self-service 
resource management and more-advanced offerings, like workload optimization, support 
for configuration of storage and network topology, shortly introduced at 1.4.3.2 section. 
Here, the two major open-source IaaS CMPs are used: OpenNebula and OpenStack. 
〕  OpenNebula 
OpenNebula is designed to help building simple and reliable, datacentre-like clouds on 
existing IT infrastructure in a cost-effective way. OpenNebula can be managed through a 
Web-based UI (Sunstone) that provides access to all features, yet it also has a CLI and a 
powerful RCP-XML API, essential to programmatically manage the cloud from other 
systems. Other main components of OpenNebula are the nodes, the image repository, the 
daemon, and the drivers. OpenNebula is structured as the classic cluster-like architecture 
with a front-end, where the API, Sunstone and other services are located, and a set of 
hypervisor-enabled cluster nodes, where VMs are instantiated. Such model is very 
convenient for our HPC cluster installations, as it permits to transfer compute nodes from 
the HPC to the cloud with a certain flexibility. 
In terms of management, OpenNebula is organized as other CMPs: VM images > VM 
templates > (VM services) > VM instances: 
- VM images refer to the disks images containing either file systems or operating 
systems. Supported formats are QCOW2, RAW, and VMDK. 
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- VM templates correspond to YAML-like files defining the set of attributes 
required to compose a VM instance. Apart from specifying one or more VM 
disks, it includes information on CPUs, virtual CPUs, RAM memory, network 
interfaces with their gateway or IP, contextualization details, and many other 
attributes. Snippet 3.1 shows a simple VM template. 
- VM services are multiple and varied, in fact, these are one of the differential 
traits among CMPs. OpenNebula offers self-provisioning tools for managing 
clusters, auto-scaling services (like OneFlow, below discussed), network 
definition tools, or VM authentication management, among others. However, 
the platform’s philosophy is offering good connectivity and interoperability 
capabilities while allowing new services implemented as add-ons. 
- VM instances are the result of deploying a VM template, either manually or via 
one the advanced services.  
 
- DESCRIPTION = "TADBIT FOR MUG"                                                      
. 
CPU = "8" 
- CPU = "12" 
MEMORY = "189152" 
MEMORY_UNIT_COST = "MB" 
DISK = [ 
  IMAGE = "mg-tool-tadbit" 
-   TARGET = "hda" 
-   DRIVER = "qcow2" ] 
FEATURES = [ 
  ACPI = "yes" ] 
GRAPHICS = [ 
  LISTEN = "0.0.0.0", 
  TYPE = "VNC" ] 
HYPERVISOR = "kvm" 
NIC = [ 
  NETWORK = "kvm-servers-mmb" 
-   IP = "range" ] 
OS = [ 
  ARCH = "x86_64", 
  BOOT = "" ] 
- CONTEXT = [ 
-   NETWORK = "YES", 
  SSH_PUBLIC_KEY = "$USER[SSH_PUBLIC_KEY]" ] 
Snippet 3.1:  Simple VM template for OpenNebula 
 
Images, templates, instances, networks and other services, are all managed either through 
the Command Line Interface (CLI) or the Sunstone UI. Additionally, OpenNebula supports 
several cloud client interfaces, such as Amazon EC2, Google Cloud or vCloud, demonstrating 
being vendor-neutral. And importantly, the Open Cloud Computing Interface (OCCI) (based 
on draft 0.8) is natively supported, providing a standard endpoint to create, control and 
monitor VMs. Indeed, the analysis platforms here presented interact with OpenNebula via 
the OCCI connector. 
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OpenNebula supports XEN, KVM, and VMWare ESX hypervisors, yet our installations are all 
based on the popular KVM virtualization platform, operationally managed via the open-
source virtualization library Libvirt. KVM is outperformed by purely bare-metal hypervisors 
like Xen, yet, it is widely used because of its simplicity and ease of use, running directly on 
Linux’s kernel and being delivered by default in most Linux distributions. 
We have had access to two cloud infrastructures managed by OpenNebula, one at the 
Barcelona Supercomputing Center (BSC), the other at the Institute for Research in 
Biomedicine (IRB). Both are based on cluster-like architectures and correspond to two 
private on-premises deployments operated and managed by us from the respective 
institutions. Details on the underlying hardware are found in Table 3.1. 
- The “INB Cloud” is hosted at the Barcelona Supercomputing Center (BSC) and 
installed on top of on a computational cluster It includes an externally accessible 
front-end which acts as a gateway for the internal cloud VLAN on HTTP(s), FTP(s) 
and SSH. A shared common storage system of some TBs is accessible to both, 
frontend and compute nodes. Accessed as a Network Attached Storage (NAS) on 
a high-speed network, disks export several NFS (v3) endpoints on top of a GPFS 
distributed file system. 
- The “MMB Cloud” cloud is hosted by the Molecular Modeling and Bioinformatics 
Unit of the Institute for Research in Biomedicine (IRB). Likewise “INB Cloud”, 
OpenNebula manages a series of homogeneous nodes virtualized in KVM and 
the storage is also block-accessed over the network, yet in this case, the NAS 
protocol is CIF, while the distributed storage solution is based on NetApp. 
Cloud Name Cores RAM Memory Storage System OpenNebula Project 
INB Cloud  
(BSC) 
4 x 12 cores 
Intel Xeon E5649 
 
4 x 96 GB RAM Shared GPFS of 78TB 
(NFS) 
OpenNebula 
(v5.2.1) 
transPLANT 
MuG 
MMB Cloud 
(IRB) 
3 x 58 cores 
Intel Xeon E5-2640 
3 x 442 Gb RAM Shared disk 7.5TB 
(CIF) 
OpenNebula 
(v4.4.1) 
MuG 
Table 3.1: OpenNebula cloud infrastructures 
 
〕  OpenStack 
OpenStack is designed to control large pools of computing, storage, and networking 
infrastructure resources to create a massively scalable, flexible cloud platform of private 
and public IaaS architectures. It consists of a series of interrelated open source software 
projects that provide both, core services, and a catalog of pluggable advanced cloud tooling. 
A minimal OpenStack installation could include: Keystone (Authentication Service), Glance 
(Image Service), Nova (Compute Service), Neutron (Network Service), Horizon (Dashboard 
Service), Cinder (Block Storage) and Swift (Object Storage). 
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OpenStack offers a full ecosystem of RESTful APIs to programmatically control these 
services, and likewise OpenNebula, some non-proprietary interfaces are also supported, 
including the OCCI standard. The graphical UI is organized in “tenancies”, groups of users 
and resources that manage their own templates, images and networks. They even might 
have a separated pool of resources. In terms of virtualization, KVM, QEMU, Xen, LXC, 
VMware vSphere, Hyper-V are supported. 
Part of the work presented here is underpinned by an OpenStack tenancy requested to the 
Embassy Cloud. Hosted by the European Bioinformatics Institute at the European Molecular 
Biology Laboratory (EMBL-EBI), the infrastructure is externally managed, unlike the above-
mentioned infrastructures. The Embassy Cloud provides IaaS to multiple tenants (e.g. 
researchers, scientific projects and institutions, etc.) from the life science domain. EMBL-
EBI features more than 4,000 cores and three petabytes of storage, with the interesting 
added value of being co-located with some of the most relevant European biomolecular 
databases (i.e. most of ELIXIR core data resources are physically hosted there, for example, 
ArrayExpress [9], PDB [5], etc.). So, even considering that the network cloud is logically 
isolated from EBI’s LAN, the mobilization of such reference data could be efficiently 
handled. Storage is also based on a shared NFS file system (under tenants’ petition), but 
some quota for object store is also offered (provided by OpenStack  Cinder storage [202]). 
The following table details the specifications of our EMBASSY tenancy: 
Name Cores Memory Storage System Network Project 
EMBASSY Tenancy 
(EMBL-EBI)  
16Gb 64 Gb RAM - 1Tb Object storage (CINDER) 
- NFS under request 
- 2 floating public IPs 
- Internal VLAN 
MuG  
Table 3.2: Cluster details of MuG development’s cloud 
 
 Provisioning Tools 
Provisioning implies the deployment and configuration of virtual appliances in a cloud 
environment. CMPs are those above-presented permit serf-service provisioning, although 
there is an increasing number of tools automatizing the process (see 1.4.3.4 introduction’s 
section). For the infrastructures presented here, provisioning is managed by one of the two 
tools hereafter described.   
〕  PMES 
Programming Model Enactment Service (PMES) allows the remote deployment and job 
management of computing virtualized services in distributed infrastructures. PMES offers a 
standard REST interface to manage VM provisioning in a uniform and elastic manner, hiding 
in this way the heterogeneities of the underlining cloud stack. Indeed, it goes beyond and 
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controls the full-service lifecycle of pre-emptible stateless VMs that act as compute units. 
Sequentially, stages are the (i) deployment of the appliance, (ii) stage in data, (iii) execution 
invocation and monitoring of the application of interest, (iv) stage out data, and eventually 
(v) un-deployment of the VM(s). Cloud provisioning tasks are undergone via the cloud 
standard OCCI (below detailed at 3.2 Open standards), which mediates PMES interactions 
with the cloud infrastructure. Thus, OCCI compliant CMPs are a requirement. The 
communication of PMES with the transient VMs is enabled via SSH using a pair of public 
keys adequately contextualized at boot time. FTP is used for data transferences, which 
permits not only the dispatching of input and output files, but also the transference of a JAR 
file containing the actual application to be executed. As such, VMs can automatically be 
provisioned with the software at boot time. 
Here, PMES is installed in two different cloud middlewares, OpenNebula and OpenStack. 
For each IaaS a stand-alone server is installed as a permanent virtual machine, accessible 
for outside the local VLAN. Two PMES components are part of that server: 
- PMES service: deployed as a Tomcat 7 [203] application 
- PMES dashboard service: NodeJS [204] application deployed  using mp2 [205]  
The installation requires the specification of the compute node resources available and 
importantly, the cloud rOCCI endpoint. Full documentation of the installation process can 
be found annexed at 8.6.1 PMES documentation. PMES service exposes two APIs 
implementations, one SOAP-based (documented online [206]), used in the transPLANT 
infrastructure, the other enabled in REST and used in openVRE platforms (documentation 
annexed at 8.6.2PMES documentation). APIs are compliant with two well-known open 
standards inherited from grid computing, BES and JSDL (further discussed below at 3.2). 
〕  OneFlow 
OneFlow is the key component of OpenNebula to build scalable services. It creates, controls 
and monitors services – composed by a single VM or a group of them – self-provisioning 
them in basis to (i) deployment dependencies between the group of VMs, (ii) elasticity 
policies. These policies establish the triggering parameters that make OneFlow scale up or 
down the number of running VMs for a given service. Interestingly, the CPU or MEM load 
of the VMs can be set as triggering parameters, thus, in front of load burst, OneFlow 
automatically makes available extra instances. OneFlow is installed as part of OneNebula, 
implemented as one of its add-ons.  
 Contextualization 
A context is a small, usually human-readable, snippet that is used to apply a role to a VM. It 
contains the relevant information from the cloud manager to configure that role at the “first 
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boot”. Hence, a context allows having a single VMI backing many different VM instances as 
long as the instances vary on settings able to be configured in the context. Considering we 
have a catalog of VMIs pre-packing bioinformatics tools, we can concurrently instantiate a 
VMI several times, each contextualized with the particular needs of that run. Typically, 
contextualization is useful for setting configurations not known until instantiation, like DNS, 
hostname, private information like user’s SSH keys or personal data volumes, or software 
that changes frequently with discrete user-defined commands.  
CONTEXT=[ 
  PUBLIC_IP="192.168.11.247”,                                                         . 
  DNS="192.168.0.202", 
  GATEWAY = "192.168.11.202", 
  MAC = "02:00:c0:a8:0b:f7", 
  MASK = "255.255.255.0", 
  SEARCH_DOMAIN = "vm.mmb.pcb.ub.es", 
  SSH_KEY="ssh-rsa AAAAB3NzaC1yc2EAAAA[...]Q/I0w== pmes@mmb", 
  HOSTNAME = "mg-192.168.11.247", 
  USER_DATA=" 
    #cloud-config 
     packages: [] 
     mounts: 
     - [vdc,none,swap,sw,0,0] 
     runcmd: 
     - echo 'Success' | wall” 
] 
Snippet 3.2 :  Example of OpenNebula context information prepared to be consumed by cloud-init 
CMPs, either OpenNebula or OpenStack, are responsible to pass the context information 
into the newly created VM. Each CMP enables different methods to do so. OpenNebula 
parametrize VMs by a iso 9660 CD-ROM image, which contains a shell script (context.sh) 
with custom variables defined on virtual machine start.  Snippet 3.2 is an example of that 
information transmitted by OpenNebula and ready to be consumed by the 
contextualization package installed at the VM. There are no fixed contextualization 
variables, and are in charge of integrating them and locally configuring the instance 
accordingly. OpenStack sends the information to a metadata server configured to serve up 
vendor data in a JSON object. Contextualization packages will reach it from there. 
During the present work, two different contextualization systems are used to achieve very 
similar parameterization tasks, yet One-context is specific for instances deployed with 
OpenNebula, while Cloud-init supports several CMPs. 
〕  One-context 
One-context is an add-on that provides contextualization packages for most Linux 
distributions (and, other Unix-like) on guest VMs or Linux containers running in the 
OpenNebula cloud. Packages are able to read context variables and prepare, accordingly, 
the networking in the running guest operating system, configure SSH keys, set passwords, 
run custom start scripts, and many others functionalities. Some of these functionalities are 
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OpenNebula-specific, like passing token-based credentials of OneGate, an OpenNebula 
module to enable authentication among VMs. 
We used One-context as part of the transPLANT VMIs (see 4.2. Results). We installed the 
corresponding DEB package (v. 5.7.0) into Ubuntu 14.04 LTS images, before importing them 
into the OpenNebula as QCOW2 images. On the other hand, OpenNebula templates need 
to be configured as Snippet 3.2 exemplifies. The system is easy to be installed and 
configured, and USER_DATA is passed as opaque key-value metadata to the VM with no 
major restrictions. However, One-context can only be used for OpenNebula IaaS.  
〕  Cloud-init 
Although few cloud open standards are still well-established, cloud-init is becoming the 
standard de facto for contextualization. Similarly to One-context, Cloud-init is used for 
actions on “first boot”, pre- and post- networking, and USER_DATA section permits also 
some post-boot configuration by means of YAML scripts. However, the most remarkable 
feature of Cloud-init is its interoperability. It provides connectors (“datasources”) for the 
most popular CMPs, including OpenNebula, OpenStack, Amazon EC2 or Azure. 
As such, VMIs with Cloud-init are ready to be portable among different cloud providers with 
no need of further configurations or conversions, a relevant feature exploited at MuG 
infrastructures, as discussed at 4.3. Results. Cloud-init (v. 0.7.5.) is installed in MuG VMIs 
and configured accordingly, choosing the correct “Datasource” and configuring some 
network details as Cloud-init demands them, like determined interface names or settings. 
 Job Managers 
Presented infrastructures propose several strategies on how to distribute and manage jobs 
across the available resources. Following are described two different components involved 
in job management: COMPSs, a job orchestrator for distributed environments, and SGE, a 
classic batch queue system. 
 COMPSs 
COMP Superscalar (COMPSs) is a programming model designed to ease the development 
of applications for distributed infrastructures (e.g. Clusters, Grids, and Clouds). To this end, 
COMPSs features a runtime system able to discover applications’ parallelism of at execution 
time and dynamically distribute the tasks. 
COMPSs hides parallelization complexities to developers so that programmers do not need 
to deal with the duties of parallelization, such as thread creation and synchronization, data 
distribution, messaging or fault tolerance. Instead, COMPSs is based on user’s sequential 
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programming, which makes it appealing to users that either lack parallel programming 
expertise or are looking for better programmability. User’s Java applications are directly 
supported by COMPSs runtime, while exists binding for other languages like Python, 
pyCOMPSs. Although programming is sequential, execution is parallel, since at run time 
COMPSs builds a workflow composed by the tasks of the application, which are connected 
through edges that denote data dependencies between them, and determined by 
annotations specifying the needs of each task. From this workflow, the COMPSs runtime is 
able to execute different application tasks at a time within a master-workers architecture 
(Figure 3.1). In this scenario, the user submits its application to the master node, which 
orchestrates the parallelization and launches the tasks in the available resources, 
distributing the input data and collecting the results. 
PMES and COMPSs form a good tandem for enabling virtual elastic compute clusters. At 
execution time, when COMPSs tasks demand extra resources, the master schedule extra 
jobs in a queue system, or provisions extra VMs on the cloud, elastically demanding the 
resources according to the specific needs of the execution. PMES server provisions these 
VMs, which become COMPSs workers and remotely start user’s execution. 
 
 
 
 
 
 
 
 Sun Grid Engine (SGE) 
Sun Grid Engine, originally developed by Sun Microsystems and now maintained by Oracle, 
is a resource management system for executing UNIX batch jobs (shell scripts) on a pool of 
cooperating resources, usually distributed and heterogeneous. SGE is typically used on HPC 
or cluster infrastructures, and is responsible for accepting, scheduling, dispatching, and 
managing the remote and distributed execution of large numbers of standalone, parallel or 
interactive user jobs. The workload is distributed among the resources based on the load 
situation of each machine and the resource requirements of the jobs. 
A typical Grid Engine cluster consists of a master host and one or more execution hosts 
accessible over the network. Multiple shadow masters can also be configured as hot spares, 
which take over the role of the master when the original master host crashes. In cloud 
Figure 3.1:  Elastic virtual clouds in COMPS and PMES  
(a) Architecture of task distribution in COMPSs. (b) COMPSs deployment on cloud with PMES deployments 
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computing, execution hosts correspond to VMs, thus, SGE acts as local on-demand 
resource VM scheduler. In this way, a virtual SGE cluster is built on top of the cloud, 
connected over the private cloud VLAN. SGE has an implementation in Nimbus and Amazon 
EC2 cloud on Hadoop nodes.  
 Authentication 
 Keycloak 
Keycloak [207] is an open-source Identity Access Management (IAM) server developed and 
maintained by the RedHat Community. It offers a broad set of authentication and 
authorization services to make easy to secure applications and services. Most relevant 
services are: 
- centralized authentication and authorization using a local MySQL or LDAP 
- centralized user management for the multi-tenant environment – (multiple realm user 
spaces) 
- two-factor authentication using a one-time password 
- brokering identity with OpenID Connect (OIDC) or SAML Identity Providers (e.g. Elixir 
AAI).  
- Single-Sign-On using OIDC 
OIDC is built on top of OAuth2, a set of token-based authentication flows widely used for 
REST services (implicit flow) and Web applications (authorization code flow). In short, at the 
implicit flow, the authentication server, here Keycloak, issues an access token to the user, 
which is submitted as part of the request header to the RESTful server. The latter validates 
the token against the Keycloak to ensure user’s identify. If it results validated, the REST 
server returns the appropriate response to the user. In the Authorization Code flow, the 
OAuth2 dialog is slightly different, as first the web application needs to get a code to interact 
with the Keycloak server on behalf of the user. 
For those applications or services serving protected resources, Keycloak supports fine-
grained authorization policies and is able to combine different access control mechanisms 
such as attribute-based, role-based and group-based. 
 LDAP 
One of the de facto standards for storing and querying authentication and authorization 
data is the Lightweight Directory Access Protocol (LDAP) — it can conveniently store 
passwords and handle authentication data. LDAP is a lightweight client-server 
authentication protocol used to access centrally stored information over any location in the 
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network. It is mostly used as the data backend for centralized authentication systems to 
consolidate information of the entire organization into a central repository, which 
additionally, supports TLS certificates for data protection. 
The solution is able to integrate and centralize user account management of Linux POSIX or 
Samba accounts. In transPLANT, the LDAP open source OpenLDAP [208] implementation is 
used to centralize authentication for transPLANT services (further discussed in Results 
section at  4.2.2.4 Authentication).  
 Summary of web applications 
The following table summarizes all web applications implemented as part of this work and 
will be discussed in context with the infrastructure they are designed for.  
 Project Frontend Application Dependencies Data tier 
IMID-clinica 
4.1 Data 
management’s 
infrastructure for 
IMIDs’ research 
HTML, PHP, 
JavaScript 
PHP (v5.2) 
- Egroupware 5.2 
MySQL 
IMID-Longitudinal 
HTML, PHP, 
JavaScript 
PHP (v5.6) 
 
MySQL 
DataManager 
4.2 transPLANT: 
trans-national 
Infrastructure for 
Plant Genomic 
Science 
HTML, PHP, 
JavaScript 
PHP (v5.6) 
 
File 
system/FTP 
MuGVRE 
4.3 MuG: 
Multiscale Complex 
Genomics VRE 
HTML, PHP, 
JavaScript 
PHP (v5.6) 
- League/oauth2-client 2.4 
- Justinrainbow/json-
schema 5.2 
- Multiscalegenomics/mg-
rest-dm 
- Mongo PHP driver 1.3.x 
Mongodb 
openVRE 
4.4 Open Virtual 
Research 
Environment 
HTML, PHP, 
JavaScript 
PHP (v7.2) 
- Auth0/auth0-php 5.0 
- Justinrainbow/json-
schema 5.2 
- League/oauth2-google 2.0 
- slim/slim 3.0 
- Mongo PHP driver 1.3.x 
Mongodb 
OEB-VRE 
HTML, PHP, 
JavaScript 
PHP (v7.2) Mongodb 
Table 3.3: List of developed web applications and its dependencies 
 
 
 Open standards 
Standardization of data formats, protocol messages, and interfaces is an important aspect 
of execution environment interoperability. For task-based frameworks on distributed 
environments, the following three proposed standards are relevant. 
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 Open Cloud Computing Interface (OCCI) 
The Open Grid Forum (OGF) has proposed the Open Cloud Computing Interface (OCCI) 
[99] as an open standard defining a RESTful API for managing cloud appliances. It has been 
one of the first standards in the cloud ecosystem and covers the basic management tasks 
for Infrastructure as a Service (IaaS) providers by means of a set interoperable REST 
endpoints that remove any kind of vendor lock-in effect in the infrastructure. In summary, 
supported operations consist on managing the compute instances (create, delete, start, 
etc.), network basics (attach/detach network) and block storage (create, delete, 
attach/detach) [209]. 
Currently, some OCCI implementations already exist for several cloud vendors like 
OpenStack, OpenNebula, Jcloud, Eucalyptus or EMOTIVE. However, OCCI is implemented in 
the form of general-purpose frameworks that can be extended with several back-ends, for 
instance, OCCI-Libvirt, which implements the interface on top of the virtualization toolkit, o 
pyOCNI, which implements OCCI with a networking extension. The most popular 
implementation is rOCCI [210]. Written in Ruby, it delivers an rOCCI-server and a r-OCCI-cli 
implementation. The rOCCI-server component stands as a standalone server that proxies 
the requests to the underlying cloud management framework (Figure 3.2). Indeed, some 
OCCI-enabled stacks like OpenNebula and OpenStack took such approach. On the other 
hand, rOCCI-cli is the client component that makes possible to interact with any OCCI-
enabled framework. PMES makes use of it. 
 
 
 
 
 
 
 
 
The following snippet is a simple example of how to create a compute instance using the 
rOCCI client.  It indicates the cloud OCCI endpoint and user’s X509 credentials, together with 
two templates containing the details of the instance: 
- Image template (os_tpl): corresponds to VM template as registered in the CMP 
(see above 3.1.2.1 OpenNebula and OpenStack). 
Figure 3.2 r-OCCI server in a typical setup with OpenNebula. 
PMES server is a OCCI client 
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- Resource template (resource_tpl): corresponds to a simpler template indicating 
only (i) cores, (ii) memory and (iii) local disk (e.g. “small” template - 1 core and 2 
GB RAM). OCCI server maintains the registry of these templates. If the image 
template contains any of these parameters, they are ignored. 
-  
occi --endpoint https://extcloud05.ebi.ac.uk:8787/occi1.1 
     --action create 
     --resource compute 
     --mixin os_tpl #54_mugTool 
     --mixin resource_tpl #small 
     --context user_data= file://$PWD/tmpEBI.json 
     --auth x509 
     --user-cred /tmp/pmes.x509 
  
> RESPONSE 
> https://extcloud05.ebi.ac.uk:8787/occi1.1/compute/2048be92-dce8-1fd7babcd1ba        . 
Snippet 3.3 Virtual machine creation using rOCCI client 
 
 Basic Execution Service (BES) 
The OGF has purposed the Basic Execution Service (BES) [59] specification as the standard 
interface for job management across different distributed environments. This specification 
is defined as a Web Service implementation in terms of a WSDL document for creating, 
monitoring and managing computational jobs, called activities. There is already some solid 
implementation of BES, all belonging to the Grid computing environment like Globus Toolkit 
[52] or UNICORE [53], and EGI is using a RESTful implementation of it [211].  
Activities are represented using JDSL (described in the following section) and are identified 
using Web Services address endpoint references.  When a client submits an activity to the 
BES server, an endpoint reference is obtained in result, which is later used in invocations to 
refer to that particular activity. BES also defines an extensible state model defining the 
states that an activity can pass through during execution: pending, running, terminated, 
failed, finished. Briefly, the basic operations considered are: 
Operation Description 
Create activity Creates and submits an activity to the infrastructure. 
Terminate activity Terminates a previously created activity. 
Get activity status Retrieves the status of the activity (e.g. running, failed, etc.) 
Get activity documents 
Gets the activity documents of an activity giving the: JSDLs [58], jobs status, 
execution progress, elapsed time and error messages. 
Table 3.4: Operation descriptions of PMES web services 
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 Job Submission Description Language (JSDL) 
Job Submission Description Language (JSDL) [58]  is an extensible XML specification from 
the Global Grid Forum (GGF) for the description of simple tasks to non-interactive 
computer execution systems. Currently at version 1.0, it is a verbose, yet straightforward 
language for defining application’s requirements and the submission preferences. It 
includes aspects of a job as:  
- Job name, description 
- Resource requirements that computers must have to be eligible for scheduling, such as 
total RAM available, total swap available, CPU clock speed, number of CPUs, Operating 
System, etc. 
- Execution limits, such as the maximum amount of CPU time, wallclock time, or memory 
that can be consumed. 
- File staging, or the transferring of files before or after execution. 
- Command to execute, including its command-line arguments, environment variables to 
define, stdin/stdout/stderr redirection, etc. 
The vocabulary and normative XML schema in use include this data, as exemplified in the 
following snippet: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
<JobDefinition 
 xmlns="http://schemas.ggf.org/jsdl/2005/11/jsdl" 
 xmlns:posix="http://schemas.ggf.org/jsdl/2005/11/jsdl-posix"> 
  <JobDescription> 
    <JobIdentification> 
      <JobName>Test job</JobName> 
    </JobIdentification> 
    <Application> 
      <posix:POSIXApplication> 
        <posix:Executable>/path/to/executable</posix:Executable> 
        <posix:Argument>arg1</posix:Argument> 
        <posix:Argument>arg2</posix:Argument> 
        <posix:Output>stdout.txt</posix:Output> 
        <posix:Error>stderr.txt</posix:Error> 
      </posix:POSIXApplication> 
    </Application> 
  </JobDescription> 
   <DataStaging> 
      <FileName>input_file.txt</FileName> 
      <CreationFlag>overwrite</CreationFlag> 
      <Source> 
        <URI>file:///local/path/to/input_file.txt</URI> 
      </Source> 
    </DataStaging> 
    <DataStaging> 
      <FileName>output_file1.txt</FileName> 
      <Target> 
        <URI>file:///group_workspaces/jasmin/some/path/to/save/outputs/</URI> 
      </Target> 
    </DataStaging> 
</JobDefinition> 
Snippet 3.4 Minimal JSDL file 
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JSDL is a well-established standard, particularly in grid computing, and systems like 
UNICORE, EMOTIVE cloud or IBM Tivoli support it. With these middlewares, interoperability 
with job schedulers and distributed resource managers. 
 
 Use Cases  
A couple of use cases are presented here to illustrate the functionalities of our 
infrastructures. Hereafter, the implementation details of the same are described. 
 Use case: plant genome annotation pipeline in 
MAKER 
transPlant infrastructure is populated with analysis tools and pipelines of interest for the 
plant genomics’ community. MAKER is one of them. Pre-packed in a VM, the following table 
describe the relevant software included as part of the pipeline. 
Software Description 
Maker (v2.28) [212] Genome annotation pipeline. Their tools identify repeats, aligns ESTs and proteins to a 
genome, produces ab initio gene predictions, and automatically synthesizes these data into 
gene annotations having evidence-based quality indices 
Exonerate (v2.2.0) 
[213] 
Splice-site aware alignment algorithm to realign, or polish, sequences following filtering and 
clustering 
Snap (v2006-07-28) 
[214] 
Ab initio gene prediction modelling 
Augustus (v2.5.5) 
[215] 
Gene-prediction algorithm that can be used to produce either ab initio or evidence-based 
predictions when provided with an external GFF3 file of EST and protein alignment data 
Blast (v2.2.28+) [216] Algorithm for comparing primary biological sequence information, such as the amino-acid 
sequences of proteins or the nucleotides of DNA and/or RNA sequences 
RepeatMasker 
(v1.295) [217] 
Screens DNA sequences for interspersed repeats and low complexity DNA sequences 
Tandem Repeats 
Finder (4.07b) [218] 
Finding tandem repeats which work without the need to specify either the pattern or 
pattern size 
Table 3.5: MAKER software dependencies 
 
Additionally, some test data is provided along with the implementation. It can be found at 
the transPLANT’s documentation page1 together with other tool’s documentation. 
- Maker configuration files: 
- maker_exe.ctl - contains the path information for the underlying executables.  
                                                     
 
1 http://transplantdb.bsc.es/documents/samples/ 
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- maker_bopt.ctl - contains filtering statistics for BLAST and Exonerate  
- maker_opt.ctl - contains all other information for MAKER, including the location of 
the input genome file.  
- Files referred into the configuration files: 
- dpp_contig.fasta: main pipeline input containing  DNA contigs in FASTA format 
- dpp_est.fasta: expressed sequence tags (ESTs) in FASTA format 
Full use case’s details are found at 4.2.4 Use case: plant genome annotation pipeline in 
MAKER. 
 Use case: Nucleosome Dynamics 
A second use case implemented as part of the MuG infrastructure is Nucleosome Dynamics 
[219], one of the tools populating the platform. For demonstrating how the method works 
in several genomic scenarios, three different MNAse-seq datasets extracted from the 
literature are used. These are made available at MuG platform under “Example Datasets”. 
- Cell-cycle dataset: MNase-seq data for S. cerevisiae cells synchronized in G1 and S 
phase as described at [220]. Raw data available under accession number 
SAMEA2698380. 
- Yeast metabolic dataset: MNase-seq data for two time points of the yeast metabolic 
cycle (YMC): T9 and T12, as described at [221]. Raw data downloaded from GEO under 
accession number GSE77631. 
- Nutrients change dataset: MNase-seq data for S. cerevisiae grown in different media 
(YPD, Gal and EtOH) [222]. Data aligned to sacCer1 downloaded from GEO using 
accession numbers GSM351492, GSM351493, and GSM351494. 
Full use case’s details are found at  4.3.4 Use case: Nucleosome Dynamics 
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This chapter presents in four separated sections the infrastructures developed 
along with the thesis under the frame of four scientific projects. Projects are 
shortly summarized to provide a context and motivation for the designed 
platforms. Architectures and components are described, stating for each case 
the candidate’s leading role in the design and/or implementation process, 
although, all the presented infrastructures are the result of group cooperation 
and team working.   
  
 Data management’s infrastructure for IMIDs’ 
research 
IMIDs stands for Immune-mediated inflammatory diseases. The work presented in the 
present section is focused on the electronic data capture (EDC) systems developed for two 
biomedical research studies of IMID patients: IMID-clinica and IMID-Longitudinal. 
The doctoral candidate has participated at the later stages of IMID-clinica project, focused 
on the extension of new features on the, at the moment, newly implanted system, as well 
as his administration and maintenance tasks to the day. In IMID-Longitudinal study, the 
candidate has been involved in the design of the clinical data acquisition system, the 
database modeling and the implementation of the EDC. 
 Context 
IMIDs are a group of inflammatory chronic diseases of unknown etymology highly 
prevalent in the general population (5-6%) and with a great impact on patient’s quality of 
life. Thus, IMIDs treatment incurs in elevated socio-sanitary expenses. Yet, they are 
multifactorial (environmental and heritable predisposition) diseases and with a very 
heterogeneous molecular pathogenesis: the most representative pathologies are systemic 
lupus erythematosus (LES), psoriasis (Ps), psoriatic arthritis (APs), arthritis rheumatoid (AR), 
ulcerative colitis (UC), Chron’s disease (EC). In the last few years, with the increasing 
availability of genomic data, Genome-Wide Association Studies (GWAS) have led to the 
identification of patient’s subgroups with specific molecular patterns and expression 
profiles. Moreover, association studies have shown predictive power over treatment’s 
responses, which more and more are biological therapies specifically designed for 
molecular targets that seeks the total disease’s remission. 
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Such objectives were pursuit by the two clinical studies presented in this work and led by 
the group of Immune-Mediated Diseases & Innovative Therapies at the Vall d’Hebron 
Institut de Recerca (VHIR): 
- IMID-clinica: Development of a kit diagnostic for IMID (PSE -10000-2006-6/PSE-
10000-2008-9). 
- IMID-longitudinal: IMID biomarkers identification and new therapies (INNPACTO: 
IPT-010000-2010-36.) 
Both projects (sequential in time) have proposed the data acquisition and curation of 
clinical, epidemiologic and serologic data in a multi-center approach across Spain. Our team 
at BSC has been in charge of developing and maintaining the clinical data infrastructure to 
support data gathering, storage, and validation. Corresponding biological samples are 
extracted to IMID patients by the Spanish IMID-Biobank, for later genomic analysis (mainly 
array-based genotyping). Such analyses, based on GWAS studies, have produced a number 
of fruitful results published on several research publications (see annex 0). 
 Motivation 
In genetic epidemiological research, the sample size is critical to the success of GWAS when 
detecting causal genes of common and complex multifactorial diseases like IMIDs. GWAS 
aims to identify the DNA allele variants (single nucleotide polymorphisms (SNPs)) that 
contribute to the disease’s risk, even those with low penetrance, shown abundantly in 
IMIDs.  Yet, sufficient statistical power is to be achieved in order to obtain significant signals. 
The collaboration and coordination among multiple health centers and hospitals have been 
a commonly chosen strategy to overcome the sample size effect. However, cross-
organizational data integration raises up standardization, validation and curation 
challenges that need to be accurately addressed for an agreed clinical data management 
plan among the participant centers to ensure true progress monitoring and high-quality and 
reliable research data. That is particularly relevant when potential data providers may not 
be familiar with data curation best practices, as they mainly belong to the assistance 
services of the participant health centers and hospitals. 
he diverse nature of the different IMIDs adds an extra layer of data heterogeneity, requiring 
not only the integration of different medical sources (e.g. images, raw medical record files) 
but also a set of very diverse clinical variables difficult to be compared among them, with 
different biomarkers, dictionaries, etc. However, one of the requirements of the project 
was precisely the integration of such diverse data types in a single platform. 
Furthermore, the implemented strategy should allow a rapid and flexible edition of case 
report forms (CRFs), as clinical variables are in constant change and reedition – new 
therapies, new serology tests, new formats, etc. The system should also enable easy 
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integration of completely new CRFs additively. Furthermore, the nature and purpose of data 
collection in clinical research can easily evolve during the analysis phase, and the data 
acquisition process can be costly and slow, so it is important to maximize the amount of 
collected data, for instance, by setting quality controls with protocols that do not interfere 
or prevent in the registration process.  
Safeguarding data privacy in another critical requirement for infrastructures dealing with 
biomedical data, still, maximizing research results to the possible extent.  IMID-clinica and 
IMID-Longitudinal are cohort studies that translate data from the healthcare system to the 
research environment, so the framework has to adopt the Ethical Legal Social Implications 
(ELSI) and contractual aspects described in the data management plan. 
 Data Management 
Traditionally, the standard method of data capture in clinical and translational projects 
includes two steps. In the first step, data is collected using paper-based case report forms 
(CRFs). In the second step, data is manually entered into electronic databases from paper-
based CRFs for the purpose of data analysis. This standard paper-based data capture 
method is inefficient in terms of data accuracy and timeliness, so as an alternative, the 
electronic data capture (EDC) method propose to directly enter into electronic databases 
using electronic CRFs. CRF define the model of data and other information collected on each 
subject participating in the study. These are paper-based and agreed among the IMID 
consortium medical committees. They include epidemiological data (e.g. lifestyle variables), 
clinical data (e.g. family history) and serological data (e.g. antigenic serology). 
The clinical data management plan (DMP) of the IMID’s consortium covers from the Case 
Report Form (CRF) design phase to the clinical database locking after data assessment. 
Certification authorities granted it ISO 9001:2008 and ISO:2012. Both studies, IMID-clinica 
and IMID-Longitudinal, follow similar governance’s plans (Figure 4.1)., primarily 
differentiated on the actors entrusted to perform some of the defined tasks. The online 
system developed here is designed to support clinicians, data managers and epidemiologic 
researchers in the different steps defined at IMID’s DMP. 
Our team at BSC was in charge of designing and providing the online systems to efficiently 
support the clinical data acquisition process from the different healthcare centers, i.e. 
developing the electronic data capture (EDC) software and the clinical database. The first 
task is the creation of the electronic CRF translated from the paper-based model to become 
part of the database. EDC’s administrator and maintainer are in charge of registering the 
clinical variables and preparing the corresponding web forms. 
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The actual data entry of patients’ information uses such online web forms, which include 
validating tools that enable a first automatic quality control to check for data completeness 
and even data coherence. Yet, the responsibility of such a task falls on different actors when 
comparing IMID-clinica and IMID-Longitudinal data governance. In the IMID-clinica study, 
data providers, i.e. participating healthcare centers, feed the data into the online system, 
and even two roles are defined in each centre (“centre coordinator” and “user”) to further 
control data registry. In IMID-Longitudinal, the project designates a centralized group of 
data curators who gather filled-in CRFs in paper from the participating centres and perform 
the data registration. Such distinction weights differently the relevance of some EDCs 
functionalities like data validation assistance.  Anyhow, in order to ensure the high-quality 
of the resulting clinical data, a clinical data manager figure is made indispensable. He/she 
audits the overall data, case by case, and ensures conflicts resolution, data discrepancy.  
EDCs also recognize this role and propose a set of tools to aid the coordinator in their 
monitoring tasks. 
Finally, to complete data’s cycle, EDCs provides extraction data options, at both, case and 
database level. After obtaining the consent from all the parts, the database is locked, and 
clean data can be extracted for statistical analysis. 
Figure 4.1: General process data flow in IMIDs project 
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 IMID-clinica 
IMID-clinica2 is the web-based EDC system designed to store multi-center clinical data from 
observational cohort studies with cross-sectional data (analysis at a specific point in time). 
The instance in production hosts the clinical and epidemiological data, and since 2010, when 
the first prototype was released, has been collecting data from of up to 90 centers of the 
Spanish National Healthcare System. The data, cross-linked with genotyped samples from 
IMID biobank, is consumed by the IMID consortium. 
IMIDs Systemic lupus erythematosus, psoriasis, psoriatic arthritis, 
arthritis rheumatoid, ulcerative cholitis, Chron’s disease 
Cases 12,173 patients ( + 2,130 controls) 
Centers 82 (whole list can be found in 8.1 Participant centers of IMID’s 
clinical studies) 
Table 4.1: Summary of IMID-clinica case study 
 
User’s perspective  
IMID-clinica offers a friendly and intuitive user interface (UI) for the CRF data collection and 
validation from centers and hospitals. IMID-clinica is implemented on top of the 
Egroupware [223][223][223][222][221][220][219] framework, a collaborative software that 
provides out-of-the-box plugins (e.g. contact list applications, shared calendars, wikis, etc) 
and allows the integration of additional tools. IMID-clinica PHP web application was 
integrated into the framework. 
 
 
 
 
 
 
 
 
                                                     
 
2 https://IMIDkitclinica.bsc.es    (*) Due to data privacy requirements access is restricted to authorized users 
Figure 4.2: Snapshot of IMID-clinica online form 
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The application is in Spanish and structured hierarchically, along with the data, as Pathology 
> Centre > Clinical Cases > Clinical Data. From user’s perspective, the most relevant views 
are those displaying the electronical CRF of each pathology study (Figure 4.2). These are 
accessible as online HTML forms when registering a new IMID clinical case on the system. 
After clinical fields are filled in, an automatic validation at type level (e.g. “date” format type 
or integer/string type) takes place, and it prevents data storage unless the indicated fields 
are fixed. 
The EDC system provides also tools and views designed to support data manager’s tasks. 
Tables at case, centre or pathology level are very useful from monitoring. In them, metrics 
for data monitoring are displayed: statistics on the completeness and unresolved issues per 
case; plots with number of completed cases per centre or pathology; etc. Moreover, the 
locking case system (data modification disabled), only permitted to privileged users, allows 
to have a fine grain control of verified and audited data. Finally, a powerful querying system 
enables an advanced filtering which allows to set search criteria on every clinical field of the 
database and even combine them with logical operators.  
And last but not least, another relevant aspect of the application is the high degree of 
adaptability in front of new CRFs. When a study for a new pathology is to be included in the 
system, the administration only needs to prepare a set of HTML templates containing all 
the new clinical fields as they are to be displayed on the online web form. Templates are 
pure HTML (including JavaScript snippets when necessary) except for specific tags that are 
to be placed where the HTML input fields (e.g. “text box”, “drop down selector”) are 
expected. Such tags should indicate the name of the variable, the type, and the default 
value (if any). The application features an importing tool to load these HTML templates and 
creates the corresponding entries on the database. 
These were the initially implemented core features of IMID-clinica, which along the 
project’s lifetime have been continuously amended, improved or automatized, thanks to 
continuous feedback of clinicians and data managers. Additional functionalities have been 
implemented, for instance, a more exhaustive data quality control (QC) system for data 
discrepancy. Such process is also applied on each “Save” request, but unlike the type-based 
validation, it allows data registration. To notify discrepancies, the system raises persistent 
queries (i.e. errors) displayed with comprehensive alert messages (Figure 4.3 shows as 
alert’s example) that are accountable and monitored across the platform not only by the 
user, but also the clinical data manager coordinator. The system reports on non-coherent 
or uncompleted clinical variables, that are the main data quality affectations. These are 
detected thanks to an advanced set of dependency and exclusion rules, listed in Table 4.2. 
These rules are individually set up for each field (or group of fields) when first time 
annotating the CRF on the system (e.g. field “α-TNF” cannot be “>1” if field “anti-TNF 
therapy” is TRUE). The resolution of such queries is mainly handled outside the system, 
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establishing a direct communication (e.g. email) between the data manager and hospital’s 
data providers. Indeed, the application is able to export query lists (among other data) as 
DOC or PDF files. 
Id. Rule  Message 
1 Variable (or group of variables) is compulsory  - Field [VAR_NAME] is required 
- The following fields are required: [VAR_NAME], […] 
2 Variable(s) is compulsory if its Boolean master variable is 
evaluated as true. Reverse applicable. 
- Field [VAR_NAME] is required in [MASTER_NAME] 
- Field [VAR_NAME] cannot without [MASTER_NAME] 
3 At least one variable in the group is compulsory if its 
master variable is defined 
- Section [MASTER_NAME]  requires more 
specifications 
4 Special rule applying to a particular group of 
interconnected variables conveniently defined together 
- At therapy [VAR_NAME] table [VAR_A] requires to 
be defined while [VAR_B] or [VAR_C] are set 
7 Variable is required if a logical expression is evaluated as 
TRUE. Reverse applicable 
- Field [VAR_NAME] is compulsory because [VAR_A] 
has a value greater than [VAR_C] 
Table 4.2 Rules applied for the Quality Control data 
 
 
 IMID-Longitudinal 
IMID-Longitudinal is a complete web-based EDC system designed for observational cohort 
studies with follow-up data – those longitudinal analyses that collects data on the same 
individual at different times along treatment. The system was first released at 2012, and 
since then, it is being used to collect data at the VHIR. The inclusion of time-based data 
itemsis where the analysis model most differs from IMID-clinica’s. Data from the same six 
IMIDs is collected at different disease stages: first visit (S0), week 12 after first visit (S12), 
disease remission (RE), treatment withdraw (SRTB), etc. (Table 4.3). 
Differences aside, most of core functionalities of IMID-clinica’s system are also in used and 
adapted for IMID-Longitudinal study, like data QC toolkit, or template’s strategy for CRF 
integration that avoid a study-specific database design. Application’s model is also 
structured hierarchically, here as: Study > Pathology > Health Centre > Disease Stage > 
Clinical Cases > Donations > Clinical Data. A “Case” refers to a patient’s data, while a 
“Donation” to a patient’s data on a given time checkpoint. 
The data collection period is still active, yet, already 103 centres of the Spanish National 
Healthcare System are engaged. The web application is only accessible inside VHIR lab 
premises, where data entry is centralized. Interestingly, the distributed approach used in 
IMID-clinica was changed to an centralized one in this second project.  Yet, the testing 
prototype, with demonstration data, can be visited3. 
                                                     
 
3 https://inb.bsc.es/Innpacto/ 
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IMIDs Systemic lupus erythematosus, psoriasis, psoriatic arthritis, 
arthritis rheumatoid, ulcerative cholitis, Chron’s disease 
Study Stages - First Visit (S0), Week 12 (S12), Week 24 (S24), Week 104 
(S104), … 
- Disease relapse (SE), remission (SRM), 4 weeks after remission 
(SRM4), therapy Withdraw (SRTB), Reactivation (SF), … 
Cases 983 patients. Still collecting data 
Centers 93 (listed in 8.1 Participant centers of IMID’s clinical studies) 
Table 4.3: Summary of IMID-longitudinal case study 
 
User’s perspective  
The EDC for IMID-longitudinal features a completely new user interface (UI). It is 
implemented as a server-side PHP web application that enables the data entry from the 
different centers and hospitals, while keeping in view the flexibility and control restrictions 
stated by project’s data management. It permits an agile navigation through the different 
data structures.  
IMID-Longitudinal’s main page offers a menu for either inserting a new donation or 
navigating among registered data (e.g. other donations, cases, centers, stages, pathologies). 
When creating a new donation, clinician already knows its identifier (which is assigned at 
consortium’s level), and the insertion creates an empty record in “on tracking” mode, for 
the selected clinical stage (e.g. first visit – S0). The CRF is displayed online, segmented in 
sections that are gradually stored while navigating from one division to the next (Figure 
4.3). CRF donations become locked when the data coordinator sets them as monitored (see 
Figure 4.4, shown them as green balls). If all the donations of a clinical case are positively 
monitored, the full case can be locked (mode “closed”), although other modes are 
contemplated to have a better control of case’s statues (e.g.” discontinued case”, “exitus 
case”, etc.). 
When displaying the general view of a patient’s case and its donations, only those clinical 
stages relevant for the given case are shown as available on the application. Such availability 
depends on each case and pathology. Thus, each pathology evaluates their patients at 
different time checkpoints (e.g. Week 12 (S12)). Besides, during these routine checkpoints, 
clinicians might discover a clinical change (e.g. disease’s remission RE) or decide on another 
therapy (i.e. therapy withdraw (SRTB)). In such cases, routine CRFs are disabled in favor to 
the specific CRFs for these clinical stages, which might have exclusive or dependence 
relationships (e.g. a case cannot have a “Reactivation” stage prior a “Remission” stage).  
Figure 4.4 shows case donations as a collection of colored balls coding availability and 
monitoring state.  
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Data validation tools were extended and further improved respect to IMID-clinica in order 
to offer a complete query’s resolution pipeline. Now, the validation based on data types 
includes allowed ranges for numeric and date values, while strings can be evaluated against 
a simple pattern. Truly missing values (i.e not evaluable) are also now tagged to 
differentiate them from not completed fields. And the platform-wide alerts emitted when 
a query (i.e. error) is detected (Figure 4.3), are now fully registered to build provenance on 
issue’s resolution (Figure 4.4). Queries might be “closed” when resolved, or “re-opened” if 
needed, and data coordinators can “send” them to the health center. Besides, data 
managers can also create queries not associated with faulty clinical fields, but with custom 
messages that enable a dialog channel on the system with data providers. 
The EDC system provides also several overviews and metrics to control the data status at 
different levels (e.g. donations positively monitored for a certain case, or overall completed 
cases per center). Such views are controlled according to the user’s role. There are also 
views for comorbidity cases, as it is a frequent scenario among IMID pathologies. Finally, 
the integration of new CRFs follows the same strategy applied in IMID-clinica as described 
above (Section ).  
Figure 4.3: Snapshot of IMID-Longitudinal online form with un error. 
The data belong to donation code IB-101999-AC. The alert reflect that at least one option in section A.1 is to be selected.  
Results 
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Database and data model  
The project aimed to collect data from a large number of patients, during a long-term 
period, and of great diversity, as data comes from six different diseases with a large number 
of fields of different nature. Therefore, the project was articulated towards the generation 
of a generic phenotypic database, based on the relational database technology (MySQL). 
Opposite to the usual strategy in relational databases, the nature of the information stored 
in it is not part neither of the database’s structure nor the associated web application, 
allowing the storage of any clinical questionnaire without changes in the database 
structure.  
The database design implemented in IMID-Longitudinal is depicted in Figure 4.5.  As 
indicated, flexibility and adaptability in front of CRF changes is achieved by storing data 
definitions as part of the database content. The storage of the CRF for a pathology study 
corresponds mainly to two tables: “Defdato” and “Formulario”. The first contains all the 
defining information about clinical fields (e.g. field named “α -TNF” is of type “float” and 
belongs to form’s section “A” of disease “Artritis Reumatoide”), including dictionary’s 
Figure 4.4. Snapshot of query issue registry in IMID-Longitudinal for a donation. 
The donation (coded IB-101999-AC) has 5 queries, 3 of them unsolved. 
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references if the field can only take a fixed list of values. The latter, “Formulario”, simply 
groups the fields in sections (e.g. form section “A- Family History” belong to pathology 
“Artritis Reumatoide”), to match the structure of paper clinical questionnaires. This overall 
strategy allows to easily integrate new CRFs (i.e. new pathologies) into the system and to 
carry out the posterior analyses quite independently from the data structure. 
The overall study structure follows the study data model: Study > Pathology > Clinical Cases 
> Disease Stage > Clinical Data, which dictates the main data structures in the system. 
“Casos” retains the identification of the stored data for a certain patient, as well as the 
confirmation of its status (e.g. under track, complete) and external database identifiers (e.g. 
IMID-clinica). Each clinical case may contain one or more “Donaciones” (sample donations) 
extracted on a certain time point (disease stage) and associated to a BioBank’s sample. 
Finally, the “DatosClinicos” table hosts the actual clinical values introduced by the 
participating centers as simple key-value triples (e.g. in donation “00000”, the variable 
“anti-TNF” takes the “0.568” value). Such data is going to be the raw data for the statistical 
analyses. 
Additionally, the EDC relies on the database for other data or operational services. 
Discrepancy data management is based on the “oblig_field” table, where internal rulings 
(listed in Table 4.2) express fields dependencies and collisions. User’s administration is 
centred on “users” table, and keeps the registration ownership, along with the access 
control derived on user’s roles: “user”, “centre coordinator”, “coordinator”, 
“administrator”. Finally, the querying system also employs the database for storing user’s 
search parameters and results. 
Security and Authentication  
Authentication and authorization are internally managed at the application level, based on 
the data stored in the MySQL database. Different data controllers with different 
permissions on the data are set up, so that users are granted rights to either access, edit or 
block groups of data, i.e. at pathology or center level. As such, the following roles are 
created: administrator, data coordinator, center coordinator and plain user. 
The security in the IMID-longitudinal system comes with the design, as given the sensitive 
nature of the data, it is fragmented into several databases belonging to IMIDs’ consortium. 
IMID-longitudinal stores already anonymized epidemiological data. Only IMID-clinica 
identifiers and a correspondence with the BioBank identifiers are retained. Participant 
health centers are the ones that keep an internal registry of the relationship between the 
IMID-clinica identifier and the actual patient’s identity. Permissions to pursue the 
investigative actions of the IMID consortium are assured through a legal contractual 
consent signed by the patient. The legal document constraint not only the use of the 
donations and data, but also its accessibility and sharing. 
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Figure 4.5: IMID-Longitudinal database design 
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 transPLANT: trans-national Infrastructure for 
Plant Genomic Science 
This section describes the design and development of the research cloud we have built in 
the context of the transPLANT project, oriented to scientific computing and data analysis. 
Doctoral candidate has directly participated in the assembly, configuration and 
maintenance of the different infrastructure components described in the Cloud 
Architecture section, also developing complementary tools to ensure the completion of 
user’s data life-cycle. These involved the development of an FTP service, a web-based access 
for the same, and the configuration of an openLDAP/PAM authentication system. 
Additionally, the candidate prepared a catalog of Virtual Machine Images (VMIs) with the 
plant genomic tooling packed in. The last part of this section presents a use case that 
illustrates the platform’s mechanics.  
 Context 
Under the frame of the European transPLANT project (FP7-INFRASTRUCTURES, grant 
agreement ID: 283496) a complete computational infrastructure for plant’s genomics data 
it has been developed. The infrastructure should address the particular challenges and 
opportunities of the field. Compared with vertebrate genomes, plant genomes may be large 
and have complex evolutionary histories, which makes their analysis a hard problem, not 
only in scientific terms, but also for their compute and storage requirements. Issues include 
genome size, polyploidy, and the quantity, diversity and dispersed nature of data in need of 
integration. To address these problems, transPLANT has developed some solutions 
exploiting the expertise of the project’s partners to provide a set of computational and 
interactive services to the plant research community. The project has built new data 
repositories, implemented novel querying systems, or contributed to the development of 
distributed computing tools. 
We have designed the cloud environment intended to offer a virtual platform for 
programmatic and interactive access to applications of interest for plant genomics 
researchers.  
 Motivation 
Data size is definitely one of the challenges the plant genomics community is confronting, 
like any other community based on the high throughput sequencing techniques that have 
evocated us to the data-driven science. Hence, special care in the management of such 
amount of data is to be taken, as it no longer allows individual laboratories to keep their 
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own databases. Genomics data is normally produced in large scale sequencing centers that 
act as data providers, together with large computational facilities performing highly 
demanding operations like mapping or assembling genomes. However, primary analysis is 
just the initial phase. A fast-evolving domain-specific corpus of analysis tools should be 
applied to the sequencing data to obtain useful information, a process that usually requires 
a fairly significant amount of expert’s manual operations.  
The present paradigm of a large sequencing center side-to-side with large computational 
facilities cannot fulfill the necessary requirements to complete downstream analyses. Thus, 
data transmission becomes a bottleneck due to two main reasons, the size of the data, and 
also possible privacy requirements. An obvious strategy to minimize the requirements for 
data transmission is to move the analysis tools to the same infrastructure that holds the 
data. As introduced, virtualization and web services are enabling technologies for building 
remote and decentralized environments. transPLANT have chosen to exploit them to offer 
a portable and flexible computational platform for the plant’s community. 
A second requirement for genomics analysis has also been considered here. Day to day, 
more analytical power is required to process the ever-increasing genomics data. For 
instance, a sequence assembler designed for processing animal genomes, can become 
useless for newly sequenced plant genomes, like crops, whose model genomes were only 
completed during the last 5 years due their complicated scaffolding processes. The reason 
is not faulty assembly algorithms, but the amount of input data they are designed for, which 
following current trends lead to unrealistic memory or CPU time consumption. As discussed, 
HPC is the solution that offers a most efficient scalability, however, the development of 
specific HPC solutions require certain stability in methods and processing, as well as 
particular expertise on the part of the software developer. transPLANT decided in favor of 
a distributed system like cloud computing. It offers also access to scalable resources able to 
smooth the impact of data size, and with no need to use specifically compiled software. On 
top of that, multi-scalable programming solutions are also employed to optimize the use of 
such distributed and scalable resources. These are characterized to be able to run 
executions of the same algorithm in very diverse architectures, from personal workstations 
to HPC supercomputers or grid-based computers. 
Specifications 
- Portable and expandable analysis platform able to get adapted to novel analysis 
tools 
- Elastic and distributed computing backend ready to absorb the processing of 
important amounts of data 
- Multi-scale parallel algorithms for better exploiting distributed resources 
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 Cloud architecture 
As depicted in the vertical diagram of Figure 4.6, transPLANT computational infrastructure 
is offered as a PaaS, where the necessary tools to develop new plant genomic applications 
are provided. Hardware resources are dynamically managed using PMES and COMPSs (see 
3.1 Software components) in a way transparent to the user, on top of OCCI compliant cloud 
management platforms. From the researcher point of view, the platform follows a SaaS 
approach with a bench of prepacked virtualized applications well known in the plant 
genomics community. These are implemented as short-lived compute instances that act as 
private virtual environments automatically contextualized in terms of computational 
resources and accessible data.  
 
 
 
 
 
 
 
 
 
 
The diagram flow described in Figure 4.7 sequentially describes the natural chain of events 
occurring across transPLANT components:  
1- Researcher accesses transPLANT execution services on the Web through PMES 
dashboard, or programmatically via PMES SOAP API. 
2- Access requires authentication. transPLANT centralize user’s management in an 
internal LDAP server for all transPLANT services. 
3- Researcher selects the tool it is interested in and configures the parameters for the 
run: arguments, location of input data files, resources, etc. 
4- PMES enables the deployment of a transient virtual machine via OCCI.  
5- PMES controls the full application lifecycle and offers the information at user’s 
interfaces. Job monitoring information is obtained from the underlying CMP, in our 
testbed, OpenNebula. 
Figure 4.6: tranPLANT cloud architecture 
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6- In a similar way, PMES delegates into OpenNebula the job prioritization and 
allocation on the compute nodes. 
7- The actual deployment occurs after provisioning cloud resources. The VMI 
encapsulating the chosen genomic application is instantiated according to PMES job 
petition, which in turn, obeys to the configuration set up at PMES dashboard. 
8- Defined input data files are loaded via FTP into the VM. For those users without 
access to FTP storages, data can be loaded into the cloud using a separated web 
application, the transPLANT “Data Manager” (step 0).  
9- Once loaded, the actual execution takes places. PMES calls the application’s main 
executable, which could be either a standalone or a COMPSs application. The latter 
is able to create an elastic virtual cluster. 
10- After the application’s execution, generated output file data is transferred into the 
FTP server, and VM(s) are eliminated, freeing allocated resources. 
Figure 4.7: Process flow on the transplant cloud. 
JSDL: Job Submission Description Language; DSL: Domain Specific Language; CMP: Cloud Management Platform 
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Hereinafter, the section describes one by one infrastructure’s components here 
summarized, and how they interact to assemble the operable compute platform. They are 
classified as belonging to the IaaS, PaaS or SaaS layer. 
 Infrastructure as a Service 
As any cloud-based infrastructure, the platform is not ligated to a specific hardware 
architecture. It can be implemented in any computer cluster of homogeneous or 
heterogeneous nature. The minimum composition requires a single computer node, acting 
as front-end and administering the resources through a CMP that implements the OCCI 
computed standard API, e.g. OpenNebula or OpenStack. 
Since transPLANT itself did not provide computational resources, a testbed of the 
infrastructure is installed at the “INB Cloud” (see 3.1.2.1 OpenNebula for hardware details), 
hosted at the Barcelona Supercomputing Center (BSC). There, the infrastructure prototype 
is developed and tested, yet the resulting products intend to be totally portable.  
 Platform as a service 
〕  PMES Server 
PMES server (see 3.1.2.2 Provisioning Tools in Methods) is the core of transPLANT’s 
compute service. It enables the deployment of pre-emptible virtual machines in remotely 
distributed infrastructures by interacting with the OCCI interface of the corresponding cloud 
infrastructure. PMES exposes a REST unified standard interface that hides from the rest of 
the platform’s components the heterogeneity of the underlying infrastructure. PMES 
sequentially undertakes the following steps: 
I. instantiate the virtual appliance according to the requirements set up in the job 
definition 
II. contextualize the VM with Cloud-init; 
III. stage in input data, via FTP; 
IV. execute the application according to the arguments given by the researcher; 
V. stage out result data, via FTP; 
VI. undeploy the virtual appliance. 
The SaaS layer, either PMES API or PMES Dashboard, compose a job definition including 
what VMI is to be instantiated, how big it should be, which user or mounting point needs 
to be contextualized, where are the files to be staged in, and what are the arguments of the 
application. Along the whole job, PMES controls the appliance lifecycle as well as collects 
logging information from the guest OS, always via the OCCI interface who mediates the 
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communication with the CMP. As such, researcher tasks are executed as batch jobs 
remotely and in sandboxed optimized environments where computational resources are 
offered on-demand and exploited efficiently.  
〕  Tool’s virtual machines  
Virtual Images 
The collection of genomic tools, usually complex applications with a multitude of 
dependencies not always automatable, are encapsulated in VMIs fully compatible with 
most common cloud providers. We have prepared a base image (QCOW2 and OVA formats), 
with the transPLANT software stack installed in it. The OS guest of choice varies depending 
on the genomic software to be installed, yet, for most cases, it corresponds to an Ubuntu 
14.04 LTS. The disk image includes: 
- COMPSs task orchestrator (see 3.1.3 Job Managers) 
- One-Context contextualization package (see 3.1.2.3 Contextualization). It is 
parameterized at boot time to ensure PMES interaction with the freshly created VM. 
Following, are the required settings:  
- IP-based hostname, 
- local user with an associated home directory, 
- SSH public keys injection to enable password-less access to that user  
The whole catalog of transPLANT VMIs is prepared by installing the genomics’ tool of choice, 
mainly assembling pipelines, on top of this base image (tools listed in annex 8.2 transPLANT 
tools). Corresponding VMIs are imported in OpenNebula, although they are also distributed 
at the project site4, together with some documentation. 
Templates 
To be able to deploy these disk images into VM instances, cloud managers require some 
extra information. VM templates collect that. We have prepared for OpenNebula a VM 
template for each VMI tool. In fact, when the OCCI connector is used, VM templates are 
split into image templates and resource templates (see 3.2.1 Open standards). At the image 
template, the network settings are prepared.  A single NIC with a dynamic IP address is 
configured. The IP belongs to the selected virtual network, a dedicated VLAN that ensures 
isolation, and also manages the number of available leased addresses. Internet access is 
routed via the cloud frontend host, that acts as a gateway. If a temporary disk to increase 
runtime storage is to be attached, it is also defined in this step. On the other hand, at the 
                                                     
 
4 http://transplantdb.bsc.es/transPlantCloud_Apps.htm 
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resource templates, CPUs and RAM memory are set up.  The OCCI server of each IaaS offers 
an extensible list of resource templates (e.g. “small” - 1 core and 2 GB RAM). A valid 
combination of both, resource and image template, is defined when launching a PMES run.  
〕  COMPSs 
For those applications that natively do not feature parallelization (threads, MPI, etc.) or 
those encapsulating a pipeline potentially parallelizable, COMPSs (see 3.1.3 Job Managers) 
can be used to orchestrate their tasks and add scalability to the system. Along the execution, 
the workflow manager transparently and dynamically assigns resources to each of the tasks 
according to their computational needs. If tasks cannot be locally allocated on the VM, 
COMPSs runtime deploys worker VMs the allocate them. In this way, a user’s virtual cluster 
is dynamically created, the master machine by the initial PMES instantiation, and the worker 
nodes as replicas of that master (Figure 3.1). COMPSs fulfills the multiscale requirement 
indicated above, the same workflow definition could be executed in single workstations, in 
a large HPC facility or in a distributed grid, without modification. 
 Software as a Service 
〕  PMES API 
In order to programmatically manage the compute services of the transPLANT, PMES offers 
a set of SOAP-based web services (3.1.2.2 Provisioning Tools in Methods). The Java API 
implementation is compliant with the Basic Execution Service (BES) standard [59], a well-
known open standard for remote job management in distributed environments. BES 
endpoints (listed in Method’s section 3.2.2) provides a common interface for remote task 
managing. Each new BES activity corresponds to a batch job petition to PMES server. These 
petitions, are expected in the Job Submission Description Language (JSDL) specification (see 
3.2.3 in method’s section). 
Well-known WS clients like Taverna [224], now part of Apache Incubator, can be used to 
remotely send tasks to the infrastructure. Following snapshot corresponds to the usual 
operations needed to submit a job using the Taverna client.   
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〕  PMES Dashboard 
For occasional or developmental uses, PMES offers a web-based Dashboard5. For not 
programmatic access, PMES Dashboard is the core manager of the infrastructure as, 
likewise the API, it allows full control of the PMES layer. It provides a UI where researchers 
configure, monitor and execute their application runs. PMES dashboard holds the registry 
of transPLANT applications, whose VMIs are in the repository of the underlying CMP. The 
flow that an end-user follows at the dashboard is essentially: 
I. Select the plants genomics’ tool of interest. Available applications with a brief 
description for each is listed. 
II. Specify the location of the input files. As will be discussed below, these should 
correspond to an FTP URLs. 
III. Set the values for the application’s arguments. They will be part of the executed 
command. 
IV. Specify where the expected output files are to be stored. 
V. Launch the job application and monitor its advance in the central panel. 
                                                     
 
5 https://transplantdb.bsc.es/pmes/ 
Figure 4.8: PMES SOAP operations to submit a new PMES job  
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VI. Check execution’s STDOUT and STDERR. 
PMES deals with both standalone and COMPSs based applications. The central panel is 
where user’s batch executions are recorded, and enables users to monitor their job 
progressions. Eventually, PMES stages out the results from the transient virtual machine to 
the user’s FTP selected location. 
 
 
 
 
 
 
 
 
 
 
 
〕  Data manager 
Although PMES dashboard perfectly manages job-related operations, user’s data 
management operations are not that well resolved, as it assumes that the end-user has 
access to an FTP server. Thus, a second Web interface is implemented in order to better 
support user’s data transferences to the transPLANT cloud platform and cover that gap. 
TransPLANT “Data Manager”6 is a web-based file server that enables users to upload and 
download their data via HTTP(S) onto the platform. Indeed, the application acts as a web 
frontend of an FTP server set behind BSC premises and configured as the web application’s 
storage. 
Behind, the FTP server, implemented with vsFTP [225], is configured with custom 
directories and virtual users accounts, integrated via PAM (Pluggable Authentication 
                                                     
 
6 https://transplantdb.bsc.es/uploader/ 
Figure 4.9 Screenshot of PMES dashboard. 
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Module) into the transPLANT authentication system. “Data Manager” populates FTP 
directories with user’s uploaded data, and thanks to an accurate permission management, 
they are also accessible by PMES via FTP. The full data flow is further discussed in 4.2.3 Data 
Management. 
 
 
 
 
 
 
 
 
 
 
  
Written in PHP, the user interface consists of a one-page application that offers an intuitive 
user’s space where the remote files and directories are displayed under a clean file system 
layout (Figure 4.10). The central panel displays the user’s current working directory, its 
space quota, the navigation menu to move around directories’ hierarchy, and some basic 
file-based operations: new folder creation, file download or deletion, and data compression 
and archiving (ZIP, TAR). The user selects one or more files from their local system, and 
these are transferred on the current working directory. All the time,  the directory FTP URL 
(ftp://datamanager.bsc.es/pmesData/$CWD/) is shown on the right-top corner of the central 
panel, as this is the only piece of information the user requires to submit a job on the 
platform, either via PMES API or PMES Dashboard (Figure 4.11). 
 
 
 
  
 
PMES DASHBOARD 
DATA 
MANAGER 
I/O data location 
Figure 4.11: “Data Manager” provides de data location URL. 
When defining the data location of new jobs in PMES dashboard, we can use the FTP URL given by the “Data Manager”.  
Figure 4.10: ScreenShot of DataManager workspace 
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“Data Manager” authenticate users against the internal transPLANT LDAP, so it does not 
handle users accounts on his own. In fact, the web application is so light that it does not 
even require a database. 
 Authentication 
An internal LDAP-based authentication system is set using a Basic authentication schema. 
It centralizes the access control of the different infrastructure components: PMES 
Dashboard, PMES API, “Data Manager”, and transPLANT FTP server.  
User accounts are granted on request through the project’s website, yet a demo user is 
published: 
- User: guest 
- Password: gu3st2014 
Accounts are set using the admin section of PMES Dashboard. When creating a new user, 
credentials are stored at the SQLite DB of PMES Dashboard, and automatically, the new 
account is also created at the transPLANT LDAP, which is configured as an LDAP POSIX-
account. Such type of entries permits a central Linux access management by means of the 
PAM module. As such, central LDAP user accounts are compatible with transPLANT FTP 
server authentication, eventually building a unified account system for all transPLANT 
services. 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Scheme of the transPLANT authentication system 
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 Data Management 
Cloud-based infrastructures consist of volumes of data which might be shared among 
multiple tenants. Thus, data management is an essential aspect for data storage in cloud, 
both for security and efficiency. Besides, transPLANT, as mentioned above, pretends to 
deliver a portable infrastructure, as hybrid or multi-cloud approaches are desirable in the 
scientific landscape for flexibly co-locating data and computational resources or simply 
extending private data centers with on-demand public clouds (hybrid cloud bursting). 
However, offloading computation not only requires dynamically managing the compute 
resources, but also moving target data into the allocated VMs. 
 User’s data 
Although some high-level solutions are lately emerging for multi-cloud environments (see 
1.4.4.2 Data-storage solutions), these are still not mature solutions with one limitation or 
another, and most existing technologies often require researchers to move data explicitly 
between the processing steps of geographically spread pipelines. Here, PMES is responsible 
to transfer the data to the local VM storage through the network using the standard FTP 
protocol. Thus, researcher’s data is to be stored in a FTP server. During the service life cycle, 
PMES server stages in input files into the virtual appliance (requesting user’s credentials if 
needed), to subsequently run the application, and eventually stage out user’s specified 
results files into researcher’s FTP server before undeploying the virtual instance. Data is 
accessed locally during the runtime, especially beneficial for processes with high I/O loads. 
Additionally, to prevent data allocation issues, user’s data is located in a separate partition 
of the VM that might be implemented as a volatile data block sizable during the deployment 
process by contextualization. 
Alternatively, “Data Manager” provides a web-based data loader to support those users 
that may not have access to an FTP server. It acts as a web frontend for the transPLANT FTP 
service, a server prepared to provide temporary storage of user’s data - according to current 
transPLANT policies, data is stored up to 7 days before it expires. 
“Data Manager” finds the data for each user under its corresponding directory, which is 
created automatically during user’s registration process and corresponds to user’s FTP root. 
The application organizes user’s data in disk following the “User > PMESdata > Workspace” 
hierarchy: 
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userData/ 
+ --- username/                      # user’s home directory. FTP user’s chroot. 
|     + --- PMESdata/                # Bellow, users freely organize their data  
|     |     --- MyInput1.txt 
|     |     --- MyInput2.txt 
|     |     + ---MyExecution/ 
|     |     |     --- MyOutput1.txt 
|     |     |     --- MyOutput2.txt 
|     |     |     --- stderr.log 
|     |     |     --- stdout.log 
Snippet 4.1: Directories hierarchy for transPLANT user’s data.  
Data organization below user’s root is free. User builds it either accessing viat FTP or navigating online with the 
“DataManager”. 
 
The application manages the permissions so that data’s ownership at the system level is 
maintained as that of the logged user account. In this way, the “Data Manager” handles 
cloud’s data on behalf of the user. By doing so, FTP credentials secure PMES transferences, 
regardless whether the FTP site had been populated directly or via the “Data Manager”. 
 Reference data 
A usual use case in the research community is also the use of reference datasets and 
databases, which we prepare in order to fulfill the particular needs of the applications 
populating our testbed installation. For reference data, an architecture based on local data 
sharing is proposed. OCCI supports the attachment of file-based or block storage devices as 
part of the contextualization process. In this way, compute VMs mount at boot time the 
shared folder where the reference data is located using a NAS protocol, either CIF or NFS. 
In the present testbed installation, the shared folder corresponds to an NFS (v3) endpoint 
on the cluster NAS storage, installed on top of a GPFS distributed file system. Context 
parameters, primarily the NFS endpoint address and the credentials of the mapped user, 
are passed as part of the job definition to the PMES server, who in turn set the adequate 
script for the contextualization package triggered on boot. Only a single and static NFS 
endpoint address is required, as the storage is configured using clustered NFS (CNFS), so 
that on node failure, the NFS serving load is transparently moved to another node. Also, to 
ensure data consistency across VMs simultaneously accessing the reference data, NAS is 
accessed in read-only mode. 
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 Use case: plant genome annotation pipeline in 
MAKER 
Following lines describe how the different components of the transPLANT cloud interact on 
the Web with the end-user. The example covers the deployment of a plant genome 
annotation service on the compute infrastructure. 
 Preparing a transPLANT application  
Annotation Pipeline 
Genome annotation is still a major challenge in plant biology, far from a straightforward, 
‘plug-and-play’ activity. transPLANT partners designed an annotation pipeline [226] (Figure 
4.13) based on MAKER2 [212], a genome annotation tools, in combination with 
InterProscan and Uniprot analyses. 
MAKER uses a combination of AUGUSTUS, SNAP and Genemark for gene model assessment, 
using either external training sets, or training sets derived from the data itself. The pipeline 
takes as input the genome assembly, a configuration file in a YML-like format, and optional 
evidence files (protein, EST, gene models). MAKER generates three different outputs: a) GFF 
file with genes and gene structures; b) FASTA file with predicted proteins, and the 
InterProscan analysis of the same; and c) the CSV alignment output from BLASTP against 
Uniprot. 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: transPLANT application: MAKER2 pipeline 
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Creating transplant application 
We have encapsulated the pipeline in a virtual machine image based on the base 
transPLANT image. For that, we have configured and installed all the necessary software, 
and prepared a Python wrapping script that would act as the appliance entry point. Next 
step consists of configuring the VM template on OpenNebula for the new image. It simply 
is going to state the VMI identifier, and the usual network configuration, by which the cloud 
middleware will dynamically assign an IP from a given local VLAN. Data requirements (i.e. 
storage attachments) are not considered at this stage, as PMES is going to make them 
available on runtime. 
Once the VMI is ready, we have configured the PaaS components in order to set how they 
need to interact with the new VM. PMES will require deployment details (e.g. target cloud, 
demanded resources, VMI OpenNebula identifier), contextualized actions on boot, 
application CLI details (e.g. arguments, input files), FTP data location, etc. If using the PMES 
API, we would need to compose the corresponding JSDL submission file with all this data. 
As it could be a tiresome process if the user does not prepare an automatic approach to set 
it up, all prepared VMIs are registered into PMES Dashboard. To do so, the Dashboard 
includes a web form where the following information regarding the new application is 
required: 
- Name: the name of the application. 
- Image: VMI OpenNebula identifier containing the application. 
- Location and Path (Optional): URL of the package to be deployed in virtual 
machines after system boot. 
- Executable: Name of the executable to run. In COMPSs applications, the name 
of the main class (e.g. simple.Simple), in standalone applications, the name of 
the command (e.g. /usr/bin/maker). 
- COMPSs: If it is a COMPSs application or not. 
- Public: If the application can be executed by other users. 
- Description (Optional): A brief description of the application. 
- Wall Clock Time (Optional): The default execution time of the application. 
- Disk Size (Optional): The default disk size for the virtual machines when running 
the application. 
- Cores (Optional): The default number of cores for the virtual machines when 
running the application. 
- Memory (Optional): The default memory for the virtual machines when running 
the application. 
- Max VMs (Optional): The maximum number of virtual machines to run the 
application. This is used only for COMPSs applications. 
- Min VMs (Optional): The minimum number of virtual machines to run the 
application. This is used only for COMPSs applications. 
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Additionally, to help PMES build the application CLI, arguments, input files and expected 
output files are to be specified. Each argument will be optional if specified or mandatory 
otherwise, and it is defined by a name, an optional default value and an optional prefix. 
Eventually, the CLI launched by PMES would look something like this: 
- COMPSs applications  runcompss executable [[prefix] [argument]] 
- Standalone applications: executable [[prefix] [argument]] 
 Running a transPLANT application on the platform 
Load user’s data using “Data Manager”  
If user has no FTP site to expose their data to PMES, first step is to do so by loading 
researcher’s data into the FTP site of the transPLANT cloud. “Data Manager” is the web 
interface that enables such data uploading. 
Users are to log in, and given their workspace - i.e. their FTP directory -, they upload the 
required data to run the annotation pipeline via HTTP from their local PC. For MAKER 
application, the compulsory input file is a FASTA file with the assembly contigs and the YAML 
configuration. An example for these files is found at the project’s site7. Once loaded, “Data 
Manager” shows the FTP URL for each of the files, which are to be used at the PMES 
Dashboard, when defining run input files. 
Configure PMES Dashboard 
On first PMES Dashboard login, some user’s configurations are to be set, so that the 
framework knows from/to which FTP server the I/O data is to be transferred, as well as 
which are the environment variables to be sent to the contextualization script, if any. These 
arrangements are stored in the Dashboard application, thus, they are only configured once. 
Adding a storage registry only requires the FTP URL of the user’s remote directory and a 
descriptive name, while contextualization variables are given as key-value pairs. For using 
the transPLANT storages of the current testbed installation, the settings are: 
- Storage: The “Data Manager” indicates the URL, i.e. 
ftp://datamanager.bsc.es/pmesData/. Credentials are not stored, only requested when 
needed, and the unified authorization system permits to share the account between 
PMES-Dashboard, “Data Manager” and the transPLANT FTP server. 
- Contextualization: In the current installation, for PMES mounting the NAS where the 
reference data is stored, the following variables are to be set:  
                                                     
 
7 https://transplantdb.bsc.es/documents/samples/maker 
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DATA2_USER = guest 
DATA2_PWD  = guestTransplant01 
It indicates PMES to attach DATA2 NFS mounting point after the BOOT. In fact, the 
credentials correspond to the NFS identity mapping (between the virtual instance and the 
network local storage). 
Run MAKER on PMES Dashboard 
MAKER application is part of the collection of tools integrated into the transPLANT platform. 
Hence, it appears as an option under “New Single Job” creation menu. There, a description 
of the application is given and users define which are application’s arguments and input 
files. For each input file, a storage (FTP site) is to be set, the information that “Data 
Manager” provides in case of using the internal transPLANT FTP server. The FTP location for 
the expected output files is also required. After application details are set, the job can be 
submitted. 
Behind, the magic happens, and the provisioning process is initiated. PMES pulls from the 
CMP the deployment status, and once the VM is running, the application life cycle 
advances. First, the VM parameterization attaches DATA2 NAS, then, the two input files are 
staged in at the allocated VM from the local FTP server, the MAKER wrapping script is 
transparently called using user-defined arguments, and finally, once the execution 
terminates, the output files are fetched from their expected appliance location and 
transferred to the user's FTP server before the virtual instance is deleted. Meanwhile, PMES 
reports the appliance STDOUT and STDERR, enabling real-time control of the execution 
progression. 
 
Download user’s data using “Data Manager”  
Before termination user’s virtual run, PMES downloads the output files into the desired 
FTP’s location, together with logging information. If the transPLANT FTP server has been 
defined, the “Data Manager” interface is used to check for those files. According to current 
transPLANT policies, the data is going to be stored for 7 days before it expires.   
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 MuG: Multiscale Complex Genomics VRE 
This section describes the design and development of the cloud-based virtual research 
environment (VRE) we have built in the context of the Multiscale Complex Genomics (MuG) 
project. 
The candidate has directly participated in the design and development of the overall cloud 
architecture as presented below, and in particular on the implementation of MuG Virtual 
Research Environment (MuGVRE), the central platform interface. A manuscript pre-print is 
attached at annex 8.7.2 Publications 
 Context 
The Multiscale Complex Genomics (MuG) project (H2020 EINFRA-9-2015; grant agreement 
ID: 676556) is born as a bottom-up approach pushed from some European 3D/4D genomics 
research groups that combined three different expertise: (i) biologists with interest in 
chromatin structure, (ii) method developers, and (iii) HPC facilities with strong history of 
supporting Bio-computational problems. Genomics is probably the fastest evolving field in 
current science. A decade ago the main concern was to obtain the sequence (the 1D code) 
of the genome; today the big challenges are to determine how genotype information is 
transferred into phenotype. Investigations elucidated that part of the gene expression 
regulation is implicitly coded in the way chromatin is folded, which lead to this new branch 
of the genomics called 3D/4D genomics and focused on the dynamics of chromatin 
structure. 
We have contributed to strength this young and dynamics field by implementing the MuG 
Virtual Research Environment (MuGVRE), a platform that aims to provide the 3D/4D 
genome community with an adequate combination of relevant data, visualizers, and 
computational tools to non-programmers. MuG partners contributed by providing 
specialized visualizers, and a complete catalog of analysis tools (annexed 8.3 MuG tools & 
visualizers). 
 Motivation 
Hundreds of laboratories are right now conforming the 3D/4D genomics field, which, even 
though eventually concerned with the same scientific problems, employ many different 
approaches to study it. Individually, they target radically different length and timescale 
data, coming from biophysics to cell biology disciplines, and use technologies as diverse as 
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HiC or ChIP-seq or microscopy. The collaboration in a field so notably multidisciplinary 
highly predetermine the framework to be developed. An easy-to-use and supportive 
environment is an essential feature in order to inclusively integrate the different expertise 
in MuG represented. 
Yet, simplicity in use should not reduce flexibility, as handling multi-scale data put very 
diverse sources together, like atomistic simulations, genome annotation, middle and high 
scale 3D genomics, and cell biology imaging data. Moreover, the youth of the field 
exacerbates the profusion of file types and formats, with no clear methodologies nor 
standards. In this situation, is essential to establish a common and domain-agnostic 
framework that permits to set relationships among the different data levels, in order to 
build an integrated view of all the components for a complete 3D/4D genomics study. 
Additionally, users are expected to be active in generating and analyzing data in a given 
expertise, and interested in browsing and integrating data from the others. This breaks the 
common paradigm in bioinformatics where most users are data consumers, while data is 
produced by a reduced and controlled community or even a single group. As a general rule, 
all members of the VRE should not only use data and computational resources, but they 
also need a set of tools to populate the platform with their own analysis. Thus, the 
computational infrastructure should ensure interoperability of analysis tools and generate 
an integrated environment with a seamless transition among the available data levels. 
From a computational point of view, 3D/4D genomics constitutes also an extraordinary 
challenge. Very much like plant genomics, data size and transmission are to be carefully 
considered, as discussed above. Hence, the single user environment is to ensure the best 
efficiency in both, data mobilization and processing. Finally, MuG infrastructure’s design 
should project the support of some transversal European e-infrastructures, namely, EGI and 
PRACE for computational capabilities, and EUDAT for shared storage, aligned with global 
initiatives like EOSC, ELIXIR, and GA4GH. 
Requirements 
- Flexible environment, able to adapt to the specific needs of the analysis tool, both 
in terms of software requirements, or computational resources. 
- Software scheduler(s), able to manage computational resources in a transparent 
and adaptable manner. This will be an elastic infrastructure with automatic 
adaptation to user’s loads. 
- Web-based centralized access. User access will integrate MuG authentication, data, 
compute and visualization services. 
- Community driven platform. Users are expected to integrate analysis tools and 
visualizers into the platform in an easy manner. 
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 Cloud architecture 
MuG computational infrastructure is using already existing components, which have been 
adapted to work in an integrated manner at the overall platform, while complemented with 
new elements when necessary. The layout has been designed as an evolution of the cloud 
infrastructure presented above for the project transPLANT. Below, Figure 4.14 details the 
layers of the new architecture. 
MuG platform is offered as a PaaS via the project’s virtual research environment (MuGVRE), 
that concentrates most of the infrastructure services following the one-stop-shop 
approach. Virtualized resources are transparently and dynamically managed using PMES 
and COMPSs, in a similar way transPLANT appliances were provisioned, though completely 
revised versions of those are used here. Additionally, a second task management strategy 
is proposed here, based on a combination of the Sun Grid Engine (SGE) queue system and 
the OneFlow auto-scaling service. 
 
 
 
 
 
 
 
 
 
 
 
 Anyhow, appliance petitions reach the IaaS, layer managed by any OCCI compliant 
platforms, like OpenNebula or OpenStack, and there, MuG VMs are instantiated (short or 
long-lived). These encapsulate MuG applications, 3D/4D genomic analysis tools provided by 
tool-developer users. Transversal to the infrastructure, a centralized authentication system 
is set up, as well as a shared storage system. 
 A description of each of these components and their interactions is summarized in Figure 
4.15. The diagram enumerates the following stages to briefly illustrate the functioning of 
the analysis platform: 
Figure 4.14: MuG cloud architecture 
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1- Users access the cloud via a unique web frontend, MuGVRE, a complete virtual research 
environment (VRE) 
2- Users access their own space after authenticating themselves against an external 
authentication server based on KeyCloak (OpenID connect with OAuth2 flow). 
3- Users load their data into the platform, internally stored in a shared storage accessible 
over the cloud network 
4- Users browse, select, and configure the analysis tool they want to run. These are found 
registered in the MuGVRE Mongodb using an ad hoc data model. 
5- Using Tool registry data, MuGVRE composes a job according to JSDL specifications 
where the virtual machine image encapsulating the selected analysis tool is targeted. 
The JSDL template is posted to PMES server, which acts as PaaS orchestrator. 
6- Using standard BES specifications and a new REST interface, PMES offers job 
monitoring, information that it retrieves from the underlying infrastructure using the 
OCCI API. At MuG’s production cloud, the CMP is OpenNebula. 
Figure 4.15: Diagram flow of the MuG cloud 
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7- Similarly, job allocation – i.e. computational resources required to instantiate the Tool 
VM - is delegated to OpenNebula. 
8- User’s data is sitting in a network-attached storage (NAS), previously loaded by users 
(step 3), and dynamically attached to deployed VMs, which avoid any extra transfer 
process. OCCI does accomplish the task, so the CDMI cloud data protocol (see 1.4.3.3 
Cloud interoperability and portability) is not implemented. 
9- PMES requests the instantiation of the selected image to OCCI server, who in turn 
interacts with the corresponding CMP provisioning service, for OpenNebula, an XML-
RCP-API. Instead, if the IaaS would be provided by OpenStack, OCCI would interact with 
its HEAT component. 
10- After instantiation, MuG VMIs are contextualized with the relevant data and 
permissions according to JSDL instructions. Afterward, PMES triggers the actual analysis 
tool. It could correspond to a standalone application or workflow, or a COMPSs 
pipeline, which would, in turn, deploy a cluster on-demand, again via OCCI. 
Following sections describes the components of the MuG cloud platform, here summarized. 
Firstly, the infrastructure layer, secondly, the PaaS components responsible for 
orchestrating the deployment process, and eventually, the outer layer, in contact with the 
researcher. 
 Infrastructure as a Service 
The cloud infrastructure currently in production for MuG corresponds to the “MMB Cloud” 
at the Institute for Research in Biomedicine (IRB), an on-premises cloud managed by 
OpenNebula. More details on the infrastructure can be found at section 3.1.2.1 in . 
Software, Data & Methodology .  
Additionally, MuG consortium also has access to two other cloud infrastructures, not 
currently in production but intended for developing purposes, mainly benchmarking of 
analysis tools under development or the exploration of a multi-cloud approach. These 
correspond to two other private clouds sitting in separate locations: 
- “INB Cloud” at the Barcelona Supercomputing Center (BSC) 
- Tenancy of the “Embassy Cloud”, located at the European Bioinformatics Institute 
(EMBL-EBI). 
Both installations are further detailed at Methods sections, under 3.1.2.1 Cloud 
management platforms. 
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 Platform as a Service 
MuG platform is conceived as a dynamic ecosystem where analysis tools are plugged in and 
out of the infrastructure. Hence, PaaS building blocks are the virtual appliances (VMs) 
encapsulating such methods. PaaS components are in charge of: 
- providing Tool developers with the means and instruments that enable a rapid 
integration of their methods into the platform 
- implementing scalable and atomization capabilities for the deployment and 
provisioning process of Tools 
- interacting with the IaaS layer 
MuGVRE communicates with PaaS components to pass through job researchers’ petitions 
collected on the VRE. Transparently and dynamically, PaaS handles IaaS resources. These 
components are primarily two different scheduling engines for task management on 
compute virtual machines. Figure 4.16  summarizes them. The first strategy uses PMES 
provisioning, as transPLANT cloud does, while the second is based in a combination of SGE 
and OneFlow. Compute VMs are configured one way or the other when integrated into the 
MuGVRE.  
 
 
 
 
 
 
 
 
 
 
〕  PMES 
PMES (see 3.1.2.2 Provisioning Tools in Methods) allows to remotely submit job execution 
requests to cloud infrastructures via OCCI. How PMES is used in our computational 
infrastructures is already explained in the transPLANT section (4.2.2.2 PMES Server). In 
short, it controls and monitors the complete life-cycle of the virtualized applications 
Figure 4.16: Two MuG scheduling engines: i) PMES and ii) SGE & OneFlow  
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provisioning pre-emptible VMs, i.e. stateless short-lived VMs acting as transient 
environments for the analysis tools, which after the execution place, they are switched off. 
A PMES server is running on each MuG cloud infrastructure. MuGVRE backend 
communicates via REST with it (Figure 4.16). Currently, PMES server is accepting petitions 
on the “MMB Cloud”, and a development installation is available at the “Embassy Tenancy“. 
Thus, PMES allows submitting jobs on remote clouds infrastructures, opening the doors to 
a MuG federated cloud. The major requirement is that cloud providers should support the 
OCCI connector, like OpenNebula and OpenStack do. 
〕  SGE & OneFlow 
The second MuGVRE job scheduler is based on the traditional Sun Grid Engine (SGE). SGE is 
designed to manage distributed software executions in heterogeneous computational 
environments. MMB-IRB’s has been using SGE as a scheduler for web application back-ends. 
To adapt it to the MuG cloud layout, the backend of the MuGVRE is defined as a master of 
the SGE system that dispatches job petitions the virtual machines encapsulating the 
applications, instead of being sent to regular compute nodes. A long-lived VM per 
application exists in the cloud, and the queue system is configured accordingly, with 
separated queues per each application. Here lies one of the differences with the PMES 
strategy, where is the job petition that triggers the provisioning of VMs. SGE requires a 
worker host alive waiting for job petitions. 
To provide elasticity to the system, a second element is added to the equation, OneFlow. 
The VM scheduler, part of OpenNebula, is able to dynamically auto-scale the number of 
VMs instantiated according to workload parameters. 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: Elastic job scheduling engine based on SGE and Oneflow. 
Application _1 in encapsulated in VMI _1, which lives in the cloud waiting for a job petition from the SGE master, installed 
at MuGVRE. At the moment the researcher launches the application _1, the VMI _1 instance receives the commitment and 
starts working. If more jobs are requested for application _1, VMI _1 will increase its CPU load, which will trigger 
OneFlow. The latter will instantiate a second instance of VMI _1, so that job petitions can be distributed among the two 
VMIs _1 and queuing time is reduced. 
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Figure 4.17 shows a schema of the structure implemented in MuG prototype. In the case of 
increased demand on a certain application (i.e. certain VM), OneFlow instructs OpenNebula 
to replicate such VM, which is translated into an increased number of hosts available in the 
queue system for such application. Once the workload for such a group of VMs decreases, 
OneFlow undeploys them one by one, always keeping at least one instance ready to accept 
new job petitions. In this way, allocated resources are dynamically and transparently 
adjusted on-demand. 
The following snippet illustrates how SGE detects the VMs hosting the queues. Oneflow 
deploys and undeploys them as it choice according the workload metrics, while SGE simply 
distribute job petitions among those hosts available 
HOSTNAME                ARCH         NCPU  LOAD  MEMTOT  MEMUSE  SWAPTO  SWAPUS 
--------------------------------------------------------------------------------------- 
dna-192-168-27-41        lx24-amd64      2 1.86   31.4G       - 1024.0M    5.9M 
dna-192-168-27-42        lx24-amd64      2 1.05   31.4G       - 1024.0M    0.86 
dna-192-168-27-43        lx24-amd64      2 0.5    31.4G       - 1024.0M    6.8M 
dna-192-168-27-44        -               -     -       -       -       -       - 
dna-192-168-27-45        -               -     -       -       -       -       - 
dna-192-168-27-46        -               -     -       -       -       -       - 
nucDyn-192-168-28-11     lx24-amd64      2  0.00   23.6G  138.5M     0.0     0.0 
nucDyn-192-168-28-12     -               -     -       -       -       -       - 
nucDyn-192-168-28-13     -               -     -       -       -       -       - 
[…] 
Snippet 4.2 Queue hosts (compute VMs) are enabled/disabled by OneFlow. 
In red, disabled VMs that will be provisioned on peak demands. dna* and nucDyn* are the hosts prepacking 2 tools 
 
〕  Tool’s virtual machines  
MuGVRE is designed such that tools’ catalog could be extended when relevant new 3D/4D 
genomics tools or visualizers may appear. Software developers, are responsible for building 
and engrossing the catalog of MuG VMIs MuG Tools include from high computationally 
demanding applications (e.g. molecular dynamics simulations) to high-throughput data 
analysis applications (like the processing of next-generation sequencing data). One of these 
tools has been selected as a use case for this dissertation, and it is further discussed at 4.3.4 
Use case: Nucleosome Dynamics. Check the complete list of integrated VMIs and the 
corresponding MuG tools at annex 8.3 MuG tools & visualizers. A VMI can encapsulate more 
than one MuG tool. This is especially recommended in case of related applications that 
require a common environment. 
The base VMI is prepared here, following a similar procedure to the one already described 
for transPLANT VMIs (section 4.2.2.2 Tool’s virtual machines). It consists of a vanilla Ubuntu 
16.04 image, configured to run on PMES-enabled clouds and with all the necessary MuG 
software stack ready to use: 
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- COMPSs (see 3.1.3 Job Managers) 
- Cloud-init (see 3.1.2.3 Contextualization) 
- MG-TOOL (discussed below) 
Major differences lay on the contextualization package used, here Cloud-init instead of One-
context, and the parameters passed through it, which now allows a job-tailored storage 
attachment as discussed in the following section focused on data management. 
Unlike transPLANT VMIs, the images now include the installation of a platform-specific 
component, MG-TOOL-API. It works as an adaptor, which does not compromise software 
portability to other infrastructures, but enhance the interaction with MuG infrastructures. 
MG-TOOL API 
MuG VMs, as any other compute unit, have a main executable that triggers the whole 
pipeline, either stand-alone or parallelized with COMPSs. Such an entry point has decided 
to be standardized for all MuG VMIs. With this purpose, a thin python wrapper called MG-
TOOL-API8 is prepared in collaboration with other MuG partners. On one hand, MG-TOOL-
API provides a common access interface for MuGVRE to all its VMIs. On the other, it absorbs 
the unavoidable heterogeneity of the different application’s CLIs, which are handled 
internally and individually as part of the VMI implementation. Thus, as shown in Figure 4.18, 
MG-TOOL-API works as an adaptor. The specifics of the standardized interface is latter 
discussed when explaining how 4.3.2.3 MuGVRE backend interacts with MG-TOOL-API on 
job submission. 
MG-TOOL-API is formalized as a MuG tool skeleton with two main classes (Tool and Pipeline) 
in which the user injects his/her application, extending and coding their own workflow in 
pure python. MG-TOOL API, designed jointly but implemented by other MuG partners, has 
a relevant role in the MuG data management plan, as discussed in the following sections. 
The wrapping library includes methods for: 
I. parsing and validating application’s arguments and input files received from 
MuGVRE job petition; 
II. easing tool developer task of coding their own pipeline in python, by providing some 
generic Classes (Pipeline, Tool), skeletons and examples. Some pyCOMPSs ready-to-
use skeletons are also prepared for those willing to orchestrate their applications in 
COMPSs; 
III. logging and monitoring to communicate MuGVRE the application progression; 
IV. gathering metadata of application’s output files 
                                                     
 
8 https://github.com/Multiscale-Genomics/mg-tool-api 
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〕  COMPSs 
Just as for the transPLANT cloud, the python binding of COMPSs is used in the MuG 
infrastructure as a workflow orchestrator. It enables the dynamic and transparent 
deployment of virtual appliances according to the pipeline demands at runtime, providing 
the system with horizontal elasticity. COMPSs stack is part of MuG VMIs, which as 
mentioned above, are provided by users themselves like in any other PaaS. Hence, the 
platform is not aware of whether the application is standalone or COMPSs. If COMPSs 
creates a virtual cluster, MuGVRE controls the master VM, from where monitoring and 
logging information is aggregated. Again, as COMPSs workflow management do not interact 
with MuG central management, VMIs can be configured with any of the two job schedulers 
enabled in the infrastructure: PMES or SGE.  
 Software as a Service  
The infrastructure is consumed in two different ways: as a SaaS or as a PaaS. 
- It is offered to the non-programmer 3D/4D genomics researcher as a unified 
environment of tools, services and data with seamless access to the MuG 
Computational Infrastructure 
- It is offered to software developers as a framework where to rapidly 
integrate their methods and offer them along other complementary 
services. 
MuGVRE (v. 1.1) is the key component to achieve so. 
Figure 4.18: MuG Tool virtual machine image. 
MG-TOOL-API is a wrapping layer that acts as an adaptor. It enables a rapid prototyping of MuG Tools, and an easy 
integration into the infrastructure 
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〕  MuGVRE frontend 
MuG Virtual Research Environment (MuGVRE) [227] (MuG Virtual Research Environment 
(MuGVRE) [227] (Figure 4.19) is the PHP server-side web application that provides a UI that 
integrates MuG analysis tools, visualizers and data for the end user. Its front-end is 
conceived as a virtual research environment designed to enhance collaborative research in 
the 3D/4D genomics community, while behind the scenes, it is responsible to collect high-
level deployment requests from the web and coordinate the resource or service 
deployment over MuG PaaS components.  
 
 
 
 
 
 
 
 
 
 
 
 
MuGVRE researcher ’s perspective 
MuGVRE9  aims to offer a responsive, effective, easy-to-use and immersive working 
environment. The central panel could be either a data-centric workspace that acts as the 
main landing zone for the users, or an application-centric form allowing to launch specific 
analysis. It interconnects most of the researcher operations at the platform, which helps 
covering for the complete user’s flow at a computational infrastructure: 
I. Authenticate to preserve data across sessions; 
                                                     
 
9 http://vre.multiscalegenomics.eu/home/ 
Figure 4.19: MuGVRE home page 
Each box represents one of the tools offered by the platform. 
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II. Import the data willing to analyzed in the personal workspace and annotate it; 
III. Select the 3D/4D Genomics application of interest; 
IV. Tune in tool’s arguments, and the job name; 
V. Launch the application and monitor the job progression. Output files will eventually 
appear back at the workspace; 
VI. Select the visualizer that can properly display the output data, together with other 
data if desired; 
VII. Feed the results into another tool to further analyze it, or just pack and download 
the whole project. 
Access to MuGVRE is open and does not require registration. Yet, an authentication system 
is put in place so that registered users can easily regain access to their projects. 
Unregistered users only can access to the previous session using a recovering link. 
Once logged in, the first step is loading the data to work with, and the very second step, 
annotate it. Imports might come from researcher’s data (either by file streaming on the 
browser or asynchronously on a given URL), or from one of the embedded public 
repositories upon one-click (i.e. ArrayExpress [9], BigNASim (8.7 Publications) [228]). 
Loaded files need to be annotated, as some MuGVRE functionalities are precisely based on 
file semantic and descriptive metadata. For instance, such curated metadata enables the 
interoperability among MuGVRE tools and visualizers, and permits to contextualize and 
guide the researcher offering adapted toolkits, dynamic available operations, etc. Minimal 
annotation includes file format (e.g. FASTQ) and data types (e.g. HiC-seq reads) (supported 
data type and formats listed at annex 8.4.1 Data Model: “File”). 
All uploaded data is accessible and navigable at the user’s personal workspace. It is based 
on a filesystem-based layout (Figure 4.20), where data is centralized and administered 
regardless it is uploaded by the user, it comes from integrated repositories, or has been 
produced at the platform by running processes. User’s workspace is organized into scientific 
projects. Each of these projects holds an independent workspace, that in turn is organized 
in folders: 
- Uploads/: uploaded data, 
- Repository/: data obtained from public repositories 
- “Run” folders:  results for pipelines and analyses 
File lists can be filtered by any of row fields (i.e. name, format, data type, or project) as well 
as a tool-based filter that select only the valid input files for a given tool. Upon a file (or a 
group of them), three interactive toolkits display the valid operations: 
- File toolkit: Rerun job, download data/folder, edit metadata, delete, pack and 
compress, rename, move. 
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- Visualization toolkit: Available visualizers supporting the selected combination of file 
formats and types. 
- Tools toolkit: Available tools supporting the selected combination of file formats and 
types. 
 
 
 
 
 
 
 
 
 
 
 
Alternatively, the operation’s selection (tool or visualizer) can be performed directly. 
MuGVRE offers a “Launch” section where the user browses the catalog of tools, organized 
as a searchable table with friendly descriptions, ownership, keywords and supported 
operations. As usual, upon tool selection, the user fills in the particular application 
parameters. In case input files have not been selected at the workspace, an additional dialog 
offers a filtered list of files across workspaces suitable for the given tool input file. This mode 
is more convenient for non-experienced users, as permits an exploration of all the available 
tools. 
Once launched, user instructions are mapped into effective job executions, which are 
monitored and debugged on the workspace. Each run creates a new “Run” folder that 
contains all the data belonging to such execution (i.e. log file, and job-related metadata), 
along with its eventual output files. These are automatically annotated (data type and 
format) so are eligible for visualizers, or other analysis tools. 
 
 
 
Figure 4.20: MuGVRE workspace 
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Currently, MuGVRE integrates three different visualizers for sequence browsing 
and visualization of 3D structures, molecular trajectories or chromatin assembly models 
(check the list at annex 8.3 MuG tools & visualizers). Users choose from their workspaces 
the different files of interest, even repository’s data, and feed it into one of the visualizers. 
 
 
 
 
 
 
 
 
 
 
 
Additionally, analysis tools may offer a custom viewer for better displaying their output 
data. Unlike generic visualizers, these displayers are not meant to interactively analyze and 
combine data across the platform, but to show the data of a particular run, as to include 
Figure 4.22: Snapshots of the three MuGVRE visualizers 
Figure 4.21: Selection of input data after tool selection. 
In the example, MuGVRE is selecting all user’s file of type “MNase-seq data” and format BAM. 
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statistical reporting, specific plots or applets, etc. (Figure 4.23). In fact, they are provided 
and plugged-in by software developers along with their methods. 
 
 
 
 
 
 
 
 
 
 
 
To support researchers on such an integrative framework, the virtual research environment 
has made special emphasis on providing documentation pages (editable online for tool 
developers), abundant help tips, dynamic toolkits, interactive monitoring, verbose error 
and progress reporting, etc. - without compromising platform’s flexibility. Moreover, 
usability is enhanced by supplying sample dataset for each tool (i.e. input and results 
examples) so that demonstration runs are available on one click. On top of that, a helpdesk 
service provides a ticketing system to address general MuGVRE petitions (e.g. disk quota, 
bring-your-own-tool support, IT general issues), and analyses related concerns, directly 
responded by the tool owners. 
MuGVRE Software developers’ perspective  
MuGVRE is not only meant to interact with the researcher, but also with those software 
developers willing to integrate their methods at the platform. Although the integration per 
se of new tools – i.e. new VMs –, involve offline configurations at the IaaS level, MuGVRE 
includes some panels and utilities to assist in the development process and keep an open 
channel between the developer and MuG support team. 
Users entitled as “tool’s developers” (permissions are requested online and require 
Administrators’ approval) have access to the panel controlling tool’s administration (Figure 
4.24). They can manage their own Tools (available statuses: active / inactive / under test / 
coming soon / obsolete) and check their usage statistics. 
Figure 4.23 : Example of custom visualizations for three different analysis tools. 
From left to right, “3D-consensus”, “MC-DNA” and “pyDockDNA”.  
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Additionally, software developers also have special views designed to facilitate the testing 
and debugging of new tools. For instance, raw view of job auxiliary files is accessible at the 
workspace per each run, as well as the metadata for each file, which is displayed in the 
native JSON format as stored in the database (Figure 4.25). Also, online editors for 
documentation pages that are expected to be filled in when plugging in a new tool in the 
system. 
 
 
 
 
 
 
 
 
 
 
And last but not least, a complete workspace (Figure 4.26) is available for assisting during 
Tool’s submission procedure (protocol more detailed in 4.3.3 Data management). 
Figure 4.24: MuGVRE Tool’s administration panel  
Figure 4.25: Pop-up windows display information about a finished job. 
Tool Developers have extended data on the run, like internal identifier, associated files, etc.   
Results 
120 
 
 
 
 
 
 
 
 
A complete protocol has been set up to allow the submission of new tools into MuGVRE. 
The whole process can be divided in two main steps, a wrapping process for preparing the 
application to be virtualized, and the actual integration of such code into the infrastructure. 
 
 
 
 
 
 
 
Application wrapping is based on the MG-TOOL. The python library is formalized as a tool 
skeleton on top of which user adapts their application. The user clones the MG-TOOL 
repository in their own development environment, and fill in the skeleton according to its 
pipeline’s requirements. If parallelization is to be enabled, PyCOMPSs decorators should 
also be added here. Once the Tool is set up, we suggest a functional testing by which a 
MuGVRE execution is emulated at user’s in-house installation. On the MUGVRE web 
interface (developer’s panel, Figure 4.26), a testing set job auxiliary files (config.json, 
in_metadata.json) are created with the developer’s help, who defines input, argument and 
outputs for the new tool. Test files can be downloaded to be used locally. If the in-house 
test is passed, the code is ready to be made available on a public software repository, as 
MuG coding guidelines suggest.  
The second part essentially implies the registration and documentation of such code on 
the MuGVRE system, which requires to establish a dialog with MuGVRE support team. 
Figure 4.27: New “Tools” integration protocol. 
The process involves not only the tool developer, but the MuGVRE support team. 
Figure 4.26: MuGVRE Developer’s workspace 
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Through the developer’s workspace, the user provides the code location (URL), tool’s 
descriptive metadata (i.e. title, keywords, etc.), deployment details (i.e. CPUs, memory, 
main executable, etc.), logo images, etc. Eventually, the tool can be “Submitted” with a click. 
At this point, the ticketing system opens a communication channel with the user, and 
MuGVRE support team is made aware of the Tool proposal. The submission is evaluated 
and validated by MuGVRE team, who deploys the MuG base VMI including the new code at 
the MuG cloud. The new tool is activated under the testing mode, and tool-related web 
pages are generated automatically based on the Tool object. Finally, the tool is debugged, 
refined and tested on the platform, example data under ‘Get Sample Data’ menu is 
prepared, and tool help pages are prepared through the MuGVRE online markdown editor. 
The whole integration protocol is fully described and documented step by step on the 
web10, including training material and tutorials11. 
MuGVRE Administrators’ perspective  
Finally, MuGVRE provides some extra sections dedicated to support not the researchers but 
platform’s administrators. Administrators have privileged access to a series of operations 
and views, like (i) the dashboard with platform’s metrics (e.g. total storage in use), (ii) user’s 
administration to control their connections and profiles (e.g. manage user’s role, assign 
tools’ ownership), (iii) job management of the whole platform, (iv) run’s accounting and 
logging, and (v) tool’s management (e.g. activation/deactivation) with access to usage 
statistics per tool. 
 
 
 
 
 
 
 
                                                     
 
10 https://www.multiscalegenomics.eu/MuGVRE/instructions/ 
11 https://www.multiscalegenomics.eu/MuGVRE/training/ 
Figure 4.28: MuGVRE panel for administering platform’s job  
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〕  MuGVRE backend 
MuGVRE collects high-level deployment requests from MuGVRE fronted and coordinates 
the resource and service deployments applications. It is based on a Mongodb database that 
maintains the operational data and metadata regarding installed tools, visualizers, users 
and user’s files. Figure 4.29 describes the main collections comprised in the MuGVRE model. 
Each collection contains a list of records (BSONs, i.e. binary JSON documents) that may 
feature varying sets of fields, with different types for each field (more details at 3.1.1.2 
MongodbError! Reference source not found.). Several PHP libraries have been prepared to 
populate the DB with instances of tools, users, files or jobs objects. MuGVRE source code is 
available at the project’s GIT repository12, together with examples and documentation. 
Users are authenticated using a central server who manage the credentials, as further 
discussed in the following section. Usernames have files associated. Each of the files and 
folders displayed at the user’s personal workspace corresponds to an entry in the database 
(“Files” collection), which is a one-to-one match of the data in the disk. The record stores 
the operational metadata of the file, including a MuG file identifier and the file location, 
currently resolved as a local file (or directory) path. Like in file systems, “File’s” records are 
a hierarchical system, with cross-references to parent and children records. When a file is 
loaded, it becomes registered at the “File” collection, and once the user fills in its descriptive 
and semantic metadata, it is stored in the “File Metadata” collection. Files are fed into and 
out of the jobs.  
                                                     
 
12 https://github.com/Multiscale-Genomics/VRE 
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Figure 4.29: Main Mongodb collections of the MuGVRE database. 
Records in each collection may present varying sets of fields, so object models described here are indicative, especially in the 
case of the catchall collection “File Metadata”. Dashed lines indicate relationships among collection fields - controlled at the 
programming layer. 
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Tool execution lifecycle 
MuGVRE is responsible to compose an operable job for PaaS components and remotely 
invoke it. Figure 4.30 shows a top-level flow diagram on the actions carried out when the 
researcher clicks the “Run Job” button, after defining the run parameters for a given tool. 
This section explains in detail each of the boxed stages depicted in the diagram. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I. When the researcher, at the frontend, starts a Tool execution, behind, a new job 
management process is triggered and registered. Firstly, a “run” folder, named 
according to user’s preferences, is created in their private workspace, registered in the 
database, and set as the execution working directory. If the action would fail – e.g. the 
directory becomes not accessible –  an error is raised until the web frontend. 
II. A set of auxiliary files are prepared on the fly containing all the application-specific 
details 
Figure 4.30: MuGVRE diagram flow for job processing 
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-  “config.json”: contains the values that application’s arguments and input files take 
for that particular run. 
- “input_metadata.json”: contains all the metadata associated with the selected input 
files as stored in the metadata database.  
As any application-specific information is enclosed into these auxiliary files, MuGVRE 
can call all the Tools using a single and generic interface. In this way, there is no need to 
learn how to build the particular CLI of each of the encapsulated applications, such 
burden is managed internally by MG-TOOL-API in each Tool implementation at the VM 
level. 
III. MuGVRE performs the remote job invocation submitting the following agreed BASH 
command: 
# (A) # For standalone applications 
 
[APPLICATION_EXECUTABLE]                            \ 
         --config [config.json]                    \  # IN 
         --in_metadata [input_metadata.json]       \  # IN 
         --log_file [log.txt]                      \  # OUT 
         --out_metadata [results.json]             \  # OUT 
 
# (B) # For COMPSs applications 
runcompss                                              \ # COMPSs runtime 
    --summary                                          \  
    --jvm_workers_opts="-Xms5120m,-Xmx5120m,-Xmn1024m" \  
    --base_log_dir = [WORKING_DIR]                     \ 
    --lang = python                                    \ 
    [APPLICATION_EXECUTABLE]                        \ 
         --config [config.json]                    \  # IN 
         --in_metadata [input_metadata.json]       \  # IN 
         --log_file [log.txt]                      \  # OUT 
         --out_metadata [results.json]             \  # OUT 
Snippet 4.3: Process submitted by MuGVRE to the corresponding Tool VM. 
The executable always responds to usage (A), for standalone applications, or (B) for runs configured with COMPSs. 
[Application_Executable] corresponds to the script provided by the software developer 
that acts as an adaptor: interprets MuGVRE job invocation and passes this information 
to the actual wrapped application. MG-TOOL-API helps developers to build such an 
adaptor. The arguments are basically the job auxiliary files above mentioned, as well as 
information about where MuGVRE can find application’s logs and output files. As such, 
application’s CLI heterogeneity is handled by software developers when coding their 
own wrapping script, a strategy that provides total transparency and flexibility. 
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IV. Job execution continues by submitting the referred command to one of the two 
schedulers: PMES or SGE. The task implies crafting valid job compositions, considering 
aspects as the following: 
 Management of application’s input requirements, in terms of input files and 
arguments.  parameters incompatibility, dependency or compulsory usage. Initial 
validation of type and format. 
- tailoring and dimensioning job petition according to the defined resource 
requirements: not only configuring job’s cores and memory, but ensuring such 
requirements could be met by the target IaaS (e.g. listing available OCCI resource 
templates). 
- ensuring data availability to the VMs: not only researcher’s data but also reference 
data, as further discussed in the following section. 
 
If SGE is enabled, a queue submit script  exemplified at Snippet 4.4 is submitted to the 
virtual machine where the relevant Tool is installed.  
#!/bin/bash 
# Generated by MuGVRE 
 
#$ -q naflex.queue 
#$ -N vre2598_naflex 
#$ -o /shared/MuG/userdata/MuGUSER59e5ead574743/__PROJ5c7cce4ed06/run000/.tool.log 
#$ -e /shared/MuG/userdata/MuGUSER59e5ead574743/__PROJ5c7cce4ed06/run000/.tool.err 
 
# Moving to working directory 
cd /shared/MuG/userdata/MuGUSER59e5ead574743/__PROJ5c7cce4ed06/run000 
 
# Running naflex tool ... 
echo '# Start time:' $(date)  
/home/NAFlex/NAFlex_wrapper.py  \ 
   --config       /shared/MuG/userdata/MuGUSER59e5ead574743/__PROJ5c7cce4ed06/run000/.config.json  \ 
   --in_metadata  /shared/MuG/userdata/MuGUSER59e5ead574743/__PROJ5c7cce4ed06/run000/.in_metadata.json \ 
   --out_metadata /shared/MuG/userdata/MuGUSER59e5ead574743/__PROJ5c7cce4ed06/run000/.results.json \ 
   --log_file     /shared/MuG/userdata/MuGUSER59e5ead574743/__PROJ5c7cce4ed06/run000/.tool.log \ 
 
echo '# End time:' $(date)  
Snippet 4.4: BASH script prepared by MUGVRE to run a standalone application  
Here, NAFlex via SGE 
 
If PMES is enabled, MuGVRE builds at runtime a job definition according to JSDL 
specifications (example at Snippet 4.5) and POST such data to the PMES 
“createActivity” REST endpoint. Data includes the identifier of the VMI to be deployed, 
along with other context parameters. 
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 { 
   "jobName": "G1-S", 
   "compssWorkingDir": "/shared/MuG/userdata/__PROJ5c93530a68/G1-S", 
   "wallTime": 1440, 
   "memory": 50, 
   "cores": 2, 
   "minimumVMs": 1, 
   "maximumVMs": 1, 
   "limitVMs": 1, 
   "initialVMs": 1, 
   "disk": 1.0, 
   "inputPaths": [], 
   "outputPaths": [], 
   "infrastructure": "mug-irb", 
   "mountPoints": [ 
        { 
           "target": "/shared/MuG/userdata", 
           "device": "/services/MMB/lab/MuG/userdata/MuGUSER5af1b916c27a2", 
           "permissions": "rw" 
        }, 
        { 
           "target": "/shared/MuG/MuG_public", 
           "device": "/services/MMB/lab/MuG/MuG_public", 
           "permissions": "r" 
        } 
    ], 
   "numNodes": 1, 
   "user": { 
       "username": "vre04385", 
       "credentials": { 
           "pem": "/home/pmes/pmes.pem", 
           "key": "/home/pmes/pmes.key", 
           "uid": 33, 
           "gid": 33, 
        } 
    }, 
   "img": { 
       "imageName": "uuid_nucldynmgtoolapi_48", 
       "imageType": "small-max" 
    }, 
   "app": { 
       "name": "nucleosomedynamics", 
       "interpreter": "python3", 
       "target": "/home/pmes/nucleServ", 
       "source": "nucleosome_dynamics.py", 
       "args": { 
         "config":      "/shared/MuG/userdata/__PROJ5c93530a68/G1-S/.config.json", 
         "in_metadata": "/shared/MuG/userdata/__PROJ5c93530a68/G1-S/.in_metadata.json", 
         "out_metadata":"/shared/MuG/userdata/__PROJ5c93530a68/G1-S/.results.json" 
        }, 
       "type": "Single" 
    }, 
   "compssLogDir": "/shared/MuG/userdata/__PROJ5c93530a68/G1-S" 
 } 
Snippet 4.5: MUGVRE job petition for PMES createActivity endpoint. Specification : JSDL 
Job 
resources 
& 
definition 
Data 
management 
Virtual user 
setting 
VMI 
template & 
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resource 
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V. Once the job is sent, MUGVRE monitors the job and reports its progress pulling the tool 
raw log file, which is processed to be nicely displayed on the web. The whole execution 
cycle is controlled via libraries designed to interact with PMES (via REST) or SGE (via 
local network). 
VI. After the job’s completion, the main task of MuGVRE is to register the output files 
created during the execution in the “Files” and “Files Metadata” Mongodb collections. 
This way, they become available in the workspace and eligible for new runs. Apart from 
receiving task managers’ error, MuGVRE detects that an error has occurred during the 
remote execution based on the fulfillment of output file requirements, which are set 
up as required or optional during the tool registration process. If a required output file 
is missing on job completion, MuGVRE considers that an error has occurred, and 
indicates so publishing on the workspace a file with the log information gathered along 
the execution.  
 Authentication and authorization 
Data privacy is maintained using the INB’s (National Institute of Bioinformatics) 
authentication and authorization server13 to securely handle user access and Web 
communications. Keycloak implements OpenID Connect on top of the OAuth2 protocol, a 
token-based authentication flow widely used for the REST services (implicit flow) and Web 
applications (authorization code flow). On the web, registered users are redirected to the 
authorization server following the authorization code grant, which accepts 
username/password credentials backed up by a local LDAP database. Alternatively, the 
server may proxy to third-party identity providers, including social IDs like Google or ORCID, 
as well as the European life research AAI facilitated by ELIXIR.  
MuG components like MuGVRE and data MuG RESTful services (e.g. DM-API [229]) have 
integrated OAuth2 clients in order to interact with this MuG authentication server. MuGVRE 
uses it not only to authenticate their users, but also to display the access token 
(automatically refreshed) on the web (Figure 4.31). In this way, researchers can consume 
MuG APIs directly, outside MuGVRE web framework.  
 
 
                                                     
 
13 http://inb.bsc.es/auth 
Computational infrastructures for biomolecular research 
 
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding the authorization, MuGVRE has three types of user accounts in order to have a 
fine grain control of the authorization roles and permissions over resources (i.e. files, jobs, 
tools): 
- Users: own and administrate their data on their personal workspace. They 
correspond to either registered user accounts, or anonymous records if they have 
not been logged in. Available functionalities are the same for both user’s modes, 
with the only difference that some tools affected with licensing issues might not be 
eligible by non-registered users, as MuG agreement terms are only accepted during 
the registration procedure.   
- Tool developers: own data, but also tools. They are authorized to submit new tool 
petitions, and manager their already integrated tools. They decide over its 
accessibility and visibility, its configuration, etc. They access their logs, statistics, and 
other debugging information.  
- Administrators: full access to all user accounts. They administrate accounts, their 
runs and their tools. 
As access controls are implemented at the application level, KeyCloak accounts are mapped 
into MuGVRE accounts, which have MuG identifiers and distinct authorization privileges 
and roles associated with them. MuGVRE keeps the two systems synchronized by injecting 
the identifier (“mug_id”) into the Authentication Server every time a new user is registered. 
Figure 4.31: Users’ access Tokens are displayed at MuGVRE 
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Doing so, we manage to securely circulate the “mug_id” as part of the user token among 
the different MuG services. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Data management 
MuG’s data repository stores both data related to the project, user workspaces and 
metadata, as well as pointers to relevant data stored in public repositories, either produced 
by MuG or by reference providers. An accurate management permits to import user’s and 
reference data in the platform, as well as to keep it private and isolated in the dynamically 
created virtual executions. Moreover, a metadata-driven system enables not only enhanced 
user experience but also the automation of the application’s management. 
 User’s Data 
Researchers import their data into the platform via HTTP(s) or FTP(s) using the MuGVRE 
frontend. Either coming from a local user’s file or a public URL (open or protected), an 
asynchronous data load is initiated using a CURL-based job, visible at user’s workspace. Like 
for transPLANT public data, user files are saved in a block storage accessible on the cloud 
Figure 4.32: MuG token-based authentication across several MuG services   
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network both by MuGVRE application and the rest of VMs that undergo job executions. 
Thus, a unique NAS per IaaS is the basis of the MuG data cloud - user’s data is staged in at 
the moment user uploads it on the UI.  
Analysis tools grant access to user’s data differently depending on the job manager that 
leads to the execution. If SGE is configured for such a tool, the virtual appliance corresponds 
to a set of long-live VM(s) which trivially access via NFS to the whole MuG shared storage 
on an auto-mount basis. If PMES is enabled, an extra layer of data privacy is granted, as the 
only piece of data mounted by contextualization is the one belonging to the particular user 
launching the job (Figure 4.33). As shown in the JSDL example of Snippet 4.5, on each run, 
different  “mount_points”  can be set, and for user’s data, the device targets a user’s 
particular directory  (i.e. /services/[…]/userdata/MuGUSER5af1b916c27a2).  
 
 
 
 
 
 
 
 
User’s data in disk is organized following the “User > Project > Workspace” hierarchy: 
MuG_userData/ 
+ --- user_id1/ 
|     + --- project_id1/ 
|     |     + --- Uploads/                # Contains data uploaded by user 
|     |     |     --- MyInput1.txt 
|     |     |     --- MyInput2.txt 
|     |     + --- Repository/             # Contains data sourced from public repositories 
|     |     |     --- SRA0000.fastq 
|     |     + --- Run000/                 # Contains data generated during a job execution 
|     |     |     --- MyOutput1.txt 
|     |     |     --- MyOutput2.txt 
|     |     |     --- .tool.log 
|     |     |     --- .tool.err 
|     |     |     --- .in_metadata.json 
|     |     |     --- .config.json 
|     |     |     --- .results.json   
|     + --- project_id2/ 
Snippet 4.6: Directories hierarchy for MuGVRE user’s data 
Figure 4.33: PMES data management based on a shared NAS. 
Pre-emptive VM’s mounts only the data belonging to the user that launched the execution   
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MuGVRE sets a working directory - “Run folder” (e.g. “Run000” in the previous snippet) – 
for each job submission, and it does so on the shared disk, so that virtual appliance can 
directly access it. As shown, the data structure inside a workspace is quite rigid, with 
thematic directories for “Uploads”, “Repository” data and n “Run” folders. User can create 
n workspaces, called “Projects”.  
Remotely, MuG data can also be accessed using a simple RESTful API14, in case data is willing 
to be accessed outside MuGVRE premises. It is implemented as a simple HTTP(S) interface 
written in PHP using the PHP Slim MVC framework.  The API features two routes secured 
using the MuG central authentication server that returns the actual data given a file 
identifier. It complements MuG APIs, implemented outside BSC, which expose MuGVRE 
files’ metadata and offer filtering and navigation options.  
 Reference Data 
MuG public data is treated very similarly to transPLANT public data. The globally accessible 
NAS is the chosen strategy, with the restriction of being accessed under read-only mode. 
However, unlike transPLANT, the UI offers a selection of 3D/4D genomics relevant datasets 
that user can, i) browse the available data in an integrated way, ii) use in MuGVRE analysis 
infrastructure, and iii) download in the appropriate formats for in-house further analysis. 
Such repositories currently include: 
- ArrayExpress [9]: a selection of HiC, MNase-seq, ATAC-seq and sequencing 
experiments related to 3D/4D genomics. 
- BigNASim (8.7 Publications) [228]: a selection of nucleic acid trajectories (molecular 
and coarse-grain) focused mainly on chromatin modeling transcription factors. 
- Senescence: chromatin assembly models of HiC senescence human data derived 
from MUG’s use cases 
Data is fetched from the original repository over the network (using annotated URLs or 
provided REST APIs) and transferred to the MuG cloud. MuGVRE tries to automatically infer 
and register the minimal descriptive metadata for the sourced files (e.g. based on the file 
extension) before displaying them on the user’s workspace, under the “Repository” 
directory.  
                                                     
 
14 https://github.com/Multiscale-Genomics/VRE_data_api 
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 Pilot for distributed data system 
Both, public and user’s data, are transparently accessible over the cloud VLAN, but not from 
outside. It limits the adoption of cloud computing federations, because even if PMES 
enables remote executions across multiple clouds, data dependencies would hamper the 
full implementation. Hence, available multi-institution storage solutions are explored with 
the aim to integrate the most convenient one into the current MuG DMP – preserving as 
much as possible the current model. 
oneData system is chosen as the most suitable solution. It permits a totally transparent use 
of the remote data resources offering a virtual POSIX file system mounted by FUSE, son no 
major disruptions are expected in the DMP already in place. The data redundancy rule 
applied is “copy on read”, convenient for unbalanced data clouds like MuG’s, very diverse 
in terms of proximity to public repositories’, capacity and accessibility. In this way, data will 
be transferred from one cloud to the other only under demand during job executions. 
Furthermore, the activation of user’s virtual storage is a POSIX-based and non-interactive 
process, essential to be latter integrated into the dynamic and user-specific 
contextualization of the storage via OCCI at boot time. Additionally, oneData supports 
OpenID connect protocol, becoming trivial to encompass it with MuG authentication 
system. And finally, the system supports mechanisms for sharing datasets, a feature that 
could well complement MuGVRE. 
Although oneData is not yet part of MuG platform, a pilot installation is built and configured 
at BSC premises in order to design a detailed integration plan. The installation is composed 
Figure 4.34: Browsing and selection of data from ArrayExpress. 
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of two VMs (oneProviderEBI and oneProviderBSC) emulating two geographically separated 
clouds each contributing with storage capacity. A third VM federates the providers under a 
unique view (oneZone), and a last VM represents a client (OneClient) accessing the storage 
via oneZone, for instance, MuGVRE or any of the VM tools. They all are emulating a scenario 
where a oneProvider server is on top of each MuG cloud, with its corresponding local NAS, 
while a Zone has access to them via TCP/IP ports. The system already interconnects with 
MuG users via MuG authentication server, and specific openID group’s membership and 
scopes are set up, as oneData uses them to manage data access across clouds. According to 
these, MuG users have access to certain oneData Spaces, virtual views of data volumes 
supported by the distinct cloud NASs. MuG users are configured to have accessible by 
default two Spaces: a private Space, analog to current MuGVRE user’s workspace, and a so 
called “public” Space, planned for caching public repositories’ data. Upon user’s login from 
the client (MuGVRE server), their spaces are transparently mounted by FUSE, making user’s 
files accessible via POSIX regardless their physical cloud datastores. Thus, MuGVRE 
visualizers, running on the web server, could gain access to remote files, which are copied 
locally only when accessed. Similarly, if the system’s login were set up during the 
contextualization of PMES-enabled VMs being deployed into the Embassy Cloud, the VM 
would access to user’s uploaded input file, initially sitting on the cloud hosting MuGVRE and 
transparently transferred to Embassy’s data block. A second execution there, would already 
find the file there. Scripts for user’s registration and Space’s configuration are prepared, all 
via REST oneData API. Next step is integrating them into MuGVRE backend.  
 Metadata 
Metadata creation and handling has sharpened important MuGVRE features in terms of 
user experience, automatic application’s administration, and reproducibility. Backend and 
frontend heavily rely on the metadata stored in Mongodb documents, whose collection 
entries are modeled after the PHP objects used in MuGVRE. The data models more relevant 
are the following:   
Data model Definition MuGVRE DB  Annex 
File 
Descriptive and 
operational metadata 
defining files and 
directories. 
MuG partners prepared REST APIs 
also based on this model.  Its 
specification is annexed. 
“Files” collection: 
operational metadata 
“Files Metadata”: rest 
of metadata 
8.4.1 Data 
Model: “File” 
 
 
8.4.2 Data 
Model : “Tool” Tool 
Metadata describing the 
applications to be 
executed on the cloud 
Defined using JSON schemas. One for 
tool developers willing to register his 
tool. A second, for internal use with 
some extra fields (e.g. identifiers) 
“Tools” collection  
Table 4.4:  MuG data models 
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Such data models include descriptive and technical metadata that help MuGVRE to 
accomplish some basic functionalities like job accounting, data provenance, new tool and 
visualizer integration, tools interoperability, etc. “File” and “Tool” models structure the 
necessary data. 
“File”  data model 
“File” defines a file or directory resource stored in the MuG infrastructure and is 
represented as exemplified in Snippet 4.7. “File” is the junction point between MuGVRE and 
the metadata management APIs implemented by MuG partners. The model corresponds to 
two synchronized collections in MuGVRE database, (i) “Files” collections, strictly storing 
operational metadata that cover the minimal functionalities of MuGVRE as a file server 
application, (ii), the rest of metadata required to build the VRE - semantics and descriptive 
metadata. 
 
{ 
 "file_id": "MuGUSER59e5ead574743_5cf8c3d1b43156.06448028",               
 "path_type": "file",                                                     
 "file_path": "MuGUSER59e5ead574743/__PROJ5c6c417267b522/uploads/G1.bam", 
 "cloud":     "mug-irb",                                                   
 "user_id":   "MuGUSER59e5ead574743",                                      
 "project":   "__PROJ5c6c417267b522.33832470",                             
 "size":      725988911,                                                  
 "parent_dir": "MuGUSER59e5ead574743_5c6c417280d635.07060077",            
 "expiration_time": {"sec": 1559806931,"usec": 0},                     
 "creation_time":   {"sec": 1559806929,"usec": 0},                   
 "source_id": ["MuGUSER59e5ead574743_566041g28dd456.675598”],            
 "tool_id":   "BAMindex",                                             
 "arguments": {"sort": true },                                       
 "data_type": "data_mnase_seq",                                
 "file_type": "BAM",                                             
 "compressed": false,                                           
 "metadata": { 
    "refGenome": "R64-1-1",                                                      
    "taxon_id": 4932,                                                      
    "description": "MNase-seq for S. cerevisiae cells synchronized in G1", 
    "paired": "paired",                                                     
    "sorted": "sorted",                                                     
    "associated_files": ["MuGUSER59e5ead574743_5cf8c3bf2151a3.62251628"],  
    "validated": true,                                                      
    "visible": true                                                                   . 
 } 
} 
Snippet 4.7 : Example for “File” data model in MuGVRE 
 
Operational metadata for user’s input and output files is collected, which provide the 
platform with a flexible data hierarchy, and a dynamic allocation system based on a unique 
“file_id” and “file_path” addresses relative to a cloud storage. Full data access is resolved 
at the application level, either by MuGVRE or MuG data APIs. Together with other metadata 
objects like “JobProcess” or “User”, MuGVRE provides job accounting and data provenance 
system by storing:  file lineage at “source_id” that records job transformation operations; 
input files and arguments values for each run; file and job timestamps with a full registry; 
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tool’s control versioning; operation logging; etc. Such metadata, together with the use of 
sandboxed executions on virtual environments are essentials for achieving reproducibility 
on the system. 
Descriptive metadata accompanying files, as well as applications and visualizers, conforms 
the basis of tool’s interoperability in the platform. “file_type” and “data_type” fields 
conform the minimal descriptive set of metadata required for MuGVRE to operate. They 
semantically define the content (e.g. “DNA sequence”) and format (e.g. “FASTA”) of a “File” 
record. In turn, they constrain suitable input files and specify expected output files when 
applied to “Tool” or “Visualizer” definitions. The metadata matching between both, “Tools” 
and” Files”, permits to interoperate input and output file tools, as well as guide user 
experience, for instance, dynamically building toolkits of “Available Tools” responsive in 
front of user’s workspace file selections. 
“Tool” data model  
“Tool” entity is the MuGVRE PaaS building block and it defines “what” and “how” a Tool 
Developer’s application is to be executed. The following snippet represents a simplified 
example: 
 
{  
    "_id" : "naflex", 
    "name" : "NAFlex analyses",                               
    "title" : "Nucleic Acids Flexibility Analysis",             
    "short_description" : "Set of analyses to extract [...]”, 
    "long_description" : "NAFlex provides a [...]”,            
    "url" : "http://mmb.irbbarcelona.org/NAFlex/",                                    .  
    "owner" : { 
        "author" : " Adam Hospital", 
        [...] 
    },  
    "status" : 1,  
    "keywords" : ["dna", "rna", "dynamics"],  
    "keywords_tool" : ["nucleic acid NA", "flexibility", "curves"],  
    "infrastructure" : { 
        "memory" : 16,  
        "cpus" : 1,  
        "executable" : "/home/MuG/NAFlex/NAFlex_Wrapper.py",  
        "clouds" : { 
            "mug-irb" : { 
                "launcher" : "PMES",  
                "minimumVMs" : 1,  
                "initialVMs" : 1,  
                "imageName" : "uuid_mugMD_99" 
            } 
        } 
    },  
    "input_files" : [ 
        { 
            "name" : "pdb",  
            "description" : "Input Structure, pdb format",  
            "help" : "Input representative structure [...]",  
            "file_type" : ["PDB" ],  
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            "data_type" : ["na_structure"],  
            "required" : true,  
            "allow_multiple" : false 
        },  
        { 
            "name" : "top",  
            "description" : "Input Topology, Amber Parmtop v7 format", 
             [...] 
        },  
        { 
            "name" : "crd",  
            "description" : "Input Trajectory, Amber mdcrd format",  
             [...] 
    ],  
    "input_files_combinations" : [ 
        { 
            "description" : "Analyses from trajectory",  
            "input_files" : ["pdb", "top", "crd"] 
        },  
        { 
            "description" : "Analyses from structure",  
            "input_files" : ["pdb"] 
        } 
    ],  
    "arguments" : [ 
        { 
            "name" : "operations",  
            "description" : "Flexibility Analysis to be computed",  
            "type" : "enum_multiple",  
            "enum_items" : { 
                "name" : ["Curves", "Nmr_NOEs", [...]],  
                "description" : ["Curves", “NMR NOEs", [...]] 
            },  
            "required" : true,  
            "allow_multiple" : false,  
            "default" : ["Curves"] 
        } 
    ], 
    "output_files" : [ 
        { 
            "name" : "NAFlex_report",  
            "required" : true,  
            "allow_multiple" : false,  
            "file" : { 
                "file_type" : "TAR",  
                "data_type" : "tool_report”,  
                "meta_data" : { 
                    "description" : "NAFlex analyses [...]",  
                    "compressed" : "gzip", 
                    "visible" : true 
                } 
            } 
        },  
        { 
            "name" : "CURVES_torsions", 
             [...] 
    ] 
  } 
Snippet 4.8: Example for “Tool” data model in MuGVRE 
 
The use of descriptive fields like “Title”, “Description”, or “keywords”, allows MuGVRE to 
automatically create help and usage applets, tool discovery and browsing functionalities, 
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etc. The “infrastructure” nested object is focused on defining how to remotely invoke the 
application from MuGVRE. It includes the location of the application main “executable” in 
the VM, how to reach it (either via PMES or via SGE depending on the particular VM 
configuration), the computational resources that tool developer estimated necessary, and 
the elasticity bounding parameters.  
On top of that, the enumeration and description of “input_files” and “arguments” per each 
tool permits MuGVRE to build automatic launching tool forms (Figure 4.35) based on PHP 
web templates - some JavaScript may be manually added, for instance, to control argument 
fields dependencies.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35: Tool web form in MuGVRE. 
It is automatically build based on registered database “Tool” record. The example corresponds with the “Tool” 
instance in Snippet 4.8 
“input_files” 
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Such metadata-driven automatism is the first stage of the complete tool management 
lifecycle (Figure 4.36), which is fully controlled by “Tool” and “File” metadata. Such data (i) 
defines MuGVRE submission into PaaS components, (ii) circulates to the deployed VMs, and 
(iii) validates application results.  To achieve so, 
I. “input_files”, “arguments” and “input_files_public” as defined in the “Tool” object 
is used to build the web form, which the researcher fills in with the values for a 
particular run. 
II. these are processed and written down in two auxiliary files. The two JSON files (i.e. 
“in_metadata.json” and “config.json”) that are stored in the newly created “Run 
folder”, which will become the tool working directory. Annex 8.4.3 Job Auxiliary Files 
contain examples of such files. 
III. the “infrastructure” fields on the Tool object (e.g. “memory”, “cores”, “comps” 
enabling, SGE “queue”, VM “image”, application “executable”, etc) are used to 
compose the job petition for the selected job processor (i.e. PMES or SGE), who 
triggers the execution on the underlying cloud. 
IV. on the triggered command the two JSON files are passed as arguments to the virtual 
instance. MG-TOOL wrapper parses these files and composes to actual application 
command with all the necessary information regarding input files and arguments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36: Metadata flow among MuG elements during a tool life cycle. 
Illustration on how user’s selection of input files and arguments are passed from the web to the virtual machine via two auxiliary 
files (config.json and in_metadata.json). “Tools” registry is the primary source. 
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V. once the application finishes, MG-TOOL wrapper writes down into “results.json”  
some relevant metadata regarding the output files just generated. Primarily, it 
includes the metadata that change on each run: “file_path” locations, file 
“source_id”, or custom metadata attributes that tool developers want to inject into 
MuGVRE metadata (“e.g. docking_grid_size”). 
VI. after job completion, MuGVRE builds a File object for each output file by aggregating 
(a) the information stored in the “Tool” object under the “output_files” section (e.g. 
“file_type”), (b) dynamic fields read from “results.json” (i.e. “path”), and (c) 
operational data (e.g. “owner”, “creation_time”, etc). Once output files are 
registered in the “Files” collection, they are eligible from user’s workspace. 
 Use case: Nucleosome Dynamics 
The present section describes the deployment and usage of one of the analysis tools offered 
on the MuGVRE platform, the Nucleosome Dynamics suite. The use case illustrates how a 
scientific method development can benefit from the integration into community-driven 
computational platforms, like MuGVRE or the well-known Galaxy. The example covers the 
integration of the tool at the MuG infrastructure as well as other implementation models. 
The corresponding publication is annexed at 8.7 Publications. 
Nucleosome Dynamics suite 
Nucleosome Dynamics is a suite of programs to define nucleosome architecture and 
dynamics from noisy experimental data. Different studies demonstrated that nucleosome 
positioning is coupled to gene function [230] and that transcriptional activity and 
nucleosome architecture are tightly coupled. The package allows both the definition of 
nucleosome architectures and the detection of changes in nucleosome organization due to 
changes in cellular conditions from MNase-seq and ATAC-seq experimental data. Results 
are annotated sequence files (GFFs and BED) that can be displayed in the genomic context 
thanks to sequence browsers, allowing the user a holistic, multidimensional view of the 
genome/transcriptome. The package shows good performance for both locating 
equilibrium nucleosome architecture and nucleosome dynamics. 
Two specific programs, nucleR and NucDyn, have been specifically developed to perform 
such studies: 
- nucleR performs Fourier transform filtering and peak calling, in order to efficiently 
and accurately define and classify the location of nucleosomes. 
- NucDyn is a method to detect changes in nucleosome architectures based on 
MNase-seq experiments. It identifies nucleosomes’ insertions, evictions and shifts 
between two experiments at the read level. 
Additionally, a list of other nucleosome-related analyses completes the suite: 
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- Location of nucleosome-free regions (NFRs) 
- Classification of transcription start sites based on the surrounding nucleosomes 
- Study of nucleosome periodicity at the gene level 
- Stiffness of the nucleosomes derived from fitting a Gaussian function to 
nucleosome profiles 
Implementation Models 
Nucleosome Dynamics is implemented as a set for R packages and libraries provided under 
several distribution models to fulfill the needs of different users. Moreover, it is also offered 
as a service in two different research platforms. All available distributions are explained at 
Nucleosome Dynamics landing page15, and summarized in Table 4.5: 
 
 
Landing page 
http://mmb.irbbarcelona.org/NucleosomeDynamics/ 
Code distribution 
Standalone 
installation 
Nucleosome 
Dynamics 
CLI 
https://github.com/nucleosome-dynamics/nucleosome_dynamics  
nucleR R 
package 
https://github.com/nucleosome-dynamics/nucleR 
Bioconductor: 
https://www.bioconductor.org/packages/release/bioc/html/nucleR.html 
NucDyn R 
package 
https://github.com/nucleosome-dynamics/NucDyn 
Bioconductor: (in review) 
Containerized 
installation 
Docker https://github.com/nucleosome-dynamics/docker 
Docker-hub: mmbirb/nucleosome-dynamics 
Singularity https://github.com/nucleosome-dynamics/nucleosome_dynamics_singularity 
Singularity-hub:  https://singularity-hub.org/collections/2579 
Platforms in use 
MuG Virtual Research 
Environment 
https://vre.multiscalegenomics.eu/workspace/?from=nucldynwf  
Galaxy Platform https://dev.usegalaxy.es (in development) 
Galaxy Tool-Shed: 
https://toolshed.g2.bx.psu.edu/repository?repository_id=822e9c879cf92fd0 
                                                     
 
15 http://mmb.irbbarcelona.org/NucleosomeDynamics/ 
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Table 4.5: Implementation models for Nucleosome Dynamics 
 MuGVRE tool application 
Nucleosome Dynamics (ND) is one of the analysis methods integrated at the platform that 
offers a set of analyses packed in a single modular MuGVRE tool, together with a custom 
report viewer. Besides, the suite can well interact with other services on the platform, (i) 
ArrayExpress repository includes MNase-seq experiments, that might be used either to 
import FASTQ reads, or bibliographically compare with other nucleosome annotated 
sequences, (ii) alignment tools (BWA, Bowtie2) can be used to produce the aligned reads 
(BAM format) that ND takes as input, and (iii) the resulting nucleosome architectures 
written as annotation files (GFF3, BW) might be visualized with two of the visualizers offered 
at MuGVRE: JBrowse and TADkit. 
Nucleosome Dynamics’ tool preparation  
ND code (Nucleosome Dynamics CLI) is installed, together with its dependencies, in a MuG 
base VMI hosted at the MMB IRB cloud ( see Method’s section 3.1.2.1), in this case, 
configured with SGE. According to MuGVRE Tool integration protocol, either (i) support 
team provides IaaS access to the virtual instance and the Tool Developer directly performs 
the installation there, or (ii) Tool Developer makes its code public, and support team installs 
it in the virtual instance. The chosen strategy mainly depends on the tool installation 
complexity. Here, we have requested direct access to the VM. 
The tool wrapping is implemented on a thin python script dependent on MG-TOOL-API, 
that is able to respond at the MuG agreed CLI. The code parses MuG auxiliary files and 
extracts from them the input file locations and ND arguments. Depending on the received 
arguments, the script builds the ND command(s) of the requested analysis (i.e. nucleR, 
nuclDyn, NFR, etc) and calls a system subprocess on each (Figure 4.37). Pipeline analyses 
are switched ON/OFF by the user on the web, and the wrapper runs them accordingly (i.e. 
arguments.NUCLER: true/false). If multiple BAM instances are given, the pipeline is 
executed multiple times. MUG metadata is read to learn the library type of the given BAM 
(single, paired) and its reference genome (e.g. hg38). ND adaptor’s code is publicly available 
at NucleosomeDynamics-MuGVRE repository16, with some documentation and test data.  
 
                                                     
 
16 https://github.com/nucleosome-dynamics/nucleosome_dynamics_MuGVRE 
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ND requires access to certain reference data, which is part of the MuG data repository 
accessible via NFS under the “public_dir” mounting point on all SGE-enabled VMs. It 
corresponds to assembly associated data (e.g. hg38 annotated genes) used to compute 
nucleosome-related statistics. MuGVRE sends the location of the public directory together 
with the rest of the arguments, and the script uses it to compose the path for the files it is 
interested in. 
Nucleosome Dynamics’ registration  
Once the code is tested and ready, it is time to register it at the platform using a Tool 
Developer user account. The new Tool petition is submitted online, and requires the 
acceptance by the MuGVRE support team. The following information is supplied to the 
platform: 
The Tool definition is the first and essential requirement. All the attributes comprised in 
the Tool data model (8.4 MuG data models) are to be filled in: list of input files, arguments, 
titles, keywords, etc. MuGVRE embeds on the developer’s panel an online JSON schema 
validator that ensures data consistency of the submitted Tools (Figure 4.38 (a)). 
"arguments": [ 
   {"name":"execution","value":"$WORKING_DIR"}, 
   {"name":"NUCLER"       ,"value": true}, 
   {"name":"NUCLER:width" ,"value": 147}, 
   {"name":"NUCLER:hthresh","value": 0.4}, 
   {"name":"NUCDYN"      ,"value": true}, 
   {"name":"NUCDYN:range","value": "All"}, 
   {"name":"NUCDYN:maxDiff","value": 70 }, 
   […] 
{ 
 "_id": "unique_file_id", 
 "file_path": 
"$INPUTS_DIR/chrII_4545.bam", 
 "file_type": "BAM", 
 "data_type": "data_mnase_seq", 
 "meta_data": { 
    "paired": "paired", 
    "assembly": "hg38", 
 […] 
  
Rscript nucleR.R --width 147 --hthresh 0.4 --type paired […] $WORKING_DIR/chrII4545.bam 
Rscript nucleRStats.R --genome $PUBLIC_DIR/hg38genes.gff --input $WORKING_DIR/NR_chrII4545.gff 
Rscript nuclDyn.R --range All --maxDiff 70 --type paired […] $WORKING_DIR/NR_chrII4545.gff […] 
Rscript nuclDynStats.R --genome $PUBLIC_DIR/hg38genes.gff --input $WORKING_DIR/ND_chrII4545.gff 
[…] 
Figure 4.37: MuGVRE wrapper for Nucleosome Dynamics build Rscript calls 
Nucleosome Dynamics Tool Adaptor 
input_metadata.js
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Nucleosome Dynamic Tool definition is available at NucleosomeDynamics-MuGVRE 
repository. 
- After ND is accepted, it appears on the web interface under “Testing” mode, so 
that only the Tool owner has access to it. Some documentation and how-to 
tutorials are then added on the help pages, which are online editable as Mark 
Down files (Figure 4.38 (b)). Extra descriptive information, logo images and ND 
snapshots are also submitted to be displayed on the home page. 
- An auto-contained HTML/JavaScript single page (hereinafter, the custom viewer) 
is prepared in order to display the ND statistical information for each run. The 
viewer prints nicely some CSV files generated during the ND execution as 
histograms and HTML tables. Tool Developers submit it, and the support team 
integrates it at the platform. This is the way the MuGVRE offers the opportunity to 
provide a custom visualization for tool results. It is displayed in the side menu 
“View Results” for each Run folder at the workspace (Figure 4.38 (c)). 
- Example datasets of ND input and output files are prepared and displayed at 
MuGVRE as sample data, enabling a one-click import of demo data at the 
workspace. Indeed, three different datasets are prepared ([220]–[222]) with the 
double propose of demonstrating ND usage to MuGVRE users, and show-casing ND 
method potential during a peer-to-peer journal review. Demo data is under “Get 
Data” section.  
 
 
 
 
 
 
 
 
Running Nucleosome Dynamics 
Running Nucleosome Dynamics (ND) at MuGVRE follows the same basic flow already 
commented on MuGVRE user’s perspective, which can be summarized as: 
I. Get Data 
II. Choose and Configure Tool 
III. Display Results 
(a) (b) (c) 
Figure 4.38 Nucleosome Dynamics Tool submission on MuGVRE. 
(a) Online validation of the Tool object definition. (b) Example of MD help page, online editable. (c) Nucleosome 
Dynamics Custom viewer  
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Choosing “Import example dataset” and “Cell Cycle Data Set” results in a quick sample data 
loading sufficient for demonstration purposes. In our active workspace, two BAM files of 
type “MNaseq data” should appear under the “Uploads” folder. 
We can reach ND Tool from either “Workspace” or “Launch Tool”. The first implies knowing 
in advance what are the input files taken for ND, selecting them at the Workspace, and 
choosing “Nucleosome Dynamics” from the “Available Tools” drop-down menu that 
appears below, next to the shopping card listing selected data. The latter is designed for a 
more exploratory use of MuGVRE.  Launch Tool section lists available tools and visualizers, 
with some descriptive data to browse among them. Nucleosome Dynamics appears under 
“Analyse MNase-seq Data”. We should now set a name for the new job (by default 
run[000]), and configure ND pipeline. The webform lists the ND different analyses grouping 
them under a switch button to enable/disable them. Input file and argument fields are to 
be filled in. If files have already been selected in the “Workspace”, the form already shows 
them in place. If not, the selection of each input field opens a dialog with all the possible 
files suitable for such field, filtering out data with not appropriated “File Format” or “Data 
Type”. 
After job submission, the Run folder appears at the “Workspace”, with all the job 
information (e.g. arguments in use, requested resources) and job status (i.e. PENDING, 
RUNNING, ERROR, FINISHED). Meanwhile, the execution progression also monitored 
checking the log file, either nicely formatted or in raw format.  
On job completion (after 5 – 15’ depending on selected ND analyses), the list of GFF and 
BED files composing ND results appears grouped inside the Run folder. Under “View 
Results”, some run’s statistical data and reports are displayed. 2D sequence annotation files 
are eligible to be displayed by either JBrowse or TADkit, the second more focused on 
chromatin models, so that we choose the generic genome browser. JBrowse is available for 
a selection of reference genomes, including S. Cerevisiae, our dataset’s yeast. ND sequence 
tracks can be visualized and comparatively analyzed with other user’s data, from its 
workspace or imported from ArrayExpress, but also with bibliographic tracks integrated into 
JBrowse a public reference data. 
 Galaxy implementation of Nucleosome Dynamics 
Galaxy platform is the second infrastructure offering Nucleosome Dynamics as an online 
service. It offers similar computational services than MuGVRE, yet Galaxy environment is 
not particularly focused on 3D/4D genomics. The software suite is implemented as a series 
of Galaxy Tools able to conform a complete analysis workflow. 
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Galaxy Tools preparation 
The set of Galaxy Tools prepared for Nucleosome Dynamics (ND) is based on a containerized 
implementation of the ND suite on Docker. The software container encapsulates the R 
libraries of NucleosomeDynamics CLI, together with its dependencies, and a Perl script able 
to interact with them all and trigger their execution. The script is set up as the container’s 
Entrypoint, and beside validating and building ND commands for individual analyses, it is 
able to sequentially evaluate a pipeline of ND commands. The corresponding build data and 
Dockerfile (installation and configuration recipe) is publicly available, as well as the Docker 
image, deposited at Docker Hub (see table Table 4.5). Interestingly identical installation 
workflow was followed to build VMIs for MuGVRE and Docker images 
Galaxy Tools are enriched XML files that serve two basic functions, (i) composition of the 
tool web form layout (e.g. form fields, text, help, etc.), and (ii), specification to Galaxy 
Central on how to invoke the application.  Twelve Galaxy Tools have been prepared 
correspondingly to the six different ND analyses included in the suite and their associated 
statistics module (e.g. NucleR.R and NucleR_stats.R). The invoked command calls BASH as 
job executor, who instantiate the ND Docker image with the appropriate arguments, but 
not before applying some renaming trick. ND software needs to preserve meaningful file 
extensions, and Galaxy erases all when internally storing the data. The temporal soft links 
applied before container instantiation manage to recover the original file extensions. A 
couple of other considerations are worth mentioning when dealing with containers in 
Galaxy. In order to make accessible Galaxy’s data into the virtualized environment and 
enable persistence for generated output files, several Galaxy directories are mounted into 
the container, bypassing permission issues by impersonating Galaxy’s UID (user identifier). 
Galaxy features a native runner for Docker-based tools, yet, it runs all the commands in the 
container, with no option to apply the renaming trick. Other Galaxy components like 
Planemo[231], for building Tool XML skeletons, and Galaxy Tool-Shed repository, for 
publishing resulting Galaxy Tools, have been plenty used.  
Galaxy Tools Installation 
ND tools have been installed in the development site of the ELXIR-ES Galaxy server (version 
19.01) (see Table 4.5). The Galaxy Tool installation procedure is widely documented. Very 
essentially, it consists of placing Tool Configuration Files above described at the right Galaxy 
hierarchy directory structure. Some configuration files need to be edited in order to let 
Galaxy know about the new instances. The actual application software is expected to be 
installed where the Tool will run, here, the same development Galaxy server. For ND, the 
only requirement is Docker, who in turn would handle image pulling if need.  
Regarding ND reference data and demo datasets, Galaxy permits to handle both. Reference 
data can be stored in any local location, while Galaxy configuration files were set 
accordingly. On the other hand, a Shared Galaxy Library is prepared with the “Cell cycle” 
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[220]  sample data. Finally, the “Nucleosome Dynamics” workflow composed by the 
combination of the twelve Galaxy Tools is also published on the site. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.39 Nucleosome Dynamics Worflow in Galaxy 
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Running Galaxy Tools 
Running Nucleosome Dynamics (ND) at Galaxy do not differ much from running any other 
analysis tool in the platform, which is extensively documented. Nonetheless, a Nucleosome 
Dynamics Galaxy wiki17 page has been prepared with step by step information 
.   
                                                     
 
17 https://github.com/nucleosome-dynamics/nucleosome_dynamics_galaxy/wiki 
Computational infrastructures for biomolecular research 
 
149 
 
 Open Virtual Research Environment 
The present chapter explains our efforts on building a neat PaaS orchestrator taking as a 
basis the virtual research environment built for the 3D/4D genomics community. To this 
end, MuGVRE is detached from all domain-specific features to become openVRE. To 
illustrate openVRE reusability, OpenEBench is presented, the ELIXIR’s benchmarking 
platform. 
The candidate has formalized openVRE, and participated in their adoption of it into the 
OpenEBench initiative. 
 Context 
Given the increasing complexity of scientific challenges, multidisciplinary collaborations, 
research process harmonization and multiscale executions are becoming common 
practices. Infrastructures as those above presented, are natural vehicles to support such 
conducts, yet designing and implementing them represent important efforts. Our aim here 
is to lift cloud administrators part of this burden and offer a neat PaaS orchestrator ready 
to be adopted for other scientific communities. 
 openVRE 
openVRE is a PaaS composer that collects job deployment requests from a web exposed 
virtual research environment, and coordinates the resource and service deployment over 
dynamic PMES virtual appliances or directly on a queueing batch system like SGE.  
openVRE aims to be a white canvas with a set of operational services and protocols to 
handle the computational and data resources on an underlying OCCI-compliant cloud 
provider. As a result, a tailored computational infrastructure is rapidly assembled, enabling 
the build, run, and operation of applications in cloud-based infrastructures. After 
configuring openVRE for a particular project, the researcher access to a tailored VRE with a 
set of ready-to-use services (datasets, analysis tools and visualizations) fully adapted to 
their needs. 
To ease the installation procedure, openVRE populate the new Mongodb with 
demonstration data, like a tool skeleton and sample data type and file type. 
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Application’s code, templates and administrative documentation is publicly available18.  
Following, the main configuration file set on bootstrap illustrates the configuration step 
required to set up the infrastructure. 
# config/globals.inc.php.sample 
// Main config 
/************************ 
$GLOBALS['SERVER']    = "https://www.mydomain.com"; // host  
$GLOBALS['BASEURL']   = "/"; // prefix 
$GLOBALS['NAME']      = "Project Name"; // project name  
$GLOBALS['SITETITLE'] = "Project Name | Virtual Research Environment"; // site title 
// Email 
$GLOBALS['mail_credentials'] = __DIR__."/mail.conf"; // SMTP credentials 
$GLOBALS['ADMINMAIL'] = "admin@mail.es"; // BBC address for VRE ticket emails 
// Mongo databases 
$GLOBALS['db_credentials'] = __DIR__."/mongo.conf"; // Mongo access  
$GLOBALS['dbname_VRE']     = "dbname"; // Database name 
//VRE installation paths 
$GLOBALS['root']       = dirname(__DIR__); // VRE root directory 
$GLOBALS['shared']     = "/data/vre/"; // VRE data directory 
$GLOBALS['dataDir']    = $GLOBALS['shared']."userdata/"; // User data directory 
$GLOBALS['pubDir']     = $GLOBALS['shared']."public/"; // Public data directory 
$GLOBALS['sampleData'] = $GLOBALS['shared']."sampleData/"; // Tool dataset directory  
// File manager config 
$GLOBALS['DISKLIMIT']       = 100 // Default user disk quota (GB) 
$GLOBALS['MAXSIZEUPLOAD']   = 4000; // Maximum upload file size (MB) 
$GLOBALS['caduca']          = "182"; // Expiration date for user files (days) 
// Tool integration data models and templates 
$GLOBALS['tool_json_schema']  = "https://github.com/projName/tool_schema.json"; 
$GLOBALS['tool_jsontemplate'] = "https://github.com/projName/tool_template.json"; 
// Oauth2 authentication 
                                                     
 
18 https://github.com/inab/openVRE 
Figure 4.40: Home snapshot of a plain openVRE instance 
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$GLOBALS['auth_credentials']       = __DIR__."/oauth2.conf"; // oauth2 client credentials 
$GLOBALS['authServer']             = 'https://auth.mydomain.come'; //external oauth2 server 
$GLOBALS['authRealm']              = 'realmName'; // keycloak realm 
$GLOBALS['urlAuthorize' ]          = $GLOBALS['authServer'].'/openid-connect/auth';     
$GLOBALS['urlAccessToken']         = $GLOBALS['authServer'].'/openid-connect/token'; 
$GLOBALS['urlResourceOwnerDetails']= $GLOBALS['authServer'].'/openid-connect/userinfo';      
/******************************* 
// Project specific definitions 
********************************/ 
// Cloud infrastructures 
$GLOBALS['cloud'] = "my_local_cloud"; // VRE central cloud. Options in GLOBALS['clouds'] 
$GLOBALS['clouds'] = Array( 
 'my_local_cloud' => array( 
  "http_host"      => "www.mydomain.com",  
  "dataDir_fs"        => "/NFS/export/path/userdata/", // NFS server 
  "pubDir_fs"         => "/NFS/export/path/public/",   // NFS server 
  "dataDir_virtual"   => $GLOBALS['dataDir'], 
  "pubDir_virtual"    => $GLOBALS['pubDir'], 
  "PMESserver_domain" => "pmes.mydomain.com", 
  "PMESserver_port"   => "80", 
  "imageTypes" =>  array(  // OCCI templates indexed by RAM (GB) 
      "2"  => array( // 2GB RAM with 1, 8 or 16 cores 
   "1"  => array("id" => "small", "name" => "small"), 
   "8"  => array("id" => "large-small", "name" => "large-small") 
   "16" => array("id" => "extra_large-small", "name" => "large-small") 
      ), // 4GB RAM with 4, 8 or 16 cores 
      "4"  => array( 
   "4"  => array("id" => "medium", "name" => "medium"), 
   "8"  => array("id" => "medium-medium", "name" => "medium-medium"), 
   "16"  => array("id" => "large-medium", "name" => "large-medium") 
            ) 
  "auth" => array("required" => False) // local access 
 ), 
 'my_remote_2' => array( //(*) 
  "http_host"      => "www.mydomain2.com", 
  "dataDir_fs"        => "/NFS/export/path2/userdata/", // NFS server 
  "pubDir_fs"         => "/NFS/export/path2/public/",   // NFS server 
  "dataDir_virtual"   => "/shared/path/for/userdata", 
  "pubDir_virtual"    => "/shared/path/for/public", 
  "PMESserver_domain" => "pmes.mydomain2.com", 
  "PMESserver_port"   => "8080", 
  "imageTypes" =>  array([...]), 
  "auth"  => array(        // openStack auth API (NOVA) 
   "OS_NO_CACHE"    => "True", 
   "OS_CLOUDNAME"   => "overcloud", 
   "OS_AUTH_URL"    => "https://extcloud05.ebi.ac.uk:13000/v2.0", 
   "NOVA_VERSION"   => "1.2", 
   "OS_USERNAME"    => "username@mail.es", 
   "OS_PASSWORD"    => "s3cr3t", 
   "OS_TENANT_NAME" => "tenancy_name"  
  ) 
 [...] 
Snippet 4.9: Sample configuration file for bootstrapping openVRE. 
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File truncated for the layout. (*)  Registration of more than one cloud infrastructure is possible, as remote operations are 
enabled via PMES. However, data storage only reaches local cloud instances, so currently only on premises clouds are fully 
supported. 
 
From MuGVRE to openVRE 
The origins of openVRE lay on a deconvolution of the MuGVRE application. As a first step, 
the MuGVRE code has been decoupled from MuG domain-specific features, abstracting a 
neat and customizable platform. It includes also the Mongodb database, where the 
registration of analysis tools and metadata for user’s input and output data is stored. Thanks 
to the modular design of MuGVRE, the abstraction updates are mainly limited to the front-
end, and the data per se that populates the database.  
Analysis and visualizer tools are set as separate entities that work as much as possible as 
pluggable appliances. They are sourced from both, a document in the Mongodb, and an 
auto-contained directory with the tool specific data (HTML templates, logo images, assets, 
etc). OpenVRE distribution includes no tools except for a skeleton tool intended to be used 
as a template for future tool integrations. In a similar way, MuG public repositories, 
browsable and ready to be loaded into the platform, have been clean. 
Descriptive and operational metadata accompanying input and output files is an important 
element of the VRE. It is stored in the database, yet loaded through the frontend and 
validated in the backend. The code has been updated in order to reduce such metadata to 
a minimal set of generic attributes, not related anymore to the 3D/4D genomics community. 
In order to improve the system’s reuse, the number of customizable parameters and 
configuration files is not restricted to connectors or VRE settings, but includes project 
descriptions and associated data, so project references are not spread over the code 
anymore. All settings have been centralized in a configuration folder, providing template 
files for a rapid deployment of new openVRE instances, and skeleton data to populate new 
databases. 
Source code is also more sustainable and easy to be installed, as third party dependencies 
have been compiled in a single Composer project file (a PHP package manager). 
An effort has been put to improve the documentation, in particular, the administrator 
information, now included in the GIT repository under the install section. Moreover, the 
code has been reorganized to be more comprehensive. 
A refactoring of several parts of the come has also been carried out, cleaning legacy code 
and fixing some bugs. They are annotated in repository’s CHANGELOG file. 
The result is an easy-to-install code, that centralizes the configuration of other platform’s 
components and permits the modular integration of computational executions reachable 
even at remote virtual environments. Minimal platform’s installation requires: 
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 OpenEBench 
openVRE seeks to be the basis to other computational infrastructures targeting specific 
communities. The VRE developed under OpenEBench’s framework is an exemplification of 
that purpose. 
Context  
In the context of the EU H2020 ELIXIR-EXCELERATE project, OpenEBench is raised as the 
software benchmarking platform. It aims a transparent performance comparison across life 
sciences tools. OpenEBench supports communities by assisting in setting up emerging 
benchmarking efforts, fostering exchange between communities and, ultimately, making 
benchmarking not only more transparent, but also more efficient. The benchmarking 
encompasses technical performance of individual tools, servers and workflows, including 
software quality metrics, as well as scientific assessment in predefined community 
competitions - e.g. RMSD metric’s comparison of predicted 3D structures in a DREAM 
challenge [232]. A fair and relevant comparison relies on the existence of scientific 
communities. They act as a proxy to identify relevant challenges, as well as can play an 
important role in defining reference datasets and metrics to assess those scientific 
challenges. OEB-VRE offers a platform to all these benchmarking communities  
VRE for OpenEBench 
The VRE for OpenEBench (OEB-VRE)19 is a prototyping platform that integrates 
benchmarking workflows, benchmarking datasets and metric’s visualizers on top of the 
OpenEBench cloud infrastructure. The VRE accomplishes a double purpose depending on 
user's role. For community managers, OEB-VRE acts like a platform as a service (PaaS), 
where community-developed benchmarking workflows are plugged into the framework as 
virtual appliances and offered as ready-to-use online applications. Furthermore, such 
workflows can be integrated with public benchmarking datasets to be used as golden data 
or reference.  A second role accomplished by OEB-VRE targets those users willing to 
evaluate their methods. The platform offers a private workspace to load and test their 
results executing the community-given benchmarking workflows. The generated metrics 
(JSON files) can be fed into a metric’s visualizer that generates dynamic plots comparing the 
performance of the submitted method against other community published methods. 
OpenEBench benchmarking workflows are formalized as a series of three different types 
of Docker containers in charge of (i) validating the file provided by the user, i.e. the 
method’s result under evaluation, (ii) computing a set of assessment metrics endorsed by 
                                                     
 
19 http://openebench.bsc.es/vre 
Results 
154 
communities’ golden datasets, and (iii), producing aggregated data based on the individual 
metrics generated during the previous steps. In the current installation, the whole 
benchmarking workflow is encapsulated in a single virtual machine, which is internally 
orchestrated by the Nextflow manager. Each VRE tool (i.e. benchmarking workflow) has a 
main executable for triggering the workflow and collecting metrics files, which indeed 
corresponds to a python wrapper that make use of MG-TOOL functionalities to ensure 
compatibility with OEB-VRE. The job processor in use is SGE, as jobs are quick and not-
demanding runs that can easily fit in the on-premises OpenEBench cloud, in the prototype 
installation, the BSC Life cluster (hardware details on table Table 3.1). 
The infrastructure is up and running, with two engaged communities (The Cancer Genome 
Atlas (TCGA) [233] and Quest for Orthologs (QfO) [234] who already have set their own 
workflows, and others organizations like DREAMS or Global Microbial Identifiers (GMI) 
[235] that plan to follow suit. 
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5 . Discussion 
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This chapter discusses from a global perspective the presented infrastructure 
solutions by addressing transversal dimensions of the same and showing the 
overall progress achieved in parallel with the progression in the field. 
 
Designs and implementations presented in the current dissertation illustrate an evolution 
that well represents the advance of the research supporting technologies in the last years, 
during which e-science principles rooted down to all the investigative community. 
Covering very diverse scenarios and divergent use cases, the first presented infrastructure 
is framed on the clinical data management field, and focuses on the data platforms build 
around two epidemiologic case studies on Immune-Mediated Inflammatory diseases 
(IMIDs), IMID-clinica and IMID-longitudinal. Making the leap to distributed infrastructures 
more oriented on analysis process support, the transPLANT infrastructure represents a first 
intrusion into the topical cloud computing model. It is focused on plant genomics and its 
design became the seed for a more integrative cloud-based solution, this time developed 
for members of the 3D/4GD genomics community. MuGVRE is the visible face of the 
resulting product. Becoming obvious the transversal potential of cloud-based 
computational infrastructures as virtual research environments, openVRE is implemented 
as an abstraction of MuGVRE. It offers a vanilla platform with computation, data and 
administration services ready to be adopted and customized by other scientific 
communities. 
Uneven in architecture, motivation or context, all the proposed software platforms 
represent an opportunity to establish better research processes through enhanced 
collaboration, data management, analysis practices, and resources’ optimization. 
User’s perspective  
Considering the integrative approaches for decentralized or heterogeneous user’s 
communities here presented, it is not surprising that a common trait between them is the 
Web accessibly. Web applications are the most popular strategy in life sciences to expose 
data and software tools to the researcher in a user-friendly way. Bioinformatics researchers 
were early adopters of web technologies, and online information and data sharing is part 
of their daily routine work. On the other hand, biomedical communities like those from 
IMIDs’ project, are not that used. 
Still today, right in the digital era, the human factor is one of the causes preventing the full 
establishment of IT health systems [236][237] in hospitals and health centres. However, 
large-scale multi-center initiatives like IMID-clinica or IMID-Longitudinal, would by 
unfeasible without online support.   Increasingly, the electronic data capture (EDC) is being 
chosen by biomedical investigators over the traditional paper-based data collection in 
observational studies, as it is shown that EDC avoids mistakes and omissions, shortens 
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clinical study duration, reduces data collection costs, and facilitates post-analysis. 
Surprisingly enough, the implementation of electronic-based studies is still an open 
discussion because of patient’s trustfulness or assistance work interference [238][239]. 
Overcoming this barrier is one of the challenges of IMIDs’ projects, addressed to clinicians 
dedicated to providing high-quality patient care while conducting clinical and translational 
research. In order to enhance user’s commitment, and offer full guidance to the clinicians 
undergoing the laborious task of entering the data into the system, IMIDs’ applications 
provide complete user-friendly web interfaces, highly contextualized and with 
automatisms, data control toolkits and complete monitoring options. In order to produce 
effective research outcomes, critical values are data quality, consistency, and integrity, so 
that the application also integrates clinical data management components like monitoring, 
reviewing, accounting, statistics, etc. e 
transPLANT community is diametrically opposed to IMIDs’. Plant genomics first concern is 
the actual computational capabilities of the infrastructure, more than its top-level user 
experience. Programmatic access via SOAP and RESTful APIs was the preferred way to gain 
access over computational services, while FTP was used to stage the data in and out of the 
cloud. Even so, the infrastructure features a dashboard to handle on the web the 
deployment and monitoring of virtual appliances as batch executions, and a web-based data 
manager to handle reference datasets, input files, and results. The two user interfaces 
accomplish with the propose of supporting the whole life cycle of genomics plant analyses 
on the web. Later, transPLANT “Data Manager” will become the seed of MuGVRE, extending 
and broadening the data-centric file manager until it grows into the workspace of a full 
research environment. 
Virtual Research Environments (VREs) are a step forward in terms of user experience. They 
seek to support research processes on a particular domain while enhancing the 
coordination and cooperation of multidisciplinary, or even interdisciplinary, teams. Their 
objective is to make computational analyses accessible to non-programmers. Resource and 
service integration (i.e. data, tools, and visualizers) under a single framework is the chosen 
approach. The young 3D/4D genomics community is intrinsically multidisciplinary, 
integrated by several omics expertise and simulation methodologies. The users show highly 
diverse profiles, not only in terms of technical skills, which are presumably higher for Tool 
Developers than for researchers, but also when considering their unequal scientific 
background. With a clear inclusive focus, MuGVRE guides and assists the researcher along 
with online tasks, aided by a rich set of functional metadata that provides framework’s 
customization, data discovery, automatic operation detection, etc. Interface’s core is a 
simple to use and versatile workspace, and features also user’s support tools like 
comprehensive help pages and tutorials or a ticketing system for addressing helpdesk issues 
to the actual tool developers. Together with the user-friendly one-stop interface, MuGVRE 
expects to contribute in shaping up the 3D/4D genomics community around the 
infrastructure. Recently, another relevant implementation has appeared in response to the 
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integration need of this community. HiC-Explorer [240] also offers a set of 3D chromatin 
modeling comprehensive tools with some specialized visualizers, in this case, based on a 
Galaxy server. 
Other research domains might find applicability in implementing a modular and integrative 
platform upon a cloud approach. To this end, openVRE offers a platform’s abstraction of 
MuGVRE where Tools, Visualizers, and datasets are decoupled from the core infrastructure 
to offer a vanilla version of the platform, ready to be adopted by other communities with 
similar needs. This is the case of OEB-VRE, the VRE for the OpenEBench ELIXIR 
benchmarking community. It aims to establish a standard methodology to objectively 
compare software performance. Tools encapsulate benchmarking workflows of scientific 
methods under evaluation. The advantage of the pluggable system is that the VRE core is 
unaware of the encapsulated code, which could be a standalone application, or a complex 
COMPSs workflow that in turn instantiates a transient virtual cluster at runtime. Actually, 
openVRE flavours (MuGVRE, OEB-VRE) are offering not only a bench of domain-specific 
tools on top of on-demand resources – i.e. a SaaS –, but also a platform where to develop 
and deploy new analysis methods, a PaaS. In these terms, Galaxy workbench follows a very 
similar approach, as well as Omics Pipe, both modular data analysis platforms offering 
comprehensible working environments and implemented as portable infrastructures (see 
1.5.2.2 Workbenches). In fact, they even support workflow management, and particularly 
in Galaxy’s case, they feature an important variety of tools. Yet, openVRE better exploits 
cloud elasticity, as it consumes virtual resources on-demand, as discussed below, while 
either of these other implementations are in fact static virtual clusters with no dynamic 
scalability mechanisms. Interestingly, Galaxy Europe has started a pilot project of 
distributed execution to partially address this issue, by extending the available resources in 
a community effort contributed by ELIXIR-ES (BSC). 
Certainly, scientific communities tackled here are as diverse as present-day, but they 
exemplify how the proposed infrastructures might act as integrative tools and unifying 
factors for scientific data management and computational analysis, as well as articulators 
of new research practices.  
Data access and management 
The way research is conducted has evolved from simple experiments to computer-assisted 
computation, from individuals working in isolated laboratories to global networks of 
researchers collaborating on a single topic. Often, this new paradigm results in important 
amounts of data, and an extensive network of researchers, which focused the attention into 
the research data lifecycle, and how to properly manage it. 
Efficient and adequate management of data is a crucial responsibility of computational 
infrastructures, especially challenging on distributed computational environments like the 
cloud. Their services are hosted in virtual environments where the services outlive the 
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computers they are hosted in - temporarily reside in virtual appliances that go up and down 
and migrate around different computers. Thus, networking is an intrinsic element of data 
management systems, and the basis of the proposed solutions. transPLANT stages user’s 
data in and out on every deployment, while openVRE’s systems are based on a centralized 
storage accessible on the network, with a pilot study of being federated. 
PMES, as part of the natural tool execution lifecycle, was able to transfer data via FTP(S) 
into virtual appliances after booting and stage it out before the instance extinction. It does 
it transparently, and permits data persistence on the pre-emptible computational virtual 
environments as long as cloud connectivity capabilities allow so. Coupling data staging with 
deployment process provides transPLANT cloud data portability. Summed up to PMES 
remove invocations, transPLANT computational services achieved full portability, 
something notably advantageous as it opens the door to practices such as cloud brokering 
to off-load peak demands or move processing closer to data centres. Furthermore, 
transPLANT was based on standard protocols and privacy-preserved data sandboxing and 
transferences. Still and all, the solution entails high data transference rates, one of the 
major barriers recognized by researchers hindering cloud computing adoption at life 
sciences [241]. Even being transparent to the user, data exchange represents important 
overheads. Accordingly, the use of local repositories where public reference data is 
integrated, limiting the portability of those applications to those cloud installations that pre-
allocating the required datasets. Another side effect of loading data into virtual appliances 
is the need for a dynamic dimensioning of the virtual local disk where files are loaded and 
output data created. Virtualization and standards like OCCI allow to dimension storage 
resources on each deployment, yet, the difficulty lays on automatically adjusting the size 
better fitting the individual run. 
Alternatively, data can be centrally allocated in a cloud repository made accessible to virtual 
machines via contextualization. This is the strategy chosen within openVRE-based 
infrastructures (MuGVRE, OEB-VRE), where the web application loads data into a network-
attached storage (NAS) via NFS, and virtual appliances access such data on the same way. 
Certainly, transferences are minimized, and privacy preserved by automatically 
contextualizing storage user-specific mounting points. The price to pay is usual NAS network 
limitations so that processes might become I/O bound unless cloud capabilities include a 
high-speed bandwidth [242]. And importantly, central data location constrains the 
deployment of applications to those IaaS where the data is being allocated, limiting 
elasticity to the resources of such specific infrastructure. The federation of several of these 
cloud datastores into a single virtual space would represent a step ahead and enable full 
portability and distribution. 
Certainly, inter-cloud data mobilization continues being an open issue in the current cloud 
market. Security and privacy are important aspects when provisioning federated clouds, as 
well as performance or networking cost, which usually are not adequate for data-intensive 
Computational infrastructures for biomolecular research 
 
161 
processing. That’s why most federation solutions (see 1.4.4.2 Data-storage solutions) are 
associated with distributed caching systems. In the MuGVRE pilot installation, oneData 
[243] stack is investigated to implement a single virtual data space among MuG clouds. 
oneData provides a uniform layering of access on top of the federated cloud datastores. It 
features a POSIX file system interface that would enable a MuG distributed storage totally 
transparent to MuGVRE tools, so for virtual environments properly contextualized, user’s 
data would be exposed as a standard file system. Moreover, oneData supports the “copy-
on-read” replication strategy, which gives the opportunity to build a data-driven distributed 
computational infrastructure, where scheduling policies would consider not only job 
balancing on federated resources, but also data context. As such, data transferences would 
be reduced as much as possible, dynamically moving computation where data is located. A 
variety of data-aware schedulers are emerging with the need for running distributed 
workflows with data-intensive tasks [244].  Indeed, there is a clear need for research data 
distribution strategies. Galaxy is starting to use CVMFS to generate a virtual repository for 
access data from their regional servers. The limitations on the management of data 
ownership of this system restrict it to publicly available reference data. 
At centralized platforms with the classical client-server architecture like IMID-clinica and 
IMID-longitudinal, challenges are more focused on implementing a flexible and extensible 
design’s rationale that leverages data and metadata handling, indeed, the core of any 
clinical and translational research. Although using a traditional relational database 
management system (RDBMS) like MySQL, IMIDs’ infrastructures implement an extensible 
data model of semi-structured clinical data very in pace with noSQL database engines 
widely popular in the present days. Based on an entity-value table, all the phenotypical data 
is coded and dumped in a single MySQL table, retaining data hierarchy based only on the 
coded identifier instead of the database schema. The non-relational use of the database 
allows untying the study-associated CRF data model from the data platform, which becomes 
a generic EDC system for either case-control or longitudinal cohort studies. Scalability and 
index cardinality are not well exploited under this approach, yet, we are not dealing with 
the terabyte-scale data. This approach, highly unusual at the time of IMID’s design, is 
adopted in modern epidemiological data managers like Opal [245]. Being based on noSQL 
technologies, first, data model is imported (a complex dictionary), and afterwards the data 
is filled in, ready to be annotated and harmonized. 
MuGVRE and OEB-VRE are web applications are already using noSQL technologies. 
Mongodb is used as a flexible storage for storing metadata about data and executions of 
openVREs, which would be difficult to map into relational tables because of its lack of a pre-
defined data model – unstructured data. Operational metadata like logging and accounting 
information is a clear example. Moreover, the engine natively supports data sharding, a 
horizontal scalability strategy that truly exploits cluster-based installations with 
heterogeneous nodes as such presented here. The document-oriented model of Mongodb 
(as JSON) is also terabyte-scale when dealing with complex data models that might be 
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mapped as programming objects at the application layer. Indeed, openVRE bases its 
interoperability on Tools and Files data models, functional metadata enclosing prospective 
and retrospective provenance information, essential for interpreting data, determining 
ownership, providing reproducible results and fault-tolerance processes. Models are 
adhered to clear field specifications. Nowadays, is under question the quality of metadata 
accompanying research data, in spite of the essential role it plays on facilitating effective 
resource discovery, access, and sharing across distributed digital collections [32]. MuG REST 
data services make accessible – to authorized users – such rich metadata, so that datasets 
can be discovered and reused, according to the FAIR guidelines.  
The nature of data handled across infrastructures is another factor highly influencing the 
research plan. Human sensitive data is entrusted under stringent legal restraints that 
restrict the purpose, ownership, security, accessibility, and distribution of data. In studies 
like GWAS, which use personally identifiable genetic markers of the participants as input, 
the privacy of the patients becomes of great importance. Such terms are considered when 
designing the IMID DMP and the specifications for the network of supporting 
infrastructures, as the biobank and the associated data infrastructures here presented, 
which store phenotypical data. IMID consortium, as most of the projects building cohort 
datasets, consume the data it produces and analyse it internally. Consequently, no open 
data distribution channels nor services are implemented. CRF data model is embodied into 
the locally accessed DBMS and remains proximal to the analysis unit. The centralized server 
perfectly serves the purpose of acquiring the data with SSL secured data transfers, patient’s 
identification anonymized, and a central authentication and authorization database. With 
the emergence of data-centric research, the focus is brought into the uptake of open 
science practices data. Although such practices are being progressively adopted for large-
scale studies, lack of credit and reward, legal, privacy issues or even financial aspects are 
hampering his adoption at medium/small studies or already structured institutions with 
legacy consents in place like IMID consortium [34][246]. Accordingly, funding agencies and 
publishers keenly encourage open access, and numerous long-term supported archives 
have emerged [247][4][9], along with a multitude of fine-grain sharing models that enable, 
for instance, closed data - open metadata [35][248]. Yet, in observational studies such as 
the present, the line between phenotypical data and metadata is blurred. 
Infrastructure behind 
The transition into the way research is being conducted would not be possible without the 
adoption of relevant IT technologies consolidated during the last years. Concepts such as 
virtualization, containerization, SOA or distributed computing are experiencing significant 
growth at the bioinformatics domain.  While these technologies are not necessarily new, it 
is how they work as a single entity that ensures their effectiveness in front of today’s data-
driven world. This is happening alongside a tendency toward automating and managing 
infrastructures for availability, reproducibility, and scalability. 
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Such transition is well visible in the technologies in use at the proposed platforms. IMIDs’ 
data platforms follow the most widely used and classical three-tier application architecture: 
a thick client server that includes the logic and presentation, and a data tier managed by a 
relational DBMS, MySQL. On the other hand, the developed computational infrastructures 
are based on the increasingly popular cloud computing model. Presentation layer 
corresponds to web applications or SOAP/REST APIs, who are also responsible for the logics 
tier together with other modules – i.e. remote job orchestrators and elastic workload 
managers, components of PaaS. Data-tier is composed of mass storage, a non-relational 
Mongodb database, and the virtual machines that conform the computing building blocks. 
Each platform is appropriately designed according to the system’s needs, avoiding 
overreliance on novel technologies unless justified. 
While using traditional technologies, IMIDs’ applications accomplish with the requirements 
dictated by the DMP and compliant with ISO 9001 in a flexible and extensible manner. As 
data platforms, their purpose is to conveniently consolidate data and securely store it. 
Although offering a custom interface, the system is designed to be highly flexible by 
decoupling the clinical case report (CRF) design from the application itself. As such, rapid 
data prototyping and low maintenance tasks are achieved. It implies the use of a template 
engine, in-house designed, for rendering user’s interface layout based on clinical variables 
in bulk – pioneer strategy at 2009. Prove of such adaptability is the fact that, albeit 
continuous renovations and extensions, IMID-clinica has been giving service to the active 
IMID consortium for nearly 10 years. IMID-longitudinal is actively collecting data for 2 years 
now. 
transPLANT infrastructure represents a totally different paradigm. Cloud computing offers 
a compelling alternative for computational infrastructures in front of traditionally based 
HPC or grid systems, with the possibility to instantiate and configure in a multi-user 
environment on-demand resources such as virtual computers, storage, operating systems, 
and software tools. For scientists, this constitutes a shift from the model of owning 
computer hardware with the explicit need to then configure connectivity, necessary 
datastores software or system libraries, which in many cases constitutes a demanding and 
time-consuming task [122]. Infrastructures as a service (IaaS) might absorb such complexity. 
Along the present work, two different cloud philosophies are used, the first corresponds to 
the two OpenNebula cluster-based installations sitting at the Barcelona Supercomputing 
Center (BSC) and at the Institute of Biomedical Research (IRB), and the second to the 
Embassy Cloud tenancy hosted at the European Bioinformatics Institute (EMBL-EBI) and 
managed by OpenStack. Both models serve different needs, while OpenStack CMP is more 
suitable for “Infrastructure provisioning” clouds mostly designed for public use, 
OpenNebula is devised as a “datacenter virtualization” cloud better targeting on-premise 
clouds, like those at BSC and IRB, meant to cover institution’s cloud needs. OpenStack offers 
a simplified view of life-cycle’s virtual resources and its underlying infrastructure while 
providing a complete set of data and network services, integrated as independent modules 
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from several vendors – some, proprietary solutions. OpenNebula provides a more 
transparent view of physical resources, works more like a IT-as-a-Service inside the 
organization, it is highly compliant with open cloud standards, features some tool for 
orchestration and networking automation, but is more focused on server consolidation, 
which makes it convenient to support legacy infrastructure components. Furthermore, it is 
easy to be adapted atop existing cluster or HPC facilities, installing a classical cluster-like 
cloud architecture (i.e. cloud frontend and heterogeneous compute nodes behind).  Bearing 
these considerations, MuG, OpenEbench, and other institution’s projects, are managed by 
the cost-effective OpenNebula CMP, while Embassy Cloud, fully dedicated to provide IaaS 
to a large number of scientific projects across Europe, is based on OpenStack.  
Hand in hand with cloud computing, the new computing model fostered the adoption of 
virtualization technologies on research environment, like virtual machines or software 
containers, as well as service architectures, which lead to two scientific major advantages: 
reproducibility and global access. Virtual machines are the building blocks of transPLANT 
and openVRE platforms, they are the deployment units encapsulating Tool Developer’s 
code – as well as other infrastructure’s software stack. VMs play a fundamental role in 
providing the custom and optimal hosting environment adapted to each users’ application 
and, at the same time, isolate the execution from the rest of the infrastructure, thus 
preventing applications from harming the hosting environment or interfering with other 
executions. In fact, the same premises are behind the idea of virtual containers instead of 
full virtual machines, which entail some tweaks and additions to Linux kernel’s “chroot” 
commands so that host and container share the same OS. In this way, they are more 
lightweight solutions with less boot/termination overheads and fewer resource 
consumption, simpler development processes and easily automatable with popular 
orchestration tools like Kubernetes or Docker Swarm. Still, there are a few limitations when 
using containers that constrain their use in multi-user infrastructures with shared facilities 
like BSC’s or IRB’s. Containers provide weak host isolation as compared to virtual machines. 
Sharing OS impacts kernel’s security, complicate setting restricted network accesses, and 
importantly, it is risky to run them with privilege mode, unavoidable when installing most 
of the analysis software and libraries, as containers are daemon processes that might 
exploit such permissions to harm the host OS [249]. Actually, in order to mitigate security 
issues, it is quite common the use of containers nested in VMs instead of running on bare 
metal, off course, in performance exchange [250]. Popular PaaS like Cloud Foundry or 
OpenShift does so. transPLANT and MuG components, as well as current cloud standards, 
perfectly interact with transient stateless, compute VMs, and some of their limitations are 
partially addressed by the platform’s design. For instance, MuGVRE includes not only PMES 
transient VMs but also permanent instances reached by a queuing system, SGE. These type 
of instances are conceived to encapsulate low-demanding applications by which a full VM 
deployment would represent an important overhead over a short and quick execution, 
while permanently allocated resources were only a minor handicap. Moreover, preparing 
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ready-to-use base images results in a rapid Tool prototyping, in particular when aided by 
PaaS programming models or adaptor like MG-TOOL-API. At the same time, the intrinsic 
portability of VMs is enhanced, using a standard image format (QCOW2) and a widely-used 
contextualization package as Cloud-init, supported by several CMPs. Finally, is worth 
mentioning that reproducibility is enabled at the VM level by design, indeed, VMs are 
blocked after the platform’s integration. Yet, the ultimate responsibility on application 
reproducibility relies on the developer and how its tool or workflow are encapsulated.  
Whatever is the job processor mechanism, PaaS components make sure to exploit at best 
the available cloud resources, as both, transPLANT and openVRE platforms, build private 
clusters of VM instances on-demand, without expecting administrators start, manage or 
resize them. Virtual appliances are built and destroyed dynamically thanks to automatic 
provisioning tools, and hence, a very efficient use of the existing hardware infrastructure is 
achieved, especially relevant on public clouds where you pay only on what you use. 
Elasticity is then enabled by PMES and/or COMPSs, capable of dynamically allocating 
resources only as they are needed. On the other hand, for tools launched using the 
traditional SGE queue system, an auto-scalability mechanism called OneFlow is coupled, so 
that the number of hosts backing the queues transparently increases and decreases based 
on system’s workload. Not many platforms include this type of “just-in-time” provision. An 
example would be CloudVR (1.4.3.5 Bioinformatics in the cloud), yet it is distributed as a 
stand-alone IaaS. 
Cloud popularity growth in research environments is undeniable, but scalable resource 
outsourcing is not free of downsides. Funding agencies need to consider resource tenancy 
pricings as applicable, although as discussed, open-source academic cloud providers are 
growing and achieving maturity. At the same time, they also contribute to dilute the 
concern on vendor lock-in, while diversifying providers and adopting open standards like 
those adopted here. It enables interoperability and portability, enabling brokering 
strategies like hybrid and multi-cloud strategies.  EOSC development partially addresses 
these concerns, but a clear approach is not yet defined. Yet, major concerns are regarding 
security and privacy issues when dealing with sensitive data, and data transference and 
archiving when handling large amounts of data. The overhead represented by data 
exchange might be very relevant, and as discussed above, seeking proximity between 
computation and storage is a usual strategy to minimize them. Meanwhile, transparency, 
confidentiality, and control are central concerns for data protection. Currently, there are 
emerging protocols that make possible to craft cloud-based setups compliant with data 
protection laws and regulations [251], [252] while GÉANT is starting to provide dedicated 
private networks under request [253].  
Actually, security is a common denominator across infrastructure services. ELSI (Ethical 
Legal Social Implications) and GDPR (General Data Protection Regulation) are aspects every 
day more relevant on research for those platforms handling and processing user’s data. For 
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addressing them, platforms include measures like the establishment of a sign-in process 
where the user has to read and understand the ELSI constraints and best practices, data 
registry which contains information on the test datasets, or ownership visibility of the 
openVRE integrated tools. Technically, virtualization layer provides isolation, web accesses 
are secured (SSL, firewalls), and authentication services are put in place: IMIDs’ platforms 
have a local authentication based on their DBMSs; transPLANT cloud is based on an LDAP 
centralized authentication server enabling standard POSIX access; and openVREs’ clouds 
implement a single sign-on (SSO) based on OpenID protocol with OAuth2 authentication 
tokens that integrate third-party identity providers like Google, ORCID or ELIXIR. The use of 
standard and widely used protocols favor the integration with other infrastructures, i.e. 
ELIXIR identity, that permits most users sign-on using their home institution credentials. It 
opens the door to exploit openID scopes for authorization flows, not only at the application 
level (i.e. mapping oneData datastores into VRE workspaces), but also across other 
European applications like EGI virtual organizations (VOs) or PRACE resources. 
Platform model 
transPLANT and openVRE computational platforms here presented follows a PaaS model, 
more specifically, a “PaaS for SaaS”, as the ultimate goal of the developed applications are 
to be offered as SaaS, either through PMES dashboard/API or from the corresponding VRE. 
PaaS is characterized to offer a resourceful approach to develop, operate and deploy 
applications at the expense of low cost and time. Certainly, we offer Tool Developers an 
offline development process based on a ready-to-use VMI contextualized to be 
interoperable with our PaaS components. Developers are not responsible nor aware, of the 
infrastructure layer, data staging, service connectivity, etc. Such layers are controlled by the 
platform. 
Here lays the difference with other PaaSs that facilitate the development of fully standalone 
applications, including the definition of a web server, IP address, ports, etc. Developers 
require much more knowledge about the underlying infrastructure, so configuration is 
more complex, and the resulting application is not meant to be part of any framework [254]. 
Indigo cloud and Phenomenal, differences aside, belong to this PaaS sub-model, 
characterized to provide a Desktop-as-a-Service, a full research environment on each 
deployment. Indigo developed their own PaaS orchestrator, Phenomenal uses Terraform, 
and in both cases, the developer configures Indigo/Phenomenal developed pieces using IaC 
technologies to provide a custom virtual framework for the researcher. Indigo focuses more 
on easing PaaS-IaaS interaction, not particularly offering VREs as the final deployed 
application, but any type of custom virtual framework. On the contrary, Phenomenal 
focuses on offering VRE instances tailored for metabolomics research.  
In our case, deployed applications correspond to bioinformatics tools intended to be 
integrated into a VRE – PaaS for SaaS. UI, web server, logging, accounting, or error handling 
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are some of the transversal services covered by openVRE that permit users to concentrate 
on developing the actual tool. Importantly, VREs add extra value to each individual 
application derived from bringing together interrelated analysis tools which might 
interoperate, take profit of similar data sources or make use of specialized visualizers. 
Interoperability, visibility, reusability, and collaboration are the appealing elements that are 
expected to attract and recruit developers to become part of community-driven 
computational platforms. Galaxy is the most mature platform showing a similar deployment 
model. The flip side of the coin is the adoption of restrictions derived from being part of an 
overall framework flow. Presented computational infrastructures support applications in 
batch mode, with no user interactivity at runtime, and file-based input and output data. 
Nucleosome Dynamics tool suite [219] (attached at  8.7 Publications), is a good 
representative of this software releasing tendency by which the developer concentrates on 
the actual application, instead of developing and maintaining their own web application to 
make the new software available. For instance, Nucleosome Dynamics is a set of R packages 
implemented as both, MuGVRE and Galaxy tools. Such practice aims to find synergies, 
economize time, and integrate and standardize methods. 
PaaS orchestrators, or simply the systems centralizing application’s control, are aware of 
the applications only after an installation procedure. In openVRE derived platforms, the 
platform integration is facilitated by MG-tool-API, that provides a Tool skeleton with some 
auxiliary methods to facilitate the testing and development process, i.e. parsing and 
validation of arguments and inputs, logging, output metadata annotation, etc. Still, the code 
is pure python, and the application would be totally functional and autonomous outside 
openVRE environment. The use of adaptors is a practice increasingly extended in front of 
the plethora of novel task managers and orchestrators. They permit the creation of building 
blocks (here VRE Tools) uniformly accessed that easily can be translated into other 
frameworks. BioExcel Building Blocks [255] (annexed in 8.7.3 Thesis not related papers) is 
an example that follows this practice. Galaxy integration is someway similar. The developer 
prepares a Tool wrapper to interact with Galaxy API. Yet, the wrapper uses an XML-based 
domain-specific language (DSL), so that the resulting application cannot operate outside 
Galaxy environment. The reason is that the Galaxy Tool wrapper not only acts as CLI 
adaptor, but also as tool registry and UI template, functions that at openVRE or transPLANT 
are separately accomplished by storing tool metadata as database entries.  In this way, 
openVRE achieves greater flexibility as Tool configuration is centralized in the database 
entry, while Tool implementation can live outside the ecosystem. 
Sustainability 
Sustainability represents a challenge within the existing funding structures. Long-term 
preservation of data and services after a project and its funding have ended is one of the 
major infrastructure dilemmas. Open Science implies, among other things, the optimal 
accessibility and sharing of research data, but without sustained services, these activities 
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are hardly feasible. The main approach is the roadmap synchronization with other national 
or European research infrastructures. 
BSC is in close relationship with European and global tendencies for cloud computing in life 
sciences. In particular, we are active in the European bioinformatics infrastructure ELIXIR, 
the European Open Science Cloud Initiative (EOSC), and the Global Alliance for Genomics 
and Health (GA4GH). Although a federated cross-border cloud ecosystem is an ambitious 
target, these initiatives are in the way of coordinating national infrastructures and setting 
up standard specifications [154]. Presented designs align with these driver projects’ 
interests, in particular, the cloud-based VRE. The global layout of openVRE infrastructures, 
including distributed data and execution, are fully aligned with the combined plans of the 
ELIXIR compute platform and the GA4GH, who is settling specifications and frameworks for 
tools’ registry (TRS), task executors (TES), and data services (DRS). This combined work is 
the basis of cloud computing management for life science at EOSC. One-to-one, the 
presented cloud components align such standards - i.e. Tool DB corresponds to a TRS 
implementation; PMES is a TES, and MuG data services might map DRS specifications. 
Actually, we are working on wrapping such functionalities under REST APIs following GA4GH 
specifications. Decomposing openVRE into such functionalities would allow the integration 
of the cloud-based backend into other platforms, like Galaxy. Some particular transPLANT 
applications were already accessible using the Galaxy UI, yet doing so via standard GA4GH 
mechanisms would ensure a more stable and sustainable integration. 
In a clear next step, seeking interactions with complementary infrastructures helps to build 
a cohesive network of research infrastructures. Therefore, future plans include supporting 
the full research data life cycle, including data sharing and publication. Onedata is the base 
technology used in well-stablished data infrastructures like EGI-DataHub or INDIGO data 
cloud. This reinforces the decision of employing it for data sharing across geographically 
distributed openVRE clouds, as an attempt to proximate data and compute resources. In 
turn, OneData, opposite to other approaches like Galaxy’s CVMFS, provides a fine-grain 
access control based on a OpenID custom method, fundamental to share dataset private 
sand full workspaces with other researchers on the platform. Moreover, the data cycle 
would be complete if generated datasets could be published to dedicated long-term 
archives, like EGA, EUDAT or DOI-issuing platforms like Zenodo. Thus, we are exploring the 
possibility to include submission portals based on REST APIs to these relevant data e-
infrastructures. 
 Security is another design principle that permits to encompass technical and software 
services and processes. Committing MuGVRE to ELIXIR AAI integrates the platform into a 
common access management system, while helping to build and maintain trust in the 
infrastructure. 
Regarding interoperability, cloud computing is a relatively new IT industry and has not yet 
been fully uniﬁed and standardized. Even so, proposed PaaS components are compliant 
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with well stablished specification widely supported. OCCI interacts with the cloud broker 
and handles deployment and provisioning of infrastructure resources. Cloud-init has 
evolved as de facto standard for virtual instances customization, and enables the 
integration with configuration management solutions like Ansible, Puppet of Chef, if 
needed. Remote job submission uses grid-inherited specifications, like BES flow and JSDL 
templates, supported by popular workload managers like LSF or UNICORE. At the 
application level, portability is ensured by VM’s sandboxing, yet, tool description is enclosed 
in an ad hoc domain-specific data model – i.e. our Tool data model. There are some 
specifications available covering similar processes, yet, none did fully meet our 
requirements. For instance, INDIGO data cloud uses TOSCA, but it provides a language to 
describe the application deployment as an orchestration of service components (e.g. 
Tomcat server, database instance), disregarding the application CLI per se as is INDIGO does 
not undergo batch executions. The command line tool description of CWL would better fit 
the purpose, yet it does not cover deployment-related details, only partially included for 
applications with container-based dependencies, and do not consider retrospective file 
metadata like “Data Type” – only format is considered. As such, and in spite of the 
undeniable benefits of adopting community standards, we are right now preserving our 
data model for representing our PaaS applications, while using, however, widely spread 
technologies like JSON and versioned JSON Schemas. Other platforms, like Galaxy, 
introduced their own DSL to cover their infrastructure needs. 
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6 . Conclusions 
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Following are enumerated the conclusions of the present dissertation 
1. We have designed and implemented IMID-clinica and IMID-longitudinal, web-based 
clinical data management systems for the recollection of phenotypical data on 
Immune Mediated Inflammatory diseases (IMIDs) across more than 90 health 
centers. The system offers a user-friendly and familiar interface and reinforce 
research quality data measures, easing the management of large scale data 
collections.  
2. The use of a non-relational data models (even on top of a traditional SQL database 
manager) allows to decouple clinical record schemas from the database design, and 
contributes to gain flexibility in accommodating different epidemiological case 
studies. Clinical data, stored as simple key-value pairs, can be easily used in multi-
cohort complex analysis.  
3. We have assembled the compute platform for the transPLANT project as a flexible 
and portable cloud-based infrastructure where plant genomics tools and pipelines 
were packed and offered either programmatically or via web-based applications 
4. TransPLANT cloud was the initial setup including all the necessary components for 
an integrated user experience, like data manager, software schedulers, and a unified 
procedure to host analysis applications in a portable structure 
5. The adoption of virtual machines as compute units, together with a set of 
middleware able to provision them on-demand offer fully personalized, portable, 
and secure environments where platform’s components conveniently scale both, 
vertically and horizontally. As such, an elastic and cost-efficient is enabled. 
6. We have designed and developed the Virtual Research Environment for the MuG 
project (MuGVRE), a web-based framework seamlessly integrating cloud-based 
resources for a selection of data, visualization, and analysis services relevant for the 
3D genomics community. 
7. The use of a Platform-as-a-Service (PaaS) model, with pluggable tools contributed 
by the research software developers, facilitates that such developers get abstracted 
from the administrative and deployment process and concentrate on the scientific 
implementation. The application Nucleosome Dynamics has benefited from this 
model, being offered through the MuGVRE platform.  
8. The VRE concept has evolved toward the building of openVRE, a neat backbone for 
a rapid prototyping of Virtual Research Environments on the cloud. As a first 
adopter, we have implemented OEB-VRE, an integrative platform for scientific 
benchmarking.  
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 Participant centers of IMID’s clinical studies 
Following, the complete list of health centers participating to one of the two IMID’s clinical 
studies here presented, IMID-Clinica or IMID-Longitudinal. 
Center Patology 
IMID 
Clinica 
IMID 
Longitudinal 
Centro de Salud Virgen de los Reyes (Sevilla) AR x x 
Complejo Hospitalario de León (León) 
EC x x 
CU x x 
Complejo Hospitalario Juan Canalejo (A Coruña) PS x x 
Complexo Hospitalario de Ourense (Ourense) AP x x 
Fundació Clínic per a la Recerca Biomédica (Barcelona) AR x x 
Fundación Hospital Alcorcón (Madrid) PS  x 
Hosiptal Universitario A Coruña (A Coruña) LE x x 
Hospital 12 de Octubre AP x x 
Hospital Clínic de Barcelona (Barcelona) AP x x 
Hospital Clínico San Carlos (Madrid) 
EC x x 
CU x x 
AR x x 
Hospital Clínico Universitario (Santiago de Compostela) 
EC x x 
CU x x 
Hospital Clínico Universitario (Zaragoza) 
EC x x 
CU x x 
Hospital Complejo Asistencial Universitario de León (León) LE  x 
Hospital de la Santa Creu i Sant Pau (Barcelona) 
EC x x 
CU x x 
PS x x 
AR x x 
Hospital del Mar (Barcelona) 
AR x x 
AP x x 
LE x x 
Hospital del SAS de Jerez de la Frontera (Cádiz) 
AP x x 
LE x x 
Hospital del Valme (Sevilla) LE x x 
Hospital do Meixoeiro (Vigo) LE x x 
Hospital Donostia (San Sebastián) 
EC x x 
CU x x 
Hospital Dr Negrin (Las Palmas de Gran Canaria) LE x x 
Hospital Fuenlabrada (Madrid) 
EC x x 
CU x x 
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Hospital Galdakao (Bilbao) 
EC x x 
CU x x 
Hospital General de Alicante (Alicante) 
EC x x 
CU x x 
Hospital General La Mancha Centro (Ciudad Real) 
AR x x 
AP x x 
Hospital General Universitario de Alicante (Alicante) 
PS x x 
LE x x 
Hospital General Universitario de Valencia (Valencia) PS  x 
Hospital Gregorio Marañón (Madrid) 
EC x x 
CU x x 
AP x x 
Hospital Infanta Sofía /Hospital Universitario La Paz (Madrid) AP x x 
Hospital Juan Canalejo (A Coruña) AR x x 
Hospital la Fe (Valencia) 
EC x x 
CU x x 
Hospital La Paz (Madrid) 
EC x x 
CU x x 
Hospital Manises (Valencia) 
EC x x 
CU x x 
Hospital Moises Broggi (Hospitalet de Llobregat) AR x x 
Hospital Monte Naranco (Oviedo) AP x x 
Hospital Mútua de Terrasa 
CU x x 
EC x x 
AP x x 
Hospital Parc Taulí (Sabadell) AP x x 
Hospital Ramón y Cajal (Madrid) 
EC x x 
LE x x 
CU x x 
Hospital Regional Universitario Carlos Haya (Málaga) 
AR x x 
LE x x 
Hospital Sant Rafael (Barcelona) AR x x 
Hospital Son Espases (Mallorca) AR x x 
Hospital Universitari de Bellvitge (Barcelona) 
LE x x 
CU x x 
EC x x 
AP x x 
Hospital Universitari German Trias i Pujol (Badalona) 
LE x x 
EC x x 
CU x x 
AR x x 
AP x x 
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PS x x 
Hospital Universitari Vall d'Hebron (Barcelona) 
AP x x 
LE x x 
PS x x 
AR x x 
EA x x 
Hospital Universitario A Coruña AP x x 
Hospital Universitario Central de Asturias (Asturias) AR x x 
Hospital Universitario Central de Asturias (Oviedo) AP x x 
Hospital Universitario de Basurto (Bilbao) AR x x 
Hospital Universitario de Canarias (Tenerife) AR x x 
Hospital Universitario de Gran Canaria Dr. Negrín (Gran Canarias) AR x x 
Hospital Universitario de la Princesa (Madrid) 
EC x x 
CU x x 
Hospital Universitario de Salamanca (Salamanca) PS x x 
Hospital Universitario 12 de Octubre (Madrid) PS x x 
Hospital Universitario Doce de Octubre (Madrid) LE x x 
Hospital Universitario Guadalajara (Guadalajara) AR x x 
Hospital Universitario Infanta Leonor (Madrid) PS x x 
Hospital Universitario La Fe (Valencia) PS x x 
Hospital Universitario La Princesa (Madrid) 
PS x x 
AR x x 
AP x x 
Hospital Universitario Marqués de Valdecilla (Santader) LE x x 
Hospital Universitario Puerta de Hierro (Madrid) 
EC x x 
CU x x 
LE x x 
Hospital Universitario Reina Sofía (Córdoba) 
EC x x 
CU x x 
Hospital Virgen de la Macarena (Sevilla) PS x x 
Hospital Virgen de la Vega (Salamanca) AP x x 
Parc de Salut Mar (Barcelona) PS x x 
Centro de Atención especializada (CAE) (Cornellà) AP x x 
Hospital clínico Virgen de la Victoria (Málaga) PS x x 
Hospital Comarcal Alt Penedés (Vilafranca) AP x x 
Hospital Sant Rafael AP x x 
Hospital Universitario Virgen de la Arrixaca (Murcia) 
AR x x 
AP x x 
Servicio de Reumatologí Hospital Universitario Araba (Alava) LE x x 
Table 8.: IMID participant health centers. 
LES: Systemic lupus erythematosus, PS: psoriasis, AP: psoriatic arthritis, AR: arthritis rheumatoid, CU: ulcerative cholitis, 
EC: Chron’s disease 
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 transPLANT tools 
List of the virtual machine images (VMI) packing the transPLANT tooling for plant genomics 
Virtual Machine 
Image 
Distribution Software Description 
COMPSs Debian (6.0.5) COMPSs (1.1.2)  
Generic VM to run COMPSs based 
applications 
gene-detection  Debian (6.0.5) 
COMPSs (1.1.2), Blast (2.2.27+), 
Blast2gene (2.2), GeneWise (2.0)  
Detects genes in a genome using a 
reference protein from a closely related 
species using Genewise. 
serial_maker+  Debian (6.0.5)  
Maker (2.28), Exonerate (2.2.0), Snap 
(2006-07-28), Augustus (2.5.5), Blast 
(2.2.28+), RepeatMasker (1.295), TRF 
(4.07b) 
Genome annotation pipeline 
bwapipeline  Ubuntu (14.04 LTS)  
BWA (0.1.17), bcftools (0.1.18), 
samtools (0.7.5a) 
Aligns paired-end reads against a 
reference genome using BWA2 
bowtie+  Debian (6.0.5) 
Bowtie (2-2.2.3), tophat (2.0.12), 
boost (1_55), samtools boost (1_55), 
samtools (0.1.80.1.8) 
Aligns paired-end reads against a 
reference genome using fast Bowtie 
Abyss Ubuntu (14.04 LTS)  Abyss (1.3.6), samtools (0.7.5a) 
De novo, parallel, paired-end sequence 
assembler, designed for short reads. 
Repet (URGI) Ubuntu (14.04 LTS)  
TEDeNovo, Blast (2.2.20 / 2.2.29+), 
Censor (4.2), genometools (1.5.2), 
Hmmer (3.1b1), MCL (12-068), Mreps 
(2.5), Piler (1.0), Recon (1.07), 
RepeatMasker (4), RepeatScout 
(1.0.5), Samtools (0.1.19), TRF (1.0), 
tRNAscan (1.23) 
Pipeline dedicated to detect, annotate 
and analyse repeats in genomic 
sequences, in particular, transposable 
elements (TEs) 
Table 8.1: TransPLANT tools 
 
 MuG tools & visualizers 
Data visualizers 
The current list of tools integrated, or in the way of being integrated (status: submitted) is 
the following: 
Visualizer Description Author Tool Status (*) 
Jbrowse A next-generation genome browser built with JavaScript and HTML5. IRB Active 
NGL 
NGL Viewer is a web application for molecular visualization. WebGL 
is employed to display molecules     like proteins and DNA/RNA with 
a variety of  representations. 
IRB Active 
TADkit 3D genome browser and TADbit front-end CNAG Active 
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CytoScape 
Software platform for visualizing molecular interaction networks and 
integrate them state data like gene  expression profiles, chromatin 
assortativity, etc. 
Centre de 
Recherches en 
Cancérologie de 
Toulouse 
Submitted 
Table 8.2: MuGVRE visualizers 
(*) Tool/visualizer are: (1) active: the tool is eligible to be run for all users (2) Inactive: the tool is not eligible to be run. (3) 
Testing: the tool is eligible only by the tool developer owing the tool. (4) Submitted: the tool has started the integration 
process but is not yet integrated. 
 
 
Analysis Tools 
The current list of tools integrated, or in the way of being integrated (status: submitted) is 
the following: 
 
Tool Description Author Tool status (*) 
3DConsensus 
Analyse a protein-DNA complex 3D structure to identify 
interactions  
UNOT Active 
Bowtie2 Align FASTQ data using Bowtie2 EMBL-EBI Testing 
BWA MEM Align FASTQ data using BWA mem EMBL-EBI Testing 
Chromatin 
Dynamics 
With the Chromatin Dynamics tool you can create your 
own 'beads-on-a-string' representation of a chromatin 
fiber. 
IRB Active 
MACS2 
MACS identifies statistically significantly enriched genomic 
regions in ChIP- and DNase-seq data 
EMBL-EBI Active 
MC-DNA 
MC-DNA is a coarse-grained DNA model in which the 
internal dynamics are described with helical parameters. 
IRB Active 
MD Energy 
Refinement 
Molecular Dynamics workflow to energetically minimize a 
structure. MD Setup + 100ps free MD. Output last 
structure from the 100ps. 
IRB Active 
NAFlex analyses 
Set of analyses to extract Nucleic Acids flexibility properties 
from Molecular Dynamics trajectories 
IRB Active 
Nucleosome 
Dynamics 
Nucleosome Dynamics Tools for performing nucleosome-
related analysis based on MNase-seq experimental data 
IRB Active 
Process ChIP-seq 
Align ChIP-seq data, filtering with BioBamBam and Peak 
Calling using MACS2.  
EMBL-EBI Testing 
Process Genomes 
Generates BWA, Bowtie2 and GEM indexes for a given 
genome 
EMBL-EBI Active 
Process RNA-seq Align RNA-seq data, gene expression calling with Kallisto EMBL-EBI Testing 
Process WGBS Align WGBS data, uses BS Seeker2 and Bowtie2 EMBL-EBI Testing 
PyDockDNA Docking Protein-DNA BSC Active 
PyDock Protein-Protein Docking BSC Active 
TADbit bin TADbit Hi-C binning. CNAG Active 
TADbit map, parse 
and filter 
TADbit Hi-C mapping, parsing mapped reads and filtering of 
artifactual reads. 
CNAG Active 
TADbit model TADbit 3D modeling. CNAG Active 
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TADbit normalize TADbit Hi-C normalize. CNAG Active 
TADbit segment TADbit Hi-C segment (TADs and compartments). CNAG Active 
ChICAGO 
CHiCAGO pipeline for calling significant interactions in 
Capture HiC data, such as Promoter Capture HiC 
EMBL-EBI Submitted 
Chromatin 
Assortativity 
Calculation of chromatin assortativity to integrate the 
epigenomic landscape of a specific cell type with its 
chromatin interaction network 
Centre de 
Recherches 
en 
Cancérologie 
de Toulouse 
Testing 
Process DamID-
seq29 
Align DamID-seq data, filtering with BioBamBam and Peak 
Calling using iDEAR 
EMBL-EBI Submitted 
BioBamBam2 
Filtering 
Mark technical duplicates using BioBamBam2 and then 
remove them with samtools 
EMBL-EBI Submitted 
FASTQ Trimming 
Trimming of single and paired end FASTQ reads using 
TrimGalore 
EMBL-EBI Submitted 
BWA ALN 
Aligns single and paired end data using the BWA ALN 
method 
EMBL-EBI Submitted 
Analyse FASTQ29 
Analyse the quality of reads within a fastq file and provide 
relevant statistics 
EMBL-EBI Submitted 
BS Seeker 2 Peak 
Caller 
WGBS BS Seeker2 Methylation  Peak Caller EMBL-EBI Submitted 
Process BS Seeker2 
Aligner 
Align WGBS data using BS Seeker2 and Bowtie2 EMBL-EBI Submitted 
Process BS Seeker2 
Filter 
Filter WGBS data, uses BS Seeker2 EMBL-EBI Submitted 
Process WGBS BS 
Seeker 2 Indexer 
Create the custom Bowtie2 index required by BS Seeker2 EMBL-EBI Submitted 
Table 8.3: MuGVRE analysis tools list 
 (*) Tool/visualizer are: (1) active: the tool is eligible to be run for all users (2) Inactive: the tool is not eligible to be run. 
(3) Testing: the tool is eligible only by the tool developer owing the tool. (4) Submitted: the tool has started the 
integration process but is not yet integrated. 
 MuG data models 
 
 Data Model: “File” 
Following table describe the fields and their dependencies of the minimal metadata set of 
a File object as defined for MuG project. 
Parameter Required Description 
file_id YES 
This is an auto-generated ID that is created when the data is entered. The ID 
is unique to the entire system 
user_id YES The unique user ID for whom the file is associated with 
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file_path YES 
Location of the file either within the file system or a URL to an archive or 
repository. 
path_type YES Defines if the file_path is a file (type= “file”) or directory (type=”dir”). 
source_id YES List of the file IDs that were used during the creation of this file. 
parent_dir YES 
Defines the file_id of the directory containing it. Personal user’s root directory 
is set as “0” 
files_dir DEPENDENT 
If the path_type = “dir”, then this parameter defines the file_ids contained by 
the directory 
creation_time YES This is the time inserted by the API and is not required from the user. 
file_type YES Format file. Several formats may support a same file_type. For example FASTQ 
data_type YES 
Semantic description of file content. MuG accepted file types listed below. For 
example, WGBS reads 
size YES Size in bytes 
taxon_id YES 
The taxonomic ID of the species from which the data was taken. Whether the 
file has been compressed. Type of compression used depends on the format 
in question. 
compressed NO 
Whether the file has been compressed. Type of compression used depends on 
the format in question. 
meta_data DEPENDENT 
There are cases where additional data is required for some files that is not 
relevant to other file types. It corresponds a catch-all section. Examples: 
 
- ‘assembly’ - Files that have been generated and are dependent on 
alignments require that the meta_data has as the key with the assembly 
for which the alignment was made against 
- ‘paired’ - If the file is a BAM, the type of library is required. Options: 
“paired”, “unpaired” 
- ‘sorted’ - If the file is a BAM, whether the reads are sorted or not is 
required- Boolean 
Table 8.4: File attributes 
(*) Described in this annex under “File Type” and “Data type” sections  
 
 
Data Model: “File Type”  & “Data Type”  
“File” data model includes attributes “data type” and “file type”, among other fields. Here, 
the complete collection of data types supported by MuGVRE, and their associated file 
types.  
Data Type (identifier) Data Type (Name) Associated File Types 
chromatin_3dmodel Chromatin 3D structure PDB 
chromatin_3dmodel_ensemble 
Ensemble of chromatin 3D 
structures 
JSON 
chromatin_compartments Chromatin compartments data TXT 
chromatin_tads Chromatin TADs BED, TXT, 
chromatin_traj Chromatin trajectory DCD 
configuration_file Tool configuration file JSON, TXT, TSV 
data_atac_seq ATAC-Seq FASTQ, BAM, BED, WIG 
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data_chip_seq ChIP-Seq BED, FASTQ, BAM, TSV 
data_dna_methylation DNA methylation FASTQ, WIG, TSV 
data_fish FISH data LIF, TIFF, PNG 
data_mnase_seq MNase-Seq FASTQ, BAM, BED 
data_rna_seq RNA-Seq FASTQ, TSV, HDF5, JSON 
data_wgbs 
Whole Genome Bisulfite 
Sequencing 
FASTQ, BAM, BAI, WIG, TSV, TXT 
docking_ranking Docking ranking score CSV, TXT, TSV 
hic_biases HiC Biases PICKLE 
hic_contacts_coverage HiC contacts coverage WIG, BW, TXT 
hic_contacts_differential HiC differential contacts TSV 
hic_contacts_matrix HiC contact matrix TXT, HDF5 
hic_contacts_peaks HiC contact peaks TSV 
hic_directionality HiC directionality index TXT 
hic_reads HiC sequencing reads FASTQ 
hic_sequences HiC aligned reads BAM 
hic_tads_scale HiC TADs scaling factor WIG 
md_restart MD restart file RST, CPT 
na_md_atom_traj_coords 
Nucleic acid MD trajectory 
coordinates 
XTC, NETCDF, MDCRD 
na_md_atom_traj_top 
Nucleic acid MD trajectory 
topology 
TOP, TPR, PARMTOP, PDB 
na_md_cg_traj Nucleic acid MD CG trajectory MDCRD 
na_structure Nucleic acid 3D structure PDB 
na_traj Nucleic acid trajectory DCD, MDCRD 
na_traj_coords 
Nucleic acid trajectory 
coordinates 
XTC, NETCDF, MDCRD 
na_traj_top Nucleic acid topology TOP, TPR, PARMTOP, PDB 
nucleosome_dynamics Nucleosome dynamics BW, GFF3, BED, WIG, RDATA 
nucleosome_free_regions Nucleosome free regions BW, GFF3, BED, WIG 
nucleosome_gene_phasing Nucleosome phasing BW, GFF3, BED, WIG 
nucleosome_positioning Nucleosome positioning BW, GFF3, BED, WIG, TXT 
nucleosome_stiffness Nucleosome stiffness BW, GFF3, BED, WIG 
prot_dna_specificity Protein-DNA specificity TSV 
prot_dna_structure Protein-DNA complex structure PDB 
prot_structure Protein 3D structure PDB 
sequence_annotation Sequence Annotation 
BED, BB, BEDGRAPH, WIG, BW, GFF, GFF3, 
GTF, VCF, TBI 
sequence_dna DNA sequence FASTA, TXT 
sequence_genomic Genomic sequence FASTA 
sequence_mapping_index_bowtie Bowtie2 index files BT2, TXT 
sequence_mapping_index_bwa BWA index files AMB, ANN, BWT, PAC, SA 
sequence_mapping_index_gem Sequence mapping index GEM 
sequence_mapping_index_kallisto Kallisto index file IDX 
sequence_prot Protein sequence FASTA 
sequence_rna RNA sequence FASTA 
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structure 3D structure PDB 
tool_intermediate_file Tool Intermediate file TAR 
tool_statistics Tool summary file TAR 
tss_classification_by_nucleosomes Nucleosome TSS BW, GFF3, BED, WIG 
Table 8.5: MuGVRE file types 
 
 Data Model : “Tool” 
“Tool” data model is specified using a JSON schema (draft 4) we prepared in order to (i) 
validate data structures received from tool developers, and (ii) validate MuGVRE internal 
operations before database insertion.  
      1.   tool definition JSON - schema 
https://github.com/Multiscale-Genomics/VRE_tool_jsons/blob/dev/tool_specification/tool_schema.json 
 
      2.   tool definition JSON - schema (internal) 
https://github.com/Multiscale-
Genomics/VRE_tool_jsons/blob/dev/tool_specification/tool_schema_internal.json 
      3.   tool definition JSON – example (another example annexed below) 
https://github.com/Multiscale-
Genomics/VRE_tool_jsons/blob/dev/tool_specification/examples/pydockdna.json 
 
Following, an example of a MuGVRE tool entry as registered in the database 
{ 
    "_id": "pydockdna", 
    "name": "pyDockDNA", 
    "title": "Protein-DNA docking", 
    "short_description": "PyDockDNA is a tool for the structural prediction of [..]", 
    "owner": { 
        "institution": "BSC", 
        "author": "Brian Jimenez-Garcia", 
        "contact": "bjimenez@bsc.es", 
        "url": "https://life.bsc.es/pid/pidweb/default/tools"}, 
    "external": true, 
    "has_custom_viewer": true, 
    "keywords": [ "protein","dna"], 
    "infrastructure": { 
        "memory": 4.0, 
        "cpus": 4, 
        "executable": "/home/user/bin/mug/pydockdna", 
        "clouds": { 
            "mug-bsc": { 
                "launcher": "PMES", 
                "workflowType": "Single", 
                "default_cloud": true, 
                "minimumVMs":1, 
                "initialVMs":1, 
                "imageName":"uuid_pydockdna_51"}, 
            "mug-irb": { 
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                "launcher": "SGE", 
                "queue":"pydock.q"}}}, 
    "input_files": [ 
        { 
            "name": "receptor", 
            "description": "Receptor PDB structure", 
            "help": "Select the input receptor", 
            "file_type": [ "PDB" ], 
            "data_type": [ "prot_structure" ], 
            "required": true, 
            "allow_multiple": false}, 
        { 
            "name": "ligand", 
            "description": "Ligand PDB structure", 
            "help": "Select the input ligand", 
            "file_type": ["PDB"], 
            "data_type": ["na_structure","prot_structure"], 
            "required": true, 
            "allow_multiple": false }, 
        { 
            "name": "complex", 
            "description": "Complex PDB structure", 
            "help": "Select the complex", 
            "file_type": [ "PDB"], 
            "data_type": ["prot_dna_structure"], 
            "required": false, 
            "allow_multiple": false 
        } 
    ], 
    "input_files_combinations": [ 
        ["receptor","ligand"], 
        ["complex"] 
    ], 
    "arguments": [ 
        { 
            "name": "scoring", 
            "description": "Available energetic scoring functions", 
            "help": "pyDockDNA is able to use different scoring […]", 
            "type": "enum", 
            "enum_items": { 
                "description": [ "pyDock-DNA" , “VdW” ], 
                "name": ["pydockdna", “VdW”]}, 
            "required": true, 
            "default": "PyDock DNA"}, 
        { 
            "name": "models", 
            "description": "Number of structures to model", 
            "help": "The number of generated models by this tool", 
            "type": "enum", 
            "enum_items": { 
                "name": ["1", "5","10", "50"]}, 
            "minimum": 1, 
            "maximum": 50, 
            "required": true, 
            "default": "10"} 
    ], 
    "output_files": [ 
        { 
            "name": "energy_table", 
            "required": true, 
            "allow_multiple": false, 
            "file": { 
                "file_type": "CSV", 
                "data_type": "docking_ranking", 
                "compressed": "null", 
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                "meta_data": { 
                    "description": "Ranking of docking poses", 
                    "visible": true}}}, 
       { 
            "name": "top10", 
            "required": true, 
            "allow_multiple": true, 
            "file": { 
                "file_type": "PDB", 
                "data_type": "prot_dna_structure", 
                "compressed": "null", 
                "meta_data": { 
                    "description": "Top10 predicted structures", 
                    "visible": true}}}, 
        { 
            "name": "results", 
            "required": true, 
            "allow_multiple": false, 
            "file": { 
                "file_type": "TAR", 
                "data_type": "tool_statistics", 
                "compressed": "gzip", 
                "meta_data": { 
                    "description": "Compressed results of the tool", 
                    "visible": false}}} 
    ] 
} 
Snippet 8.1 Example of MuGVRE tool: pyDockDNA 
 
A description of the individual attributes appearing in “Tool” schema is listed in the 
following table: 
Field name 
Field 
type 
Field description 
_id string Internal tool identifier. It cannot have spaces nor special characters. 
name string 
Short tool name, which appears in the MuGVRE tool selectors. Maximum 
characters: 25. 
title string 
Long tool name, which appears in the specific tool MuGVRE pages. Maximum 
characters: 50 
short_description  
Short description of the tool. It is going to appear on the “Launch Tool” table 
that list all integrated tools. Maximum characters: 150. 
short_description  
Longer description of the tool. It is going to appear on the “Launch Tool” table, 
after selecting the tool, as well as at the home page. Maximum characters: 500. 
owner object Defines tool’s author 
owner.institution string Research institute affiliation 
owner.author string Tool’s author’s name 
owner.contact string Contact mail of tool author. 
owner.url string Tool reference URL ( web page, code repository, etc) 
owner.licence string Type of code licence. Check accepted options in the schema. 
publication string DOI reference of the tool publication, if any. 
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Field name 
Field 
type 
Field description 
keywords array 
Keywords that will be used in the main home page to classify the tool. Available 
options are: “Chromatin”, “Dynamics”, “Visualization”, “Hi-C”, “Epigenetics”, 
“Nucleosome”, “Modelling”, “Next Gen Sequencing”, “Interaction”, “RNA”, 
“DNA”, “Protein”, “Sequence”, “Structure”, “other”. Check them also at Check 
accepted options in the schema. 
keywords_specific array Keywords that will be used in the “Launch Tool” table for discovering tools 
infrastructure object Defines how the tool VM is to be deployed 
infrastructure. 
     memory 
string Size of the tool virtual machine. RAM memory in Gbs. By default “1.0” (1Gb). 
infrastructure.cpus integer Size of the tool virtual machine. Cores. By default, 1. 
infrastructure. 
     executable 
string 
Path to the main executable of the tool. This file will be called by the MuGVRE 
core when the end user selects your tool from the web portal. It should be the 
absolute path, and be local to the tool virtual machine with execution 
permissions (+x). 
infrastructure.clouds object 
List of ‘cloud’ objects. Define in which MuG cloud your tool VM is loaded. 
Formally, available options are in the schema, yet currently, the only cloud in 
production is “mug-irb”. 
infrastructure.cloud string Defines the deployment requirements in each cloud installation 
Infrastructure.cloud 
    .workflowType 
string 
Type of workflow orchestration implemented in the tool. Check accepted 
options in the schema. 
Infrastructure.cloud 
    .default_cloud 
boolean 
Whether the cloud is the default one or not. If only one production cloud 
available, by default it is set to “true”. 
input_files array List of ‘input files’ objects. Defines the input files accepted by the tool. 
input_files.name string 
Unique name that will identify the input file. Used in the execution 
configuration files to refer to this input_files object. No spaces or special 
characters allowed. 
input_files.description string Full input file name as it will be printed in the tool web form. 
input_files.help string 
Long description of the input file. It will appear in the tool web for under the 
‘question mark’ toolkit. 
input_files.file_type array 
List of the allowed file formats for the input file. A comprehensive list of the 
accepted file types is in the file types section, yet, check accepted options in the 
schema. 
input_files.data_type array 
List of allowed data types for the input file. A comprehensive list of the 
accepted file types is in the data types section, yet, check the identifiers for the 
accepted options in the schema. 
Input_files.required boolean true if not optional 
input_files. 
     allow_multiple 
boolean true if more than one instance of this input file is allowed. 
arguments array List of ‘arguments’ objects. Defines all the arguments accepted by the tool 
arguments.name string 
Unique name that will identify the argument. Used in the execution 
configuration files to refer to this argument object. No spaces or special 
characters allowed. 
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Field name 
Field 
type 
Field description 
arguments.description string Full argument name as it will be printed in the tool web form. 
arguments.help string 
Long description of the input file. It will appear in the tool web for under the 
‘question mark’ toolkit. 
arguments.type string 
Type of the argument. Accepted options are “integer”, “number”,”string”, 
“enum”,”enum_multiple”, “boolean”, yet you can check them in the schema. 
There is correspondence between this type and the way the argument is 
displayed in the web form. For instance: 
“type: integer” → visualized as a input text field 
 
”type:boolean” → visualized as a ON/OFF button. 
 
“type: enum” → visualized as a drop down selector 
 
“type: boolean multiple” → visualized as a multiple drop down selector 
 
arguments.required boolean true if not optional 
arguments. 
    allow_multiple 
boolean true if more than one instance of this input file is allowed. 
arguments.default string Default value given for the argument 
output_files array List of outputfiles’ objects. Defines the output files generated by the tool. 
output_files.name string 
Unique name that will identify the output file. Used in supplementary file that 
defines the tool output medatada in some special cases. No spaces or special 
characters allowed. 
output_files.required boolean 
true if not optional. A tool execution will be considered as failed if a output file 
set as required is not generated. 
output_files.allow_mu
ltiple 
boolean true if more than one instance of this output file is generated. 
output_files.file object Defines the metadata associated with the output file 
output_files.file.file_ty
pe 
string 
File format for the output file that the tool will generate. A comprehensive list 
of the accepted file types is in the supported data section, yet, check accepted 
options in the schema. 
output_files.file. 
    data_type 
string 
Data types for the output file the tool will generate. A comprehensive list of the 
accepted file types is in the supported data section, yet, check the identifiers 
for the accepted options in the schema. 
output_files.file. 
    file_path 
string 
File name for the expected output name. If the tool names the output file after 
the input file, or the file name is dynamically set during the execution, this field 
does not need to be defined here, but when wrapping your tool through a 
second tool output medatada file. 
output_files.file. 
    compressed 
string 
Defines whether the output file is compressed. And if so, which algorithm is 
used. Check accepted options in the schema. 
output_files.file. object Defines all extra metadata attributes of the output file. 
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Field name 
Field 
type 
Field description 
    metadata 
output_files.file. 
    description 
string 
Short description for the outfile generated. End use will have it accessible at his 
workspace 
output_files.file. 
    visible 
boolean 
If set to false, the output file will be saved and registered by MuGVRE, but not 
listed in the user workspace. A hidden output file is useful when the tool wants 
to send some data to MuGVRE transparently. Default: true 
Table 8.6: Attributes description of Tool data model 
 
 
 Job Auxiliary Files 
 
These are illustrative examples of the files MuGVRE builds to submit a job (1, 2, 3). The last 
example corresponds to how MG-tool-API annotates the metadata for the output files generated 
during the execution. 
 
      1.   Input metadata File  (example) 
https://github.com/Multiscale-
Genomics/VRE_tool_jsons/blob/dev/tool_execution/sample_project/myPydockProject/.input_metadata.json 
      2.   Configuration Job File (example) 
https://github.com/Multiscale-
Genomics/VRE_tool_jsons/blob/dev/tool_execution/sample_project/myPydockProject/.config.json 
      3.   PMES JSDL File  (example) 
https://github.com/Multiscale-
Genomics/VRE_tool_jsons/blob/dev/tool_execution/sample_project/myPydockProject/.submit 
      4.   Output metadata File  (example) 
https://github.com/Multiscale-
Genomics/VRE_tool_jsons/blob/dev/tool_execution/sample_project/myPydockProject_out/.results.json 
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 OpenVRE classes 
Following, a schema of the main PHP programming classes used at OpenVRE.  
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 PMES documentation 
 PMES server and dashboard 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Computational infrastructures for biomolecular research 
  
207 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annexes 
 
208 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Computational infrastructures for biomolecular research 
  
209 
 
 
 
 
 
 
 
 
 
 PMES REST API  
 
 
Annexes 
 
210 
Computational infrastructures for biomolecular research 
  
211 
Annexes 
 
212 
 
 
 Publications 
 
Following, the list of papers related to each of the sections present dissertation: 
 Data management infrastructure for IMIDs’ research 
1) Aterido, Adrià, Cañete, J. D., Tornero, J., Ferrándiz, C., Pinto, J. A., Gratacós, J., … Codó, 
L., Gelpí, J. L. …, Julià, A. (2019). Genetic variation at the glycosaminoglycan metabolism 
pathway contributes to the risk of psoriatic arthritis but not psoriasis. Annals of the 
Rheumatic Diseases, 78(3), 355–364. https://doi.org/10.1136/annrheumdis-2018-214158 
2) Aterido, Adrià, Palau, N., Domènech, E., Nos Mateu, P., Gutiérrez, A., Gomollón, F., … 
Codó, L., Gelpí, J. L. …, Julià, A. (2019). Genetic association between CD96 locus and 
immunogenicity to anti-TNF therapy in Crohn’s disease. The Pharmacogenomics Journal. 
https://doi.org/10.1038/s41397-019-0090-4 
Computational infrastructures for biomolecular research 
  
213 
3) Aterido, Adrià, Julià, A., Ferrándiz, C., Puig, L., Fonseca, E., Fernández-López, E., … Codó, 
L., Gelpí, J. L. …, Marsal, S. (2016). Genome-Wide Pathway Analysis Identifies Genetic 
Pathways Associated with Psoriasis. Journal of Investigative Dermatology, 136(3), 593–
602. https://doi.org/10.1016/j.jid.2015.11.026 
4) Julià, A., Blanco, F., Fernández-Gutierrez, B., González, A., Cañete, J. D., Maymó, J., … 
Codó, L., Gelpí, J. L. …, Marsal, S. (2016). Identification of IRX1 as a Risk Locus for 
Rheumatoid Factor Positivity in Rheumatoid Arthritis in a Genome-Wide Association 
Study. Arthritis & Rheumatology, 68(6), 1384–1391. https://doi.org/10.1002/art.39591 
5) Julià, A., González, I., Fernández-Nebro, A., Blanco, F., Rodriguez, L., González, A., … 
Codó, L., Gelpí, J. L. …, Marsal, S. (2016). A genome-wide association study identifies 
SLC8A3 as a susceptibility locus for ACPA-positive rheumatoid arthritis. Rheumatology, 
55(6), 1106–1111. https://doi.org/10.1093/rheumatology/kew035 
6) Julià, A., Pinto, J. A., Gratacós, J., Queiró, R., Ferrándiz, C., Fonseca, E., … Codó, L., Gelpí, 
J. L. …, Marsal, S. (2015a). A deletion at ADAMTS9-MAGI1 locus is associated with 
psoriatic arthritis risk. Annals of the Rheumatic Diseases, 74(10), 1875–1881. 
https://doi.org/10.1136/annrheumdis-2014-207190 
7) Julià, A., Domènech, E., Ricart, E., Tortosa, R., García-Sánchez, V., Gisbert, J. P., … Codó, 
L., Gelpí, J. L. …, Marsal, S. (2013). A genome-wide association study on a southern 
European population identifies a new Crohn’s disease susceptibility locus at RBX1-EP300. 
Gut, 62(10), 1440–1445. https://doi.org/10.1136/gutjnl-2012-302865 
 
 
 MuG: Multiscale Complex Genomics VRE 
8) Buitrago, D†,. Codó, L.†, Illa, R., de Jorge, P., Battistini, F., Flores, O., … Orozco, M. (2019). 
Nucleosome Dynamics: a new tool for the dynamic analysis of nucleosome positioning. 
Nucleic Acids Research. https://doi.org/10.1093/nar/gkz759 
   † The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors 
9) Codó, L., Bayarri, G., Cid-Fuentes, J. A., Conejero, J., Hospital, A., Royo, R., … Gelpí, J. L. 
(2019). MuGVRE. A virtual research environment for 3D/4D genomics. BioRxiv, 602474. 
https://doi.org/10.1101/602474 
10) Hospital, A., Andrio, P., Cugnasco, C., Codó, L., Becerra, Y., Dans, P. D., … Gelpí, J. L. 
(2016). BIGNASim: a NoSQL database structure and analysis portal for nucleic acids 
simulation data. Nucleic Acids Research, 44(D1), D272–D278. 
https://doi.org/10.1093/nar/gkv1301 
Annexes 
 
214 
 
 Thesis not related papers 
11) Andrio, P., Hospital, A., Conejero, J., Jordà, L., del Pino, M., Codó, L., … Gelpí, J. L. (2019). 
BioBB: BioExcel Building Blocks, a software library for interoperable biomolecular 
simulation workflows. Nature Scientific Data, 6(1), 169. https://doi.org/10.1038/s41597-019-
0177-4 
12) Georgieva, M. V, Yahya, G., Codó, L., Ortiz, R., Teixidó, L., Claros, J., … Aldea, M. (2015). 
Inntags: small self-structured epitopes for innocuous protein tagging. Nature Methods, 
12(10), 955–958. https://doi.org/10.1038/nmeth.3556 
 
 
 
Computational infrastructures for biomolecular research 
  
 
 
 
 
 
1) Aterido, Adrià, Cañete, J. D., Tornero, J., Ferrándiz, C., Pinto, J. A., Gratacós, J., … 
Codó, L., Gelpí, J. L. …, Julià, A. (2019). Genetic variation at the glycosaminoglycan 
metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. 
Annals of the Rheumatic Diseases, 78(3), 355–364. 
https://doi.org/10.1136/annrheumdis-2018-214158 

  355Aterido A, et al. Ann Rheum Dis 2019;78:355–364. doi:10.1136/annrheumdis-2018-214158
Psoriatic arthritis
CLINICAL SCIENCE
Genetic variation at the glycosaminoglycan 
metabolism pathway contributes to the risk of 
psoriatic arthritis but not psoriasis
Adrià Aterido,1,2 Juan D Cañete,3 Jesús Tornero,4 Carlos Ferrándiz,5 
José Antonio Pinto,6 Jordi Gratacós,7 Rubén Queiró,8 Carlos Montilla,9 
Juan Carlos Torre-Alonso,10 José J Pérez-Venegas,11 Antonio Fernández Nebro,12 
Santiago Muñoz-Fernández,13 Carlos M González,14 Daniel Roig,15 Pedro Zarco,16 
Alba Erra,17 Jesús Rodríguez,18 Santos Castañeda,19 Esteban Rubio,20 
Georgina Salvador,21 Cesar Díaz-Torné,22 Ricardo Blanco,23 
Alfredo Willisch Domínguez,24 José Antonio Mosquera,25 Paloma Vela,26 
Simon Angel Sánchez-Fernández,27 Héctor Corominas,22,28 Julio Ramírez,3 
Pablo de la Cueva,29 Eduardo Fonseca,30 Emilia Fernández,31 Lluis Puig,32 
Esteban Dauden,33 José Luís Sánchez-Carazo,34 José Luís López-Estebaranz,35 
David Moreno,36 Francisco Vanaclocha,37 Enrique Herrera,38 Francisco Blanco,39 
Benjamín Fernández-Gutiérrez,40 Antonio González,41 Carolina Pérez-García,42 
Mercedes Alperi-López,8 Alejandro Olivé Marques,43 Víctor Martínez-Taboada,23 
Isidoro González-Álvaro,19 Raimon Sanmartí,3 Carlos Tomás Roura,44 
Andrés C García-Montero,45 Sílvia Bonàs-Guarch,46 Josep Maria Mercader,46 
David Torrents,46,47 Laia Codó,48 Josep Lluís Gelpí,48 Mireia López-Corbeto,1 
Andrea Pluma,1 Maria López-Lasanta,1 Raül Tortosa,1 Nuria Palau,1 Devin Absher,49 
Richard Myers,49 Sara Marsal,1 Antonio Julià1
To cite: Aterido A, 
Cañete JD, Tornero J, 
et al. Ann Rheum Dis 
2019;78:355–364.
Handling editor Josef S 
Smolen
 ? Additional material is 
published online only. To view 
please visit the journal online 
(http:// dx. doi. org/ 10. 1136/ 
annrheumdis- 2018- 213588).
For numbered afﬁliations see 
end of article.
Correspondence to
Antonio Julià and Sara Marsal, 
Rheumatology Research Group, 
Vall d’Hebron Research Institute, 
Barcelona 08035, Spain;  
 toni. julia@ vhir. org,  
 sara. marsal@ vhir. org, Juan 
D Cañete, Rheumatology 
Department, Hospital Clínic 
de Barcelona and IDIBAPS, 
Barcelona 08036, Spain;  
 jcanete@ clinic. ub. es
Received 24 July 2018
Revised 16 November 2018
Accepted 16 November 2018
Published Online First 
14 December 2018
© Author(s) (or their 
employer(s)) 2019. No 
commercial re-use. See rights 
and permissions. Published 
by BMJ.
ABSTRACT
Objective Psoriatic arthritis (PsA) is a chronic 
inﬂammatory arthritis affecting up to 30% of patients 
with psoriasis (Ps). To date, most of the known risk loci 
for PsA are shared with Ps, and identifying disease-
speciﬁc variation has proven very challenging. The 
objective of the present study was to identify genetic 
variation speciﬁc for PsA.
Methods We performed a genome-wide association 
study in a cohort of 835 patients with PsA and 1558 
controls from Spain. Genetic association was tested 
at the single marker level and at the pathway level. 
Meta-analysis was performed with a case–control cohort 
of 2847 individuals from North America. To conﬁrm 
the speciﬁcity of the genetic associations with PsA, we 
tested the associated variation using a purely cutaneous 
psoriasis cohort (PsC, n=614) and a rheumatoid 
arthritis cohort (RA, n=1191). Using network and 
drug-repurposing analyses, we further investigated the 
potential of the PsA-speciﬁc associations to guide the 
development of new drugs in PsA.
Results We identiﬁed a new PsA risk single-nucleotide 
polymorphism at B3GNT2 locus (p=1.10e-08). At 
the pathway level, we found 14 genetic pathways 
signiﬁcantly associated with PsA (pFDR<0.05). From these, 
the glycosaminoglycan (GAG) metabolism pathway was 
conﬁrmed to be disease-speciﬁc after comparing the 
PsA cohort with the cohorts of patients with PsC and 
RA. Finally, we identiﬁed candidate drug targets in the 
Key messages
What is already known about this subject?
 ? Psoriatic arthritis (PsA) has a higher heritability 
than psoriasis, indicating the presence of a 
speciﬁc genetic risk component.
 ? So far, very little genetic variation has been 
speciﬁcally associated with the development of 
PsA.
What does this study add?
 ? Using a pathway-based genome-wide 
association study on two case–control 
cohorts, we have identiﬁed multiple pathways 
associated with PsA risk.
 ? The glycosaminoglycan (GAG) metabolism 
pathway is speciﬁcally associated with PsA risk 
and is not associated with purely cutaneous 
psoriasis or rheumatoid arthritis.
 ? Network-based analysis of the GAG pathway 
suggests two new drug candidates for PsA.
How might this impact on clinical practice or 
future developments?
 ? The integration of biological knowledge on 
to genetic analysis can improve the ability to 
identify more effective therapies for PsA.
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GAG metabolism pathway as well as new PsA indications for approved 
drugs.
Conclusion These ﬁndings provide insights into the biological 
mechanisms that are speciﬁc for PsA and could contribute to develop 
more effective therapies.
INTRODUCTION
Psoriatic arthritis (PsA) is an inflammatory arthritis affecting up 
to 0.5% of the population and ~30% of patients with psori-
asis (Ps).1 2 Compared with patients having skin-only affectation 
(ie, purely cutaneous psoriasis, PsC), patients with PsA have a 
substantially worse quality of life.3 Most of the drugs currently 
used to treat Ps are also indicated for PsA,4 but the efficacy can 
differ significantly. Therefore, there is a need to better under-
stand the biological mechanisms underlying PsA in order to 
develop more effective therapies.
Familiar aggregation studies have demonstrated that PsA has 
a larger sibling recurrence rate (λs) than Ps (PsA λs~37 vs Ps 
λs~7),
5–8 indicating the presence of a specific genetic risk. To 
date, more than 15 genome-wide association studies (GWAS) 
have been performed in Ps,9–14 identifying more than 50 suscep-
tibility loci. Conversely, only a few GWAS have been performed 
exclusively in PsA. These studies have allowed the identification 
of 15 PsA risk loci.15–22 However, most of these risk variants are 
shared with Ps, indicating that the biological mechanisms that 
cause autoimmunity to the skin are also central for PsA. Iden-
tifying disease-specific loci has proven elusive, and to date only 
PTPN22, CSF2-P4HA2 and ADAMTS9-MAGI1 have shown a 
significant association with PsA. Taking into account the effects 
of all known risk loci, less than 50% of the heritability for PsA 
is currently explained.11 13 23 Therefore, new biological mecha-
nisms could still be discovered that are relevant for disease aeti-
ology, resulting in more effective therapies than the present ones.
A major challenge in the genetics of complex diseases is the 
identification of genes with small effects.24 To overcome this 
problem, the predominant approach has been to recruit increas-
ingly larger patient cohorts.25 While this can help to identify new 
risk variation, this is extremely costly and time-consuming. Most 
of these GWAS have been performed at the single marker level, 
and therefore the statistical power to detect new risk variation 
soon becomes insufficient. To address this issue, different strate-
gies have been developed. One of the most successful approaches 
has been to leverage the biological information underlying DNA 
variation like biological pathway annotation.26 Genome-wide 
pathway analysis (GWPA) efficiently integrates the risk variation 
from multiple, functionally related genes into a unique statistic.27 
Additionally, using well-curated biological information in GWPA 
significantly accelerates the translation of the genetic associa-
tion results.28 With this strategy, new genetic variation has been 
identified in different common diseases, including autoimmune 
diseases like Ps.29 30
To identify new genetic variation specifically associated 
with PsA, we have performed a GWAS at the single marker 
and pathway levels. We genotyped 835 patients with PsA and 
1558 controls from Spain and performed a meta-analysis with 
a previous GWAS of PsA consisting of 1430 cases and 1417 
controls from North America. Using this approach, we identi-
fied a new association at B3GNT2 locus and 14 genetic path-
ways associated with PsA risk. We next tested these genetic 
associations in GWAS cohorts of patients with PsC and rheu-
matoid arthritis (RA), and we found the glycosaminoglycan 
(GAG) metabolism pathway to be specific for PsA. Based on this 
evidence, we propose the GAG metabolism as a new source for 
drug discovery in PsA. Using network analysis and knowledge 
on drug action, we find evidence that the GAG pathway could 
be a useful target to treat PsA. These findings confirm the utility 
of GWAS to identify specific biological mechanisms and suggest 
repositioning of existing drugs for PsA.
METHODS
Study population
Patients with PsA were selected from the rheumatology depart-
ments of 16 Spanish hospitals belonging to the Immune-Me-
diated Inflammatory Disease Consortium.31 All patients with 
PsA were diagnosed according to the Classification Criteria for 
Psoriatic Arthritis.32 Controls were recruited from healthy blood 
donors from Spanish hospitals in collaboration with the Spanish 
DNA Bank. A case–control cohort of 835 patients with PsA and 
1588 controls were finally recruited and used for GWAS.
Meta-analysis was performed with a previous GWAS 
performed on 1430 patients with PsA and 1417 controls 
collected from USA and Canada.15 To identify PsA-specific varia-
tion, we used GWAS data from a cohort of 614 patients with PsC 
and 1191 patients with RA from Spain. Patients with PsC were 
defined as patients with plaque-type Ps for >10 years and free 
of any inflammatory disease in the joints. The main features of 
these cohorts are shown in online supplementary material 1 and 
online supplementary table S1.
Genome-wide genotyping and imputation
GWAS genotyping of the 2393 individuals from Spain was 
performed using the Illumina Quad610 array (Illumina, USA). 
Genotype calling and quality control (QC) were performed 
using GenomeStudio V.2011.1 (Illumina) and PLINK soft-
ware, respectively (online supplementary material 1 and online 
supplementary figure S1). After QC, 506 926 single-nucleotide 
polymorphisms (SNPs) from 744 patients with PsA and 1454 
controls were available for analysis.
We conducted genotype imputation to facilitate meta-anal-
ysis with the North America GWAS data. Only high-quality 
and directly genotyped SNPs (n=506 926 SNPs) were used for 
this analysis. After prephasing the haplotypes of each loci using 
SHAPEIT V.2-644 software, imputation was conducted with the 
IMPUTE V.2 software.33 We used the phase 1 release of the 1000 
Genomes Project V.3 as reference panel.34 Only SNPs showing an 
minor allele frequency (MAF) >0.05 and an imputation quality 
>0.8 were selected for the GWPA. After filtering, 1 387 382 
variants were available for analysis.
GWAS genotyping of the independent PsA case–control 
cohort was performed using the Illumina HumanOmni1-Quad 
array (Illumina) as previously described.15 After QC, 791 217 
SNPs from 1430 patients with PsA and 1417 controls were used 
for the single marker and pathway meta-analyses.
The disease specificity of the validated loci and pathways 
was tested using GWAS data from two cohorts of patients with 
PsC and RA. These data sets were generated using the Illumina 
Quad610 array (Illumina) as previously described.29 35
In order to investigate the existence of PsA-specific variation 
across the human leukocyte antigen (HLA) region, we performed 
imputation of the classical alleles and amino acid polymorphisms 
from the HLA class I (HLA-A, HLA-B, HLA-C) and class II (HLA-
DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1 and HLA-DRB1) 
loci in the PsA and PsC cohorts from Spain. HLA imputation was 
conducted using the SNP2HLA V.1.0.3 software.36
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Association analysis of single genetic markers
The SNPs previously associated with Ps risk (p<5e-08; online 
supplementary table S2) were tested for association using a 
logistic regression model. The same analytical procedure was 
followed to analyse the association between whole genome vari-
ation and PsA risk in the Spain cohort using the SNPTEST V.2 
software.37
The imputed HLA alleles and amino acid polymorphisms from 
the HLA class I and class II loci were tested for association using 
a stepwise logistic regression model. In this analysis, the most 
strongly associated marker was included as a covariate by addi-
tion to the null model until no markers reached the significance 
threshold determined by the false discovery rate (FDR) method. 
Since HLA haplotypes HLA-C*06:02 and HLA-B-27 have been 
previously shown to be differentially associated in PsA compared 
with PsC,38 39 the stepwise association analysis was started condi-
tioning on these two established disease risk markers.
Genome-wide meta-analysis in PsA
The two independent PsA case–control cohorts were genotyped 
using different Illumina arrays (nQuad610-QC=1 387 382 SNPs; 
nHumanOmni1-QC=791 217 SNPs). Before GWAS meta-analysis, we 
identified the genetic variants that were commonly genotyped in 
both cohorts (n=720 582 SNPs; online supplementary table S3). 
We subsequently performed the GWAS meta-analysis using the 
METAL software.40 The association statistics were weighted by 
the sample size of the two cohorts and adjusted for the genomic 
inflation factor (?Spain Spain 1.08, ?NorthAmerica North America 1.26).
Genome-wide pathway analysis
A total of 1077 reference pathways from the Molecular Signa-
tures Database were included in the study. The SNP-gene 
mapping was performed using proximity-based criteria, which is 
the predominant approach in GWPA.26 41 According to reference 
studies in GWPA,26 28 42 we used an SNP-gene distance window 
of 20 Kb. The National Center for Biotechnology Information 
(NCBI) RefSeq Database Release 63 was used for SNP anno-
tation (online supplementary table S4). Given the high linkage 
disequilibrium and gene density of the HLA region, the prox-
imity-based criteria could yield false-positive results for path-
ways including genes within this locus. Similar to previous 
studies, the HLA region genes were excluded from the GWPA 
(online supplementary material 1).29 43 The statistical association 
between genetic pathways and disease risk was analysed using 
the set-based method implemented in PLINK, as described in 
online supplementary material 1.29 30
Gene expression analysis of the GAG metabolism pathway
To investigate the specificity of the GAG metabolism pathway in 
PsA at the functional level, we used whole blood transcriptomic 
data obtained from a previous study on patients with PsA, patients 
with PsC and healthy controls (Gene Expression Omnibus data 
set: GSE61281).44 In this previous study, the whole genome 
expression profile was evaluated aiming to identify differentially 
expressed genes. Here, based on our previous evidence at the 
genetic level, we hypothesised that the GAG pathway as a whole 
would be differentially expressed in PsA. To do this, after QC and 
quantile normalisation of the gene expression data, we tested for 
differential expression of the GAG metabolism pathway genes 
(t-test, nominal significance p=0.05) between patients with PsA 
(n=20) and PsC (n=20), and between each disease and healthy 
controls (n=12). We then used the binomial test to assess 
whether the observed number of differentially expressed genes 
in the pathway is greater than expected by chance. Furthermore, 
we also studied the changes in the coexpression of the GAG 
metabolism pathway between diseases. For this objective, we 
calculated the intramodular connectivity (IMC) measure. IMC 
is a network measure that efficiently captures gene coexpression 
information and is computed as the average of the gene connec-
tivity within the pathway genes. The IMC is implemented in the 
WGCNA software.45 Student’s t-test was used to compare the 
IMC values of the GAG metabolism pathway between diseases.
Exploratory drug-repurposing analysis of the GAG pathway
To investigate the GAG metabolism as a new source for drug 
discovery in PsA, we combined network and drug-repurposing 
analyses. First, we performed a network analysis on the GAG 
metabolism pathway to identify those genes that are central 
to the network and, therefore, more likely to be key for the 
pathway functionality. Second, we screened the drugs approved 
by the Food and Drug Administration (FDA) to identify drugs 
that target central genes in the GAG metabolism pathway. Third, 
we defined a topology-based measure to evaluate the functional 
impact of these drugs on the GAG metabolism. Fourth, we 
compared the topology-based measure between the GAG metab-
olism and the rest of human biological processes for each of 
the candidate drugs. The details of this exploratory analysis are 
described in online supplementary material 1 and online supple-
mentary tables S5, S6, S7.
RESULTS
Replication of established Ps risk variation
We found that 17 out of the 77 SNPs previously associated with 
Ps risk were also associated with PsA susceptibility in the Spain 
cohort (p<0.05; table 1). The ‘DNA repair’ pathway, a gene set 
previously associated with Ps risk, was also associated with PsA 
in our cohort (p=0.01; online supplementary table S8).
Identiﬁcation of new genetic loci associated with PsA
In the GWAS meta-analysis, we identified five loci associated 
with PsA at the genome-wide scale (p<5e-08; table 2). From 
these, the B3GNT2 locus (rs10865331, p=1.10e-08) has not 
been previously associated with PsA risk (figure 1). The complete 
list of associated markers is shown in online supplementary table 
S9.
In the association analysis of the HLA markers comparing 
patients with PsA and PsC, we confirmed the genome-wide 
significant association between the HLA-C*06:02 allele and PsA 
risk (p=6.96e-11). The amino acid residues HLA-B Leu95 and 
HLA-C Ala305 were found to be also strongly associated with 
the risk of developing PsA (p<5e-8). In the stepwise conditional 
analysis, only the amino acid residue HLA-A Ala77 remained 
significant (pFDR<0.05). The complete list of associated HLA 
markers is shown in online supplementary table S10 (p<0.05).
Identiﬁcation of genetic pathways associated with PsA
In the Spain cohort, we identified 76 genetic pathways signifi-
cantly associated with PsA risk (pFDR<0.05; online supple-
mentary table S11). Fifty out of these pathways (65.8%) were 
found to include genes from the HLA region and/or the IL12B 
gene (online supplementary table S12), which are the stron-
gest genetic risk loci for both Ps and PsA. To confirm that the 
observed pathway associations are not only due to the strong 
signals present at these loci, we retested the pathways after 
removing these regions (HLA region: 25.6–33.3 Mb in chromo-
some 6, n=4021 SNPs; IL12B: 158 741 791–158 757 481 bp in 
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Table 1 Established Ps risk variants associated with PsA susceptibility in the Spanish cohort
SNP Chr Pos Gene RA Phenotype P value OR (95% CI)
rs12044149 1 67600686 IL23R T PsA-controls 1.73e-05 1.35 (1.18 to 1.56)
rs1990760 2 163124051 IFIH1 T PsA-controls 1.32e-03 1.24 (1.09 to 1.41)
rs4921482 5 158764478 IL12B, ADRA1B T PsA-controls 6.73e-03 0.83 (0.72 to 0.95)
rs918520 5 158826310 IL12B G PsA-controls 4.26e-02 0.85 (0.72 to 0.99)
rs33980500 6 111913262 TRAF3IP2 T PsA-controls 1.01e-07 1.84 (1.47 to 2.29)
rs4795067 17 26106675 NOS2 G PsA-controls 1.29e-03 1.24 (1.09 to 1.41)
rs146571698 5 150471878 TNIP1 T PsC-controls 8.10e-03 1.38 (1.09 to 1.74)
rs918520 5 158826310 IL12B G PsC-controls 4.26e-02 0.85 (0.72 to 0.99)
rs9481169 6 111929862 TRAF3IP2 T PsC-controls 1.29e-05 1.55 (1.27 to 1.89)
rs7536201 1 25293084 RUNX3 C Ps-controls 1.76e-03 1.22 (1.08 to 1.39)
rs9988642 1 67726104 IL23R T Ps-controls 1.90e-02 0.75 (0.59 to 0.96)
rs10865331 2 62551472 B3GNT2 A Ps-controls 3.62e-07 0.72 (0.63 to 0.81)
rs17715343 2 163167746 IFIH1 C Ps-controls 4.23e-03 0.73 (0.58 to 0.92)
rs27432 5 96119273 ERAP1 A Ps-controls 3.00e-02 0.87 (0.76 to 0.99)
rs2233278 5 150467189 TNIP1 C Ps-controls 7.67e-03 1.38 (1.09 to 1.75)
rs918520 5 158826310 IL12B G Ps-controls 4.26e-02 0.85 (0.72 to 0.99)
rs33980500 6 111913262 TRAF3IP2 T Ps-controls 1.01e-07 1.84 (1.47 to 2.29)
rs610037 11 65546857 AP5B1 C Ps-controls 4.02e-03 1.20 (1.06 to 1.37)
rs34394770 13 40333369 COG6 T Ps-controls 4.11e-03 0.82 (0.71 to 0.94)
rs367569 16 11365500 PRM3, SOCS1 C Ps-controls 1.72e-02 0.84 (0.73 to 0.97)
rs545979 18 51819750 POLI T Ps-controls 6.93e-03 1.21 (1.05 to 1.38)
P values <0.05 are shown.
Chr, chromosome; Phenotype, phenotype comparison; Pos, base pair in GRCh37/hg19; Ps, psoriasis; PsA, psoriatic arthritis; PsC, purely cutaneous psoriasis; RA, risk allele (genetic 
variants whose reference allele was found to confer risk for the indicated phenotype are shown); SNP, single-nucleotide polymorphism.
Table 2 Genetic variants associated with PsA risk at the genome-wide scale
SNP* Chr Pos Gene A1 A2 ORS PS ORN PN ZM PM
rs458017† 6 111696091 REV3L T C 1.85 (1.45 to 2.35) 9.29e-07 1.65 (1.37 to 1.99) 1.16e-07 −6.66 2.68e-11
rs4921483 5 158768365 IL12B A G 1.40 (1.19 to 1.65) 4.31e-05 1.43 (1.25 to 1.63) 1.34e-07 6.13 8.94e-10
rs10865331 2 62551472 B3GNT2 A G 1.39 (1.23 to 1.58) 3.62e-07 1.22 (1.10 to 1.36) 2.06e-04 5.72 1.10e-08
rs74817271 5 150469973 TNIP1 A G 1.38 (1.09 to 1.74) 8.10e-03 1.79 (1.47 to 2.17) 3.20e-09 5.64 1.66e-08
rs2546890 5 158759900 IL12B A G 0.81 (0.71 to 0.91) 8.77e-04 0.75 (0.68 to 0.84) 1.37e-07 5.64 1.70e-08
P values (pM<5.00e-08) are shown.
*The new PsA risk loci are shown in bold. Independent (linkage disequilibrium r2<0.45) non-HLA SNPs are shown.
†The SNP rs458017 is in high linkage disequilibrium with the SNP rs33980500 at the known PsA risk gene TRAF3IP2 (r2=0.74).
Z, z-statistic that summarises the magnitude and direction effects relative to the reference allele)A1, minor allele; A2, major allele; CI, conﬁdence interval; Chr, chromosome; M, 
meta-analysis; N, PsA case–control cohort from North America; OR, odds ratio and 95% conﬁdence interval (the odds ratios shown are relative to the minor allele); OR, odds 
ratio; Pos, base pair in build GRCh37/hg19; PsA, psoriatic arthritis; S, PsA case–control cohort from Spain; SNP, single-nucleotide polymorphism.
chromosome 5, n=81 SNPs). After excluding these regions, we 
found that 9 genetic pathways were still significantly associated 
with PsA, giving a total of 35 pathways for validation in the inde-
pendent cohort. Using the North America case–control cohort, 
we replicated the association of 16 genetic pathways with PsA 
risk (45.7%, pFDR<0.05; table 3).
Biological pathways can share a varying number of genes, and 
therefore redundancy in pathway association can occur. To filter 
out highly redundant results, we computed the gene overlap 
between the PsA-associated pathways. We found a marked gene 
overlap (>95% shared genes) between the ‘Costimulation by the 
CD28 family’ (n=63 genes) and ‘CD28 costimulation’ pathways 
(n=32 genes), as well as between the ‘Metabolism of carbohy-
drates’ (n=247 genes) and ‘GAG metabolism’ pathways (n=111 
genes; online supplementary figure S2). In these two cases, we 
selected the pathway most significantly associated with PsA for 
downstream analyses (ie, ‘Costimulation by the CD28 family’ 
and ‘GAG metabolism’ pathways).
GAG metabolism pathway is speciﬁcally associated with PsA
In order to test for disease-specific risk, we tested the new PsA 
locus and pathways in the PsC and RA cohorts. We found that 
B3GNT2 risk allele is significantly associated with PsA in both 
comparisons (p[PsAvsPsC]=0.029, OR[95% CI]=1.16 [1.02 to 1.36]; 
p[PsAvsRA]=2.41e-04, OR[95% CI]=1.26 [1.08 to 1.44]). When 
comparing each disease with the control cohort, we found a 
significant association between PsC and B3GNT2 (p=6.11e-3, 
OR[95% CI]=1.21 [1.05 to 1.38]) but not with RA (p=0.07, OR[95% 
CI]=1.11 [0.99 to 1.24]).
In the pathway analysis we found that the GAG metabolism 
pathway was significantly associated with PsA when compared 
with PsC (p=0.018; online supplementary table S13) and RA 
(p=0.0018; online supplementary table S13). Subsequent testing 
of these two autoimmune diseases against the control cohort 
showed no evidence of association (p=0.71 and p=0.58 for PsC 
and RA pathway analyses, respectively).
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Table 3 Genetic pathways associated with PsA risk and validated in the replication stage
Genetic pathway Database
Gene 
(n) SNPsS* PS FDRS PSE FDRSE SNPsN1 PN FDRN PNE FDRNE PC
Type I diabetes mellitus†‡ KEGG 44 1791 <1.00e-08 <6.50e-07 4.00e-04 7.50e-03 1436 <1.00e-08 <9.00e-08 1.32e-04 2.11e-03 <3.78e-15
JAK-STAT signalling †‡ KEGG 155 4193 8.10e-04 1.98e-02 5.00e-03 3.12e-02 2594 <1.00e-08 <9.00e-08 5.00e-04 4.00e-03 <2.15e-10
Costimulation by CD28 family‡ Reactome 63 1410 8.00e-06 4.43e-04 7.00e-04 8.00e-03 964 1.50e-06 7.80e-06 1.73e-02 4.61e-02 3.14e-10
Th1/Th2 differentiation‡ Biocarta 19 523 2.00e-05 9.16e-04 1.34e-02 8.00e-03 355 1.50e-06 7.80e-06 1.21e-02 3.87e-02 7.57e-10
Purine metabolism KEGG 159 5360 2.90e-04 8.72e-03 4.20e-03 3.07e-02 3295 4.00e-05 9.45e-05 8.30e-03 3.32e-02 2.24e-07
G alpha signalling Reactome 195 6271 1.84e-03 3.28e-02 1.05e-02 4.38e-02 3890 2.00e-05 5.78e-05 4.20e-03 2.24e-02 6.67e-07
CD28 costimulation Reactome 32 786 1.40e-04 5.08e-03 – – 488 2.95e-03 4.79e-03 – – 6.48e-06
Extracellular matrix Biocarta 24 743 6.00e-05 2.34e-03 – – 439 8.16e-03 1.06e-02 – – 7.60e-06
mTOR signalling KEGG 52 1280 5.80e-04 1.57e-02 – – 780 1.04e-03 1.80e-03 – – 9.24e-06
Rac-1 cell motility signalling Biocarta 23 751 6.50e-04 1.71e-02 – – 459 4.83e-03 6.98e-03 – – 4.29e-05
Glycosaminoglycan metabolism Reactome 111 6035 1.04e-03 2.38e-02 – – 3705 3.41e-03 5.22e-03 – – 4.81e-05
ErbB signalling‡ KEGG 87 4099 1.70e-03 3.14e-02 – – 2459 7.36e-03 1.01e-02 – – 1.54e-04
Met signalling Biocarta 37 1402 8.80e-04 2.11e-02 – – 890 1.74e-02 1.74e-02 – – 1.85e-04
Metabolism of carbohydrates Reactome 247 8964 1.52e-03 3.01e-02 – – 5469 1.14e-02 1.35e-02 – – 2.07e-04
Interleukin-7 signal transduction Biocarta 17 689 2.76e-03 4.21e-02 – – 432 1.49e-02 1.55e-02 – – 4.56e-04
Glycosaminoglycan biosynthesis of 
keratan sulfate
KEGG 15 651 3.35e-03 4.83e-02 – – 428 1.32e-02 1.43e-02 – – 4.88e-04
*Number of SNP mapping to the indicated pathway.
†Increased permutations to reﬁne the p value (n=1.00e-08).
‡Pathways previously associated with the overall Ps risk.
SNP, single-nucleotide polymorphism.C, combined; E, exclusion of IL12B and/or HLA genes; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; N, PsA case–control cohort from North America; 
Ps, psoriasis; PsA, psoriatic arthritis; S, PsA case–control cohort from Spain.
Figure 1 Regional association plot of the new genetic variant rs10865331 associated with psoriatic arthritis (PsA) risk. Each circle represents a 
genetic variant that is plotted according to its association with PsA risk in the negative logarithmic scale. Circles are coloured according to the linkage 
disequilibrium with the SNP rs10865331 (ie, violet circle). The blue line shows the recombination rate across the plotted region (data source: 1000 
Genomes Project; build GRCh37/hg19). In the bottom line, the genes mapping to the PsA-associated locus are shown.
GAG metabolism is associated with PsA at the transcriptomic 
level
Using whole blood transcriptomic data from patients with PsA 
and PsC,46 we found that 14 out of the 111 genes included in 
the GAG metabolism pathway were differentially expressed 
between the two diseases (online supplementary table S14). This 
difference is higher than expected by chance (pBinomial????????
figure 2). When comparing each disease with the control group 
(online supplementary table S14), the number of differentially 
expressed genes was also found to be significant in PsA (pBino-
mial??????????????????????????Binomial=0.27).
In the coexpression analysis of the GAG metabolism pathway, 
we detected that the pathway genes have a higher coexpression 
in PsA (IMC=1.43) than in PsC (IMC=1.38). Of relevance, 
when comparing the coexpression of the pathway between the 
PsA cohort and the mixed cohort of patients with PsA and PsC 
(IMC=0.54), the coexpression of the pathway was found to 
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Figure 2 GAG metabolism pathway genes are differentially expressed in patients with PsA and PsC. Network representation of the GAG 
metabolism pathway. Genes, represented as nodes, are connected by edges according to the evidence of functional association between their 
encoded proteins. Differentially (p<0.05) and non-differentially (p≥0.05) expressed genes are represented by rhombus and grey circles, respectively. 
Differentially expressed genes that are upregulated and downregulated in PsA are coloured in red and orange, respectively. Gene diameter is 
proportional to the signiﬁcance of differential expression in the negative logarithmic scale. GAG, glycosaminoglycan; PsA, psoriatic arthritis.
significantly drop when both diseases are analysed together as a 
single disease entity (p=8.37e-10).
GAG metabolism is a new source for drug discovery in PsA
In this exploratory analysis, we identified six FDA-approved 
drugs that target proteins encoded by GAG pathway genes 
(figure 3A). The analysis of the network topology of the GAG 
pathway showed that NCAN and VCAN genes, both targeted by 
the hyaluronic acid drug (HAd), and the DCN gene, targeted by 
the tromethamine drug (TMd), have the highest centrality prop-
erties (figure 3B). Since a higher network centrality is indica-
tive of a predominant regulatory role in the pathway,47 we next 
evaluated the impact of HAd and TMd in the regulation of the 
GAG pathway. We found that both HAd and TMd significantly 
modulate the GAG pathway functionality (pHAd=0.0097 and 
pTMd=0.017), and therefore these two drugs could be repurposed 
as candidates for PsA treatment.
DISCUSSION
The identification of genetic variation that is associated with PsA 
and not with PsC has proven very challenging. Here, we have 
analysed two large PsA case–control cohorts from independent 
populations to identify disease-specific variation both at the 
single marker and at the pathway levels. Using this approach, we 
have identified a significant association of B3GNT2 locus as well 
as 14 genetic pathways with PsA risk. From these, we have found 
that genetic variation at the GAG metabolism pathway is specif-
ically associated with PsA. Investigating the GAG metabolism 
pathway with drug-repurposing and network analyses, we have 
identified potentially new PsA indications for common drugs as 
well as new candidate drug targets for PsA.
The SNP rs10865331 associated with PsA risk is located on 
chromosome 2p15 at 99.6 Kb downstream of the B3GNT2 gene, 
which encodes for a transmembrane enzyme that synthesises 
the carbohydrate structure of polylactosamine onto glycopro-
teins.48 This polymorphism maps to a genomic region enriched 
in promoter and enhancer histone marks from blood, which 
has a marked immune cell burden.49 According to the Geno-
type-Tissue Expression, there is evidence of strong cis-regula-
tion between this SNP and B3GNT2 expression in whole blood 
(p=5.1e-13; online supplementary figure S3).50 Previous studies 
in other arthritic diseases have shown that the SNP rs10865331 
is associated with ankylosing spondylitis and the B3GNT2 locus 
with RA.51 52 Consistently, B3gnt2 knockout mice have shown 
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Figure 3 Drug-repurposing and network analyses in the GAG metabolism pathway. (A) Six FDA-approved drugs (amiloride, hyaluronic acid, 
N-acetyl-D-glucosamine, palifermin, sargramostim and tromethamine) have target genes in the GAG metabolism pathway. (B) Identiﬁcation of the 
most central genes in the functional-based network of the GAG metabolism pathway. Gene diameter is proportional to its degree centrality value 
and is coloured according to its betweenness centrality value, ranging from white (lowest) to red (highest). FDA, Food and Drug Administration; GAG, 
glycosaminoglycan.
hyperactivation of T and B lymphocytes as well as enhanced 
macrophage activation.48 53 In a GWAS meta-analysis, B3GNT2 
has also been associated with Ps risk.11 In this previous study, 
however, a stratified analysis with patients affected with PsA was 
not performed, and consequently it remains unclear the contri-
bution of each disease to the observed association. Here we 
show, for the first time, that the SNP rs10865331 at B3GNT2 
locus is associated with PsA at the genome-wide level and that 
the frequency of the risk allele is significantly higher in PsA than 
in PsC.
The identification of disease-specific genetic variation is highly 
useful to discover relevant pathogenic mechanisms in complex 
diseases.54 In PsA, the existence of disease-specific variation 
is supported by the evidence of a larger familial aggregation 
compared with Ps.5–8 Using the GWAS data from this study, we 
find that, while PsA and PsC show a significant genetic correla-
tion (r2=0.73, SE=0.12, p=3.76e-9), the SNP-based heritability 
of PsA (46%, SE=12%) is significantly higher than PsC (34%, 
SE=2%, p<0.05) (online supplementary material 1). In line 
with familial aggregation studies, our findings also support the 
existence of PsA-specific genetic variation. To this regard, when 
directly comparing the PsA and PsC cohorts, we have not only 
replicated the association of the HLA-C*06:02 and HLA-B*27 
haplotypes,38 39 but also we have identified a new association 
between the HLA-A Asp77 and PsA risk. At the pathway level, 
we have identified a specific association between PsA and the 
GAG metabolism pathway. GAGs are linear, negatively charged 
oligosaccharides that include hyaluronic acid (HA), chondroitin 
sulfate and keratan sulfate (KS).55 Of relevance, GAGs are crucial 
components of proteoglycans and the major component of the 
cartilage, which is the main target tissue of PsA inflammatory 
destruction.56 57 Our results suggest that cartilage degradation 
in PsA could derive from an altered GAG metabolism that is not 
perturbed in other arthritis like RA.
GAG metabolism has been shown to be altered in complex 
diseases including autoimmune diseases.58 59 In in vitro models, 
uncontrolled proteolysis of aggrecan (ie, cartilage-specific proteo-
glycan) in response to proinflammatory cytokines promotes 
cartilage damage in the articular joint.60 After aggrecan destruc-
tion, GAGs are released from the extracellular matrix (ECM) 
to the synovial fluid.61 Accordingly, the levels of GAGs like HA 
have been found increased in patients with PsA compared with 
control subjects, both in serum and synovial fluid.62 63 Previous 
experimental studies have demonstrated the existence of a 
GAG-mediated mechanism for cartilage destruction that is driven 
by the degradation of HA by chondrocytes and that is indepen-
dent from aggrecanases.64 Consistent with this evidence, genetic 
variation at the GAG metabolism pathway could diminish the 
cartilage-specific biosynthesis of HA, and consequently reduce 
its availability for both aggrecan and cartilage formation in 
patients with PsA.
In this study we also validated the association between 13 
genetic pathways and PsA risk. From these, JAK-STAT signal-
ling, type 1 diabetes mellitus, costimulation by CD28 family, 
Th1/Th2 differentiation and ErbB signalling pathways had been 
previously associated with Ps risk.29 Crucial proinflammatory 
cytokines for the development of Ps like interleukin (IL)-12 and 
IL-23 rely on the JAK-STAT signalling pathway. Importantly, 
small molecule inhibitors of JAK proteins (eg, ruxolitinib and 
tofacitinib) have been recently proven successful for the treat-
ment of the disease.65 Our results provide additional genetic 
evidence supporting the functional role of this group of biolog-
ical pathways in the aetiology of Ps. The eight remaining path-
ways (ie, G alpha signalling, purine metabolism, KS biosynthesis, 
extracellular matrix, mTOR signalling, IL-7 signal transduction, 
Rac-1 cell motility signalling and Met signalling) were found to 
be only significantly associated with PsA. Recent studies have 
shown that the mTOR signalling pathway is responsible for 
inducing the proliferation of a synovial T cell subpopulation (ie, 
Th9 cells) that enhances the immune response in PsA.66 There 
is also previous evidence supporting the implication of the IL-7 
signal transduction pathway in the development of PsA. In in 
vitro models, lymphocytes and synovial fluid fibroblasts have 
shown to produce IL-7 cytokine and promote the formation 
of osteoclasts,67 which are the main mediators of bone matrix 
degradation in PsA. Additional studies on independent PsA and 
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PsC cohorts will be needed to confirm the PsA-specific nature of 
these additional pathway associations.
Current drug discovery research is shifting from targeting 
single genes towards the modulation of specific biological path-
ways.68 Here, we show that the GAG metabolism could be a 
druggable pathway for PsA treatment. Our analyses suggest that 
FDA-approved drugs HAd and TMd are good candidates for 
repurposing for PsA, since they target central genes in the GAG 
metabolism network and have a significant impact on its func-
tionality. We, like others, show the power of genetics to identify 
potential new drug targets and opportunities for drug repur-
posing in autoimmune diseases.69 In all these studies, however, 
downstream validation of the in silico findings in adequate in 
vitro and in vivo studies is still an indispensable step. There-
fore, future experimental and clinical studies will be necessary 
to corroborate the utility of these two new drug targets to treat 
PsA.
Compared with previous GWAS, the use of PsC and RA cohorts 
to differentiate the genetic pathways that are PsA-specific from 
those that are not is a distinctive strength of the present study. 
The pathway-based analysis methodology used here has limita-
tions, nonetheless. One limitation is the SNP annotation to 
the genes within each pathway. SNPs that are located far from 
the genes or in other chromosomes and that could regulate 
gene expression through cis-expression Quantitative Trait Loci 
(eQTL) and trans-eQTL mechanisms were not included in the 
present GWPA. To our knowledge, there is yet no pathway-based 
method that integrates this information and that has been able 
to identify disease risk variation. One of the major problems for 
this approach is the context-dependent nature of many eQTLs. 
There is growing evidence that many eQTLs are cell type-depen-
dent and also vary in relation to many contextual aspects like the 
level and type of stimulation.70–72 The integration of this regu-
latory information is therefore still a challenge for GWPA anal-
ysis methods. With the increasing regulatory information that 
is currently being derived from single-cell expression studies,73 
a more profound ascertainment of the impact of SNP variation 
on gene expression levels will be obtained, and eventually more 
comprehensive GWPA methods will be developed.
In conclusion, we have identified variation at B3GNT2 locus 
and 14 pathways significantly associated with the risk of PsA. 
From these, the GAG metabolism pathway showed a specific 
association with PsA when contrasted to PsC and RA. Using 
network and drug-repurposing analyses, we provide evidence 
that the GAG pathway could be a new source for drug discovery 
in PsA. This study represents an important step towards the 
characterisation of biological mechanisms that are specific for 
PsA and the finding of more effective drugs in PsA treatment.
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Abstract
The production of antibodies to anti-tumor necrosis factor alpha (TNF) agents is one of the main causes of treatment failure
in Crohn’s disease (CD). To date, however, the contribution of genetics to anti-TNF immunogenicity in CD is still unknown.
The objective of the present study was to identify genetic variation associated with anti-TNF immunogenicity in CD. We
performed a two-stage genome-wide association study in a cohort of 96 and 123 adalimumab-treated patients, respectively.
In the discovery stage, we identiﬁed a genome-wide signiﬁcant association between the CD96 locus and the production of
antibodies to anti-TNF treatment (P= 1.88e–09). This association was validated in the replication stage (P < 0.05). The risk
allele for anti-TNF immunogenicity was found to be also associated with a lack of response to anti-TNF therapy (P= 0.019).
These ﬁndings represent an important step toward the understanding of the immunogenicity-based mechanisms that underlie
anti-TNF response in CD.
Introduction
Crohn’s disease (CD) is an immune-mediated gastro-
intestinal disorder that affects ~0.5% of the worldwide
population [1]. This chronic disease has a multifactorial
etiology where genetic and environmental factors contribute
to trigger inﬂammatory processes in the intestinal mucosa
[2]. To date, there is no curative medical treatment for CD
and therefore current therapeutic strategies are aimed at
inducing remission and minimizing adverse reactions to
improve the patients’ quality of life.
There is compelling evidence that the proinﬂammatory
cytokine tumor necrosis factor alpha (TNF) plays a key role
in the pathogenesis of CD [3]. In the last years, the intro-
duction of anti-TNF drugs has greatly improved the disease
course and quality of life in many patients with severe and
moderate CD [4]. However, up to 50% of the anti-TNF-
treated patients experience a loss of clinical response over
time that will require either dose escalation or treatment
discontinuation [5].
One of the main causes of anti-TNF treatment failure is
the production of antidrug antibodies [6]. These antibodies
can neutralize the biological activity of anti-TNF agents and
increase their clearance [7]. Accordingly, the presence of
antidrug antibodies has been associated with low clinical
response in CD [8]. Adalimumab is one of the most com-
mon anti-TNF agents used to treat CD [9]. Despite being a
fully humanized monoclonal antibody [10], it has shown to
be immunogenic. Recently, multiple studies have demon-
strated the presence of anti-adalimumab antibodies (AAAs),
although there is substantial heterogeneity on the percentage
of AAA-positive patients, ranging from 9 to 35%
adalimumab-treated patients [8, 11–13]. This heterogeneity
could be due to drug properties but also to host-related
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factors like genetic variation [14]. To date, however, the
contribution of genetics to anti-TNF immunogenicity in CD
is still unknown.
The association between genetic variation and the pro-
duction of antibodies to anti-TNF drugs has been yet
investigated in CD. So far, only a few candidate studies in
rheumatoid arthritis (RA) have tested genetic variants with
this objective. IGHG1 immunoglobulin heavy chain-coding
gene was tested for association with antibodies to inﬂix-
imab, but no association was found [15]. In adalimumab-
treated RA patients, the production of AAA has been
associated with genetic variation at IL-10 gene, a key par-
ticipant in B-cell differentiation [16]. Although this genetic
association has not been yet tested for replication, it sug-
gests the existence of a genetic basis for anti-TNF immu-
nogenicity in autoimmune diseases.
In order to identify new genetic variation associated with
the production of AAAs, we have performed a genome-
wide association study (GWAS) for immunogenicity to
anti-TNF therapy in CD. For this analysis, we have used a
discovery cohort of 96 CD patients and an independent
validation cohort of 123 CD patients who had received anti-
TNF therapy. Furthermore, we have investigated whether
this genetic variation is also associated with the clinical
response to anti-TNF therapy. The results of this study
provide new insights into the genetic basis of anti-TNF
immunogenicity in CD.
Materials and methods
Patients and samples
Discovery cohort
A total of 96 CD patients were recruited for the discovery
stage of present study. All patients were collected between
July 2007 and June 2012 from the outpatient’s clinics of the
gastroenterology departments from 15 Spanish University
Hospitals belonging to the Immune-Mediated Inﬂammatory
Disease Consortium (IMIDC). The IMIDC is a Spanish
network of researchers investigating the genomic basis of
immune-mediated inﬂammatory diseases [17]. All patients
were diagnosed as having CD according to the Lennard-
Jones diagnostic criteria [18], were Caucasian European,
and with the four grandparents born in Spain.
Replication cohort
An independent cohort of 123 CD patients was used to
validate the signiﬁcant genetic associations identiﬁed in the
discovery stage. As described for the discovery cohort, the
patient collection was also conducted by the IMIDC
between July 2007 and June 2012, and the disease diagnosis
was performed according to the Lennard-Jones diagnostic
criteria. All patients included in the replication cohort were
also Caucasian European and with all four grandparents
born in Spain.
Patient treatment
The CD patients included in the present study had received
adalimumab therapy. The protocol used for the adalimumab
treatment included an initial dose of 160 mg at baseline
followed by 80 mg at week 2, as well as a maintenance dose
of 40 mg/week. The treatment protocol allowed con-
comitant treatment with corticosteroids. Only the patients
treated with adalimumab to induce or maintain remission in
the inﬂamed gastrointestinal tract were selected for the
GWAS. Consequently, those patients who received
adalimumab to promote the ﬁstula closure or to follow a
postoperative prophylaxis therapy were not included.
The patients who experienced delayed hypersensitivity,
anaphylactic, or infusion reactions were also excluded from
the analysis. After this stringent clinical criteria ﬁltering, a
total of 62 and 88 CD patients were used for the discovery
and replication stages, respectively.
Patient characteristics before treatment initiation
All patients from both the discovery and replication cohorts
were naive to anti-TNF therapy at the moment of treatment
initiation. In addition, to increase the homogeneity of the
cohorts, only patients with at least 3 years of follow-up
since diagnosis were included in the present study.
Identiﬁcation of AAA-positive CD patients
In order to identify those CD patients who are positive for
the production of AAA, we ﬁrst assessed the AAA con-
centration in each CD patient. For this objective, we mea-
sured the AAA concentration in plasma samples using a
commercial enzyme-linked immunosorbent assay (ELISA,
Promonitor® Anti-Adalimumab, Progenika Biopharma
S.A., Spain) and following the instructions provided by the
manufacturer (Progenika Biopharma, Spain). Importantly,
to increase the sensitivity of the test and avoid the
occurrence of false-negative results, we conducted a pre-
vious acidiﬁcation of the samples to dissociate potential
adalimumab–AAA complexes, as previously described
[19]. A total of 20 μL of serum was mixed with 100 mL of
300 mM acetic acid to a ﬁnal pH of 3.0. After incubation at
room temperature during 15 min, samples were neutralized
by adding 31 μL of 1M Tris base solution. The samples
were then incubated during 5 min with gentle shaking and,
subsequently, 49 μL of the kit dilution buffer were added to
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obtain a ﬁnal dilution factor 1:10. All samples were ana-
lyzed in duplicate for AAA using the Promonitor kits with
acid pre-treatment. The CD patients were ﬁnally reported as
AAA positive if the concentration of AAA was higher than
the cut-point value of 10 AU/mL established by the manu-
facturer (Supplementary Table S1).
DNA extraction and genome-wide genotyping
Whole blood samples (5 mL) were collected from all CD
patients of the discovery cohort. Genomic DNA was then
isolated using the Chemagic Magnetic Separation Module I
(PerkinElmer, USA).
Genome-wide genotyping of the 62 individuals from the
discovery group was performed using Illumina Quad610
Beadchip array (Illumina, USA) at HudsonAlpha Institute
for Biotechnology (Huntsville, Alabama, USA). This gen-
otyping array scans 618,150 polymorphisms, including
598,258 Single Nucleotide Polymorphisms (SNPs) and
19,892 Copy Number Variants (CNV) probes. The geno-
type calling and the quality control (QC) analysis were
performed using the GenomeStudio (v2011.1, Illumina,
USA) and PLINK softwares, respectively [20]. From the
582,539 autosomal SNPs that were selected for the QC
analysis, we excluded those SNPs showing >5% of missing
data (1.61% SNPs) and a minor allele frequency (MAF)
<0.05 (5.62%). Using an additional cohort of 1454 healthy
controls from the same population [21], we tested the
deviation of the SNPs from the Hardy–Weinberg equili-
brium (HWE). Those SNPs that were not in HWE (0.03%
SNPs, P < 1e–4) were subsequently removed. After the QC
analysis, a ﬁnal data set of 540,221 SNPs were available for
the association analysis.
Population stratiﬁcation (i.e., allele frequency differences
between patients due to systemic ancestry differences) is
one of the most important confounding factors that can
yield biased results in large-scale GWAS if not properly
addressed [22, 23]. To evaluate the presence of stratiﬁcation
in the CD discovery cohort, we used the additional cohort of
1454 controls and the principal component analysis imple-
mented in EIGENSOFT (v4.2) software [24]. Using the ﬁrst
10 Principal Components (PCs) of variation over 10 itera-
tions, no samples showing an outlier genetic background
were detected (Supplementary Fig. S1). After population
stratiﬁcation analysis, a total 62 CD patients remain avail-
able for the association analysis.
The genotyping of the associated SNP rs9828223 in the
validation group of CD patients was performed using the
Taqman Real-Time PCR genotyping platform (Thermo
Fisher Scientiﬁc, USA). The TaqMan assay used for the
SNP genotyping was C__29625246_10 and the thermal
cycle conditions were as follows: 50 °C for 2 min and 95 °C
for 10 min, followed by 40 cycles of 92 °C for 15 s and
60 °C for 1 min. All PCR and end point ﬂuorescent readings
were performed using an ABI PRISM® 7900 HT detection
system (Thermo Fisher Scientiﬁc, USA).
Treatment response deﬁnition
The clinical response to adalimumab treatment was
assessed using the Harvey–Bradshaw index (HBI) at
4 weeks after the ﬁrst infusion of adalimumab in CD
patients [25]. Based on the HBI after adalimumab therapy,
remission was deﬁned as a HBI equal or lower than four at
the end of the induction period. Partial response was
deﬁned as a reduction of more than three points on the
HBI. Non-response was deﬁned as a decrease of at least
three points on the HBI. Accordingly, patients with CD
that were in remission or showed a partial response were
combined into a single responder group, whereas patients
who failed to achieve the previously described decrease on
the HBI were deﬁned as non-responders. Those patients
whose treatment response was not determined were
excluded from the association analysis between genetic
variation and the clinical response to adalimumab therapy
(N= 16 CD patients).
Statistical analysis
In order to compare the distribution of each clinical
and epidemiological variable between the discovery
and replication groups, between AAA-positive and
AAA-negative patients, as well as between clinical
responders and non-responders, we used the Student’s
t-test and Fisher’s exact test for quantitative and qualita-
tive variables, respectively (Table 1). According to refer-
ence GWAS [26, 27], the Cochran–Armitage trend test
with one degree of freedom was used to perform the
genome-wide association analysis between genetic varia-
tion and adalimumab immunogenicity under the additive
genetic model [28]. The odds ratios (OR) and their 95%
conﬁdence intervals (CIs) were computed using the
logistic regression model. In order to obtain the global
statistical signiﬁcance of the validated associations, we
combined the P-values resulting from the discovery and
replication stages using the Fisher’s method [29].
The statistical association analysis between variation at
CD96 locus and clinical response to adalimumab therapy
was performed using the χ2 statistical test in R statistical
software [30], and following a retrospective study design. In
order to increase the statistical power of the analysis, we
combined the discovery and replication groups of patients.
Combining both patient cohorts, data on clinical response to
adalimumab was available for a total of 134 CD patients,
from which 121 (81%) had a positive response and 13 (9%)
were non-responders.
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Results
Phenotypic characterization of the study cohorts
The main epidemiological and clinical characteristics of the
discovery and replication cohorts of CD patients treated
with anti-TNF therapy are shown in Table 1. No signiﬁcant
differences in the distribution of the different epidemiolo-
gical and clinical variables were found between the dis-
covery and replication cohorts (Table 1).
Genetic variation associated with anti-TNF
immunogenicity in the discovery stage
In the discovery stage, we found that the 14.5% of the
62 CD patients treated with adalimumab were positive
for AAA production (Supplementary Table S1). The
clinical characterization of both the AAA-positive and
AAA-negative CD patients is shown in Table 2. The
body mass index was found to be signiﬁcantly higher in
AAA-positive compared with AAA-negative CD patients
(P= 0.019).
When analyzing the association between genetic variation
and adalimumab immunogenicity, we identiﬁed a single
genome-wide signiﬁcant association between genetic varia-
tion at CD96 locus (P= 1.88e–09; OR= 20.2; 95% CI,
5.57–73.27; MAF= 13.1%) and the production of AAA in
CD (Fig. 1). No association was detected between the pre-
viously reported variation at IL-10 and adalimumab immu-
nogenicity. The complete list of markers showing nominal
signiﬁcance is shown in the Supplementary Table S2.
Replication of the association between the CD96
locus and anti-TNF immunogenicity
In the replication stage, we detected that 3.4% of the 88 CD
patients treated with adalimumab were positive for AAA
production (Supplementary Table S1). No signiﬁcant dif-
ferences in the distribution of the clinical variables were
found between AAA-positive and AAA-negative CD
patients (Table 2). In the validation analysis, we replicated
the association between variation at CD96 locus and ada-
limumab immunogenicity (P= 0.044; OR= 1.16; 95% CI,
1.09–1.23; MAF= 10.0%; Pcombined= 1.83e–09, Table 3).
Table 1 Main epidemiological
and clinical features of Crohn’s
disease patients
Characteristicsa Discovery group Replication group P-value
Individuals (N) 62 88 –
Genetic population Caucasian European Caucasian European –
Males 27/35 (43.54) 44/44 (50.00) 0.51
Age 39.02 ± 12.22 37.12 ± 12.54 0.33
Age disease onset 29.24 ± 12.07 30.27 ± 12.52 0.77
Body mass index 23.74 ± 3.49 23.82 ± 3.78 0.25
Smoking
Current smoker 20/36 (35.71) 29/56 (34.11) 0.99
Ex-smoker 14/42 (25.00) 22/63 (25.88) 1.00
Never smoker 22/34 (39.29) 33/52 (38.83) 1.00
Disease location
Ileal (L1) 9/35 (20.45) 19/36 (34.55) 0.18
Colonic (L2) 11/33 (25.00) 9/46 (16.36) 0.32
Ileocolonic (L3) 24/20 (54.55) 27/28 (49.09) 0.69
Upper gastrointestinal tract (L4) 9/34 (20.93) 8/41 (16.33) 0.60
Disease behavior
Inﬂammatory 33/22 (60.00) 46/42 (52.27) 0.39
Stenosing 22/34 (40.00) 25/63 (28.41) 0.20
Fistulizing 19/39 (32.76) 22/66 (25.00) 0.35
Extraintestinal manifestations 19/36 (34.54) 20/68 (22.73) 0.13
The comparison between the discovery and replication cohorts was conducted using the Fisher’s exact test
for categoric variables and Student’s t-test for quantitative variables
M mean, N sample size, SD standard deviation
aFor categoric variables, we show the number of patients displaying and non-displaying the indicated
characteristic as well as the percentage of positive patients for this variable. For quantitative variables, we
show the mean (i.e., years for ages and kg/m2 for body mass index) together with the standard deviation
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Table 2 Clinical characterization of Crohn’s disease patients according to their capacity to produce antidrug antibodies
Clinical characteristicsa AAA-positive
discovery (N= 9)
AAA-negative
discovery (N= 53)
P-value
discovery
AAA-positive
replication (N= 3)
AAA-negative
replication (N= 85)
P-value
replication
Males 4/5 (44.44) 23/30 (43.39) 1.00 2/1 (66.67) 42/43 (49.41) 1.00
Age 41.49 ± 18.08 38.36 ± 11.12 0.48 29.06 ± 5.33 37.29 ± 12.59 0.26
Age disease onset 31.16 ± 18.54 28.92 ± 10.83 0.61 22.33 ± 5.05 30.64 ± 12.57 0.25
Body mass index 25.96 ± 2.75 23.37 ± 3.01 0.019 24.69 ± 2.85 23.38 ± 3.99 0.58
Smoking
Current smoker 4/5 (44.44) 16/31 (34.04) 0.71 2/1 (66.67) 27/55 (32.93) 0.26
Ex-smoker 3/6 (50.00) 11/36 (23.40) 0.68 0/3 (0.00) 22/60 (26.83) 0.57
Never smoker 2/7 (22.22) 20/27 (42.55) 0.46 0/3 (0.00) 33/49 (40.24) 0.28
Disease location
Ileal (L1) 1/5 (16.67) 8/30 (21.05) 1.00 1/2 (33.33) 18/34 (34.62) 1.00
Colonic (L2) 1/5 (16.67) 10/28 (26.32) 0.98 0/3 (0.0) 9/43 (17.31) 1.00
Ileocolonic (L3) 4/2 (66.67) 20/18 (52.63) 0.67 2/1 (66.67) 25/27 (48.08) 0.61
Upper gastrointestinal
tract (L4)
2/5 (40.00) 7/29 (25.93) 0.62 1/2 (33.33) 7/39 (15.22) 0.42
Disease behavior
Inﬂammatory 5/3 (62.5) 28/19 (59.57) 1.00 3/0 (100.00) 43/42 (50.59) 0.24
Stenosing 5/4 (55.56) 17/29 (36.96) 0.46 1/2 (33.33) 24/61 (28.24) 1.00
Fistulizing 2/7 (22.22) 17/32 (34.69) 0.71 0/3 (0.00) 22/63 (25.88) 0.57
Extraintestinal
manifestations
3/5 (37.5) 16/31 (34.04) 1.00 0/3 (0.0) 20/65 (23.52) 1.00
The comparison between AAA-positive and AAA-negative CD patients was conducted using the Fisher’s exact test for categoric variables and
Student’s t-test for quantitative variables
AAA production of antidrug antibodies, M mean, N sample size, SD standard deviation
aFor categoric variables, we show the number of patients displaying and non-displaying the indicated characteristic as well as the percentage of
positive patients for this variable. For quantitative variables, we show the mean (i.e., years for ages and kg/m2 for body mass index) together with
the standard deviation
Fig. 1 Manhattan plot for immunogenicity to adalimumab therapy in
the discovery cohort. This ﬁgure represents the genome-wide P-values
of association between genetic variation and the formation of antidrug
antibodies in Crohn’s disease. The y axis shows the −log10 P-values of
540,221 SNPs, and the x axis shows their chromosomal positions
(SNP base pair in build GRCh37/hg19). The horizontal red line
represents the genome-wide signiﬁcance threshold (P= 5.00e–8)
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Association between the CD96 locus and the clinical
response to anti-TNF therapy
Given that antidrug immunogenicity is one of the main factors
inﬂuencing the clinical response to anti-TNF therapy, we
further investigated the association between the validated
CD96 polymorphism and the clinical response to adalimu-
mab. Combining both patient cohorts to increase the statistical
power of the analysis (Nresponders= 121; Nnon-responders= 13;
Table 4), we found a signiﬁcant association between the
clinical response to adalimumab and genetic variation at
CD96 locus (P= 0.019; OR= 1.77, 95% CI, 1.09–5.02). As
expected, the risk allele for the development of adalimumab
immunogenicity (A) was also the allele associated with a lack
of clinical response to adalimumab therapy.
Discussion
One of the major challenges in the treatment of CD is to
understand the biological mechanisms responsible for anti-
TNF failure. Although the genetic basis for anti-TNF
immunogenicity has been investigated in autoimmune dis-
eases, the genetic component underlying the production of
antibodies to anti-TNF has not been so far analyzed in CD.
In order to identify new genetic variation, we have per-
formed, for the ﬁrst time, a GWAS on anti-TNF immuno-
genicity in CD patients. Using a discovery cohort from
European ancestry and a validation cohort from the same
ancestry, we have identiﬁed and validated the association
between CD96 locus and the production of antibodies to
anti-TNF therapy.
The SNP associated with AAA—rs9828223—is located
36-kb upstream from the CD96 gene. CD96 is a member of
the immunoglobulin superfamily, and is mainly expressed in
the cell membrane of natural killer (NK), CD8+T and CD4
+T cells as well as some subsets of B cells [31]. Also, CD96
expression has been found to be higher in the terminal ileum
compared with other human tissues (Supplementary Fig. S2)
[32]. CD96 is a membrane receptor that shares a common
ligand, CD155, with membrane receptors CD226 and TIGIT
[33]. Recent studies in Cd96 knockout mice have demon-
strated that CD96 negatively regulates the cytokine response
of NK cells competing with CD226 to bind to their ligand
CD155 expressed on antigen presenting cells [34]. Impor-
tantly, genetic variation at CD155 has been previously asso-
ciated with an increased production of neutralizing antibodies
to rubella vaccine in humans [35, 36]. Consistent with this
ﬁnding, we have also detected evidence of association
between CD155 and adalimumab immunogenicity in our CD
cohorts, although not in the previously reported polymorph-
ism (Supplementary Table S2).
Table 3 Genetic association
between the CD96 locus and
both the production of antidrug
antibodies and anti-TNF
response
SNP Chr Pos Locus Clinical phenotypea Risk allele P-value OR
rs9828223 3 111224925 CD96 Antidrug antibodies A 1.83e–09 15.87 (4.38–57.49)
Anti-TNF response A 0.019 1.77 (1.09–5.02)
Chr chromosome, Pos base pair in build GRCh37/hg19, OR odds ratio and 95% conﬁdence interval (the
odds ratios shown are relative to the minor allele)
aFor antidrug antibody production, the association statistics that are shown in this table result from
combining the discovery and replication groups
Table 4 Clinical characterization of Crohn’s disease patients according
to their response to anti-TNF therapy
Clinical
characteristicsa
Responders
(N= 121)
Non-responders
(N= 13)
P-value
Males 60/61 (49.59) 5/8 (38.46) 0.56
Age 37.82 ± 11.56 41.99 ± 11.32 0.22
Age disease onset 29.80 ± 11.91 33.12 ± 14.66 0.35
Body mass index 23.76 ± 3.82 23.81 ± 2.68 0.96
Smoking
Current smoker 40/73 (35.40) 4/9 (30.77) 1.00
Ex-smoker 32/81 (28.32) 3/10 (23.10) 1.00
Never smoker 41/72 (36.28) 6/7 (46.15) 0.56
Disease location
Ileal (L1) 54/25 (68.35) 2/8 (20.00) 0.0046
Colonic (L2) 16/63 (20.25) 1/9 (10.00) 0.68
Ileocolonic (L3) 38/41 (48.10) 7/3 (70.00) 0.31
Upper
gastrointestinal
tract (L4)
12/61 (16.44) 2/5 (28.57) 0.59
Disease behavior
Inﬂammatory 62/52 (54.39) 8/5 (61.54) 0.77
Stenosing 44/75 (36.97) 2/10 (16.67) 0.21
Fistulizing 27/87 (23.68) 4/8 (33.33) 0.48
Extraintestinal
manifestations
34/81 (29.56) 1/11 (8.33) 0.18
The comparison between clinical responders and non-responders to
anti-TNF was conducted using the Fisher’s exact test for categoric
variables and Student’s t-test for quantitative variables
M mean, N sample size, SD standard deviation, anti-TNF tumor
necrosis alpha inhibitory drugs
aFor categoric variables, we show the number of patients displaying
and non-displaying the indicated characteristic as well as the
percentage of positive patients for this variable. For quantitative
variables, we show the mean (i.e., years for ages and kg/m2 for body
mass index) together with the standard deviation
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In Cd155 knockout mice, this CD96 ligand has been
shown to be implicated in the development of the humoral
response. Cd155–/– mice show a less efﬁcient humoral
response to orally administered antigens due to a decreased
production of IgG and IgA compared with wild-type mice
[37]. Also, signiﬁcantly higher titers of Th1-associated
IgG isotypes IgG2a/c are detected after subcutaneous
immunization in Cd155–/– mice compared with wild-type
littermates [38]. This ﬁnding suggests that CD155
promotes polarization of naive CD4+T cells to the Th2
phenotype. Taken together, these experimental observations
are consistent with our results. Genetic variation at
CD96–CD155 signal transduction pathway could therefore
predispose to produce antidrug antibodies by promoting
CD155 upregulation and subsequent polarization to the Th2
phenotype that leads to the activation of B cells.
The present study has limitations, which are mainly due
to the retrospective nature of the study and the modest
sample size of the patient cohorts. Therefore, further studies
following a prospective design and using larger cohorts of
adalimumab-treated CD patients are warranted. Despite
these limitations, we have been able to successfully identify
and replicate the ﬁrst genetic variant associated with ada-
limumab immunogenicity in CD. Studies involving other
anti-TNF therapies approved for CD and even other biolo-
gical therapies for which antidrug antibodies are a relevant
cause for the lack of efﬁcacy should be carried out to
determine the implication of CD96 variation.
In conclusion, we have identiﬁed and validated an
association between CD96 locus and immunogenicity to
adalimumab in CD. We have also found that variation at
this locus is associated with the clinical response to adali-
mumab therapy in CD. Taken together, these results provide
new insights into the genetic basis of immunogenicity and
clinical response to anti-TNF therapy in CD patients.
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Genome-Wide Pathway Analysis Identiﬁes
Genetic Pathways Associated with Psoriasis
Adria` Aterido1, Antonio Julia`1, Carlos Ferra´ndiz2, Lluı´s Puig3, Eduardo Fonseca4,
Emilia Ferna´ndez-Lo´pez5, Esteban Dauden6, Jose´ Luı´s Sa´nchez-Carazo7, Jose´ Luı´s Lo´pez-Estebaranz8,
David Moreno-Ramı´rez9, Francisco Vanaclocha10, Enrique Herrera11, Pablo de la Cueva12,
Nick Dand13, Nu´ria Palau1, Arnald Alonso1, Marı´a Lo´pez-Lasanta1, Rau¨l Tortosa1,
Andre´s Garcı´a-Montero14, Laia Codo´15, Josep Lluı´s Gelpı´15, Jaume Bertranpetit16, Devin Absher17,
Francesca Capon13, Richard M. Myers17, Jonathan N. Barker13,18 and Sara Marsal1
Psoriasis is a chronic inﬂammatory disease with a complex genetic architecture. To date, the psoriasis herita-
bility is only partially explained. However, there is increasing evidence that the missing heritability in psoriasis
could be explained by multiple genetic variants of low effect size from common genetic pathways. The
objective of this study was to identify new genetic variation associated with psoriasis risk at the pathway level.
We genotyped 598,258 single nucleotide polymorphisms in a discovery cohort of 2,281 case-control individuals
from Spain. We performed a genome-wide pathway analysis using 1,053 reference biological pathways. A total
of 14 genetic pathways (PFDR  2.55  10e2) were found to be signiﬁcantly associated with psoriasis risk. Using
an independent validation cohort of 7,353 individuals from the UK, a total of 6 genetic pathways were signif-
icantly replicated (PFDR  3.46  10e2). We found genetic pathways that had not been previously associated with
psoriasis risk such as retinol metabolism (Pcombined ¼ 1.84  10e4), the transport of inorganic ions and amino
acids (Pcombined ¼ 1.57  10e7), and post-translational protein modiﬁcation (Pcombined ¼ 1.57  10e7). In the latter
pathway, MGAT5 showed a strong network centrality, and its association with psoriasis risk was further vali-
dated in an additional case-control cohort of 3,429 individuals (P < 0.05). These ﬁndings provide insights into
the biological mechanisms associated with psoriasis susceptibility.
Journal of Investigative Dermatology (2016) 136, 593e602; doi:10.1016/j.jid.2015.11.026
INTRODUCTION
Psoriasis is a common chronic inﬂammatory disease of the
skin that affects approximately 2% of the worldwide popu-
lation (Nestle et al., 2009). In psoriasis, immune cells inﬁl-
trate the skin leading to an increased proliferation of
keratinocytes (Ferenczi et al., 2000; Gudjonsson and Elder,
2007). It is a genetically complex disease with a complex
mode of inheritance (Vyse and Todd, 1996). HLA class I gene
HLA-C*0602 haplotype association explains the largest part
of the known heritability of psoriasis (Nair et al., 2006;
Strange et al., 2010).
Genome-wide association studies (GWAS) have been
successful in the characterization of the genetic architecture
of many complex human diseases (Manolio, 2010). To date,
more than 15 GWAS have been performed using large pso-
riasis cohorts from Caucasian and Asian populations and
have collectively identiﬁed more than 50 susceptibility loci
for psoriasis (Bowes et al., 2015; Tsoi et al., 2015b; Yin et al.,
2015; Zuo et al., 2015). Despite progress in characterizing
psoriasis genetic etiology, loci outside the HLA region only
explain less than 25% of the estimated psoriasis heritability
(Tsoi et al., 2012; Yin et al., 2014).
Recent research has shown that the missing heritability of
complex human diseases can be explained by common
genetic variants, rare variants or a combination of genetic,
epigenetic, and environmental interactions (Gibson, 2012).
From these, common genetic variants could explain more
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than 60% of the heritability of the most prevalent autoim-
mune diseases (Golan et al., 2014). Importantly, most of these
common genetic variants are characterized by having low
effect sizes (Park et al., 2010).
Although GWAS based on single markers have successfully
identiﬁed disease-susceptibility variants, this strategy is not
adequate to identify genetic variants with low effect sizes that
are genuinely associated with disease risk (Du et al., 2012). In
single-marker GWAS, a large number of genetic variants are
tested for association with a complex trait. To avoid false
positive results, a stringent genome-wide signiﬁcant
threshold must be used (Johnson et al., 2010). This conser-
vative threshold, however, does not allow the identiﬁcation
of modest effect risk loci, unless extremely large samples
sizes of cases and controls are used (Wang et al., 2010).
Importantly, single-marker GWAS consider only the individ-
ual effect of each single nucleotide polymorphism and ignore
the joint effect of multiple causal genetic variants as well as
the biological context where disease genes operate (Zhang
et al., 2010).
Functionally related genes have been shown to collectively
contribute to disease susceptibility, including those loci that
do not reach individually the genome-wide signiﬁcant
threshold (Zhong et al., 2010). Recently, new methods that
are able to analyze genetic associations at the pathway level
have been developed (Gui et al., 2011). Pathway-based ap-
proaches are robust statistical methodologies that integrate
genetic and biological knowledge to test whether sets of
functionally related genes are jointly associated with a
complex trait (Ramanan et al., 2012). Therefore, pathway-
based methods increase the statistical power of the associa-
tion analysis by reducing the number of association tests that
must be performed and allow a functional interpretation of
the results (Wu et al., 2010).
Pathway-based analyses have been recently performed to
study the genetic basis of cancer subtypes using either selected
candidate pathways, but also at a genome-wide scale (Chen
et al., 2014; Koster et al., 2014). Although the genome-wide
pathway analysis can have a high computational cost, this
approach is able to identify novel genetic pathways associated
with disease risk. The identiﬁcation of new pathways associ-
ated with disease risk could increase the probability to develop
new therapeutic strategies in complex diseases such as psori-
asis. To date, however, the genome-wide pathway analysis
approach has not been performed in psoriasis.
To gain a better understanding of the genetic risk basis
of psoriasis, we performed a genome-wide pathway
analysis on a large multicenter cohort of patients with
psoriasis. In this study, we analyzed the association of
1,053 reference biological pathways using 1,263 patients
with psoriasis and 1,558 controls from Spain. Using an
independent cohort of 2,178 cases and 5,175 controls
from the UK, we then performed a validation study of the
signiﬁcantly associated pathways in the discovery cohort.
With this approach, we identiﬁed genetic pathways that
had not been previously associated with psoriasis risk
such as retinol metabolism, transport of inorganic ions and
amino acids, and post-translational protein modiﬁcation.
These results provide important insights into the genetic
etiology of psoriasis.
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RESULTS
Identiﬁcation of genetic pathways associated with
psoriasis risk
In the discovery stage, the genome-wide pathway analysis
identiﬁed a total of 26 genetic pathways signiﬁcantly asso-
ciated with psoriasis risk after multiple test correction (PFDR <
0.05, Supplementary Table S1 online). The complete results
of the genome-wide pathway analysis performed in the dis-
covery study are shown in Supplementary Table S2 online.
From the 26 signiﬁcantly associated pathways, we found
that 14 pathways included IL12B gene. After HLA-C*0602,
IL12B is one of the strongest known genetic risk factors for
psoriasis. To conﬁrm that the observed pathway associations
were the result of the joint effect of multiple genes and not
the result of a single risk locus strongly associated with the
disease, we removed IL12B from these genetic pathways and
tested again for association. After extracting IL12B, two ge-
netic pathways—“Inﬂammatory response” and “Natural killer
T cell”—remained signiﬁcantly associated with psoriasis risk
(PFDR < 0.05). Consequently, only these two pathways from
the group containing IL12B gene were selected for replica-
tion. Together with the other 12 pathways, a total of 14
different genetic pathways were ﬁnally tested for validation in
the UK population. Using this independent case-control
cohort we signiﬁcantly validated the association of 9
genetic pathways with psoriasis risk (PFDR < 0.05, Table 1).
Characterization of the genetic pathways associated with
psoriasis risk
To discard the presence of redundant pathways, we evalu-
ated the level of gene overlap between all associated path-
ways. From the nine validated genetic pathways, we found
that the “Amino acid transport across the plasma membrane”
and “Transport of inorganic ions and amino acids” pathways,
as well as the “Asparagine N-linked glycosylation,” “Trans-
port to the Golgi and subsequent modiﬁcation,” and “Post-
translational protein modiﬁcation” pathways had a high
degree of overlap between them (>95% of shared genes,
Figure 1a). Consequently, and to avoid redundancy, only the
pathway showing the highest level of signiﬁcance was
selected to represent each biological process. The “Transport
of inorganic ions and amino acids” (Pcombined ¼ 1.57  10e7,
Figure 1b) and “Post-translational protein modiﬁcation”
(Pcombined ¼ 1.57  10e7, Figure 1c) pathways were there-
fore selected from each overlapping pathway group. The
“Inﬂammatory response” (Pcombined ¼ 1.06  10e12), “Nat-
ural killer T cell” (Pcombined ¼ 1.06  10e12), “DNA repair”
(Pcombined ¼ 1.10  10e9), and “Retinol metabolism”
(Pcombined ¼ 1.84  10e4) pathways did not show a signiﬁ-
cant degree of overlap and were therefore considered as
independent biological processes.
Within the ﬁnal group of six genetic pathways associated
with disease risk and representing independent biological
processes, we analyzed the association between each partic-
ular gene and psoriasis risk (Table 2). We found 37 small-effect
genes that were nominally associated with psoriasis risk both
in the discovery and replication cohorts (P  1.29  10e2,
Table 3). The complete list of genetic associations obtained
from each genetic pathway is shown in Supplementary
Table S3 online. The linkage disequilibrium pattern between
the SNPs mapping to each genetic pathway associated with
psoriasis risk is shown in Supplementary Figure S1 online.
Functional-based networks associated with psoriasis risk
To understand the relevance of each particular gene within the
genetic pathway associated with psoriasis risk, we used bio-
logical knowledge to build the associated functional-based
network (Figure 2). Using known or predicted functional
Figure 1. Gene overlap of genetic pathways associated with psoriasis risk. (a) Heat map representing the percentage of genes that are shared between each
pathway pair. (b) Venn diagram of the overlapping pathways representing the transport of inorganic ions and amino acids process as well as the number of genes
shared between them. (c) Venn diagram of the overlapping pathways representing the post-translational protein modiﬁcation process as well as the number of
genes shared between them.
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associations between the pathway genes, functional-based
networks are a powerful approach to represent and analyze
the topological structure of a biologic pathway.
To characterize the network properties of the resulting
functional-based networks, we determined the betweenness
centrality (BC) and degree centrality (DC) statistics
(Supplementary Table S4 online). These two measures are
useful to identify those network elements (genes in this case)
that are likely to be more inﬂuential in the structure of the
network. BC and DC have been widely used to identify the
genes that are more likely to be essential for pathway func-
tionality (Hahn and Kern, 2005; Joy et al., 2005;
Vallabhajosyula et al., 2009). We found that SLC7A11 from
the “Transport of inorganic ions and amino acids” pathway
andMGAT5 from the “Post-translational protein modiﬁcation”
pathway had markedly high BC values (BC  0.1). From these,
MGAT5 gene also showed a much stronger DC value than
SLC7A11 (DCMGAT5 ¼ 19, DCSLC7A11 ¼ 3).
Given the strong network centrality properties found for
MGAT5 gene in the “Post-translational protein modiﬁcation”
pathway, we decided to further test the association of this key
gene with psoriasis risk in an independent case-control
cohort. Using this additional replication cohort, we signiﬁ-
cantly validated the association of MGAT5 gene with psori-
asis risk (P ¼ 1.3  10e2; odds ratio [95% conﬁdence
interval] ¼ 0.85 [0.74e0.96]).
Functional analysis of MGAT5 variation
MGAT5 encodes for a key enzyme in the N-glycosylation
pathway, a post-translational process that is directly impli-
cated in T-cell activation and differentiation (Demetriou
et al., 2001). To assess the functional role of MGAT5 in
psoriasis pathogenesis, we evaluated the association between
genetic variation at MGAT5 gene and the levels of T-cell
surface glycosylation. Flow cytometry analysis of in vitro
activated CD4þ and CD8þ T cells obtained from 27 patients
with psoriasis showed an increase in N-glycosylation levels
in patients carrying one or two copies of the protective allele
(G) compared with homozygous individuals for the risk allele
(A) (Figure 3). The increased glycosylation levels in in-
dividuals carrying at least one copy of (G) allele was
observed both in activated CD8þ and CD4þ T cells. In CD4þ
T lymphocytes, the glycosylation level was signiﬁcantly
higher in GG homozygotes compared with AA homozygotes
(P ¼ 0.01, Figure 3).
DISCUSSION
Genome-wide association analyses have successfully identi-
ﬁed more than 50 loci associated with psoriasis susceptibility.
To date, however, the genetic basis of psoriasis is still not
completely understood. In this study, we have performed a
genome-wide pathway analysis of psoriasis genetic risk. Us-
ing a discovery cohort from Spain and an independent cohort
from the UK, we have identiﬁed and validated the association
of six genetic pathways with psoriasis susceptibility. Impor-
tantly, these validated pathways include biological processes
such as retinol metabolism, transport of inorganic ions and
amino acids, and post-translational protein modiﬁcation that
had not been previously associated with psoriasis risk at the
genetic level. In addition, analyzing the network properties of
these validated pathways we have found that MGAT5 gene
has a strong centrality in the post-translational protein
modiﬁcation pathway. Using an additional independent
case-control cohort from Spain, we have further replicated
the association of MGAT5 with psoriasis risk. Taken together,
Table 3. Genes associated with psoriasis risk in the
discovery and replication stages for each validated
pathway
Pathway1 Database Gene2 PD PR
Inﬂammatory
response
Biocarta IL12A 3.35  10e3 1.06  10e3
IL12B 3.02  10e10 1.69  10e18
IL13 4.18  10e5 2.41  10e3
IL4 4.18  10e5 2.41  10e3
TGFB2 2.82  10e3 7.56  10e4
Natural killer T cell Biocarta CXCR4 3.09  10e3 2.61  10e5
IL12A 3.35  10e3 1.06  10e3
IL12B 3.02  10e10 1.69  10e18
IL4 4.18  10e5 2.41  10e3
IL4R 7.35  10e3 1.37  10e3
TGFB2 2.82  10e3 7.56  10e4
Retinol metabolism KEGG ADH1B 5.82  10e5 1.21  10e2
UGT2B4 5.21  10e4 6.13  10e3
RPE65 5.10  10e3 7.34  10e3
DNA repair Reactome FANCL 3.22  10e3 1.13  10e3
MGMT 1.86  10e3 9.51  10e4
RAD50 4.18  10e5 2.41  10e3
REV3L 3.16  10e6 1.40  10e13
RFC3 2.14  10e3 1.94  10e3
Transport of inorganic
ions and amino acids
Reactome SLC16A10 2.34  10e7 2.38  10e9
SLC1A4 2.04  10e3 7.44  10e3
SLC38A1 1.34  10e3 9.44  10e3
SLC43A2 1.29  10e2 1.15  10e2
SLC7A1 6.91  10e4 6.62  10e3
SLC7A11 1.14  10e3 6.22  10e3
SLC7A7 5.09  10e3 2.77  10e3
SLC8A1 8.75  10e6 1.30  10e3
SLC9A8 1.09  10e4 6.81  10e5
SLC9A9 4.37  10e3 3.22  10e3
Post-translational
protein modiﬁcation
Reactome ALG10 3.89  10e3 4.15  10e3
B3GNT2 7.88  10e5 1.01  10e3
EDEM1 1.69  10e4 5.81  10e4
EIF5A 3.42  10e4 2.09  10e5
FUT8 5.30  10e3 1.87  10e4
GALNT1 5.22  10e4 9.72  10e4
MAN1A1 2.82  10e4 1.04  10e2
MAN2A1 7.29  10e3 3.53  10e3
MGAT5 8.04  10e5 9.34  10e3
SEMA6D 2.06  10e3 1.46  10e3
ST8SIA6 8.17  10e3 8.68  10e5
TUSC3 1.02  10e4 6.07  10e3
Abbreviations: D, discovery cohort; KEGG, Kyoto Encyclopedia of Genes
and Genomes; OR, odds ratio; P, P-value; R, replication cohort.
1The detailed description of the “Inﬂammatory response” and “Natural
killer T cell” pathways corresponds to the association results before
excluding the IL12B gene from the genome-wide pathway analysis.
2Genes contained in the genetic pathways that were nominally associated
with psoriasis risk in the discovery and replication stages.
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these ﬁndings contribute to a better understanding of the
genetic risk basis of psoriasis and provide important insights
into the biological mechanisms associated with the disease
pathogenesis.
Retinol has been demonstrated to inhibit inﬂammatory
processes in dermatological diseases (Balato et al., 2013). In
particular, retinol inhibits the regulatory activity of the nu-
clear factor kappa B (NFKB) in the skin (Austenaa et al.,
2004). NFKB is an established transcriptional factor that
regulates multiple proinﬂammatory genes that are key in
psoriasis pathogenesis like tumor necrosis factor and
interleukin-17 (Goldminz et al., 2013). The NFKB signaling
pathway has also been associated with the regulation of the
proliferation of epidermal keratinocytes (Tsuruta, 2009).
These ﬁndings are consistent with the elevated levels of NFKB
that have been found in lesional and non-lesional psoriatic
Figure 2. Functional-based network of each genetic pathway associated with psoriasis risk. (a) “Inﬂammatory response.” (b) “Natural killer T cell.” (c) “Retinol
metabolism.” (d) “DNA repair.” (e) “Transport of inorganic ions and amino acids.” (f) “Post-translational protein modiﬁcation.” The color of each gene represents
the P-value of its association with psoriasis in the negative logarithmic scale, ranging from the lowest signiﬁcance (green) to the strongest (red). The gene shape
represents the association with the disease in neither the discovery nor the replication study (square), only in either the discovery or the replication study (circle)
and the association found in both discovery and replication studies (rhombus). The edge width is proportional to the conﬁdence of the functional association
between two genes. Disconnected genes are hidden.
A Aterido et al.
Genome-Wide Pathway Analysis in Psoriasis
Journal of Investigative Dermatology (2016), Volume 136598
skin samples compared with non-psoriatic skin (Lizzul et al.,
2005). Therefore, genetic variation in the retinol metabolism
pathway could reduce the retinol production leading to a
weakened NFKB signaling and, consequently, promoting
both inﬂammatory and proliferative hallmarks of psoriasis.
Psoriasis risk was also associated with the genetic pathway
implicated in the transport of both inorganic ions and amino
acids. An increased transport of inorganic ions in CD4þ
helper T cells has been shown to contribute to autoimmune
and inﬂammatory diseases (Lang et al., 2014). In particular,
the intracellular transport of calcium is crucial for controlling
the expression of proinﬂammatory genes in immune cells
(Khananshvili, 2013; Vig and Kinet, 2009). Accordingly, the
transport of inorganic ions and amino acids pathway asso-
ciated with psoriasis risk includes the SLC8A1 gene, which
modulates the cytoplasmic calcium concentration (Clapham,
2007). The transport of amino acids into T cells is essential to
maintain the increased production of proinﬂammatory cyto-
kines in activated human T cells (Hayashi et al., 2013).
Importantly, the expression of amino acid transporters has
been found to be differentially regulated in psoriatic inﬂam-
matory processes (Jaeger et al., 2008). These results therefore
suggest that genetic variation in the transport of amino acids
and inorganic ions pathway could increase the risk to
develop psoriasis by modulating T-cell functionality.
The post-translational protein modiﬁcation pathway is
responsible for the N-linked glycosylation of the asparagine
residues in the HLA molecules (Rudd et al., 2001). This post-
translational modiﬁcation pathway has been found to be
necessary for the immune system tolerance to self-antigens
(Ryan and Cobb, 2012). Previous studies have found that a
deﬁcient or aberrant asparagine glycosylation can induce
autoimmune diseases (Green et al., 2007). Also, post-
translationally modiﬁed autoantigens have been associated
with psoriasis (Iversen et al., 2011). In patients with psoriasis,
the peptide glycosylation activity has been found to be
markedly increased in comparison with healthy controls
(Damasiewicz-Bodzek and Wielkoszynski, 2012). Further-
more, speciﬁc post-translational modiﬁcations on glycopro-
teins expressed on the surface of T lymphocytes have been
shown to target these cells to the inﬂamed skin (Fuhlbrigge
et al., 1997). Therefore, genetic variation in the post-
translational protein modiﬁcation pathway could perturb the
glycosylation processes that are crucial to maintain the im-
mune system tolerance.
MGAT5 encodes for a key enzyme in the N-glycosylation
pathway. This pathway has been directly implicated in T-cell
activation and autoimmunity (Demetriou et al., 2001). Recent
research has found an association between MGAT5 glyco-
sylation activity and multiple sclerosis etiology both in
experimental models and in humans (Grigorian and
Demetriou, 2011; Mkhikian et al., 2011). In this study, we
have found that the MGAT5 is a key gene in the post-
translational protein modiﬁcation pathway associated with
psoriasis. Subsequently, we found that genetic variation at
MGAT5 is associated with the level of glycosylation of in vitro
activated T cells. This result is consistent with previous ﬁnd-
ings showing that deﬁciency of MGAT5 glycosylation activity
reduces the T-cell activation threshold and, consequently,
promotes the triggering of autoimmune diseases (Demetriou
et al., 2001). Further studies evaluating the implication of
the T-cell surface glycosylation in clinically relevant outcomes
in psoriasis such as skin severity are warranted.
The association of psoriasis risk with the inﬂammatory
response and the natural killer T-cell pathways involves more
than 10 immune-related genes, including IL12B. In a recent
pathway analysis study using association results of a meta-
analysis for psoriasis risk (Tsoi et al., 2015a), these two
pathways were also found to be associated. These ﬁndings,
however, were not validated using an independent cohort.
Our study, therefore, provides strong conﬁrmation of the
implication of these two genetic pathways in the risk of
psoriasis. Also, the permutation-based approach used in our
study allowed to control for the potential bias associated with
the presence of strong linkage disequilibrium patterns within
genes. Our results indicate that the association of these
pathways is not only driven by IL12B gene, but it is the result
of the joint contribution of other small-effect genes in these
pathways. One of these genes is CXCR4, which encodes for a
chemokine receptor from the natural killer T-cell pathway
(Colantonio et al., 2002). Although CXCR4 gene has not been
previously associated with psoriasis risk in single-marker
GWAS, CXCR4 chemokine has been shown to reduce kera-
tinocyte proliferation and, consequently, the expansion of
psoriatic plaques by regulating the proliferative cytokine
signals that are activated in psoriatic lesions (Takekoshi et al.,
2013). In addition, the inﬂammatory angiogenesis of psoriatic
skin that leads to vascular remodeling has been recently
shown to be modulated by CXCR4 chemokine (Zgraggen
et al., 2014). Using the pathway analysis, we can therefore
identify small-effect genes like CXCR4 that cannot be
Figure 3. N-Glycosylation on activated T lymphocytes according toMGAT5
genotype. Boxplots of mean ﬂuorescence intensity (MFI) of cell membrane
glycosylation of in vitro activated CD4þ (left) and CD8þ (right) T cells from
patients with psoriasis. Patients with one and two copies of the protective
(G) allele ofMGAT5 SNP rs3791318 tend to have higher glycosylation levels,
thus increasing the threshold for T-cell receptor-mediated response as well as
lowering the threshold for cytotoxic T-lymphocyte-associated antigen-4-
mediated arrest of T-cell proliferation.
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detected by single-marker GWAS but that are biologically
implicated in key processes of the disease pathophysiology.
In this study, we have also found a signiﬁcant association
between the DNA repair genetic pathway and psoriasis risk.
Together with the dysregulation of immune system processes,
the epidermal hyperproliferation is another well-known bio-
logical process implicated in the psoriasis pathophysiology
(Wolf et al., 2012). The application of ultraviolet radiation in
psoriasis skin lesions to induce apoptosis in aberrantly
proliferating keratinocytes has proved to be a successful
treatment for the clearance of plaque psoriasis in approxi-
mately 70% of patients (Weatherhead et al., 2011). The ul-
traviolet radiation induces DNA damage that promotes the
transcription of the DNA repair pathway genes (Roos and
Kaina, 2006). Consequently, the enzymatic machinery of
the pathway repairs the DNA damage and also triggers the
cell death by activating the p53 apoptotic signaling (Lavin
et al., 2005). Therefore, these results suggest that genetic
variation in the DNA repair pathway promotes an inefﬁcient
activation of the p53 apoptotic signaling that leads to an
increased keratinocyte proliferation, as well as an inefﬁcient
response to ultraviolet therapy in patients with psoriasis.
Although the pathway-based analysis is a powerful
approach to identify small-effect genetic variants associated
with disease risk, this methodology is not exempt of limita-
tions. Intergenic SNPs across the whole genome that map
physically far away from genes were not included in this
study. These genetic variants could be known risk loci (e.g.,
rs12188300 is associated with psoriasis risk and is located
at >20Kb from IL12B gene) or may regulate the expression of
genes through cis- and trans-expression quantitative trait loci
mechanisms (Gilad et al., 2008). Also, some SNPs might not
be functionally related to the closest genes. With the
increasing regulatory information derived from expression
quantitative trait loci and epigenomic data (Bernstein et al.,
2010; Martens and Stunnenberg, 2013; Raney et al., 2011),
intergenic SNPs could be integrated in the pathway-based
analysis in the next few years.
The complex linkage disequilibrium structure of the HLA
region together with the strong association with the suscepti-
bility to multiple common diseases has been shown to
generate false positive results in pathway-based methods
(Wang et al., 2010). Following recent studies, in this study we
removed the SNPs mapping to this locus to perform the pre-
sent pathway analysis (Chen et al., 2014). As a result, known
pathways associated with psoriasis risk that include genes from
the HLA region, like the NFKB pathway, were not analyzed in
this study. Importantly, however, in this study we have found
and validated the association between genetic pathways
related to IL12 signaling, an established genetic risk pathway
for psoriasis and psoriasis risk. Also, within the associated
pathways there are known risk genes for psoriasis (e.g., REV3L
and IL4 within the DNA repair and inﬂammatory response
pathways, respectively). Together, these results conﬁrm the
accuracy of the present pathway-based approach to identify
relevant genetic variation associated with psoriasis risk.
The present genome-wide pathway analysis has two
important strengths. First, we used PLINK software (Boston,
MA) to identify genetic pathways associated with psoriasis
risk. This pathway analysis method uses genotype data in
contrast to the methodologies that are only based on asso-
ciation statistics. An important limitation of these latter
methodologies is that they do not account for the linkage
disequilibrium between SNPs. This can result in highly biased
results and a signiﬁcant increase in false positive results
(Wang et al., 2010). Instead, the pathway analysis approach
that we used, although can be computationally costly, efﬁ-
ciently overcomes these biases by maintaining the correct
linkage disequilibrium patterns between SNPs. Finally,
compared with previous pathway-based studies in other
complex diseases, we have performed a two-stage pathway
analysis in two large cohorts from different populations.
Using an independent population, we have validated genetic
pathways associated with psoriasis risk.
In conclusion, using a genome-wide pathway analysis
approach we have identiﬁed to our knowledge previously
unreported genetic pathways associated with psoriasis risk.
These biological pathways include retinol metabolism,
transport of inorganic ions and amino acids, and post-
translational protein modiﬁcation. The results of this study
represent an important contribution to the characterization of
the genetic risk basis of psoriasis.
MATERIALS AND METHODS
Study population
A total of 1,263 patients with psoriasis and 1,558 controls were
recruited for the discovery stage (Supplementary Table S5 online).
An independent case-control cohort of 7,353 individuals from the
UK was used to validate the signiﬁcantly associated pathways in the
discovery cohort. An independent cohort of 1,381 patients with
psoriasis and 2,048 controls from Spain was used to replicate the
association betweenMGAT5 gene and psoriasis risk (Supplementary
Materials, Supplementary Table S6 online).
All the procedures were followed in compliance with the prin-
ciples of the Declaration of Helsinki and all patients provided
written informed consent to participate in this study. The study and
the consent procedure were approved by the local Institutional Re-
view Board of each participating center.
DNA extraction and genome-wide genotyping
GWAS genotyping of the 2,821 individuals from the discovery
cohort was performed using Illumina Quad610 Beadchips (Illu-
mina, San Diego, CA) (Supplementary Materials). After the quality
control analysis, a ﬁnal data set of 541,926 SNPs from 1,172 pa-
tients with psoriasis was available for the pathway-based analysis.
The genome-wide genotyping of the patients with psoriasis from
the validation stage was performed using the Illumina
Human660W-Quad (Illumina) and the healthy controls were gen-
otyped using the Illumina custom Human1.2M-Duo (Illumina) as
has been previously described (Strange et al., 2010). The ﬁnal data
set used for the replication study included 515,703 SNPs from
2,178 patients with psoriasis. The genotyping of the MGAT5
replication cohort was performed using the Taqman real-time PCR
platform (Applied Biosystems, Foster City, CA) (Supplementary
Materials).
Pathway-based analysis
Gene set deﬁnition. Reference biological pathway annotation
databases BioCarta (www.biocarta.com), Kyoto Encyclopedia of
Genes and Genomes (Kanehisa and Goto, 2000), and Reactome
(Croft et al., 2014) were used to determine the global pathways
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(Supplementary Materials, Supplementary Tables S7 and S8 online).
The ﬁnal gene set included in this study was composed of 215,948
SNPs mapping to 1,053 pathways.
Gene-set association analysis. The statistical association anal-
ysis was performed using the PLINK set-based test (Purcell et al.,
2007) (Supplementary Materials). To obtain the global statistical
signiﬁcance of each validated pathway, we combined the empirical
P-values resulting from the discovery and replication stages using
Fisher’s method (Kugler et al., 2010). We tested the association of
1,053 pathways with psoriasis risk. The false discovery rate (FDR)
method (Hochberg and Benjamini, 1990) was used to account for
multiple testing.
Sensitivity analysis by removing the HLA and IL12B loci. In
pathway-based analysis, the presence of a single marker with very
strong effects can lead to false positive associations. In these cases,
the joint contribution of the pathway genes to disease risk is masked
and not adequately evaluated (Wang et al., 2010). Similar to pre-
vious studies, to avoid this type of spurious associations, we
removed all SNPs mapping to the HLA region (Megabases 25.6 to
33.3 in chromosome 6) (Chen et al., 2014). In the discovery stage,
we found genetic pathways in which the IL12B gene was signiﬁ-
cantly associated with disease risk at a genome-wide scale. IL12B is
a well-known psoriasis risk gene that shows a large effect on disease
susceptibility and, like the HLA region, could generate false positive
results (Cargill et al., 2007; Nair et al., 2008; Zhu et al., 2013).
Accordingly, we removed this psoriasis susceptibility locus (from
158,741,791 to 158,757,481 base pairs in chromosome 5) from the
signiﬁcant pathways and we repeated the analysis. We excluded 73
and 58 SNPs from the discovery and replication studies, respectively.
Characterization of the genetic pathways associated with
psoriasis risk
Genetic pathways involved in similar biological processes may share
genes. To identify pathways representing different and independent
biological processes, we computed the gene overlap between each
pair of genetic pathways associated with psoriasis risk
(Supplementary Materials).
The statistical signiﬁcance of the association between pathway
genes and psoriasis risk was determined according to the most sig-
niﬁcant SNP mapping to each particular gene.
Analysis of the functional-based networks associated with
psoriasis risk
The biological knowledge representing the functional association
between gene pairs was used to build the functional-based network
of each genetic pathway associated with psoriasis risk. To identify
those genes that are more likely to play a central role in the genetic
pathways associated with psoriasis risk, we analyzed the net-
work statistical properties of each functional-based network
(Supplementary Materials). Using the genes that were nominally
associated with psoriasis risk in both discovery and replication
stages, we identiﬁed the most inﬂuential gene according to the
highest values of these network statistics.
Functional analysis of MGAT5 variation
Following the methodology previously described (Chen et al., 2009),
we evaluated the association of MGAT5 psoriasis risk variant with
the level of cell surface glycosylation of in vitro activated CD4þ and
CD8þ T cells isolated from n ¼ 27 patients with psoriasis
(Supplementary Materials).
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Identification of IRX1 as a Risk Locus for Rheumatoid Factor
Positivity in Rheumatoid Arthritis in a
Genome-Wide Association Study
Antonio Julia,1 Francisco Blanco,2 Benjamın Fernandez-Gutierrez,3 Antonio Gonzalez,4
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Objective. Rheumatoid factor (RF) is a well-
established diagnostic and prognostic biomarker in rheu-
matoid arthritis (RA). However, ~20% of RA patients
are negative for this anti-IgG antibody. To date, only
variation at the HLA–DRB1 gene has been associated
with the presence of RF. This study was undertaken to
identify additional genetic variants associated with RF
positivity.
Methods. A genome-wide association study
(GWAS) for RF positivity was performed using an
Illumina Quad610 genotyping platform. A total of 937
RF-positive and 323 RF-negative RA patients were geno-
typed for >550,000 single-nucleotide polymorphisms
(SNPs). Association testing was performed using an
allelic chi-square test implemented in Plink software.
An independent cohort of 472 RF-positive and 190
RF-negative RA patients was used to validate the most
significant findings.
Results. In the discovery stage, a SNP in the
IRX1 locus on chromosome 5p15.3 (SNP rs1502644)
showed a genome-wide significant association with RF
positivity (P 5 4.13 3 1028, odds ratio [OR] 0.37 [95%
confidence interval (95% CI) 0.26–0.53]). In the valida-
tion stage, the association of IRX1 with RF was replicated
in an independent group of RA patients (P 5 0.034, OR
0.58 [95% CI 0.35–0.97] and combined P 5 1.14 3 1028,
OR 0.43 [95% CI 0.32–0.58]).
Conclusion. To our knowledge, this is the first
GWAS of RF positivity in RA. Variation at the IRX1
locus on chromosome 5p15.3 is associated with the pres-
ence of RF. Our findings indicate that IRX1 and HLA–
DRB1 are the strongest genetic factors for RF pro-
duction in RA.
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Autoantibody generation by pathogenic B cells is
one of the hallmark features of rheumatoid arthritis
(RA) (1). Approximately 80% of RA patients are posi-
tive for rheumatoid factor (RF), and ;75% express
anti–cyclic citrullinated protein antibodies (ACPAs).
Although less specific than ACPAs, the presence of RF
has been used to diagnose RA both in classic and in
recently updated diagnostic criteria (2). Despite evi-
dence of a genetic basis of this key trait (3), however,
to date only variation at the HLA–DRB1 locus has
been reproducibly associated with the presence of RF in
RA (4).
RF is an antibody that targets the Fc portion of
IgG. The ability to bind to other antibodies facilitated
its identification in early studies investigating the high
agglutination properties of serum from RA patients
compared to that from controls (5). However, as was
also noted very early on (6), not all RA patients are pos-
itive for this autoantibody. In addition, it was later
shown that RF is not specific to RA; it is present in
patients with other autoimmune and inflammatory dis-
eases (7) and, although at a much lower frequency, in
healthy individuals (8). Nonetheless, its association with
key features of RA, such as disease severity (9–11) and
treatment response (12,13), as well as the fact that its
presence may precede the onset of the disease (14,15),
have extended the relevance of this protein biomarker
in the study and management of RA. Importantly, evi-
dence of a direct pathogenic role of RF in RA etiology
has recently emerged (16), renewing interest in the bio-
logic mechanisms associated with this autoantibody.
In recent years, genome-wide association studies
(GWAS) have drastically improved knowledge of the
genetic basis of RA. To date,.100 genomic regions have
been consistently associated with the risk of developing
the disease (17). Of relevance, the loci showing stronger
penetrance in RA risk are mainly associated with ACPA-
positive RA (18,19). In ACPA-negative patients, a differ-
ent set of risk loci is starting to be defined (20). Recently,
GWAS directly comparing ACPA-positive patients to
ACPA-negative patients have confirmed this genetic het-
erogeneity, suggesting its usefulness as a tool for classify-
ing patients (21). To date, however, no GWAS has been
performed to identify the genetic variation associated
with the presence of RF in RA.
In the present study, we undertook for the first
time a GWA analysis of RF positivity in RA. Using a
discovery cohort of 1,260 patients and an additional vali-
dation cohort of 662 patients of Southern European
ancestry, we sought to identify the genetic variation
associated with the presence of this autoantibody in RA.
PATIENTS AND METHODS
A GWAS design was used to identify new genetic var-
iants associated with RF positivity. In the discovery phase, a
total of 1,260 patients with RA were recruited by the Immune-
Mediated Inflammatory Disease Consortium (IMIDC) (22).
The IMIDC is a biomedical research consortium that includes
rheumatology departments from 15 Spanish university hospi-
tals from different regions in Spain. All RA patients satisfied
the American College of Rheumatology diagnostic criteria for
RA (23) and were followed up for .2 years after diagnosis.
Importantly, all patients had erosive disease, defined as $1
erosion in at least 2 joint groups in the hands and/or feet. All
patients were Caucasian with all 4 grandparents born in Spain.
The replication cohort was recruited following the same clini-
cal and epidemiologic criteria as in the discovery phase. A
total of 662 RA patients were recruited for the replication
phase. The study was undertaken in compliance with the Dec-
laration of Helsinki. Informed consent was obtained from all
participants, and protocols were reviewed and approved by
local institutional review boards.
Genome-wide genotyping of 937 RF-positive RA
patients and 323 RF-negative RA patients was performed
using Illumina Quad610 BeadChips. Quad610 arrays contain
probes that genotype a total of 598,821 single-nucleotide poly-
morphisms (SNPs). GWA genotyping was performed at the
National Genotyping Center. After excluding mitochondrial
and X and Y chromosome SNPs, a total of 582,591 SNPs were
genotyped for each patient in the discovery phase. SNP geno-
type calling was performed using Illumina GenomeStudio soft-
ware version 2010.1. After excluding samples with ,95%
genotype completion rate (1.1%; n5 15), we selected SNPs
with a .95% call rate (.99% of SNPs) and a minor allele fre-
quency (MAF) of .0.05 (93.9% of SNPs). As an additional
quality check, only those SNPs that showed Hardy-Weinberg
equilibrium in samples of control individuals from the same
ancestry and genotyped with the same platform (22) were
included in the GWAS (99.5% of SNPs; P. 0.0001).
In order to exclude outlier individuals according to
ancestry, we performed a principal components analysis
(PCA) using EigenStrat software (24). In order to improve the
estimation of the genetic variation of the Spanish population,
we also included a previously described cohort of 1,493 healthy
controls (22). Outlier patients were characterized as those
individuals showing a clear deviation (i.e., .6 SD) in any of
the 10 top principal components. A total of 35 outliers were
identified and removed from the study (see Supplementary
Figure 1, available on the Arthritis & Rheumatology web site at
http://onlinelibrary.wiley.com/doi/10.1002/art.39591/abstract).
The estimated genomic inflation was very close to 1 (l5 1.01),
indicating a very low probability of population stratification.
Association analyses were nonetheless performed using logis-
tic regression including the 10 first principal components, in
order to exclude any potential confounding effect due to strati-
fication. Association analyses were performed using Plink
(version 1.07) (25). The statistical power of this study was esti-
mated using Genetic Power Calculator software (26). Given
the RF-positive and RF-negative sample sizes of the discovery
stage, and assuming a MAF frequency of 0.2, the present study
had 80% power to detect an effect size as low as an odds ratio
(OR) of 1.7 at a significance level of P5 5 3 1028 under a
multiplicative model.
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The association between established risk loci for RA
and RF status was determined (17). A total of 100 SNPs, rep-
resenting the strongest reported signal from each of the known
RA risk loci, were tested for association with RF positivity. In
those cases where the SNP was not genotyped in the Quad610
Illumina array, the marker genotype was imputed using
SHAPEIT version 2 phasing software (27) and IMPUTE ver-
sion 2 (28) imputation software. Data from the European
cohort from the 1,000 Genomes Project was used as the refer-
ence panel for imputation (29).
Replication genotyping of 472 RF-positive patients
and 190 RF-negative patients was performed at the Hudson-
Alpha Institute for Biotechnology (Huntsville, AL) using an
Illumina GoldenGate assay. Five percent of the samples
were genotyped in duplicate, giving an ;1% genotyping
error rate.
Table 1. RA susceptibility loci significantly associated with RF positivity*
Locus SNP Chr. bp
Minor
allele
Major
allele
MAF in RF1
patients
MAF in RF2
patients
Imputation
quality score P OR (95% CI)
HLA–DRB1 rs9268839 6 32,428,772 G A 0.61 0.52 1.00 0.00038 1.44 (1.19–1.75)
TEC rs2664035 4 48,220,839 A G 0.42 0.33 0.98 0.00088 1.43 (1.16–1.75)
ZNF438 rs793108 10 31,415,106 T C 0.48 0.41 NA 0.0022 1.32 (1.09–1.6)
PLCL2 rs4452313 3 17,047,032 T A 0.34 0.28 1.00 0.0047 1.33 (1.08–1.64)
CCR6 rs1571878 6 167,540,842 C T 0.46 0.53 0.99 0.0079 0.75 (0.61–0.91)
ACOXL rs6732565 2 111,607,832 G A 0.37 0.31 1.00 0.013 1.31 (1.06–1.60)
IRF8 rs13330176 16 86,019,087 A T 0.19 0.14 0.93 0.018 1.43 (1.05–1.94)
ARAP1 rs11605042 11 72,411,664 A G 0.47 0.41 1.00 0.025 1.23 (1.02–1.49)
LOC100506023 rs2105325 1 173,349,725 A C 0.21 0.26 1.00 0.027 0.76 (0.61–0.95)
CXCR5 rs10790268 11 118,729,391 A G 0.22 0.28 0.93 0.034 0.73 (0.54–0.98)
RUNX1-
LOC100506403
rs8133843 21 36,738,242 G A 0.39 0.34 0.97 0.037 1.27 (1.02–1.58)
* Association results are listed for the single-nucleotide polymorphisms (SNPs) from the 10 established rheumatoid arthritis (RA) risk loci that
show a significant (P, 0.05) association with rheumatoid factor (RF) positivity. SNPs are listed in order of the significance of the association. In
all loci except CCR6 and ACOXL, the risk allele is associated with the presence of RF. Chr.5 chromosome; MAF5minor allele frequency;
OR5 odds ratio; 95% CI5 95% confidence interval; NA5 not applicable (directly genotyped).
Figure 1. Association results for the IRX1 locus with rheumatoid factor positivity in rheumatoid arthritis. A regional plot with the significance
of the single-nucleotide polymorphisms (SNPs) in the IRX1 locus, i.e., 2log10(P), as a function of location in chromosome 5p15.3 (basepair) is
shown. The genome-wide significant SNP (rs1502644) is shown as a purple diamond, and the remaining SNPs are shown as circles, with color
indicating the level of linkage disequilibrium (r2) with rs1502644. The estimated recombination rates in this genomic region are plotted as a con-
tinuous background line (cM/Mb).
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RESULTS
After quality-control analysis and PCA identifi-
cation of genetic background outliers, 896 RF-positive
RA patients and 282 RF-negative RA patients were
included in the discovery stage. A total of 509,374 SNPs
passed all quality and frequency filters and were used
for GWA analysis.
In the discovery stage, the previously described
significant association between the HLA–DRB1 locus
and RF status was replicated (P5 0.00038; OR 1.44
[95% confidence interval (95% CI) 1.19–1.75]) (Table 1).
Ten additional RA risk loci were found to be nominally
associated with RF positivity (P, 0.05) (Table 1).
In the discovery stage, a SNP in chromosome
5p15.3 (rs1502644), a genomic region not previously asso-
ciated with RA risk, showed a genome-wide significant
association with RF positivity (MAF 0.051; P 5 4.13 3
1028) (OR 0.37 [95% CI 0.26–0.53]) (Figure 1). This
genetic marker lies 69.5 kb downstream of the 30 end of
IRX1. No other genomic region, including the HLA
region on chromosome 6, showed a highly significant asso-
ciation (defined as P, 13 1026) with the presence of the
autoantibody (Figure 2). Supplementary Table 1 (avail-
able on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.39591/abstract)
lists the genomic regions showing moderate and high evi-
dence of association with RF positivity (P, 53 1025).
In the independent cohort of RA patients, we vali-
dated the association between the IRX1 locus SNP
rs1502644 and RF status, with the same direction of effect
as in the discovery stage (replication P 5 0.034, OR 0.58
[95% CI 0.35–0.97] and combined P 5 1.14 3 1028,
OR 0.43 [95% CI 0.32–0.58]).
In order to functionally characterize IRX1, and
in particular its association with B cell activity, we used
a GenomicScape high-throughput data analyzer (30).
GenomicScape is an online tool that allows rapid and
easy characterization of the functionality of genes based
on their expression in multiple human tissues available
from large public repositories of gene-expression micro-
array studies. The GS-DT-1 microarray data set, which
includes whole-genome expression profiling of human B
cells during lymphopoiesis, was selected to analyze
IRX1 expression. This data set includes transcriptional
data from 8 different differentiation states in B lympho-
cytes, from naive B cells to mature bone marrow plasma
cells (31). Comparing the gene expression in different
stages of lymphopoiesis, we found that IRX1 is signifi-
cantly overexpressed in bone marrow plasma cells com-
pared to previous developmental stages (P5 0.01 by
analysis of variance) (Figure 3).
DISCUSSION
RF is a key diagnostic and prognostic marker for
RA. Recent studies have confirmed the initial hypothe-
sis that RF participates directly in RA pathophysiology.
To date, however, only variation at the HLA–DRB1
locus has been significantly associated with the presence
of this autoantibody. In order to identify additional
genetic risk factors, we performed the first GWAS of
RF positivity. Using a large cohort of RA patients, we
identified an association between the IRX1 locus SNP
rs1502644 at the genome-wide level of significance
(P , 5 3 1028). We replicated the association of IRX1
with RF in RA in an independent cohort of patients.
Additionally, 10 established RA risk loci showed a nom-
inal level of association with RF positivity.
IRX1 encodes for a member of the Iroquois pro-
tein family. This group of genes has been associated
with many developmental processes in vertebrates (32).
Examination of the gene expression profile of IRX1 in
the different stages of B cell differentiation (31) showed
that there is a clear increase in the expression of this
Figure 2. Genome-wide association results for rheumatoid factor
(RF) positivity in rheumatoid arthritis. A Manhattan plot of the sig-
nificance (2log10[P]) of the association of the 509,374 tested single-
nucleotide polymorphisms (SNPs) with RF status is shown. Each dot
corresponds to the significance of association of a SNP, and its posi-
tion on the x-axis shows its position in the chromosome. Black and
gray indicate SNPs from different chromosomes. Green indicates
SNPs in the IRX1 locus in chromosome 5p15.3, which show high lev-
els of statistical significance. The horizontal line shows the threshold
for significance at the genome-wide level (i.e., P5 5 3 1028). Color
figure can be viewed in the online issue, which is available at http://
onlinelibrary.wiley.com/journal/doi/10.1002/art.39591/abstract.
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gene in plasma cells compared to less-differentiated B
cell subtypes. Bone marrow plasma cells are the end-
stage differentiation of B lymphocytes and are responsi-
ble for the production of circulating antibodies. It is
therefore possible that variants affecting the activity of
plasma cells can also have an impact on the production
of antibodies, including autoantibodies like RF. Of rele-
vance, a recent GWAS of antibody levels generated by
smallpox vaccination (33) identified a highly suggestive
association signal at the IRX1 locus (P 5 8.8 3 1027).
Although the SNP identified in this study is likely to
represent an independent association signal (linkage
disequilibrium r25 0.07 between the variants associated
in the 2 studies), the presence of genetic associations for
similar phenotypes supports the implication of this
genomic region in the molecular mechanisms associated
with antibody production.
Several RA risk loci, mainly in the HLA–DRB1
locus, have previously been shown to be associated with
different clinical phenotypes in RA. Therefore, RA sus-
ceptibility loci also have a higher probability of being
associated with RF positivity. In the present GWAS of
RF, we validated the previously established association
between RF positivity and HLA–DRB1. The estimated
effect size of this main RA risk locus in RF positivity is,
however, clearly lower than the effect size for IRX1 (OR
1.44 for HLA–DRB1 versus OR 2.70 for IRX1), indicat-
ing that variation at the newly discovered locus could be
more influential for the presence of this trait in RA.
Additionally, 10 RA risk loci were also found to be
associated with RF positivity at the nominal level
(P , 0.05). In 8 of these loci—TEC, ZNF438, PLCL2,
LOC100506023, IRF8, RUNX1-LOC100506403, ARAP1,
and CXCR5—the allele associated with RA risk was
also associated with RF positivity. In CCR6 and
ACOXL, however, the risk allele for RA was associated
with RF-negative RA. To our knowledge, this is the first
time that these RA risk loci have also been shown to be
associated with the presence of RF. Of interest, several
of these genes, such as IRF8 (34), TEC (35), CXCR5
(36), CCR6 (37), and PLCL2 (38), have been found to
be directly associated with different key aspects of B cell
functionality. These results further strengthen the hypoth-
esis that genetic variation at B cell pathways influences
the risk of expressing RF in RA.
In RA, there is a significant correlation between
ACPA positivity and RF positivity. Despite this, there is
a large fraction of patients positive for only 1 autoanti-
body (39,40), suggesting the presence of independent
genetic factors. In the discovery stage of this study, we
controlled for ACPA positivity and found that the asso-
ciation of IRX1 with RF was still highly significant
(P5 0.0006) (data not shown). In contrast, when testing
for an association of IRX1 SNP rs1502644 with ACPA
positivity, controlling for RF, we found no evidence of
association (P . 0.1) (data not shown). Our results
therefore support the notion that variation at the IRX1
locus is associated specifically with the presence of RF
in RA. Additionally, we evaluated the association of loci
recently found to be associated with ACPA positivity
(41) in our discovery data set. Of all loci showing the
most significant association with ACPA in the previous
study (41) (after directly comparing autoantibody-negative
positive patients to autoantibody-negative patients, as in
the present study), only the HLA–DRB1 locus showed a
significant association with RF positivity in the present
study (data not shown). This result confirms the relevance
of HLA region variation to autoantibody positivity, and
suggests that non-HLA genetic variation associated with
Figure 3. Gene expression levels of IRX1 at different stages of B cell
differentiation. Normalized gene expression levels of IRX1 measured
in human naive B cells (sample 1), centroblasts (sample 2), centro-
cytes (sample 3), memory B cells (sample 4), preplasmablasts (sample
5), plasmablasts (sample 6), early plasma cells (sample 7), and bone
marrow plasma cells (sample 8) are shown. IRX1 gene expression lev-
el is significantly increased in the latest stage of B cell differentiation
(P 5 0.01 versus all other cell types, by analysis of variance) when B
cells are responsible for most long-term antibody production. Data
are shown as box plots. Each box represents the upper and lower
interquartile range (IQR). Lines inside the boxes represent the medi-
an. Whiskers represent the highest and lowest values. Asterisks indi-
cate outliers (.1.5 times the upper and lower IQRs). Color figure
can be viewed in the online issue, which is available at http://onlineli-
brary.wiley.com/journal/doi/10.1002/art.39591/abstract.
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ACPA positivity is independent of the variation associated
with RF positivity.
Identification of the genomic variation that influ-
ences the expression of the autoantibodies RF and
ACPA has been a challenge for studies of RA genetics.
Before GWA techniques were available, family-based
linkage studies attempted to identify the genomic
regions associated with the presence of RF. In particu-
lar, the North American RA Consortium collection of
491 multiplex RA families was analyzed by multiple
independent studies to try to identify genomic regions
associated with RF expression. Similar to other complex
traits, however, the linkage signals obtained from differ-
ent studies were low and had little overlap, with the
exception of the short arm of chromosome 6, which har-
bors the HLA region (42–44). Interestingly, in the origi-
nal study where this multicase RA family cohort was
recruited (42), one of the strongest linkage signals for
RF titer was found on chromosome 5p15.2. IRX1 is
located in chromosome 5p15.33, and despite being
more than 7.9 Mb away, it is possible that this original
linkage peak could have captured part of the genetic
association with RF production (45). However, the rela-
tively low statistical evidence (logarithm of odds score
1.21) and the lack of replication in other linkage analy-
ses might have precluded an in-depth analysis of the
association of this chromosomal region with RF levels.
More recently, a GWAS of a large cohort of
healthy individuals from a Japanese population evaluated
the GWA of ACPA and RF positivity (46). In an analysis
of .3,000 individuals, only ;6% of healthy individuals
were found to be positive for RF, thereby greatly reduc-
ing the power to identify genetic variants associated with
this trait. Consequently, no genetic variant surpassed the
genome-wide level of significance in that study.
Identifying genetic variation associated with a
specific trait in a heterogeneous disease like RA can be
challenging. In order to increase the statistical power of
such studies, reducing patient heterogeneity is consid-
ered a useful approach (47). In the present study, all
recruited RA patients had erosive disease and were
therefore homogeneous for this key pathologic feature.
There is evidence that RF-negative patients have a low-
er likelihood of developing joint erosions (48). Thus, the
inclusion of patients with nonerosive disease would have
led to a higher proportion of such patients in the RF-
negative group. Additional studies are needed to show
how the inclusion of patients with no evidence of joint
damage influences the association of the IRX1 locus
with RF positivity.
Recently, evidence has been found to support
the notion of a direct role of RF in RA pathophysiology
(16). Rather than being a mere surrogate of the chronic
inflammation in RA, RF could directly participate in
the amplification of the inflammation in the synovial
membrane. In this disease model, immune complexes
accumulating in the synovial joint and formed mainly by
ACPAs would be recognized by macrophages via RF,
leading to an increase in the production of proinflam-
matory cytokines, including tumor necrosis factor. Con-
sequently, factors influencing the expression of RF
could affect both the risk of developing RA and the risk
of developing more severe forms of the disease. In the
present study, IRX1 SNP rs1502644 allele frequency was
found to be significantly different from healthy controls
in both the RF-positive and the RF-negative RA sam-
ples (MAF 0.10 for RF-negative RA patients, MAF
0.040 for RF-positive RA patients, and MAF 0.053 for
controls; P , 0.05) (data not shown), suggesting the
possibility of a pleiotropic effect of this locus in RA
(17,49). Additional studies evaluating the influence of
the IRX1 locus with clinically relevant phenotypes, such
as disease severity or response to anti-TNF therapy in
RA, are therefore warranted.
In this study, we performed the first GWAS of
RF positivity in RA and identified IRX1 as a risk locus
for this trait. We also showed that several established
RA risk loci are associated with RF status. These find-
ings are an important step in the characterization of the
genetic basis of RF positivity in RA.
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Clinical Images: A digital vascular malformation masquerading as synovitis
The patient, a 49-year-old woman with a history of seronegative rheumatoid arthritis (RA), presented with swelling of her right index
finger, which was most marked around the metacarpophalangeal joint and proximal phalanx. The swelling was warm and boggy. After
previous unsuccessful treatment with hydroxychloroquine, the patient had been taking oral methotrexate 15 mg/week for the past 2
years. The remainder of her joints were not swollen or tender, and blood tests revealed normal levels of inflammation markers. There
was no history of trauma, and the lesion had developed progressively over the past 9 months. An edema-sensitive coronal magnetic
resonance imaging sequence (fat-suppressed, proton density) showed a multilobulated, high-signal, infiltrative lesion within the palmar
subcutaneous tissues extending toward the second web space (left). An axial fat-suppressed (T1) postcontrast image again demonstrat-
ed an infiltrative, heterogeneously enhancing lesion abutting the second flexor tendon sheath, consistent with a low-flow venous mal-
formation (right). No evidence of synovitis was noted, confirming the clinical impression of RA in remission. This case serves as a
reminder to consider in a timely manner other pathologies in patients with RA who present with isolated RA-like symptoms.
Douglas H. N. White, FRACP
Waikato DHB
and University of Auckland
Glenn Coltman, MBChB
Waikato Hospital
Hamilton, New Zealand
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Concise report
A genome-wide association study identifies SLC8A3
as a susceptibility locus for ACPA-positive
rheumatoid arthritis
Antonio Julia`1, Isidoro Gonza´lez2, Antonio Ferna´ndez-Nebro3,
Francisco Blanco4, Luis Rodriguez5, Antonio Gonza´lez6, Juan D. Can˜ete7,
Joan Maymo´8, Mercedes Alperi-Lo´pez9, Alejandro Olive´10, He´ctor Corominas11,
Vı´ctor Martı´nez-Taboada12, Alba Erra13, Simo´n Sa´nchez-Ferna´ndez14, ,
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Abstract
Objective. RA patients with serum ACPA have a strong and specific genetic background. The objective of
the study was to identify new susceptibility genes for ACPA-positive RA using a genome-wide association
approach.
Methods. A total of 924 ACPA-positive RA patients with joint damage in hands and/or feet, and 1524
healthy controls were genotyped in 582 591 single-nucleotide polymorphisms (SNPs) in the discovery
phase. In the validation phase, the most significant SNPs in the genome-wide association study repre-
senting new candidate loci for RA were tested in an independent cohort of 863 ACPA-positive patients
with joint damage and 1152 healthy controls. All individuals from the discovery and validation cohorts
were Caucasian and of Southern European ancestry.
Results. In the discovery phase, 60 loci not previously associated with RA risk showed evidence for
association at P< 5104 and were tested for replication in the validation cohort. A total of 12 loci
were replicated at the nominal level (P<0.05, same direction of effect as in the discovery phase).
When combining the discovery and validation cohorts, an intronic SNP in the Solute Carrier family 8
gene (SLC8A3) was found to be associated with ACPA-positive RA at a genome-wide level of significance
RA [odds ratio (95% CI): 1.42 (1.25, 1.6), Pcombined = 3.19108].
Conclusions. SLC8A3 was identified as a new risk locus for ACPA-positive RA. This study demonstrates
the advantage of analysing relevant subsets of RA patients to identify new genetic risk variants.
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Rheumatology key messages
. ACPA-positive RA has a specific genetic risk background.
. Reducing patient heterogeneity is a powerful approach to identify new risk loci for RA .
. SLC8A3 is a new risk locus for ACPA-positive and erosive RA.
Introduction
RA is the most common inflammatory arthritis in the
western world, and it develops on the background of
a complex genetic susceptibility. Genome wide associ-
ation studies (GWAS) have radically improved our
knowledge of the genetic variability associated with
the risk of developing RA. To date more than 100 dif-
ferent loci have been associated with RA at the
genome-wide level of statistical significance [1].
However, these new risk loci collectively explain
<10% of the heritability of RA. Therefore, the likelihood
that additional, undiscovered loci contribute to RA risk
is very high.
One major advance in the understanding of the genetic
basis of RA has been the identification of a differential
genetic background between ACPA-positive patients
and ACPA-negative patients [2]. In ACPA-positive RA, a
larger number of genes influence the risk of developing
the disease and, also, they show a stronger penetrance
compared with ACPA-negative patients [3]. The most
compelling example of this differential genetic component
is that the two loci most strongly associated with RA,
HLA-DRB1 and PTPN22 genes, are essentially not asso-
ciated with ACPA-negative RA [4]. Integrating this
acquired knowledge into the study of RA genetic aetiology
is proving to be a powerful strategy to identify additional
risk factors [5].
Although joint destruction is the hallmark of RA and is
the focus of many actual therapeutic interventions, it is
not present in all patients [6]. This variability in the
clinical presentation of the disease might reflect the
presence of underlying genetic heterogeneity.
Therefore, analysing only RA patients with radiographic
joint damage represents a useful strategy to reduce
heterogeneity and so increase the power to identify
new genetic factors associated with the disease.
In the present study we performed a case-control
GWAS using ACPA-positive RA patients with radio-
graphic joint damage in hands and/or feet. The
most significant results from the GWAS that were sug-
gestive of new risk loci for RA were subsequently cor-
roborated using an independent validation cohort of
ACPA-positive RA patients, also with radiographic
joint damage. The results of this study show that
analysing relevant groups of RA patients can help to
identify additional genetic variation associated with dis-
ease risk.
Methods
Study subjects
In the discovery phase, a total 924 RA patients were re-
cruited by the Immune-Mediated Inflammatory Disease
Consortium [7]. All RA patients satisfied the ACR diagnos-
tic criteria for RA, were ACPA-positive and had >2 years
of follow-up since diagnosis. Importantly, all patients had
erosive disease defined as 51 erosions in, at least, two
joint groups in hands and/or feet. All patients were
Caucasian European and with all four grandparents born
in Spain. Supplementary Table S1, available at
Rheumatology Online, describes the main characteristics
of the RA patient cohorts in this study.
The control cohort was also collected by the Immune-
Mediated Inflammatory Disease Consortium, in collabor-
ation with the Spanish National DNA biobank [7]. All
healthy control individuals were >18 years old and without
an autoimmune disease. In order to increase the power of
the study, control individuals with a first or second degree
relative affected with an autoimmune disease were
excluded from the study. A total of 1524 healthy control
individuals were recruited for analysis in the discovery
phase. All controls were also Caucasian and with all four
grandparents born in Spain.
The replication cohort was recruited following the same
criteria as in the discovery phase. Anti-CCP-positive pa-
tients and healthy controls were all Caucasian and with all
grandparents born in Spain. A total of 863 ACPA-positive
patients with erosive disease and 1152 controls were re-
cruited for the replication phase.
This study was undertaken in compliance with the
Declaration of Helsinki. Informed consent was obtained
from all participants, and both the protocols and study
were reviewed and approved by the Vall d’Hebron
University Hospital review board.
GWAS
Genome-wide genotyping was performed using Illumina
Quad610 Beadchips (Illumina, San Diego, CA, USA) on
924 ACPA-positive RA patients and 1524 healthy controls.
The Quad610 arrays genotypemore than 550000 single
nucleotide polymorphisms (SNPs). GWAS genotyping was
performed at the Centro Nacional de Genotipado (CeGen,
Spain). Details on the quality control procedure used in
this stage are described in ‘GWAS and Replication
Quality Control Procedures’ in supplementary Fig. S1,
available at Rheumatology Online.
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Replication study
Replication genotyping was performed at the
HudsonAlpha Institute for Biotechnology (Huntsville, AL,
USA) using the Illumina GoldenGate assay (Illumina, San
Diego, CA, USA) on 863 ACPA-positive patients with joint
damage and 1152 controls. Details on the quality control
measures are included in ‘GWAS and Replication Quality
Control Procedures’ in the supplementary data, available
at Rheumatology Online.
Results
After quality-control analysis, a final number of 890 ACPA-
positive RA patients and 1493 controls were used in the
discovery stage. A total of 506 950 SNPs passed all qual-
ity and frequency filters and were used for association
analysis.
In the discovery cohort, 25 of the established risk loci
for RA were found to be significantly associated (P< 0.05)
with ACPA-positive RA [1] (supplementary Table S2, avail-
able at Rheumatology Online). From these, 10 loci had not
been previously associated to this specific group of RA
patients. To our knowledge, MTF1-INPP5B, PLCL2,
ATG5, ZNF348, WDFY4, PLD4-AHNAK2 and MED1 loci
have not been previously associated with ACPA-positive
RA. RCAN1 had been analysed in a previous GWAS in
ACPA-positive patients from Asian ancestry [5] but was
not significantly associated.
In the discovery phase, 60 genomic regions not previ-
ously associated to RA or ACPA-positive RA showed high
statistical evidence of association (P< 5104, supple-
mentary Table S3, available at Rheumatology Online).
This group of candidate risk loci was selected for valid-
ation in the independent case-control cohort. Using the
validation cohort, a total of 12 loci were replicated at the
nominal level loci (P< 0.05, same direction of effect as in
the GWAS, Table 1).
When combining the data from the discovery and val-
idation phases, SNP rs17175346, located in an intron of
the solute carrier family 8 member 3 gene (SLC8A3) in
chromosome 14q24.1, reached a genome-wide level of
significance [P=3.19  108, odds ratio, OR (95%
CI): 1.44 (1.2, 1.73)] (Fig. 1).
In order to gain insights to the possible regulatory po-
tential of the SLC8A3 SNP rs17175346 associated with
ACPA-positive RA we screened public functional annota-
tion databases [8]. We found that the chromosome
14q24.1 region where rs17175346 lies has strong regula-
tory evidence (supplementary Fig. S2, available at
Rheumatology Online). For example, DNAseI screening
studies performed by the ENCODE project have shown
that this genomic region is hypersensitive to cleavage in
112 out of 125 different human cell types, strongly sup-
porting its role as an active genetic regulatory site. Similar
evidence obtained using other genomic regulation char-
acterization approaches like the Roadmap Epigenomics
Consortium (http://www.roadmapepigenomics.org/, sup-
plementary Fig. S3, available at Rheumatology Online)
also support the existence of an important regulatory
element in the chromosome region that harbours the
SNP associated to ACPA-positive RA.
Given that the biological role of the SLC8A3 gene is still
poorly understood, we used the GeneNetwork genomic
database (www.genenetwork.nl) to predict its function. This
functional analysis tool uses the co-expression patterns in
more than 80000 genome-wide expression analyses in
mouse and human to predict significant biological functions
of genes. Using this method we found that, from all tested
biological annotations, the Gene Ontology database biolo-
gical processes regulation of ion transmembrane transport
TABLE 1 Association results for the new loci for ACPA-positive RA identified in our study
GWAS Validation Combined
Chr SNP Gene MAF P
OR
(95%CI) P
OR
(95% CI) P OR (95% CI)
2 rs6435818 SPAG16 0.15 0.00044 1.36 (1.15, 1.62) 0.024 1.21 (1.01, 1.45) 6.76  105 1.29 (1.14, 1.46)
3 rs2664122 SRGAP3 0.4 7.82  105 1.28 (1.13, 1.44) 0.017 1.16 (1.01, 1.32) 1.91  105 1.21 (1.11, 1.33)
3 rs807193 CACNA1D 0.22 1.85  105 1.38 (1.19, 1.59) 0.043 1.15 (0.98, 1.34) 1.11  105 1.27 (1.14, 1.41)
4 rs10517086 LOC645481 0.41 3.67  105 1.29 (1.14, 1.46) 0.0044 1.19 (1.05, 1.36) 1.44  106 1.24 (1.14, 1.36)
5 rs1991493 EBF1 0.21 0.00018 0.77 (0.67, 0.88) 0.013 0.84 (0.73, 0.98) 1.67  105 0.8 (0.72, 0.89)
7 rs11496005 AGR3 0.35 1.43  105 1.32 (1.17, 1.5) 0.027 1.15 (1, 1.31) 6.07  106 1.24 (1.13, 1.36)
8 rs870615 SGCZ 0.28 7.41  105 1.31 (1.15, 1.5) 0.045 1.13 (0.98, 1.31) 3.79  105 1.23 (1.11, 1.35)
9 rs11788776 BNC2 0.5 7.65  105 1.27 (1.13, 1.43) 0.048 1.11 (0.98, 1.26) 4.30  105 1.2 (1.1, 1.3)
12 rs789331 C12orf28 0.38 3.41  105 0.78 (0.69, 0.87) 0.044 0.89 (0.79, 1.01) 4.41  105 0.83 (0.76, 0.91)
13 rs927788 CLDN10 0.42 6.95  105 1.28 (1.13, 1.44) 0.039 1.12 (0.99, 1.28) 3.52  105 1.2 (1.1, 1.31)
14 rs17175346 SLC8A3 0.16 8.53  105 1.4 (1.18, 1.66) 5.97  105 1.44 (1.2, 1.73) 3.19 108 1.42 (1.25, 1.6)
14 rs7146876 SERPINA13 0.23 0.00042 1.29 (1.12, 1.49) 0.025 1.17 (1, 1.37) 8.16  105 1.24 (1.11, 1.37)
Association results of the 12 new candidate loci for ACPA-positive RA identified in the GWAS stage and nominally replicated
(P< 0.05) in the validation stage. GWAS: association statistics for the discovery cohort; Validation: association statistics for the
validation cohort; Combined: association statistics for GWAS and validation cohorts combined; Chr: chromosome; MAF: minor
allele frequency; OR (95%CI): odds ratio of SNP and 95% confidence interval; P: P-values for association; SNP: single-
nucleotide polymorphism.
1108 www.rheumatology.oxfordjournals.org
Antonio Julia` et al.
Downloaded from https://academic.oup.com/rheumatology/article-abstract/55/6/1106/1744801 by guest on 18 September 2019
(GO:0034765) and ossification (GO:0001503) showed the
most significant associations for SLC8A3 function (P=1.26
 1010 and P=1.85  109, respectively; supplementary
Table S4, available at Rheumatology Online).
Discussion
Using a GWAS approach, we have identified SLC8A3 as a
new risk locus for ACPA-positive RA. Analysing 890
ACPA-positive patients with joint damage and 1493
healthy controls we have identified several candidate
risk loci. Using an independent cohort of 863 ACPA-posi-
tive patients with joint damage and 1152 healthy controls,
we replicated the association of 12 of these new candi-
date risk loci for RA at the nominal level (P< 0.05, same
direction as in GWAS). When combining the data from the
discovery and validation phases, we have found a
genome-wide significant association for rs17175346
(combined P=3.19  108), an intronic SNP from
SLC8A3 gene located on chromosome 14q24.1.
SLC8A3, also known as NCX3, encodes a highly con-
served protein that mediates sodium and calcium ion
exchange across the cell membrane [9]. To date, little is
known about the biological processes and cell types that
depend on SLC8A3. Recent evidence, however, indicates
that it is a gene that is constitutively expressed in mono-
cytes/macrophages [10]. Importantly, SLC8A3 activation
in cultured macrophages has been associated to an in-
crease of TNF cytokine production [10]. TNF secretion by
macrophages is clearly one of the main pathophysio-
logical mechanisms associated with RA aetiology [11].
Therefore, genetic variants influencing the regulation of
TNF secretion in this key cell type in RA could increase
the risk of the disease.
In silico prediction of SLC8A3 biological activity also
suggests an association of this Na+-dependent
Ca2+ transporter with bone metabolism. Also, the asso-
ciated SNP rs17175346 lies in a CTCF binding site, a
regulatory variant that insulates from enhancer and silen-
cer signals, and it has been characterized in bone forming
cells (osteoblasts) (supplementary Table S5, available at
Rheumatology Online). In RA, the disequilibrium between
enhanced osteoclast differentiation and the inhibition of
osteoblast-mediated bone repair contributes to bone
FIG. 1 Association results for SLC8A3 locus with ACPA-positive RA
Regional plot with the significance [i.e. log10 (P-values), y-axis] of the SNPs in SLC8A3 gene region in the discovery
phase as a function of basepair location in chromosome 14q24.1 (x-axis). The validated SNP (rs17175346) is shown as a
purple diamond with significance value from the combined (GWAS and validation) cohort association analysis. The
remaining SNPs are shown as circles with colour coding indicating the level of LD (i.e. r2, legend) with respect to
rs17175346. The estimated recombination rates (centimorgans/megabase, right y-axis) are plotted as a continuous
background line. LD: linkage disequilibrium; SNP: single-nucleotide polymorphism.
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erosion, which is the hallmark of the disease. SLC8A3 has
been shown to be expressed in osteoblasts during their
differentiation and following bone formation [12].
Furthermore, there is increasing evidence that SLC8A3
is the main cellular translocator of Ca2+ from osteoblasts
into the bone extracellular matrix [13]. Our results there-
fore suggest that genetic variation in the biological path-
ways affecting the target tissue in RA can also increase
the risk of developing the disease.
Joint destruction is the most important severity feature
of RA. In the present study we recruited ACPA-positive
patients with radiographic joint damage, thus increasing
the homogeneity of the patient cohort. To our knowledge,
this is the first GWAS for RA where all patients both in the
discovery and in the replication cohort are positive for
ACPA and joint destruction in hands and/or feet. Using
this approach we have increased the homogeneity of
the patient cohort and we have therefore significantly
increased the power to identify new genetic variants rele-
vant for this predominant group of patients. A recent
meta-analysis with Caucasian European and Asian RA co-
horts increased to 101 the number of genetic variants
associated to RA [1]. Despite the large sample size of
this study, SLC8A3 SNP rs17175346 did not show evi-
dence of statistical association (P> 0.05, supplementary
Table S6, available at Rheumatology Online). In this meta-
analysis, however, patients were selected neither for
positivity to ACPA nor for the presence of erosions.
ACPA-negative patients and patients without erosions
can represent up to 30% of individuals diagnosed with
RA [6]. As suggested previously, including different patient
subsets in the genetic analysis can clearly undermine the
statistical power to identify new risk variants in RA [14,
15]. Of relevance, one of the nominally replicated genes
in this study, SPAG16, has been recently found to be
associated with the radiological progression rate in RA
at the genome-wide level of significance [16]. Despite
being a GWAS for a RA phenotype (and therefore a
case-only study), it shares several features with the pre-
sent GWAS for disease risk. Like in our study, in this
recent GWAS only ACPA-positive RA patients were
analysed. Also, similar to our study, the associated
SPAG16 variant does not show a significant association
in the global RA meta-analysis study (P> 0.05, data not
shown). Together, these results highlight the importance
of patient selection criteria in the identification of add-
itional relevant genetic variants in RA.
In the validation phase we replicated the association of
11 additional risk loci with ACPA-positive RA at the nom-
inal level (P< 0.05). Although none of these additional loci
reached a genome-wide level of statistical significance
after combining both cohorts (i.e. P< 5108), there is
a clear enrichment of nominally significant genes
(P=0.00017, binomial test). This result clearly supports
that within this group of replicated genes there are add-
itional true risk factors for ACPA-positive RA. Apart from
SPAG16, another highly suggestive candidate for ACPA-
positive RA risk based on its biological function is early B
cell factor (EBF1) gene. EBF1 activity has shown to be
crucial for B cell lineage commitment to mature anti-
body-secreting cells [17]. Variation at this gene has been
recently associated with the risk of SS [18]. If validated in
an independent dataset, this gene would add to the group
of B cell pathway genes that have been previously asso-
ciated with RA susceptibility [1].
In this study, we performed a GWAS in ACPA-positive
RA with joint damage. We have identified SLC8A3 as a
new risk locus for ACPA-positive RA and we have also
identified several additional loci with suggestive evidence
of association with this prevalent disease group. These
findings underline the importance of patient selection to
characterize the missing heritability of RA.
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ABSTRACT
Objective Copy number variants (CNVs) have been
associated with the risk to develop multiple autoimmune
diseases. Our objective was to identify CNVs associated
with the risk to develop psoriatic arthritis (PsA) using a
genome-wide analysis approach.
Methods A total of 835 patients with PsA and 1498
healthy controls were genotyped for CNVs using the
Illumina HumanHap610 BeadChip genotyping platform.
Genomic CNVs were characterised using CNstream
analysis software and analysed for association using the
χ2 test. The most signiﬁcant genomic CNV associations
with PsA risk were independently tested in a validation
sample of 1133 patients with PsA and 1831 healthy
controls. In order to test for the speciﬁcity of the variants
with PsA aetiology, we also analysed the association to
a cohort of 822 patients with purely cutaneous psoriasis
(PsC).
Results A total of 165 common CNVs were identiﬁed
in the genome-wide analysis. We found a highly
signiﬁcant association of an intergenic deletion between
ADAMTS9 and MAGI1 genes on chromosome 3p14.1
(p=0.00014). Using the independent patient and control
cohort, we validated the association between ADAMTS9-
MAGI1 deletion and PsA risk (p=0.032). Using next-
generation sequencing, we characterised the 26 kb
associated deletion. Finally, analysing the PsC cohort we
found a lower frequency of the deletion compared with
the PsA cohort (p=0.0088) and a similar frequency to
that of healthy controls (p>0.3).
Conclusions The present genome-wide scan for CNVs
associated with PsA risk has identiﬁed a new deletion
associated with disease risk and which is also differential
from PsC risk.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inﬂammatory
arthritis that affects 10–30% of patients with
psoriasis.1 2 To date, genome-wide association
studies (GWAS) as well as candidate gene studies
have shown that both diseases share a substantial
genetic component. However, sibling recurrence
rates (λs) are much higher for PsA than psoriasis
(PsA λs∼37 vs psoriasis λs∼7),3–5 indicating that
additional, perhaps disease-speciﬁc, risk factors
need to be identiﬁed.
GWAS based on single-nucleotide polymorph-
isms (SNPs) have been highly successful in identify-
ing >30 loci associated with psoriasis and PsA
susceptibility.6–8 The cumulative risk exerted by
these loci, however, is <50%,9 and additional
genetic factors still need to be identiﬁed in order to
explain the missing heritability. Strategies to com-
plete the characterisation of the genetic architecture
of psoriasis and PsA include the use of large sample
sizes or the combination of different studies
through metaanalysis,10 the deep sequence charac-
terisation to identify rare variants with large effect
sizes11 and, also, the analysis of other types of
genetic variation that cannot be completely cap-
tured by SNP-based genotyping platforms such as
copy number variants (CNVs).
CNVs are fragments of DNAwith sizes that range
from hundreds of bases to several megabases, and
that can either be absent (ie, deletions), repeated a
certain number of times (ie, ampliﬁcations) or even
rearranged.12 Psoriasis was one of the ﬁrst chronic
inﬂammatory diseases where CNVs were found to
be associated with the disease risk. The ampliﬁca-
tions of the β-defensin genes on 8p23.1 region13
and the deletion affecting LCE3B and LCE3C
genes14 have been clearly associated with psoriasis
aetiology. The association of these CNVs with PsA
aetiology, however, is still not clear,2 15 suggesting
that they could participate in the chronic inﬂamma-
tory processes in the skin rather than in the patho-
logical process occurring in the joint.
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In the present study, we have performed the ﬁrst genome-
wide analysis of CNVs in PsA. We have ﬁrst analysed a discovery
panel of 835 patients with PsA and 1498 healthy controls from
the Spanish population using a microarray platform. The CNVs
showing a more signiﬁcant association to PsA risk were subse-
quently selected and validated in an independent cohort of
1133 patients with PsA and 1831 healthy controls. In order to
test for the speciﬁcity of the CNV association with PsA aeti-
ology, we have also analysed a set of 822 psoriasis patients
without arthritis. Using this approach, we have identiﬁed a new
deletion associated with PsA risk that is not associated with
purely cutaneous psoriasis (PsC).
PATIENTS AND METHODS
Study subjects
To identify new loci associated with psoriasis risk using the
GWAS approach, we recruited 835 patients with PsA and 1498
healthy controls from the Spanish population. Patient and
control individuals were obtained by the Immune-Mediated
Inﬂammatory Disease Consortium (IMIDC).16 The IMIDC is a
Spanish biomedical research collaboration project that includes
biomedical and clinical researchers on rheumatology, dermatol-
ogy and gastroenterology, and that is devoted to the study of
prevalent autoimmune diseases. In the present study, a total of
26 rheumatology departments—15 in the GWAS stage and 11
additional in the replication stage—and 11 dermatology depart-
ments from different university hospitals in Spain participated
in the patient recruitment and clinical data collection. All
patients with PsA included in this study had a clinical diagnosis
made by a consultant rheumatologist. All patients with PsA were
diagnosed according to the Classiﬁcation Criteria for Psoriatic
Arthritis criteria,17 were >18 years old—although the disease
could have started earlier in life—and had at least 1 year of evo-
lution of the disease. Exclusion criteria for the present study
were (i) presence of any other inﬂammatory joint disease, (ii)
presence of any inﬂammatory bowel disease and (iii) positivity
of rheumatoid factor.
Control individuals for the GWAS stage were recruited from
blood bank donors attending at 13 hospitals from different
regions in Spain in collaboration with the Spanish National
DNA Bank (http://www.bancoadn.org). Eligible individuals were
screened for the presence of PsA or any other autoimmune dis-
order, as well as for history of autoimmune disorders in ﬁrst-
degree relatives, and positive individuals were discarded from
this study. Additionally, in order to increase the ‘hypernormal-
ity’ of the control cohort,18 only individuals who were
>30 years old were included. In total, 1498 controls, 40% of
whom were women, were analysed in the GWAS. Of note,
>96% of the control individuals were >40 years old at the time
of recruitment.
All patients and controls in the GWAS and replication cohorts
were Caucasian European. In those cases where any of the four
grandparents was not born in Spain, the individual was dis-
carded from the study. The DNA samples from patients and
controls in both stages of the study were obtained from whole
blood samples.
A total of 1131 patients with PsA and 1831 controls were
used to validate the most signiﬁcant loci identiﬁed in the GWAS
phase. Both cohorts were collected using the same clinical and
epidemiological selection criteria as for the GWAS. Additionally,
a sample of 822 patients diagnosed with psoriasis and without
PsA (ie, PsC) was also analysed in the validation phase. All
patients with PsC were diagnosed and recruited by a consultant
dermatologist participating in the IMID Consortium.2 Psoriasis
patients with plaque psoriasis affecting torso and/or extremities
and with at least one year of duration were included. Patients
with a single clinical localisation of plaque psoriasis (ie, scalp,
face, palmoplantar), with exclusively inverse plaque psoriasis or
with an inﬂammatory bowel disease, were excluded from the
study. Finally, psoriasis patients diagnosed with PsA by a
rheumatologist were excluded from this group.
Genome-wide CNV analysis
We performed a CNV genome-wide scan by using Illumina
610Quad Beadchips (Illumina, San Diego, California, USA),
which contains a total of 620 901 probes. Sample genotyping
was performed at the HudsonAlpha Institute for Biotechnology
(Alabama, USA). After excluding mitochondrial as well as X and
Y chromosome SNPs, a total of 600 470 probes were considered
for GWAS CNVanalysis.
Before proceeding to perform PsA risk analysis, we performed
several quality control analysis steps. First, only those samples
that had a >95% genotype completion rate were considered for
analysis (99% of samples). Second, we used the SNPs genotype
information to estimate the main axes of variation using the
principal component analysis implemented in the Eigenstrat
software.19 With this approach, individuals showing a high devi-
ation in any of the 10 top principal axes of variation were con-
sidered outliers and were consequently removed (>6 SDs from
the centre of each component, n=42 outliers). Online supple-
mentary ﬁgure S1 shows the patient with PsA and control distri-
butions according to the ﬁrst and second principal components
after excluding the outliers.
Since CNV genotyping is subject to more technical biases
than SNP genotyping, several additional quality control ﬁlters
must be applied to the GWAS data. Following previous GWAS
CNV studies,20 samples with a substantial deviation from the
mean log Ratio (|m log R ratio| > 0.1) or with an excessive
variability (σ log R ratio > 0.2), were excluded (n=556 indivi-
duals, 23.8%). After applying all the quality control ﬁlters, a
total of 658 patients with PsA and 1063 controls were ﬁnally
available for the CNV GWAS. Online supplementary ﬁgure S2
shows a schematic representation of the global CNV analysis
workﬂow.
CNV identiﬁcation and genotyping was performed using
CNstream software (ﬁgure 1A).21 CNstream ﬁrst applies a nor-
malisation procedure to control for the presence of potential
intensity biases from samples processed at different time points
(ie, batch normalisation). It then applies a second normalisation
step to minimise the difference of sensitivity between the two
colour channels used to analyse each probe (ie, intensity normal-
isation).22 Once the data are normalised, CNstream jointly ana-
lyses sets of consecutive probes (n=5 in this study) to identify
the presence of a CNV in a particular region of the genome and
generate a genotype call for each individual.
After genome-wide CNV identiﬁcation and calling, the associ-
ation with disease risk was tested using the genotypic χ2 test. In
the case of low-frequency CNVs (minor allele frequency <5%),
the genotype counts for CNV homozygous (0N) as well as indi-
viduals with 1 deletion (1N) were merged in a single
CNV-positive group and compared with non-CNV carriers
(2N). Statistical association analyses were performed using R
software V.3.0.1.23
Targeted sequencing of ADAMTS9-MAGI1 locus
In order to characterise the chromosome 3q14.2 sequence har-
bouring the deletion associated with PsA risk in the CNV
GWAS, we performed a targeted resequencing analysis in
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selected samples from the discovery phase. Next-generation
sequencing was performed at the HudsonAlpha Institute for
Biotechnology (Alabama, USA). A total of 100 patients with PsA
and 100 control individuals were selected for sequencing of
ADAMTS9-MAGI1 locus. The individuals were selected so that
deletion carriers and non-carriers—as determined by GWAS
genotyping—were equally present in both groups.
Consequently, 100 sequenced individuals carried one or two
deletions (ie, 1N or 0N) and 100 individuals had no deletion
(ie, 2N individuals).
The Illumina sequencing platform (Illumina, San Diego, USA)
was used to characterise the deletion sequence. In order to iden-
tify yet undiscovered variants in the two ﬂanking genes that
could be responsible for the observed association with PsA risk,
we also sequenced ADAMTS9 and MAGI1 genes and their 50
and 30 ﬂanking sequences. First, the DNA quality of these
samples was assessed by running 1–3 mL on a 1% agarose gel
that contained 1× Sybr Green I dye (Life Technologies, USA).
Next we followed the CATCH-Seq procedure we reported
recently.24 In brief, we puriﬁed CTD-2216H2, CTD-2255G2,
CTD-2517E23, RP11-841H13, RP11-1080G20, RP11-411F5
and RP11-257J13 BAC DNAs that are commercially available
(Life Technologies). BAC DNAs were pooled by percentage of
the total target size (1.1 Mb) according to a 4 mg total input
mass, and the pool was sheared by E220 Covaris sonication.
Linkers containing T7 promoter sequences were ligated to
sheared BAC fragments, and biotinylated RNA probes were
synthesised by in vitro transcription using a MEGAscript kit
(Ambion) and biotin-11-UTP (Life Technologies) with T7-BAC
fragments as template. Illumina libraries were prepared accord-
ing to standard protocol using 24 inline barcoded adapters.
For capture of library within the ADAMTS9/MAGI1 chromo-
some 3 region, hybridisation reactions were assembled with 4
barcoded libraries (125 ng of each), 20 mg of Cot-1 DNA (Life
Technologies), 236 ng probe, 20 U SUPERase-In (Life
Technologies) and 2× hybridisation buffer in a ﬁnal volume of
Figure 1 ADAMTS9-MAGI1 deletion characterisation. (A) Map of chromosome 3p14.1 region showing ADAMTS9 and MAGI1 genes (blue
segments), and the intergenic deletion (green rectangle) associated with psoriatic arthritis (PsA) risk. The horizontal red lines indicate the location of
the two Taqman assays (Hs03225015_cn and Hs03225295_cn, red vertical lines) used to genotype the deletion. (B) CNStream deletion calling using
multiple probes within the deletion sequence. This software method combines the copy number estimation of consecutive probes (left: probe at
chr3:65 191 847 pb; right: probe at chr3: 65 196 123 pb). (C) Log2 intensity reads of six individuals for the chromosome 3 region harbouring the
deletion. Starting from the top, the ﬁrst two individuals show the characteristic drop in intensity corresponding to hemizygous (ie, 1N) individuals.
The third, fourth and sixth individuals show the expected log2 reads of a 2N individual, with most of the intensities centred around 0. Finally, the
ﬁfth individual clearly shows the presence of an individual homozygous for the deletion, with no sequence reads mapping to this region of the
chromosome. (D) Sequence of the reference and deletion alleles. Physical coordinates are on the reference human genome (build 37).
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26 mL incubated at 65°C for 70 h. Hybridisation reactions were
incubated with 25 μL MyOne Streptavidin C1Dynabeads (Life
Technologies) for 30 min with frequent pulse vortexing. Bead
captures were washed twice for 15 min each at room tempera-
ture in 0.5 mL wash buffer 1 (1×SSC, 0.1% SDS), followed by
four stringency wash steps at 65°C in 0.5 mL preheated wash
buffer 2 (0.1×SSC, 0.1% SDS) for 10 min each. Captured
libraries were eluted in 50 μL 0.1 M NaOH and neutralised in
70 μL 1 M Tris pH 7.5. Final libraries were cleaned with 1.8×
solid-phase reversible immobilisation beads and eluted in 33 mL
water for assembly of library ampliﬁcation PCR containing 1 mL
Platinum Taq (Life Technologies) and 5 mL 5 M betaine (Sigma)
in 50 mL reactions (98°C 1 min, 95°C 30 s and 62°C 3.5 min
for 20 cycles). Final 4-plex library concentrations were deter-
mined by KAPA QPCR (KAPA Biosystems) and adjusted to
15 nM each. Stock 4-plex libraries were pooled appropriately
for ﬁnal 24-plex libraries each for a single lane on HiSeq2000
sequencer (Illumina) using 50 bp paired end conditions.
Sequencing reads from individual samples were demuxed
based on inline barcode sequences and aligned to the human
reference genome (hg19) with BWA.25 Relative read depth was
calculated as the number of bases mapped to 100 bp windows
per total bases mapped for a given sample. Then a log2 ratio
between each sample at each 100 bp window to the mean of all
samples at that window was used to plot a normalised read
depth, representing the read depth relative to a theoretical
diploid reference. The plots of these normalised read depths
across the locus were used to conﬁrm the presence of the dele-
tion (ﬁgure 1B).
CNV replication analysis
Replication genotyping was performed using the TaqMan
Genotyping System (Applied Biosystems, Foster City, California,
USA). Two pre-designed Taqman CNV assays Hs03225015_cn
and Hs03225295_cn were found to be located within the esti-
mated deletion boundaries. In order to validate the two assays,
we genotyped the group of 200 individuals that were previously
used to sequence the deletion. The correspondence between the
calls of the two CNVs between the Taqman and sequencing ana-
lysis was 100%. Consequently, we used the two Taqman assays
to genotype the ADAMTS9-MAGI1 deletion in an independent
group of 1133 patients with PsA, 1831 healthy controls and
822 patients with PsC. Quality control measures similar to the
GWAS were applied, including genotyping call rate >95%,
sample completion rate >90% and Hardy–Weinberg disequilib-
rium p value of control group p>0.001. The CNV genotype
concordance between the two Taqman assays was >99%.
Meta-analysis of the GWAS and replication association statistics
was performed using METAL software.26
RESULTS
CNV identiﬁcation and genotyping
Table 1 summarises the main features of the GWAS and replica-
tion PsA patient cohorts.
Using a total of 658 patients with PsA and 1063 healthy con-
trols, we identiﬁed a total of 2674 CNV segments. After
merging segments belonging to the same genomic region (dis-
tance <10 kb and/or r2>0.9), we performed the genotype
calling in a total of 1953 different CNV regions. Among them,
165 CNVs appeared in >5% of the samples and were subse-
quently used to test for association with PsA risk. Online supple-
mentary table S1 describes the characteristics of these CNVs.
CNV GWAS for PsA risk
Using the group of common CNVs, we performed a GWAS for
PsA risk. We found a very strong association signal at an inter-
genic deletion located between the HLA-C and HLA-B genes
(p=5.37e-11, OR (95% CI) 2.08 (1.47 to 2.95), MAF=0.18,
ﬁgure 2). Since HLA-C locus is an established risk locus for PsA
we sought to estimate the association of the deletion after cor-
recting for the HLA haplotypes associated with psoriasis risk as
recently described.27 We found that, after correcting for
HLA-C*0602 and HLA-B*3801 alleles, the deletion was no
longer associated with PsA risk (p=0.81, see online supplemen-
tary table S2). Consequently, this CNV was considered a proxy
for the HLA allele association and was not included for
replication.
We also found another highly signiﬁcant association for a
deletion located in the chromosome 3q14.2 intergenic region,
between ADAMTS9 and MAGI1 genes (p=0.00014, OR (95%
CI) 1.94 (1.37 to 2.75), MAF=0.04, ﬁgure 2). This genomic
region had not been previously associated to any SNP-based
Figure 2 Plot of the copy number variant (CNV) genome-wide
association studies results. The −log10 p values (y-axis) are plotted for
each of the CNVs identiﬁed by CNSstream. Each chromosome is coded
in a different colour. The probes mapping the intergenic deletion in
HLA-C/-B locus in chromosome 6 (light blue dots) were found to have a
high signiﬁcance; however, after correcting for HLA-C and HLA-B alleles
this association disappeared. In chromosome 3, an intergenic deletion
between genes ADAMTS9 and MAGI1 (purple dot) shows a signiﬁcant
association that withstands multiple test correction.
Table 1 Phenotypic summary of GWAS and replication patient
cohorts
Characteristic
GWAS
cohort
Replication
cohort
Gender (% female) 45.3% 48.6%
Age (mean±SD) 52.9
±12.8
54.4±13.2
Chronic plaque psoriasis (%) 92.0% 90.9%
Age at onset psoriasis (mean±SD) 33.9
±15.4
35.7±15.5
Age at onset PsA (mean±SD) 42.5
±13.5
42.6±15.1
RF positive (%) 0% 0%
Fulfilling Classification Criteria for
Psoriatic Arthritis criteria
100% 100%
GWAS, genome-wide association studies; PsA, psoriatic arthritis; RF, rheumatoid
factor.
1878 Julià A, et al. Ann Rheum Dis 2015;74:1875–1881. doi:10.1136/annrheumdis-2014-207190
Clinical and epidemiological research
P
rotected by copyright.
 on S
eptem
ber 18, 2019 at H
ospital S
an Joan D
e D
eu.
http://ard.bm
j.com
/
A
nn R
heum
 D
is: first published as 10.1136/annrheum
dis-2014-207190 on 19 M
ay 2015. D
ow
nloaded from
 
GWAS in PsA or any other related disease. After correcting for
the number of CNVs analysed, the deletion association was still
found to be signiﬁcantly associated with PsA risk (p=0.023,
Bonferroni multiple test correction). Consequently, we selected
this region for replication in the independent data set of patients
and controls. In the remaining group of CNVs, we found 12
additional CNV regions nominally associated with PsA risk
(p<0.05, see online supplementary table S3). However, after
multiple test correction none of these variants was statistically
signiﬁcant and therefore they were not selected for replication.
Additionally, evaluating the concordance between these CNVs
and neighbouring SNPs, we did not ﬁnd a strong linkage dis-
equilibrium (LD) (r2>0.8) with markers previously associated
with PsA, Ps or other autoimmune diseases.
CNV replication in the validation cohorts
The deletion genotypes determined using the quantitative
RT-PCR assays showed a 100% concordance with the number
of copies (0, 1 or 2) estimated using sequencing. We subse-
quently used these two RT-PCR assays to genotype an
independent cohort of 1133 patients with PsA and 1831 con-
trols. We replicated the association of the ADAMTS9-MAGI1
intergenic deletion with PsA risk (p=0.032, OR (95% CI) 1.3
(1.0 to 1.7), meta-analysis p=5.97e-5, OR (95% CI) 1.48
(1.21 to 1.82)).
Finally, comparing the frequencies of ADAMTS9-MAGI1 dele-
tion of patients with PsA with patients with PsC, we also found
a statistically signiﬁcant increase of the deletion in the group of
patients with PsA similar to that observed when comparing to
healthy controls (freq PsA=11.0%, freq PsC=7.7%, freq con-
trols=8.8%, p=0.0088). Accordingly, when comparing patients
with PsC to healthy controls, we did not ﬁnd a statistically sig-
niﬁcant difference between the deletion frequencies of groups
(p=0.33).
ADAMTS9-MAGI1 deletion sequence characterisation
Using a next-generation sequencing approach, we characterised
the deletion region in chromosome 3q14.2 associated with PsA
risk. Using a sample of 100 patients with PsA and 100 controls
selected to have a higher frequency of the deletion (in total, 100
deletion carriers vs 100 2N individuals), we determined the
physical extent and molecular nature of ADAMTS9-MAGI1 dele-
tion polymorphism. PCR capture and sequencing of the dele-
tion breakpoints revealed that the deletion removes 25 879
nucleotides (ﬁgure 1D).
In order to explore the LD pattern associated with the dele-
tion and the relation with the two ﬂanking genes, we sequenced
ADAMTS9 and MAGI1 genes and their proximal 50 and 30
untranslated regions. LD analysis showed clearly that only very
few close polymorphisms have moderate to high correlation
with the deletion (r2>0.7, n=20 SNPs, ﬁgure 3). From the
>18 000 DNA variants identiﬁed after sequencing both
ADAMTS9 and MAGI1 genes, none showed a signiﬁcant LD
with the deletion (ﬁgure 3).
DISCUSSION
GWAS based on SNPs have been highly successful in identifying
genetic variants associated with the risk to develop psoriasis and
PsA. However, there is still a large fraction of the genetic basis
of PsA that has not been identiﬁed. In the present study, we
have performed a GWAS of CNVs to identify new genomic loci
associated with PsA risk. Using a discovery cohort of Spanish
patients with PsA and controls, we have found a signiﬁcant asso-
ciation of a deletion located between ADAMTS9 and MAGI1
genes with PsA risk. We have subsequently validated this associ-
ation in an independent cohort of patients and controls.
Furthermore, using a cohort of patients with psoriasis without
concomitant arthritis we provide evidence that the deletion is
speciﬁc for PsA.
ADAM metallopeptidase with thrombospondin type 1 motif 9
(ADAMTS9) gene belongs to a family of enzymes specialised in
the degradation of the extracellular matrix. In particular,
ADAMTS9 belongs to the family of the aggrecanases (which
also includes ADAMTS-1, ADAMTS-4, ADAMTS-6,
ADAMTS-8 and ADAMTS-15) that are specialised in the deg-
radation of aggrecan, one of the main proteoglycan constituents
of the cartilage extracellular matrix.28 Aggrecanase activity has
been found to be associated with cartilage degradation in
inﬂammatory joint diseases including PsA.29 30 Importantly, in
vitro studies with chondrocytes have found that after stimula-
tion with tumour necrosis factor (TNF)-α and interleukin
(IL)-1, two of the most abundant cytokines in PsA synovium,31
Figure 3 Pairwise linkage disequilibrium (LD) between the deletion and ﬂanking sequence variants. The LD (r2) between the deletion and the
>18 000 variants identiﬁed after sequencing the regions ﬂanking the copy number variants as well as ADAMTS9 and MAGI1 loci. From these
results, it is clear that only a small proportion of close variants show a high correlation with the deletion (ie, r2>0.9, centre region of the plot) and
that there is no variant within the transcribed or the ﬂanking regions of ADAMTS9 (left region) or MAGI1 (right region) that could explain the
observed association. The 3p14.1 chromosome regions between these three loci and that were not sequenced are left blank.
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ADAMTS9 was clearly the most highly induced among all the
different aggrecanases.32 33 Consequently, genetic variants that
inﬂuence the rates of matrix turnover in the cartilage and bone
of the inﬂamed synovial joint could be crucial in determining
the level of tissue degradation in PsA.
Membrane-associated guanylate kinase, WW and PDZ domain
containing 1 (MAG1) is a member of the membrane-associated
guanylate kinase family of genes. MAGI1 is known to be
expressed in cell-to-cell contacts, acting as a scaffold protein to
stabilise cadherin-mediated adhesions and has been found to be
expressed in epithelial and endothelial tight junctions.34 MAGI1
activity has been related to several pathological junction-
associated processes, including oncogenic35 as well as virus-
associated invasiveness.36 To date, there is no evidence of a
direct implication of MAGI1 in PsA pathology or, even, in auto-
immune diseases. There is evidence, however, that MAGI1
interacts with phosphatase and tensin homologue protein, a sig-
nalling protein that participates in the negative regulation of
regulatory T cells (Tregs),37 which are master inhibitors of auto-
immunity. While the implication of Treg has been clearly
deﬁned in rheumatoid arthritis or psoriasis aetiology,38 there are
yet no studies directly analysing the implication of this key
immune regulator in PsA,39 although there is recent evidence of
their activity in the disease pathology.40 Clearly, future studies
aimed at characterising the implication of MAGI1 activity in
autoimmunity are necessary.
The deep sequence analysis found that there is very little cor-
relation between the ∼26 kb intergenic deletion associated with
PsA risk and the polymorphisms located in the transcribed
sequences and proximal regions of ADAMTS9 and MAGI1
genes. Also, our sequencing analysis clearly shows that very few
neighbouring markers are in moderate or high LD with this
CNV, suggesting that the deletion itself is the genetic variant
implicated in the aetiology of PsA. Exploration of the chromo-
some 3q14.2 deleted region in multiple biomedical databases
including ENCODE41 did not show regulatory evidence asso-
ciated with this variation. Also analysing available cis and
trans-eQTL regulatory data sets42 we did not ﬁnd an association
between this deletion and the expression of other genes.
However, it is increasingly becoming evident that a large frac-
tion of regulatory variants in the genome will be only detected
under the speciﬁc target tissue where they are expressed and,
perhaps, only under the adequate stimulation.43 For example,
ADAMTS9 expression in chondrocytes was found to be
expressed only after stimulation by proinﬂammatory cytokines
TNF and IL-1.32 Additional studies aimed at characterising the
functional implications of this deletion and their role in PsA
aetiology are therefore warranted.
To date, there is evidence that the frequency and penetrance
of multiple risk loci in PsA and psoriasis risk is different popu-
lations with different ancestries.44 It will be therefore necessary
to evaluate the frequency and effect size of this deletion at
3p14.2 in other non-Caucasian populations. Also, the associ-
ation of the ADAMTS9-MAGI1 CNV with different PsA
phenotypes could be of high relevance. In our discovery
cohort, we analysed the association of the deletion with axial
disease, arthritis mutilans, gender, age of start of the disease
and PsA familial aggregation, but we did not ﬁnd a signiﬁcant
association (data not shown). These results support that the
deletion at chromosome 3q14.2 is speciﬁcally associated to the
risk to develop PsA. It is possible, however, that once the
speciﬁc biological mechanisms inﬂuenced by this genetic
variation are identiﬁed, more targeted analysis will reveal
association to other PsA phenotypes.
In the present study, we have performed the ﬁrst CNV GWAS
in PsA. We have identiﬁed a new deletion in ADAMTS9-MAGI1
locus associated with PsA risk and we have validated this associ-
ation in an independent patient and control cohort.
Additionally, using a cohort of patients with PsC we have
demonstrated that the variation is speciﬁcally associated with
the development of PsA. The present study represents an
important step in the characterisation of the common genetic
variation associated with PsA.
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ABSTRACT
Objective Genome-wide association studies (GWAS)
have identiﬁed multiple risk loci for Crohn’s disease
(CD). However, the cumulative risk exerted by these loci
is low, and the likelihood that additional, as-yet
undiscovered loci contribute to the risk of CD is very
high. We performed a GWAS on a southern European
population to identify new CD risk loci.
Design We genotyped 620 901 genome markers on
1341 CD patients and 1518 controls from Spain. The
top association signals representing new candidate risk
loci were subsequently analysed in an independent
replication cohort of 1365 CD patients and 1396
controls.
Results We identiﬁed a genome-wide signiﬁcant
association on chromosome 22q13.2 in the intergenic
region between the RBX1 and EP300 genes (single
nucleotide polymorphism rs4820425, OR 1.27, 95% CI
1.17 to 1.38, p=3.42E-8). We also found suggestive
evidence for the association of the IFNGR2 (21q22.11),
FOXP2 (7q31), MACROD2 (20p12.1) and AIF1 (6p21.3)
loci with CD risk.
Conclusions In this GWAS performed on a southern
European cohort, we have identiﬁed a new risk locus for
CD between RBX1 and EP300. This study demonstrates
that using populations of different ancestry is a useful
strategy to identify new risk loci for CD.
INTRODUCTION
Crohn’s disease (CD, OMIM (266600)) is one of
the most common chronic inﬂammatory disorders
of the gastrointestinal tract, with an average preva-
lence of approximately 70 cases per 100 000 in
European populations.1 Compared to other chronic
inﬂammatory disorders, the contribution of genetic
variation to CD susceptibility is high (sibling rela-
tive risk, λs=17−35).2 Until very recently, however,
only NOD2 variants on chromosome 16q21 and
the IBD5 locus on chromosome 5q31 had been
convincingly associated with CD susceptibility.3
Over the past 5 years, genome-wide association
studies (GWAS) have identiﬁed more than 70 new
loci convincingly associated with CD.4 Many of
Signiﬁcance of this study
What is already known on this subject?
▸ CD is a common inﬂammatory bowel disease
with high heritability.
▸ Over the past few years, GWAS in populations
of northern European ancestry have been
successful in identifying more than 70 new loci
convincingly associated with CD risk.
▸ The cumulative risk exerted by the CD risk loci
identiﬁed so far is small and the likelihood that
additional, undiscovered loci contribute to CD
risk is very high.
What are the new ﬁndings?
▸ Using a GWAS on a large southern European
cohort we have found a new risk locus for CD
on chromosome 22q13.2 in the intergenic
region between the RBX1 and EP300 genes.
▸ We have found suggestive evidence of an
association with four additional loci with CD
risk. One of these loci, FOXP2, is signiﬁcantly
associated with UC in a large GWAS
meta-analysis of populations of northern
European ancestry.
▸ Analysing large case–control cohorts of
previously unscreened populations is a powerful
strategy to uncover the genetic architecture
of CD.
How might it impact on clinical practice in
the foreseeable future?
▸ GWAS have been fundamental in highlighting
the role of speciﬁc biological pathways in CD
aetiology, some of which had not previously
been associated with this inﬂammatory
disease.
▸ Efforts are currently under way to translate this
knowledge into new therapeutic approaches.
▸ The results from this GWAS increase our
knowledge of the genetic basis of CD and
therefore could contribute to the development
of new and improved treatments.
1440 Julià A, et al. Gut 2013;62:1440–1445. doi:10.1136/gutjnl-2012-302865
Inﬂammatory bowel disease
 on S
eptem
ber 18, 2019 at H
ospital S
an Joan D
e D
eu. P
rotected by copyright.
http://gut.bm
j.com
/
G
ut: first published as 10.1136/gutjnl-2012-302865 on 30 A
ugust 2012. D
ow
nloaded from
 
these newly discovered loci involve key pathological features of
CD, such as the epithelial barrier defence, immune cell recruit-
ment or T-cell regulation.3 5 6 Importantly, other associated loci
involve speciﬁc biological pathways, such as autophagy, which
had not previously been associated with CD pathology.7
Together, these results conﬁrm the success of the GWAS
approach for the discovery of the genetic basis of CD.
The cumulative risk exerted by the CD risk loci identiﬁed so
far is less than 30%.4 Therefore, the likelihood that additional,
undiscovered loci contribute to CD risk is very high. GWAS on
large cohorts of previously unscreened populations should
therefore be a powerful means to identify these new risk var-
iants. In the present work, we have performed a GWAS on a
large case–control cohort of southern European ancestry to
identify new CD genetic risk factors. We have subsequently per-
formed a replication study on an independent case–control
cohort on those loci showing the strongest signiﬁcance signals.
Using a combined cohort of 5620 individuals, we have found a
new risk locus for CD on chromosome 22q13.2 in the inter-
genic region between the RBX1 and EP300 genes as well as sug-
gestive evidence of an association with four additional loci.
MATERIALS AND METHODS
Study subjects
To identify new loci associated with CD risk using the GWAS
approach, we recruited 1341 CD patients and 1518 controls
from the Spanish population. Both cohorts were collected as
part of the Immune-Mediated Inﬂammatory Disease
Consortium (IMIDC) between June 2007 and December 2010.
The IMIDC is a network of Spanish researchers working on the
genomic basis of immune-mediated inﬂammatory diseases. For
this study, a total of 15 gastroenterology departments from dif-
ferent hospitals participated. All selected CD patients fulﬁlled
the standard Lennard–Jones diagnostic criteria for CD.8 To
increase the homogeneity of the case cohort, only patients with
at least 5 years of follow-up since diagnosis were included.
Control individuals were recruited from blood bank donors
attending at 13 hospitals from different regions in Spain in col-
laboration with the Spanish National DNA Bank. All the con-
trols included in this study were screened for the presence of
CD or any autoimmune disorder, as well as for a family history
of autoimmune disorders in ﬁrst-degree relatives. Individuals
with an autoimmune disease or a family history of autoimmune
disease were excluded. To increase the hypernormality in this
cohort, only control individuals who were more than 30 years
old and who fulﬁlled the previous criteria were included in the
study. In total, 1518 controls, 40% of whom were women, were
genotyped. Of note, more than 95% of the control individuals
were over 40 years old at the time of recruitment (mean age
±SD 49.7±8 years).
All case and control individuals in the GWAS and replication
cohorts were Caucasian European and born in Spain. In the
Spanish population, the impact of genetic variation due to
ancestry is relatively small and comparable to other central
Europe populations.9 10 However, to reduce the potential
impact of recent demographic events that could introduce strati-
ﬁcation, the grandparents of both patients and controls also had
to be born in Spain.
A total of 1365 CD patients and 1396 controls was used to
validate the most signiﬁcant loci identiﬁed in the GWAS phase.
CD patients were selected using the same clinical and epidemio-
logical selection criteria as for the GWAS. Of the replication
cohort patients, 60% were collected from the IMIDC, whereas
the remaining 40% were obtained from the ENEIDA project
collection.11 Control individuals were selected from the Spanish
DNA bank repository using the same epidemiological criteria as
in the discovery phase.
Informed consent was obtained from all participants, and
protocols were reviewed and approved by local institutional
review boards. This study was conducted in accordance with the
Declaration of Helsinki principles.
Genotyping and quality control
The genome-wide scan was performed using Illumina Quad610
Beadchips (Illumina, San Diego, California, USA) on 1341 CD
patients and 1518 controls. The Quad610 arrays scan over
550 000 single nucleotide polymorphisms (SNP) and have
approximately 60 000 probes speciﬁc for copy number variant
(CNV) detection. GWAS genotyping was performed at the
Centro Nacional de Genotipado (CeGen, Spain). After exclud-
ing mitochondrial, X and Y chromosome SNP, a total of
600 470 markers was considered for GWAS analysis, of which
17 879 were exclusively CNV probes. The SNP genotype
calling was performed using Illumina GenomeStudio software
v2010.1 (Illumina, San Diego, California, US), and CNV calls
were performed using CNstream software.12 Only samples that
had a greater than 95% genotype completion rate were consid-
ered for analysis (99.6% of samples), and only SNP that had a
greater than 95% call rate (98.3% of SNP) and a minor allele
frequency (MAF) greater than 0.05 (94.9% of SNP) and that
showed Hardy–Weinberg equilibrium (99.6% of SNP, p>0.0001
in controls) were considered for association analysis. Also, SNP
showing a differential rate of missingness between cases and
controls (0.7% SNP signiﬁcantly different at p<1e-7) were
excluded from any further analysis. From this set of QC-ﬁltered
SNP (n=508 934), we selected those markers showing low pair-
wise linkage disequilibrium (LD; r2<0.2, n=118 294 SNP) to
infer the main axis of variation using the principal component
approach implemented in EIGENSTRAT software.13 Using the
10 ﬁrst principal components, n=82 outlying samples were
excluded. Supplementary ﬁgure S1A (available online only)
shows the case and control distribution according to the ﬁrst
and second principal components after excluding the outliers.
Supplementary ﬁgure S1B (available online only) also shows the
projection of our GWAS cohort onto the eigenvectors calculated
from the Hapmap reference samples. The genomic inﬂation
factor was close to 1 (λ=1.052, see supplementary ﬁgure S2,
available online only), and consequently, no adjustment was per-
formed over the GWAS association statistics.
Replication genotyping was performed at the HudsonAlpha
Institute for Biotechnology (Huntsville, Alabama, USA) using
the TaqMan OpenArray Genotyping System (Applied
Biosystems, Foster City, California, USA) on 1365 CD patients
and 1396 controls. Similar quality control measures were
applied, including genotyping call rate over 95%, sample com-
pletion rate over 90%, Hardy–Weinberg disequilibrium p value
of control group p>0.001 and MAF greater than 5%. In the
control group, three markers were excluded for low genotyping
call rate, and one was excluded for signiﬁcant Hardy–Weinberg
disequilibrium . For the remaining SNP (n=28), the average call
rate was 99%.
Statistical analyses
Using the set of QC-ﬁltered GWAS data, we performed a case–
control association analysis using an allelic χ2 test of association
using PLINK software V.1.07.14 A total of 32 SNP was selected
for replication. Of these, 31 SNP were the most signiﬁcant asso-
ciation signals in the GWAS study (p<6E-5) representing new
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candidate loci for CD. From the group of markers showing a
moderate level of association (p>6E-5 to p<5E-4), we also
selected SNP rs1869839 from the FOXP2 locus. Recently, the
forkhead box (FOX) transcription factors FOXP1 and FOXP3
were found to participate in key immune regulatory processes,
and therefore we considered FOXP2 to be a plausible candidate
gene for this autoimmune disease.15 16 The one-tailed p value
of replicating markers was combined with the discovery p value
using Fisher’s combined probability method to produce the
combined p value from both study cohorts.
We evaluated 71 loci associated with CD risk in previous
GWAS on populations of northern European ancestry.4 For each
locus, we estimated the statistical power for replication of our
GWAS cohort using genetic power calculator software.17 For
each of the known CD risk loci, we selected the marker
showing the highest evidence of an association, as described in
the recent large-scale GWAS meta-analysis performed by Franke
et al.4 Power estimation was performed using the reported allele
frequencies and risk estimates and considering a signiﬁcant level
of replication at α=0.05. Next, for each of the 71 CD risk loci,
we performed an allelic test of association to determine their
association in our GWAS cohort. Of the 71 SNP, 39 were not
directly genotyped by the Illumina Quad610 microarray and
had to be imputed. For genotype imputation, we used MACH
imputation software on Caucasian European Hapmap phased
data (ie, CEU) as described previously.18 19
RESULTS
Table 1 summarises the main epidemiological variables of both
the GWAS and the replication cohorts. After QC ﬁltering, a
total of 508 934 SNP was tested for their association with CD
risk using 1277 patients and 1488 controls. Thirty-one out of
the 71 previously known CD risk loci were replicated at
p<0.05 (see supplementary table S1, available online only).
After discarding previously associated loci, we found a new
strong association signal on chromosome 22q13.2 (SNP
rs4820425, OR 1.36, CI 1.21 to 1.54, p<5E-7) in the inter-
genic region between the genes for the RING-box protein 1
(RBX1) and the E1A binding protein p300 (EP300) (ﬁgure 1).
The second most signiﬁcant new association signal in the CD
GWAS was found in a SNP in the third intron of the gene for
the interferon gamma receptor 2 (IFNGR2) (rs2834215, OR
0.88, CI 0.79 to 0.98, p<1.3 E-6). In addition, 29 other loci
were identiﬁed at signiﬁcance levels of p>1.3 E-6 to p<6E-5.
From the group of SNP showing a moderate level of association
(p>6E-5 to p<5E-4), we also selected SNP rs1869839 from
the FOXP2 locus (p<2.2 E-4) for replication.
Using an independent cohort of 1365 CD patients and 1396
controls, the SNP from RBX1-EP300, IFNGR2, AIF1,
MACROD2 and FOXP2 were nominally replicated (p<0.05,
table 2) (see supplementary ﬁgure S3, available online only).
Applying a standard genome-wide signiﬁcance threshold of
5E-8 for the combined GWAS and replication signals, we found
that SNP rs4820425 from RBX1-EP300 surpassed this thresh-
old. The second most associated SNP in the GWAS analysis,
IFNGR2, was also signiﬁcant in the combined sample, although
it did not reach a genome-wide level of statistical association
(pcombined=4.43E-07, OR 0.82, CI 0.76 to 0.89).
A total of 2674 CNV was identiﬁed in our GWAS cohort
using CNstream software. For this group of CNV, we found no
evidence of an association with CD risk at p<1E-4 (see
supplementary ﬁgure S4, available online only).
With the sample size of our GWAS case–control cohort and
according to previously reported effect sizes, we estimated a
greater than 80% power of replication in 17 out of 71 known
CD risk loci (see supplementary table S1, available online only).
Testing all 71 SNP in our GWAS cohort, we replicated the asso-
ciation of 31 of these markers with CD risk (p<0.05, see
supplementary table S1, available online only).
The associated RBX1-EP300 locus SNP, rs4820425, is 62.3 kb
from the RBX1 30 end and 57.3 kb from the EP300 50 end. The
LD patterns in this region both in our GWAS data and in the
Hapmap CEU data indicate that the haplotype block that
includes rs4820425 is close to the EP300 promoter region (see
supplementary ﬁgure S5, available online only). Examining pub-
licly available expression quantitative trait locus (eQTL) data-
bases, we found that the strongest eQTL for EP300 gene
Table 1 GWAS and replication cohort epidemiological and
clinical statistics
GWAS CD
GWAS
controls
Replication
CD
Replication
controls
% Female 50% 40% 49% 48%
Age (median±SD) 42.6 (12.8) 49.7 (8) 42.9 (14.6) 44.4 (14.5)
% Familial
autoimmunity
32.7% 0% 32.9% 0%
% Familial IBD 17.8% 0% 17.5% 0%
% Familial CD 11.7% 0% 12% 0%
% ≥5 years of disease
duration
100% NA 93% NA
Age at diagnosis (IQR) 22–37 NA 22–41 NA
Familial autoimmunity: presence of one or more first or second order relatives with
an autoimmune disease (including IBD).
CD, Crohn’s disease; GWAS, genome-wide association study; IBD, inflammatory
bowel disease; NA, not applicable.
Figure 1 Recombination plot showing the association between
Crohn’s disease risk and the RBX1-EP300 locus. Plot showing the
pattern of associations at chromosome 22q13.2 in the genome-wide
association studies stage, the recombination rate (build 36 HapMap
Caucasian European) and the genes located in the region. The single
nucleotide polymorphism (SNP) showing the main signal is labelled as
a blue diamond (rs4820425); other SNP are colour-coded according to
their linkage disequilibrium with rs4820425 (red r2>0.8, orange 0.5–
0.8, grey 0.2–0.5, white <0.2).
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expression is cis SNP rs4821990 (p<1.6E-7), which is only
7.4 kb from rs4820425. This gene expression correlation was
identiﬁed on a recent eQTL GWAS performed on transcrip-
tomes from circulating monocytes of 1490 individuals geno-
typed with Affymetrix Genome-Wide Human SNP Array 6.0.20
Although this genotyping platform does not include the SNP
associated in our study, both SNP are in perfect LD (r2=1, CEU
Hapmap data), suggesting that they represent a common eQTL
association with EP300 expression.
Evaluating the signiﬁcance of the loci associated in our study
with the association data available at the International IBD
Genetics Consortium (IIBDGC, http://www.ibdgenetics.org/), we
were able to conﬁrm that RBX1-EP300 is also associated with
CD risk in this large meta-analysis (p=0.0035, see
supplementary data, available online only). As in our GWAS
study, SNP rs4820425 is the strongest association signal within
the RBX1-EP300 locus.
The other four loci nominally replicated in our study do not
attain genome-wide signiﬁcance, and therefore, additional evi-
dence is necessary to conﬁrm their association with CD risk. In
the IIBDGC data, SNP rs2834215 (IFNGR2), rs1869839
(FOXP2) rs6105269 (MACROD2) are not signiﬁcantly asso-
ciated (p>0.05). Importantly, however, other markers in the
same LD block show nominally signiﬁcant association with CD
(p<0.001, see supplementary ﬁgure S5, available online only).
In particular, SNP rs2284553 from the ﬁrst intron of IFNGR2
shows a remarkable nominal association signal with CD risk in
northern European ancestry cohorts (p<1.7E-5). The fact that
the LD blocks from Hapmap CEU data encompass our associ-
ation signal as well as the signiﬁcant signals from the IIBDGC
data increases the likelihood that these are risk loci for CD. This
result also raises the possibility that as yet unidentiﬁed genetic
variants within these loci are associated with CD. Therefore,
additional studies using more dense sequence information in
these regions will be needed to conﬁrm deﬁnitively their impli-
cation with disease risk.
In a recent meta-analysis of three GWAS in CD6 a genome-
wide association was identiﬁed for the ﬁrst time within the HLA
region (SNP rs3763313, p<5e-8). In our GWAS, however, the
association for this SNP was considerably lower (p=0.033).
Instead, our strongest signal within the HLA region was 800 kb
upstream, close to the AIF1 gene (SNP rs9348876, p=5.3e-6).
Importantly, when the previous CD meta-analysis was expanded
to include three additional GWAS4 the strongest signal within
the HLA region was notably closer to our signal (SNP
rs1799964, at only 32 kb from SNP rs9348876). SNP
rs1799964 was not available in our genotyping platform;
however, after imputing its genotype we found a lower signiﬁ-
cance compared to our most associated SNP (p=0.0007).
Furthermore, conditioning the association of AIF1 SNP
rs9348876 to rs1799964 genotype, we found that the associ-
ation with CD risk was still strong (p=0.0001). Therefore,
while both our study and the meta-analysis of Franke et al4
identify the strongest signal close to the AIF1 gene, our study
further suggests that the risk conferred by this region does not
depend on a single variation but, instead, it may be inﬂuenced
by multiple independent genetic variants in this region.
Many CD risk genes are also associated with ulcerative colitis
(UC) susceptibility.21 On evaluating the association signals in the
IIBDGC meta-analysis for UC, we found that EP300, IFNGR2
and MACROD2 do not seem to be common risk factors for UC.
The FOXP2 SNP, rs1869839, however, shows signiﬁcant evi-
dence of replication with UC risk (p=0.00051). The same allele
associated with CD risk in our study is associated with UC in
that meta-analysis, suggesting a common biological pathway for
both diseases. To our knowledge, this is the ﬁrst study to suggest
an association of the FOXP2 locus with an autoimmune disease.
DISCUSSION
Using a GWAS on a large case–control cohort of southern
European ancestry, we have identiﬁed a new genome-wide sig-
niﬁcant risk locus for CD in the intergenic region between the
RBX1 and EP300 genes on chromosome 22q13.2. We have also
found suggestive evidence of an association with four other loci
not previously associated with CD risk. As expected, a signiﬁ-
cant number of loci previously associated with CD in GWAS in
populations of northern European ancestry were also associated.
As more large-scale GWAS are performed in populations of dif-
ferent ancestry, we can expect the number of newly identiﬁed
CD risk loci to increase.
The EP300 gene encodes an acetyltransferase that interacts
with several transcription factors.22 23 Mutations in this gene
have been associated with colorectal cancer (OMIM
#114500).24 The EP300 protein has been shown to interact
with STAT3, a risk locus for CD,25 and therefore, it could con-
tribute to CD risk through the previously associated IL-23 sig-
nalling pathway.26 There is functional evidence, however, that
EP300 is a critical factor in CD4 T-cell differentiation, stabilis-
ing Th-inducing POK, a key transcription factor in the CD4
lineage.27 More important, there is recent evidence that EP300
is crucial for the FOXP3-dependent differentiation of CD4
regulatory T cells.28 Therefore, genetic variations inﬂuencing
EP300 regulation could affect self-tolerance and consequently
increase the risk of an autoimmune process. Very recently,
genome-wide eQTL analyses on immune cell transcriptomes
have shown that lysozyme gene (ie, LYZ) expression in mono-
cytes is tighly regulated by a promoter SNP that is likely to
harbour an EP300 protein binding site.29 Gene expression cor-
relation between LYZ and EP300 under the eQTL ancestral
allele support this ﬁnding. Of relevance, we found suggestive
Table 2 GWAS and replication association statistics
SNP Chr Coordinate Gene(s)
Minor
allele
MAF
cases
MAF
controls
OR GWAS
(95% CI) p GWAS
OR replication
(95% CI)
p
Replication
OR combined
(95% CI)
p
Combined
rs9348876 6 31683255 AIF1 T 0.09 0.06 1.63 (1.32 to 2) 5.30E-06 1.22 (1 to 1.5) 0.029 1.41 (1.22 to 1.63) 2.60E-06
rs1869839 7 114144779 FOXP2 G 0.32 0.36 0.81 (0.72 to 0.9) 0.00021 0.85 (0.76 to 0.95) 0.0022 0.83 (0.77 to 0.9) 7.30E-06
rs6105269 20 14348165 MACROD2 A 0.39 0.34 1.25 (1.12 to 1.39) 7.92E-05 1.13 (1.01 to 1.26) 0.017 1.19 (1.1 to 1.28) 1.99E-05
rs2834215 21 33718756 IFNGR2 A 0.36 0.42 0.76 (0.68 to 0.85) 1.29E-06 0.88 (0.79 to 0.98) 0.012 0.82 (0.76 to 0.89) 2.89E-07
rs4820425 22 39761288 RBX1-EP300 A 0.3 0.24 1.36 (1.21 to 1.54) 3.76E-07 1.18 (1.04 to 1.33) 0.0043 1.27 (1.17 to 1.38) 3.42E-08
GWAS, genome-wide association study; MAF, minor allele frequency in the GWAS cohort.
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evidence that RBX1-EP300 locus SNP, rs4820425, is a strong
cis-eQTL for EP300, and this evidence was also found speciﬁc-
ally in monocytes. Therefore, these results also suggest that
EP300 could contribute to CD risk through the regulation of
this antimicrobial peptide in monocytes/macrophages.30
The analysis of populations with different genetic back-
grounds can increase our ability to identify the genetic risk com-
ponents for CD. To date, however, most large-scale studies of
CD have focused on populations of northern European
origin.3 4 6 31 32 More recently, a GWAS performed on a popu-
lation of Jewish origin has identiﬁed new risk loci for CD.33
Our study is the ﬁrst GWAS performed on a large case–control
cohort of southern European ancestry. The observation of
genetic heterogeneity with CD risk factors within European
populations is not new and has previously been demonstrated
for NOD2.34 In particular, it has been shown that the NOD2
Leu1007fsinC frameshift variation is substantially lower in
northern populations such as Ireland (4%) or Sweden (2%) but
is frequent in southern countries such as Spain (14%) or France
(12%). A more extreme case for population-speciﬁc variation in
CD genetic aetiology is present in the Asian population, in
which there has been scarce replication of risk loci identiﬁed in
European populations.35 For IRGM1 locus, this lack of associ-
ation even extends to major functional differences between both
populations, suggesting the interplay of complex genetic
mechanisms in the risk of developing CD.36 Therefore, as yet
unidentiﬁed genetic and environmental factors could inﬂuence
our ability to identify new risk loci for CD.
In a highly heterogeneous disease such as CD, other factors
besides the population origin of samples can inﬂuence the
power to detect genetic associations.37 The existence of several
subphenotypes strongly associated with one or another risk
variant could impair or maximise our ability to associate them
with CD risk.38 39 The study, for example, of early-onset
patients has provided additional power to identify new genetic
variants associated with CD risk that could not be detected by
previous genome-wide scans.40 Therefore, additional studies
evaluating the association of genetic factors with speciﬁc CD
clinical subphenotypes are needed. In our study, both the GWAS
and the replication cohorts had very similar demographic and
clinical parameters, which should have reduced the level of
phenotype heterogeneity and consequently increased our power
to identify and replicate new genetic variants. Finally, we used
hypernormal controls (ie, individuals with a low liability to
develop an autoimmune disease) that, while a more costly
recruitment strategy, can lead to a substantial gain in statistical
power.31
In summary, this CD GWAS on a southern European popula-
tion has led to the identiﬁcation of a novel risk locus for this
disease in the region between RBX1 and EP300. Our study has
identiﬁed suggestive evidence for four additional risk loci for
CD, one of which, FOXP2, could also be a risk factor for UC.
This study increases the knowledge of inﬂammatory bowel
disease risk factors and demonstrates the power of using popula-
tions of different origin.
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ABSTRACT
We present Nucleosome Dynamics, a suite of pro-
grams integrated into a virtual research environment
and created to deﬁne nucleosome architecture and
dynamics from noisy experimental data. The pack-
age allows both the deﬁnition of nucleosome archi-
tectures and the detection of changes in nucleoso-
mal organization due to changes in cellular condi-
tions. Results are displayed in the context of ge-
nomic information thanks to different visualizers and
browsers, allowing the user a holistic, multidimen-
sional view of the genome/transcriptome. The pack-
age shows good performance for both locating equi-
libriumnucleosome architecture and nucleosomedy-
namics and provides abundant useful information in
several test cases, where experimental data on nu-
cleosome position (and for some cases expression
level) have been collected for cells under different ex-
ternal conditions (cell cycle phase, yeast metabolic
cycle progression, changes in nutrients or difference
in MNase digestion level). Nucleosome Dynamics is
a free software and is provided under several distri-
bution models.
INTRODUCTION
Eukaryotic chromatin is organized in a hierarchical man-
ner, where the basic structural units are repetitive elements
named nucleosomes. Each of them is defined by around
147 base pairs of DNA wrapped around a protein octamer,
the histones. The position of the nucleosomes in the cell is
not random and recurrent patterns have been detected in
cell populations (1–3), indicating a maintenance of the nu-
cleosome architecture which seems to be crucial for a cor-
rect regulation of genome activity (4). The protein octamer
serves as an anchoring point for proteins recognizing his-
tone epigenetic signals, while unwrapped DNA is targeted
by transcription factors and enhancers (5,6). Thus, nucleo-
somes shifting due to alterations in the sequence (7), DNA
methylation (8) or the action of chromatin remodelers (5,9–
13) can result in dramatic changes in gene expression. Char-
acterizing such changes is crucial for the understanding of
the connection between chromatin structure and genome
functionality (6).
Experimental determination of nucleosome positioning
is typically performed by treating a group of cells (in
the range 106-109) with enzymes acting on nucleosome-
free DNA. ATAC-seq (14) uses a hyperactive transposase
for tagging nucleosome-free DNA segments for sequenc-
ing (the linkers). MNase-seq, the most widely used tech-
nique for nucleosome localization, uses Micrococcal nucle-
ase to degrade linker DNA preserving the DNA segments
wrapped in the nucleosomes, which are then sequenced.
Both MNase-seq and ATAC-seq, after filtering nucleoso-
mal reads by size (14), provide at the end the same type of
information: DNA reads that need to be grouped into in-
dividual nucleosomes using a variety of computational ap-
proaches (15–18), which in all cases suffer from the intrinsic
dispersion in read coverage. The resulting nucleosomemaps
show well defined depleted regions (the nucleosome free re-
gions, NFR), well-positioned (W) nucleosomes, and a large
number of ‘fuzzy’ (F) nucleosomes giving partial protection
signals longer than 147 bps (19). Fuzzy positioning signals
are the result of nucleosomes not being in exactly the same
*To whom correspondence should be addressed. Tel: +34 93 40 37156; Fax: +34 93 40 37157; Email: modesto.orozco@irbbarcelona.org
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genomic position in the cell population, and are intrinsically
difficult to annotate by any nucleosome calling algorithms
(15,17). While it is known (20,21) that this technique can be
affected by MNase concentration and sequence-preference
biases that affect the detection of the so called ‘fragile’ nu-
cleosomes, it is still the most widely used to detect nucleo-
some positioning for its versatility and accuracy. In 2012,
Brogaard et al. developed a chemical cleavage method that
provides a very accurate positioning of nucleosomes (22).
However, this technique requires to do genetic engineering
replacing the endogenous histone H4 (or H3 (23)) by a mu-
tated version, therefore restricting its use (24–27). More-
over, it has been shown that the MNase sequence bias can
be corrected using digested naked DNA as baseline (20,21),
obtaining more pronounced nucleosome coverage peaks.
The noisy nature of experimental data such as MNase-
seq, makes very difficult to compare nucleosome architec-
ture in two samples, as the signal is masked by the intrin-
sic fuzziness of the maps. Methods available such as DAN-
POS andDimnp (15,28) can detect only a limited number of
changes affecting large percentage of the cells, as they work
at the level of the fragment coverage, missing the opportu-
nity to work with the raw data: the fragments themselves.
We present here Nucleosome Dynamics, a complete vir-
tual framework to characterize the structure and dynamics
of nucleosome architectures. The package consists of two
main blocks: an improved version of our nucleR algorithm
for nucleosome location (17), and NucDyn, an algorithm
specifically created to detect changes (shifts, evictions and
insertions) in nucleosome architectures based on the direct
processing of raw data (the sequencing reads) obtained from
pairs of experiments. The Nucleosome Dynamics package
(available under the Apache 2.0 License) can be installed
from the source code, obtained from BioConductor (29), or
run as a web tool hosted by the MuGVRE workspace (30)
as well as in a Galaxy server (31), where additional analysis
algorithms, browsers and visualization tools are included.
MATERIALS AND METHODS
Package overview
The input data for Nucleosome Dynamics is one or sev-
eral files containing sequence reads aligned to the reference
genome and stored in BAM format. The user can select (see
Figure 1) between: (i) processing a single file to define the
consensus nucleosome architecture using an extended ver-
sion of nucleR (17) or (ii) detecting changes in nucleosome
distribution between two experiments, by comparing pairs
of mapped sequence files using the newly developed Nuc-
Dyn module. For a complete description of the parameters
of the available functionalities, see Supplementary Table S1.
In theMuGVRE implementation (see Table 1), the user has
access to a wide range of analysis and visualization tools to
characterize the nucleosome patterns, their changes across
different conditions, and to put all the data in the context
of other information mapped to the genome (genome struc-
ture, expression, epigenetic signals, etc). We have evaluated
the performance of nucleR and NucDyn generating syn-
thetic nucleosome maps and have tested their descriptive
power using publicly available nucleosome positioning ex-
perimental data.
Single experiment analysis
Nucleosome positioning and coverage. BAM files from a
single MNase-seq experiment are processed to define nu-
cleosome coverage, which can be directly visualized using a
genome browser (Figure 2A) or processed to obtain nucle-
osome positions. Accordingly, following signal theory the
read coverage is described as a combination of periodic
waves, which are then subjected to Fast Fourier Transfor-
mation (FFT) to remove the high frequency components re-
sponsible for the noise (see Supplementary Figure S1). The
parameters for FFT filtering can be adjusted taking into ac-
count the nucleosome repeat length and noise level of each
organism and cell type (see Supplementary Table S1). Clean
profiles are processed to annotate the nucleosome dyads (lo-
cated at the local maxima of the distributions). Putative nu-
cleosomes are then scored based on the shape of the asso-
ciated peaks (see Supplementary Figure S1). Those leading
to sharp signals are labelled as well-positioned (W) nucleo-
somes (high localization score), while flat peaks are labelled
as ‘fuzzy’ (F) nucleosomes (low localization score). Once all
nucleosomes are localized, the software analyses the nucleo-
some architecture (see Supplementary Figure S2A) around
the transcription start sites (TSS) and classifies the nucle-
osome architecture for each gene based on (19): the exten-
sion of the nucleosome free region (NFR) around the core
promoter (open (o), closed (c) or missing −1 or +1 nucleo-
some) and the degree of localization of the +1 (downstream
the TSS) and−1 (upstream the TSS) nucleosomes (see Sup-
plementary Figure S2A). Data are presented at the individ-
ual gene level as well as summarized at global level (Fig-
ure 2). Nucleosome Dynamics performs a global detection
of all NFRs, as these regions usually are the main recog-
nition sites for effector proteins, and well-defined and ex-
tended NFRs typically signal active regions in the genome.
Periodicity at coding regions. The software evaluates the
periodicity in the nucleosome pattern inside the genes, fol-
lowing signal propagation theory from two ‘emitting sites’
located at well-positioned nucleosomes. The first signal
comes from the 5′ end of the gene (the +1 nucleosome lo-
cated just downstream the TSS) and the second from the
3′ end of the gene (the –last nucleosome located just up-
stream the transcription termination site; TTS). We assume
that both signals proceed in opposite directions (from +1
to –last nucleosome) following an exponential decay peri-
odic function (32).We found out that when the +1 and –last
originated waves are in phase the signals sum up and nu-
cleosomes are well located inside the gene body, while when
they are in antiphase the signals cancel out and the gene typ-
ically shows fuzzy nucleosomes. The periodicity (T) of the
signal is obtained by maximizing the autocorrelation func-
tion (Equation 1: see an example in Supplementary Figure
S2):
R (T) = ∫X1X2 I(x) ∗ I(x− T)dx (1)
whereX1 andX2 are the intervals of thewindow, I(x) stands
for the coverage. This value will be dependent on the nucle-
osome repeat length of each species and cell type (see Sup-
plementary Table S2 for suggested T in different cell types).
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Figure 1. Analysis pipeline for Nucleosome Dynamics. A single MNase-seq experiment can be analysed, obtaining: nucleosome calls with nucleR, their
fuzzy/well-positioned classification and stiffness estimation, Nucleosome Free Regions location, classification of TSS according to−1 and +1 nucleosomes,
and nucleosome phasing along the gene body. Comparing two MNase-seq experiments, NucDyn identifies hotspots of changes (SHIFT +, SHIFT -,
INCLUSION and EVICTION), and reports a significance score of the difference in the coverage profiles at base-pair level. Summary statistics per gene
as well as genome-wide are also reported for each calculation.
Table 1. Implementation models for Nucleosome Dynamics
Code distribution
Standalone installation Nucleosome Dynamics CLI https://github.com/nucleosome-dynamics/nucleosome dynamics
nucleR R package https://github.com/nucleosome-dynamics/nucleR Bioconductor:
http://bioconductor.org/packages/nucleR/
NucDyn R package https://github.com/nucleosome-dynamics/NucDyn Bioconductor:
(in review)
Containerized installation Docker https://github.com/nucleosome-dynamics/docker Docker-hub:
mmbirb/nucleosome-dynamics
Singularity https://github.com/nucleosome-dynamics/
nucleosome dynamics singularity Singularity-hub:
https://singularity-hub.org/collections/2579
Platforms in use
MuG Virtual Research Environment https://vre.multiscalegenomics.eu/workspace/?from=nucldynwf
Galaxy Platform https://dev.usegalaxy.es (in development) Galaxy ToolShed:
https://toolshed.g2.bx.psu.edu/repository?repository id=
822e9c879cf92fd0
A ‘phased’ gene is defined when the distance between +1
and –last nucleosome is close to amultiple of T (Supplemen-
tary Figure S2B). An ‘antiphased’ gene is defined when the
modulus of the ratio between the distance of the +1 and –
last nucleosomes and T is close to T/2 (Supplementary Fig-
ure S2C). The package provides a theoretical nucleosome
map based on signal propagation theory with +1 and –last
nucleosomes as emitting sites. Comparison of the predicted
and the real nucleosome maps helps to detect anomalies in
the gene nucleosome distribution emerging from interacting
proteins or from the effect of the remodelling machinery.
Nucleosome stiffness. Nucleosome Dynamics also analy-
ses the sliding propensities of nucleosomes by computing its
apparent resistance to be displaced along the sequence. For
this purpose, we map the original reads around located nu-
cleosomes and estimate the normalized Gaussian that bet-
ter fits the distribution of reads (see Supplementary Figure
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Figure 2. Visualization of Nucleosome Dynamics results in MuGVRE. (A) Nucleosome positioning along ACE2 (YLR131C) gene from S. cerevisiae
between G2 and M cell cycle phases (a) YLR131C open reading frame; (b) ACE2 full length transcripts; (c), (c’) coverage of MNase-seq reads aligned to
reference genome (in G2 andM phase, respectively); (d), (d’) nucleosome calls obtained with nucleR (G2 andM phase, respectively); (e) NFR coordinates
in G2 phase; (f) prediction of the nucleosome coverage along each gene, using signals from +1 and -last nucleosomes; (g) genes shown as coloured boxes
according to the phasing between the +1 and -last nucleosomes; (h) TSS classification based on nucleosomes −1 and +1 (W, F, missing) and the distance
between them (open or close) represented as coloured boxes, with an arrow indicating the direction of the gene; (i) nucleosomes are coloured by their
apparent stiffness value: darker blue nucleosomes are more stiff and lighter are less stiff; (j) significance of the differences in nucleosome coverage between
G2 and M phases (-log10 of the p-value) (k) movement hotspots represented as colour coded boxes: purple for shift +, blue for shit -, green for inclusion
and red for eviction; (l,m, n, o) Tracks from publicly available data representing (l) TATA elements (Rhee et al., 2012), (m) TFIIB binding sites (Mayer
et al., 2010), (n) H3K4me3 histone mark enrichment (Liu et al., 2005) and (o) gene expression changes during cell cycle (Deniz et al., 2016). (B) Detailed
view around a hotspot identified by NucDyn in chrXII. (C) Genome wide statistics of NFR width around TSS, in G2 phase. (D) Genome wide frequency
of changes detected by NucDyn between G2 and M.
S2) fromwhich stiffness is derived by the elastic approxima-
tion as shown in Equation (2):
θ = 2kBT
sd2
(2)
where kBT is the thermal energy at room temperature and
sd is the standard deviation of the Gaussian fitted to reads
associated to the nucleosome.
Defining changes in nucleosome distribution
Pairs of BAM files are processed to determine changes in
the nucleosome architecture between two experiments. For
this purpose (see Supplementary Figure S3) the program
pairs the reads obtained from one experiment to the other
to discard those that are unchanged. It also removes reads
that share the same starting or ending point or those that
can be fitted in longer read in the paired experiment, as
they are likely to be generated by spurious differences in
Downloaded from https://academic.oup.com/nar/advance-article-abstract/doi/10.1093/nar/gkz759/5557727 by guest on 18 September 2019
Nucleic Acids Research, 2019 5
nuclease degradation activity. The remaining reads are then
paired between the two experiments using a dynamic pro-
gramming algorithm designed to maximize: (i) the number
of matches, (ii) the proximity in the middle points of the
paired reads, (iii) the assignment of the paired reads to the
same nucleosome. To achieve these objectives the dynamic
programming highly penalizes gaps and scores read pairs in-
versely proportional to their distance, with a –infinite score
when the distance between the middle point of the reads is
longer than half the length of the nucleosome. The final out-
put of the procedure is a set of read pairs shifted in one
experiment with respect to the other. These shifts are ac-
cumulated to define hotspots that are further analysed to
determine their statistical significance as markers of shifts
in the nucleosome architecture.
A second type of changes detected by the program is re-
lated to differences in occupancy (insertions and evictions)
between the two experiments, that are determined directly
from the coverage. To reduce the impact of experimental
noise we analyse the coverage data by computing a Z-score
for every position x across the genome, normalizing it in 10
000 bp windows, which allows us to find locally normalized
differences in coverage (Equation 3).
Z = m− E (m)
(V (m))
1
2
(3)
where m is the number of reads covering position x in ex-
periment 1, E (m) = n f (with f being the fraction of total
reads in the window (N) that corresponds to experiment 1
(M) and n is the number of reads covering position x in both
experiments) and V(m) is the expected variance of a hyper-
geometric distribution, i.e. V (m) = n f (1 − f ) N−nn−1 . Posi-
tive Z-score peaks mean that at that point the read cover-
age found at experiment 1 is higher than the coverage at ex-
periment 2 and an eviction hotspot is annotated. Similarly,
negative Z- peaks signal inclusions.
The statistical significance of the detected hotspots
(shifts, inclusions and evictions) is scored using theP-values
derived from Fisher’s test from a contingency table between
the reads in each experiment (columns) and the reads at a
given position compared to reads within the window (rows):
Exp 1. Exp. 2 Total
Covering x M – m N –M – n + m N – n
Not covering
x
m n – m n
Total M N –M N
Software availability and implementation
The Nucleosome Dynamics package is available in dif-
ferent deployment models to fulfil the needs of different
users. Moreover, it is also offered as a service in two dif-
ferent research platforms. All available distributions are
explained at Nucleosome Dynamics landing page: http:
//mmb.irbbarcelona.org/NucleosomeDynamics/, and sum-
marized in Table 1.
Code distributions.
• Nucleosome Dynamics is written in R and composed of
two packages (nucleR and NucDyn), and a series of R
wrappers providing a unified interface to such core func-
tionalities and other additional analyses (TSS classifica-
tion, NFR, Phasing, Stiffness, etc., see above). Source
code and documentation are available for standalone in-
stallation (see Table 1). Both nucleR and NucDyn pack-
ages are also distributed via BioConductor. Although
the native R interface is recommended for experienced R
users, other deployments built on top of the R software
are also provided for further accessibility and portability.
• Nucleosome Dynamics package depends on a series of
other R packages and helper applications. To minimize
the possibilities of collision with existing installations,
and to avoid installation issues to the non-experts, the
packages are offered as software containers in both, the
well-known Docker implementation and the Singularity
format, the latter intended for multi-user systems where
running Docker containers natively is not trivial – i.e.
HPC systems. A single container allows the user to obtain
all functions of the package directly from the command-
line, and additionally, the launcher is able to accept a list
of Nucleosome Dynamics analysis commands in bash to
orchestrate a custom workflow. Furthermore, the use of
the containers allows seamless software update. The im-
ages are registered at the corresponding hubs (see Table
1).
Use in research platforms.
• MuG Virtual Research Environment (MuGVRE) is an
integrated workspace designed to put together a series
of applications related to the study of 3D/4D genomics
(30). The MuGVRE workspace allows to combine data,
either uploaded to the workspace or obtained from pub-
lic repositories such as ArrayExpress (33). MuGVRE in-
cludes applications covering a wide range of levels in the
study of chromatin, from atomistic simulation or protein-
nucleic acids docking to coarse-grained simulation of
large nucleic acids molecules or chromatin fibers, as well
as the analysis of Hi-C data. All those applications share
a common data space where interoperability is assured
through a common data model, and a specific protocol to
incorporate new tools. MuGVRE is a cloud-based appli-
cation that simplifies the deployment and provides user
access to visualization tools, additional data in external
repositories, and to a variety of other programs for the
analysis of chromatin at different levels of resolution.
• The server provides a graphical interface based on an
embedded sequence browser, Jbrowse (34), that allows
visualization of nucleosome architectures in the context
of other omics data (see Figure 2A). For this purpose,
the outputs of all calculations are generated in GFF3 or
bigWig format. Nucleosomes are represented as boxes
coloured with different tones of blue according to their
positioning score, with regions where nucleosome are too
fuzzy displayed in a lighter colour. Similarly, nucleosome-
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free regions are highlighted by yellow boxes in a different
row (see Figure 2A). In both cases, numerical information
(scores, characteristics of the nucleosome orNFR) can be
obtained by clicking on the corresponding boxes. The nu-
cleosome architecture around TSS is classified based on
the length of the NFR and the location score of the +1
and −1 nucleosome (see above). The results are shown as
boxes between the −1 and +1 nucleosome dyads, color-
coded by the corresponding architecture class. The analy-
sis of nucleosome phasing generates a bigWig file with the
theoretical prediction of the nucleosome positions inside
the gene body, based on periodicity considerations and
the +1 and –last nucleosomes (see above), and aGFF3 file
which is displayed as a coloured box indicating whether
the gene shows ‘phased’, ‘antiphased’ or intermediate nu-
cleosome phasing (see Figure 2A). Similarly, the stiffness
associated to the nucleosomes is represented (through a
GFF3 file) as a boxmapping to the nucleosome, coloured
according to the estimated stiffness (see Figure 2A). Nu-
cleosome Dynamics data can be put into genomic con-
text by a series of additional tracks (Supplementary Ta-
ble S3) providing gene annotations and relevant litera-
ture data. Further analyses can be obtained from the web
server, such as detailed plots of nucleosome coverage and
changes in nucleosome distribution between the two ex-
periments (Figure 2B), genome-wide statistics of nucleo-
some architecture around TSS (Figure 2C), and overall
frequency of inclusions, evictions and shifts between the
two experiments (Figure 2D). Finally, Nucleosome Dy-
namics also generates a table listing the number of nucle-
osomes, their status (fuzzy/well-positioned), the identi-
fied nucleosome changes (inclusions, evictions, shifts), the
classification of the promoter and the width of the NFR
at the TSS for every single gene in the genome (Supple-
mentary Table S4). These analyses are useful to test the
effect of a treatment/growth conditions on nucleosome
positioning both globally, or at gene level.
• Running Nucleosome Dynamics on the galaxy platform:
Galaxy is a web-based scientific analysis platform widely
used by scientists to analyse biomedical datasets such
as genomics, proteomics, metabolomics or imaging (31).
Nucleosome Dynamics docker has been wrapped in a
series of Galaxy tools, one for each analysis. Users
can launch them individually, or as part of a Galaxy
workflow, building a custom pipeline that may inte-
grate other Galaxy applications. The tools are published
in the Galaxy ToolShed (see Table 1) and adopted by
the ELIXIR ES Galaxy server (currently in develop-
ment phase), together with a complete ready-to-use Nu-
cleosome Dynamics workflow. The output calculations,
mainly GFF3 and bigWig files, are treated in the plat-
form as any other sequence annotation file. Plain files like
GFFs are locally displayed using a column-based visual-
ization, while the genomic-context analysis is based on
the UCSC genome browser (35). Galaxy transparently
loads the data to the central UCSC browser service, and
there, the sequences are loaded as custom tracks and vi-
sualized together with the other UCSC annotations.
Benchmarking data sets
The ability of the package to determine the location and
nature of nucleosomes and nucleosome architectures was
evaluated using synthetic maps from single cell nucleosome
architectures that are combined to create in silico MNase
digestion maps approaching closely to those found in real
yeast MNase-seq experiments. For this purpose, we created
multiple single cell nucleosome architectures by first placing
NFRs at specific positions separated by ∼2000 bp (the typ-
ical range of NFR-NFR distances in yeast) in a 10 kbDNA
fragment. As the NFR are highly conserved, their positions
are located with small noise in the different cells. Once the
NFRs for a single cell have been placed, we definedwindows
for nucleosome positioning using the known average nucle-
osome periodicity (165 bp for yeast in the experiments sim-
ulated here). Each window was associated to either a W or
F nucleosome following probability functions reproducing
their expected populations at different distances fromNFR.
Windows that (in a given cell) appeared to be associated to
W nucleosomes have a high probability to be occupied by
a nucleosome, which is placed within a narrow range from
the centre of the window (see Supplementary Figure S4).
On the contrary, windows associated to F nucleosomes have
a higher probability to be empty in a given cell, and once
the nucleosome is assigned, its position is variable within
the window. Once obtained, the population of in silico cells
was processed by in silico MNase digestion repeating this
process many times, introducing ‘digestion noise’ to repro-
duce the distributions of read lengths observed in typical
yeast experiments. The integration of the reads for the entire
population provides an in silico MNase-seq map where we
know exactly the real population and fuzziness of all nucle-
osomes at all positions in the pool of cells. This constitutes
an unambiguous benchmark to validate the performance
of nucleosome annotation software. The probability func-
tions used to generate the different cell nucleosome archi-
tectures were adjusted to qualitatively reproduce reads ob-
tained in real MNase-seq experiments (Supplementary Fig-
ure S4). Synthetic data simulating ATAC-seq experiments
can be derived in a very similar manner.
The synthetic data obtained as explained above were the
starting point to generate pairs of in silico experiments sim-
ulating changes in nucleosome architectures. To this end, a
percentage of the reads was either shifted or removed for a
given nucleosome. Shifts from 1 to 5 turns of DNA (1 DNA
turn = 10 bp) were introduced generating 100 replicates in
each case to evaluate the sensitivity of the method to detect
shifts of different lengths and affecting different percentage
of the total population.
RESULTS
Performance using in silico datasets
NucleR. We explored the ability of the software to posi-
tion nucleosomes using as reference our highly controlled
synthetic data (see Methods). As a control, we repeated
the exercise using another widely used program for nucle-
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osome annotation, DANPOS (15). Both packages show a
good ability to represent the nucleosome architecture us-
ing MNase-seq data. In terms of occupancy DANPOS per-
forms slightly better than the nucleR module implemented
in ourNucleosomeDynamics package (R2 = 0.97 forDAN-
POS versus R2 = 0.93 for nucleR), while nucleR can detect
better the nucleosome fuzziness (R2 = 0.94 for nucleR ver-
sus R2 = 0.87 for DANPOS; see Supplementary Methods.
for description of the metrics). The location of W nucleo-
somes is nearly identical in both methods, but for F nucleo-
somes the results are quite different, as DANPOS annotates
a wide region of sequence reads as a single nucleosome po-
sitioned with a large uncertainty, while nucleR can assign
several nucleosomes to the wide signal, even when in some
cases the two nucleosomes can partially overlap (see Fig-
ure 3A). As a result, DANPOS provides, probably, the best
‘average’ distribution of nucleosomes, but nucleR provides
a more realistic picture of the cellular variability, capturing
the presence of alternative nucleosome architectures in the
cellular population. As it can be seen in Figure 3A, where
selected examples of DANPOS and nucleR nucleosome dis-
tributions are compared with the real nucleosome architec-
ture existing in our synthetic data; in Figure 3B, where we
compare the ability of DANPOS and nucleR to detect the
presence of a percentage of cells showing a different nucle-
osome architecture and in Figure 3C, where we report the
average distance between the real position of the dyads of
the synthetic nucleosomes and those located by DANPOS
or nucleR.
NucDyn. We tested the ability of our method to detect re-
arrangements in the nucleosome architecture using again
our controlled in-silico MNase-seq data, simulating dis-
placement (shift), insertion or eviction of one nucleosome,
occurring in a different percentage of the cells. Sizeable
changes such as nucleosome insertion or eviction are de-
tected with good sensitivity by our method, even when they
affect a relatively small percentage of cells (Figure 3D),
while DANPOS or Dimnp only detect such changes when
affecting a very large proportion of cells. Small nucleosome
shifts (implying less than one turn of DNA) are not de-
tectable by our algorithm unless they occur in a large per-
centage of the cells; while shifts implying a displacement of
at least two turns ofDNA (20 base pairs) are detectable with
good sensitivity, even when affecting less than half of the
cellular population (see Figure 3E). In this case, the com-
parison with other programs is difficult, as only DANPOS
(15) allows an indirect way to detect nucleosome shifts by
looking at distances between nucleosome peaks in both ex-
periments. Unfortunately, with our synthetic data, DAN-
POS achieved poor sensitivity (less than 0.20 for 5 turns of
DNA shift in 70% of cells and <0.1 for 3 turns shifts affect-
ing also 70% of cells; see Supplementary Figure S5).
In summary, analysis of well-controlled in silico data
shows that the Nucleosome Dynamics package (including
NucDyn and nucleR) is not only a very powerful tool to de-
fine nucleosome families fromMNase-seq experiments per-
formed with a population of cells, but also a powerful ap-
proach to detect subtle changes in nucleosome architecture
affecting a percentage of the cells in the studied sample.
Test cases
In order to illustrate the information derived from Nucle-
osome Dynamics, we applied our method in different real
cases where experimental MNase-seq data were available.
It is important to mention that the biological relevance of
this type of comparison depends on the quality of the data
and especially on the similar level ofMNase digestion of the
samples being compared. Indeed, several groups, including
ours, have demonstrated the impact of the level of MNase
digestion on the final nucleosome maps in several organ-
isms, essentially at the level of the so-called ‘fragile’ nucle-
osomes (19,36–38). To illustrate this observation, we took
advantage of the extensive studymade by (36) and usedNu-
cleosome Dynamics to compare nucleosome positioning in
the input of two H2B and two H4 MNase-ChIP-seq sam-
ples, one under-digested and one over-digested (50U and
400 U of MNase respectively for H2B; 25 U and 300 U
MNase respectively for H4). First, we focused on the H2B-
input samples and confirmed that the number of nucleo-
some detected by nucleR decreases as the amount ofMNase
increases (from 80 160 down to 72 775, Supplementary Ta-
ble S5) which is corroborated by the detection by Nuc-
Dyn of 3559 evictions genome wide (Supplementary Ta-
ble S6). At the promoter level, the proportion of W-open-
W TSS increases from 123 to 2026 while the W-close-W
TSS decreases from 2656 down to 346 (Supplementary Fig-
ure S6A). Regarding the phasing analysis, the percentage of
phased genes does not change significantly due to the level
of MNase digestion (Supplementary Figure S6B). Similar
numbers were obtained for the H4-input samples. Hence, it
is important to control MNase digestion level before using
Nucleosome Dynamics package. Another technique that is
not influenced by the level of MNase digestion is chemical
cleavage mapping. NucleR can be applied to map nucleo-
some positions using the coverage obtained from these ex-
periments (Supplementary Figure S7),
Cell cycle. The first example comes from the analysis of
the changes in nucleosome organization occurring along
the cell cycle in yeast, using our own previously published
data (39). As shown in Figure 4A, the nucleRmodule of the
Nucleosome Dynamics package suggests that nucleosomes
tend to be fuzzier (F) in S and M phases compared to G1
and G2 phases. The increase in fuzziness in S andM phases
impacts on the promoter classification as the number of W-
open-W andW-closed-W promoters decreases compared to
G1 andG2 (Figure 4B), but overall the ratio of closed/open
NFRs (nucleosome free regions) is not dramatically altered
along cell cycle (Supplementary Figure S8). Very interest-
ingly, the changes in nucleosome architecture detected by
NucDyn are not randomly distributed along the genome,
but appear to be localized in specific families of genes, which
are related to cell cycle progression, as shown by Gene On-
tology (GO) Enrichment Analysis (40) in Figure 4C. Exam-
ples of the detailed information provided by Nucleosome
Dynamics for some specific genes are shown in Figure 4D,
where we report nucleosome maps of PRY2 (a gene related
to lipid transport), whose expression peaks in G1 phase,
YHP1 (involved in negative regulation of transcription of
certain cell cycle genes), and GIC1 (a GTPase-interaction
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Figure 3. Performance of nucleR and NucDyn. (A) Coverage of three synthetic nucleosome maps (shown in grey), containing well-positioned (dark blue)
and fuzzy nucleosomes (light blue). Two possible nucleosome families generate different nucleosome positioning in fuzzy regions (Fam1 and Fam2).
Predicted nucleosome positions using nucleR andDanpos are shown in green and purple, respectively. (B) Comparison of nucleR andDanpos for detection
of a second family of nucleosomes (light blue nucleosome in the bottom-right panel). Y-axis shows the number of cells required in the second family in
order to be detected by the algorithm. (C) Distance between the dyads identified by nucleR (green) and DANPOS (purple) to the dyad position in the
true synthetic nucleosome map for fuzzy and well positioned nucleosomes. (D) Sensitivity of the EVICTION prediction for NucDyn, DANPOS and
Dimnp. Evictions were simulated removing reads from a given percentage of families (10%, 20%, . . . , 90%) and were identified from DANPOS output as a
nucleosome with point log2FC < −1 and point diff FDR < 0.01 (point with highest difference in the two samples, as reported by the software), and with
default parameters for Dimnp. (E) Sensitivity of the SHIFT prediction computed on synthetic nucleosome maps. Shifts were introduced displacing reads
from 1 to 5 DNA turns and modifying different percentages of the families (10%, 20%, . . . , 90%).
component involved in mitosis regulation) expressed in S
phase (39). In the three cases, expression changes correlate
with significant variation in nucleosome architecture at the
promoter region between two stages of cell cycle. Typically,
eviction or shifts reducing the presence of nucleosome in the
core promoter region are related to active states of the genes
(4,19,28,41,42).
Yeast metabolic cycle. A second example of use of our tool
was the comparison of nucleosome architecture amongst
cells at different stages of the yeast metabolic cycle (YMC).
We took advantage here of high resolution experiments (43)
in which the authors analysed simultaneously gene expres-
sion and MNase-seq maps at regularly spaced periods of
time after adding fresh culture media. At two of these time
points (T9 and T12 in Nocetti and Whitehouse 2016) dra-
matic changes of expression in genes related to reductive
charging (poorly transcribed at T9 and highly transcribed
at T12) and oxidative phase (highly transcribed at T9 and
poorly transcribed at T12) have been detected. Analysis
of global nucleosome architecture shows moderate changes
between T9 and T12 (Figure 5A), but differences are more
noticeable when the analysis is focused on Ox-genes (in-
volved in amino acid synthesis, sulphur metabolism, ribo-
some and RNA metabolism (44), which are expressed in
T9 and repressed in T12) and R/C genes (involved in non-
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Figure 4. Nucleosome Dynamics along the cell cycle. (A) Percentage of fuzzy and well-positioned nucleosomes and (B) promoter classification (number
of genes in each class) for every cell cycle stage. (C) GO terms enriched in genes with nucleosome changes between G1 and S detected by NucDyn. (D)
Example of three cell-cycle dependent genes that present differential nucleosome architectures between G1 and S. In gray, the normalized coverage from
the BAM files of the two cell cycle stages, 500 bp upstream and 1000 bp downstream the TSS. Below each BAM file, the nucleosome calls obtained with
nucleR are represented (dark blue for well-positioned nucleosomes, light blue for fuzzy nucleosomes). The fifth track contains shifts (yellow for positive,
blue for negative), inclusions (green) and evictions (red) identified by NucDyn.
respiratory metabolism, protein degradation, autophagy
and vacuole (44), which are expressed in T12 and repressed
in T9). Nucleosome Dynamics allows the detection and
quantification of the alterations in nucleosome architecture
coupled to such changes in expression. Thus, for Ox-genes
(Figure 5B), the fuzziness at the −1 nucleosome decreases
whenmoving fromT9 to T12, in agreement with the general
rule that reduced NFR upstream the well positioned +1 nu-
cleosome correlates with inactive genes. On the contrary, for
R/C genes (Figure 5C) the NFR upstream well positioned
+1 nucleosome enlarges, since the −1 nucleosomes become
fuzzier, again in perfect agreement with the changes of ex-
pression. To discard any biases resulting from the MNase
digestion conditions, we confirmed that the length of the se-
quenced fragments was comparable in both samples (Sup-
plementary Figure S9). Examples of the detailed informa-
tion provided by Nucleosome Dynamics for three Ox-genes
(NSR1, RRP4 and SNU13, all of them related to riboso-
mal biogenesis and RNA metabolism) are shown in Figure
5D, where upon T9→T12 transition, shifts and even inser-
tions are shown leading to a reduction in the width of the
NFR upstream the TSS: a fingerprint of gene deactivation.
Similarly, Figure 5E provides the same type of informa-
tion for three R/C genes (CTA1, SUE1 and SAF1), which
are associated respectively with peroxisome, cytochrome C
degradation and proteasome (see above). In the three cases,
T9→T12 transition is coupled with massive nucleosome
eviction upstream the TSS, leading to open configurations
of NFR, typical of highly expressed genes.
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Figure 5. Nucleosome Dynamics in two points of the YMC. Promoter classification in the two time points (T9 and T12) for (A) all genes, (B) genes from
the Ox cluster and (C) genes from the R/C cluster. (D and E) Example of three genes fromOx and 3 fromR/C clusters that present differential nucleosome
architectures between T9 and T12. In grey, the normalized coverage from the BAM files of the two time points, 500 bp upstream and 1000 bp downstream
the TSS. Below each BAM file, the nucleosome calls obtained with nucleR are represented (dark blue for well-positioned nucleosomes, light blue for fuzzy
nucleosomes). The fifth track contains shifts (yellow for positive, blue for negative), inclusions (green) and evictions (red) identified by NucDyn.
Changes in nutrients. As a last test, we applied Nucleo-
some Dynamics to explore the modifications in nucleosome
architecture in yeast, linked to the change in the media from
glucose-rich to either galactose-rich or ethanol-rich (45).
Changes in the TSS nucleosome architecture classification
occur among the three conditions (Figure 6A). There are
not complete expression data in Kaplan et al. 2009, but we
expected that replacement of glucose by galactose in the
media would imply changes in expression in genes related
to carbohydrate metabolism and transport which encour-
agingly, are those where sizeable changes in nucleosome ar-
chitecture are detected by Nucleosome Dynamics (Figure
6B). Similarly, replacement of glucose by ethanol was ex-
pected to have an impact on the cell through: (i) expres-
sion of stress response genes, (ii) changing completely hex-
ose metabolism in the absence of hexoses and (iii) eliminat-
ing ethanol through oxidation generating changes in the re-
dox state of the cell which need to be corrected (46). Very
encouragingly again, genes involved in stress response, hex-
ose metabolism and redox activities are those for which the
largest changes in nucleosome architecture have been de-
tected (Figure 6C).
We analysed in detail some genes which are ex-
pected to change dramatically their expression upon
glucose→galactose substitution, as they are crucial to inte-
grate galactose in normal hexose metabolism: GAL1, cod-
ing for a Galactokinase, GAL10, coding for the UDP-
glucose-4-epimerase, and GAL7, coding for the galactose-
1-phosphate uridyl transferase (Figure 6D). In the three
cases evictions and shifts (in some cases noticeably) generate
wider NFRs upstream the gene, changes that in some cases
extend to the coding regions and that signal a pronounced
increase in expression of these galactose-related genes.
A similar detailed analysis was made for three genes
which are expected to be overexpressed when ethanol sub-
stitutes glucose as energy source: two stress response genes
HSP26 and HSP12, and HXK1, a hexokinase activated
when cells are shifted to a non-fermentable carbon source
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Figure 6. Nucleosome Dynamics under different nutrient conditions. (A) Promoter classification in glucose, galactose and ethanol rich media. (B and C)
GO terms enriched in genes with nucleosome changes detected by NucDyn, changing the medium from glucose to galactose or ethanol, respectively. (D
and E) Example of three genes involved in galactose and ethanol metabolism, respectively, that present differential nucleosome architectures depending
on the carbon source. In gray, the normalized coverage from the BAM files of the two cell cycle stages, 500 bp upstream and 1000 bp downstream the
TSS. Below each BAM file, the nucleosome calls obtained with nucleR are represented (dark blue for well-positioned nucleosomes, light blue for fuzzy
nucleosomes). The fifth track contains shifts (yellow for positive, blue for negative), inclusions (green) and evictions (red) identified by NucDyn.
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such as ethanol (47). Results in Figure 6E illustrate themag-
nitude of the changes (mainly evictions) detected by Nucle-
osome Dynamics, which affect the NFR, and even in some
cases the coding regions.
DISCUSSION
Different studies demonstrated that nucleosome architec-
ture is coupled to gene function (4,43,48) and that transcrip-
tional activity and nucleosome architecture are tightly cou-
pled.Unfortunately, detecting changes in nucleosome archi-
tecture is complex as nucleosomes are dynamic and even
a population of ‘identical’ well synchronized and grown
under identical conditions cells might have nucleosomes
placed at different positions. This, combined with the in-
trinsic uncertainties of MNase- or ATAC-seq experiments,
generate noisy data which are difficult to process for pre-
cisely locating nucleosomes and even more difficult to de-
tect significant changes in nucleosome arrangements due to
internal or external stimuli. The suite of programs incorpo-
rated in Nucleosome Dynamics allows not only a robust lo-
cation of nucleosomes, even in cases of heterogeneous pools
of cells, but also the detection of changes in nucleosome ar-
rangements, even those affecting a moderate population of
cells. To increase its utility, Nucleosome Dynamics is inte-
grated into a powerful virtual research environment, where
it is combined with different tools for analysis of data and
visualization in the context of genomic metadata, which
help the user not only to analyse nucleosome architecture
and dynamics, but also to put them in the context of known
genomic information (Figure 2).
We validated the methodology using synthetic data that
mimic typical MNase-seq maps, in which the positions of
the nucleosome in the different cells are unambiguously
known. The two main modules of Nucleosome Dynamics
(nucleR and NucDyn) perform very well capturing cellu-
lar diversity and detecting shifts, evictions and inclusions
that affect amoderate percentage of the cellular population.
Furthermore, we tested the power of the methodology by
exploring nucleosome rearrangements occurring along cell
cycle, yeast metabolic cycle, and those linked to the change
in the source of energy from glucose to galactose or ethanol.
In the tested cases, Nucleosome Dynamics provides accu-
rate global and local descriptions of nucleosome structure
and dynamics and deciphers the nature of the connection
between nucleosome organization and gene expression.
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ABSTRACT 
Multiscale Genomics (MuG) Virtual Research Environment (MuGVRE) is a cloud-based          
computational infrastructure created to support the deployment of software tools addressing the            
various levels of analysis in 3D/4D genomics. Integrated tools tackle needs ranging from high              
computationally demanding applications (e.g. molecular dynamics simulations) to        
high-throughput data analysis applications (like the processing of next generation sequencing).           
The MuG Infrastructure is based on openNebula cloud systems implemented at the Institute for              
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research in Biomedicine, and the Barcelona Supercomputing Center, and has specific interfaces            
for users and developers. Interoperability of the tools included in MuGVRE is maintained             
through a rich set of metadata allowing the system to associate tools and data in a transparent                 
manner. Execution scheduling is based in a traditional queueing system to handle demand             
peaks in applications of fixed needs, and an elastic and multi-scale programming model             
(pyCOMPSs, controlled by the PMES scheduler), for complex workflows requiring distributed or            
multi-scale executions schemes. MuGVRE is available at https://vre.multiscalegenomics.eu and         
documentation and general information at https://www.multiscalegenomics.eu. The       
infrastructure is open and freely accessible. 
 
INTRODUCTION 
While major milestones have been achieved in determining the sequence of DNA,            
understanding its 3D folding, the connection between chromatin structure and genome           
functionality and the links between changes in chromatin structure and pathology are still major              
challenges that are attracting a large research effort and have created a new area of               
knowledge: 3D/4D genomics. Opposite to traditional sequencing projects, 3D/4D genomics          
faces a major problem related to the diversity of data types and formats generated, the variety                
of analysis methods, and the multi-resolution nature of the navigation in a multi-scale data              
space. Data used in the field range from simple sequence (1D genomics), typically enriched by               
functional and structural annotations (2D Genomics) to contact maps, single or multiple            
structures (at a very wide range of resolutions) and images.  
ENA (1), EGA (2) and Ensembl (3) are the most common sources of 1D genomic data in                 
Europe, whose contents are visualized thanks to tools such as “Genome browsers” (4-8) that              
provide an integrated view of both sequence and annotations (2D genomics). Many research             
infrastructures deal with this level of data, Galaxy (9), being by far the most popular.  
A second level of data includes nucleic acid and protein structures determined at the atomistic               
level by X-Ray crystallography or NMR spectroscopy and deposited in the Protein Data Bank              
(10). Analysis and visualization of data at this level have, in practice, little overlap with the 2D                 
genomics level. This represents a major caveat for people interested in specific DNA-protein             
complexes. An additional type of data includes simulation trajectories, i.e. a set of structures              
defining the conformational ensemble of DNA (and associated proteins), which is typically            
obtained through atomistic or coarse-grained molecular dynamics (MD) simulations (11-17).          
Specific databases on DNA simulation data (18) or protein-DNA complexes (19, 20), and tools              
to perform flexibility analysis of nucleic acids like NAFlex (21) or 3DNA (22) are available. Few                
tools allow mapping 3D structures onto the genomic sequences (23-25).  
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A third level of data is represented by nucleosome and protein positioning studies (26-30). Raw               
data is obtained from sequencing analysis (MNAse-seq, Chip-seq) and is usually limited to the              
annotation of specific binding sites. Data at this level is available from public repositories like               
ArrayExpress (31), where it is presented in a 1D manner without any connection to the 3D                
structure and flexibility of the chromatin fiber. At the upper end of the scale the main                
experimental strategies include FISH (32), and chromosome conformation capture (3C-like          
techniques (33)), which provide chimeric sequences representing interactions within the          
genome, from which structural insight can be derived after a complex manipulation of the data.               
Data visualization at this level is complex (34); several tools are already available (35-38), but               
they ignore any atomistic detail, or even the general description of the nucleosome string.  
In summary, 3D (structure) and 4D (dynamics) genomics cover a large variety of data types and                
experimental and theoretical strategies. Tools and data repositories exist; but they are not             
integrated. As a result, research at the different levels is performed in isolation, and researchers               
almost ignore alternative views coming from different levels. The Multiscale Complex Genomics            
project (MuG, http://www.multiscalegenomics.eu/MuG) is one of the initiatives aiming to bridge           
the gap among the different levels of chromatin study and provide such an integrated view.               
Here, we present the MuG Virtual Research Environment (MuGVRE) infrastructure, designed to            
provide researchers with a single access point where data and tools covering the full spectrum,               
from sequence and atomistic data to chromosome capture results, can be used and combined              
to obtain a holistic picture of chromatin. MuGVRE is cloud based, allowing for an easy               
deployment and extension at the technical level. It is a base infrastructure where additional tools               
can be plugged-in to extend the functionality. The initial offer of tools already hosted, includes               
sequence, structure and Hi-C data analysis and visualizers; tools to handle nucleosome            
positioning, and tools for performing and analyzing simulation data from atomistic to            
coarse-grained levels. All the tools are accessible through an intuitive personal workbench,            
where most technical decisions are taken automatically by the system, allowing the user to              
concentrate on the scientific aspects of the analysis. We believe that MugVRE is the missing               
element to integrate the different views of physiological DNA. 
 
INFRASTRUCTURE DESIGN AND COMPONENTS 
The MuGVRE infrastructure has been designed to fulfil the following principles: 
Technical:  
1. Flexible structure, able to adapt to the specific needs of the analysis tools, both in terms                
of software requirements, and computational resources.  
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2. Software scheduler(s), able to manage analysis workflows, and computational         
resources in a transparent and adaptable manner. This should constitute an elastic            
infrastructure with automatic adaptation to user loads. 
3. Multi-scale execution. Analysis workflows should be executed either at the cluster level,            
in HPC environments, or distributed infrastructures like EGI (https://www.egi.eu), and          
eventually in the forthcoming European Open Science Cloud (EOSC) ecosystem. 
Usage: 
4. Web-based access centered on the user workspace and complemented by full           
programmatic access using well-established interfaces. 
5. Data should be kept private, through the appropriate Authentication and Authorization           
Infrastructure applied to all data transactions. 
 
Supplementary Figure S1 shows a general schema of the computational infrastructure           
underlying MuGVRE.  
 
MuGVRE Main components 
Cloud deployments: MuGVRE infrastructure has been designed as a fully virtualized           
environment. At its present state, MuGVRE has been deployed in at the Starlife cloud              
infrastructure (https://www.bsc.es/marenostrum/star-life), at the Barcelona Supercomputing      
Center, using OpenNebula (https://opennebula.org/) and the KVM hypervisor        
(https://www.linux-kvm.org).  
 
Process management: MuGVRE uses two complementary layouts for process management: i)           
Sun Grid Engine (SGE, https://sourceforge.net/projects/gridscheduler/), in combination with        
OneFlow 
(https://docs.opennebula.org/5.4/advanced_components/application_flow_and_auto-scaling/app
flow_use_cli.html), a component of the OpenNebula framework that allows managing Multi-VM           
applications and auto-scaling. SGE is used to manage applications where no complex            
workflows are necessary, requiring only to deploy additional workers on peaks of demand, ii) the               
COMPS Superscalar (COMPSs) programming model (and its python binding pyCOMPSs (39)),           
managed by the Programming Model Enactment Service (PMES) (40), which interacts with            
cloud infrastructures through Open Cloud Computing Interface (OCCI, http://occi-wg.org/)          
servers. PMES/pyCOMPSs are used to control complex workflows and distributed execution.  
 
Database manager: Operational data and metadata regarding installed tools, public          
repositories, and user’s files are maintained in a MongoDB database          
(https://www.mongodb.com). The MongoDB server also contains reference data as a copy of            
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Protein Data Bank (10), Uniprot (41), and BiGNASim (18) database. User’s data is stored in a                
standard filesystem in its original format. 
Authentication and authorization system: Data privacy is maintained using the authentication           
and authorization server Keycloak (http://www.keycloak.org/) to handle all internal         
communications and user access. Keycloak implements OpenID Connect which allows for Web            
access on the code authorization flow of OAuth2, and a token-based authentication for the              
REST services. For registered users, authentication schemes based on username/password,          
but also third-party identity providers (Google, LinkedIn, Elixir) are accepted. 
See Supplementary Material Section 1 for additional information about MuGVRE software           
components. 
 
USER WORKSPACE 
User access  
MuGVRE can be accessed without authentication. Users are granted a private workspace to             
hold data and analysis results. Data is maintained for one week after the last access and can be                  
recovered during this period through a unique URL address. Users desiring a longer interaction              
with MuGVRE are advised to register to get a permanent workspace. In such cases the user                
space is maintained up to two months after the last access. 
Personal workspace 
The MuGVRE personal workspace is the central environment for user activity. It is based on a                
filesystem-based layout (see Figure 2), where both uploaded data and analysis results are             
available. Uploaded data should be annotated to specify data types and formats. This allows the               
MuGVRE workspace to offer an adapted toolkit for each file, including only compatible tools and               
visualizers (see Suppl. Material Section 2 for a description of the procedure, and Suppl.Table              
S3 for a description of accepted data types and formats). The user workspace has been laid                
out to provide an intuitive look-and-feel. The workspace itself is structured in projects, to keep               
data logically organized. Within each project the input data is distributed in folders: Uploads              
(uploaded data), and Repository (data obtained from public repositories). The remaining folders            
correspond to analysis operations (a new folder is generated for any new process started in the                
VRE). File lists can be filtered by any of the fields (name, format, data type, or project).                 
Additionally, a tool-based filter is available to select only valid input files for the given tool.  
Three interactive toolkits containing the following options are available: 
● File toolkit: Download, rename, move, compress, delete files and folders, edit their            
metadata, rerun jobs. 
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● Visualization toolkit: Available visualizers for the specific file/s selection (based on their            
data type and format). 
● Tools toolkit: Available tools for the specific file/s selection (based on their data type and               
format).  
Tools based access 
In addition to the data centric approach, more experienced user may prefer to access directly to                
the analysis operation. To this end, user may select the desired operation from an ontology,               
covering all the operations provided by the installed tools. The user should then select the               
desired tool and fill in the required parameters. At this point, a selection of input files filtered out                  
from the user workspace are suggested according to the metadata accompanying both, user’s             
data and tool input restrictions. 
Applications and developer access 
MuGVRE is designed as an infrastructure open to any application designed for the analysis of               
3D/4D genomics data. Tools installed in MuGVRE should accept free, unrestricted usage.            
Guidelines are available for developers (see Suppl. Material, Section 2). Developers wishing to             
include their applications are granted access to a specific workspace to manage tool definitions              
and execution details, and to edit the tool’s help pages, and perform execution tests. Also               
developers get access to usage statistics, execution logs, and job associated files and             
metadata. The current offer of tools is detailed in Suppl. Table S4. Several data visualizers are                
available (Suppl, Table S5). Figure 2 shows a representative set of the types of data than can                 
be visualized in the infrastructure. JBrowse (5) is used for sequence data (see Figure 2A). In the                 
figure, data from a Nucleosome Dynamics analysis of MNase-seq data is depicted (blue blocks              
for nucleosome calls, and coverage plot). The NGL visualizer (42) is used for 3D atomistic (see                
Figure 2B for a transcription factor-DNA complex) or coarse-grained structure data (output from             
Chromatin Dynamics, Figure 2D, depicting the structure of a fragment of chromatin fiber             
containing nucleosomes at positions shown in Fig. 2A). Finally, the TadKit visualizer            
(http://3DGenomes.org/tadkit, Figure 2C) allows the combination of 1D to 3D information taken            
from chromosome capture data. 
USAGE 
Users can populate the MuGVRE workspace in several ways: 
● Direct upload into the workspace, using the HTTPS protocol  
● Create files using an embedded text editor. This is intended for data or metadata of               
reduced size.  
● Upload from an External URL: MuGVRE can access external sites to download. This is              
the recommended procedure to obtain data from public repositories, or import bulky            
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data, as the upload process becomes a batch job. HTTP and FTP protocols are              
accepted, also when user credentials are required. 
● From repository: Data imported from the list of public repositories made browsable at             
the infrastructure (currently ArrayExpress (31) and BigNASim(18)). 
● From sample data: selected input and output examples for the available tools are             
provided as help to start using the interface. 
Files can be selected anywhere in the workspace, and added to the execution list, where a                
specific tool should be then selected. Alternatively, the user can select first an analysis tool from                
a list of available operations. Either selection mode opens a configuration screen where the user               
can assign data files (Suppl. Figure S7) to the appropriate input parameters, define additional              
settings, and launch the tool. Executions are performed in the background and do not require               
the user to keep the interactive session open. Results of the analysis are added to the                
workspace under a separate folder that contains the output files generated by the tool, log files,                
and a customized results page (Suppl. Figure S10). For a complete usage example, see              
Supplementary Material Section 3, where we show a series of screenshots of a session              
centered on the analysis of MNase-seq data from yeast Chr II on phases M and G2 of the cell                   
cycle (data taken from (43)), analyzed with the Nucleosome Dynamics tool.??
DISCUSSION 
3D/4D Genomics is an emerging field originated from the unplanned aggregation of different             
disciplines which have developed their tools, and associated data types and formats,            
independently. This diversity is a major obstacle towards the generation of a complete picture of               
chromatin structure and dynamics. MuGVRE has been designed as an integration space. It             
follows the traditional concept of the personal workbench, already used in general genomic             
workbenches like Galaxy (9) or GenePattern (44), or spaces designed for simulation data             
analysis like NAFlex (21). In this kind of environment, data and tools are available and the user                 
has the freedom to design his/her own analysis pipelines. MuGVRE has an initial offer of tools                
and visualizers covering all levels of resolution, from atomistic simulation to chromatin fiber             
simulation, or Hi-C data analysis. Tools and visualizers are offered in a single space where, for                
example, chromosome conformation capture or nucleosome positioning data can be visualized           
along with sequence annotations and the structures and binding modes of the transcription             
factors affecting the same DNA region. A strong commitment of MuGVRE design is to free the                
user from understanding the technical side of the infrastructure. With this aim, not only the               
computational layout is hidden, but also most technical decisions are taken automatically by the              
system. For example, we have designed a comprehensive ontology of data types and formats              
that are checked internally to configure the options offered to the user. The user can just select                 
a tool, and the workspace selects those files that match its input requirements. Output from the                
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analyses are reusable following the same philosophy. As a result, the user can easily configure               
a pipeline taking only scientific decisions and not bothering about technicalities.  
MuGVRE has been designed as a large and sustainable infrastructure, which relies now on the               
computational capabilities of the Barcelona Supercomputing Center (http://www.bsc.es), but         
technical decisions have been taken to assure the compatibility with other infrastructures like             
Elixir computational platforms (http://elixir-europe.org), EGI (https://www.egi.eu), or EUDAT        
(https://eudat.eu). The choice of a fully flexible cloud system, controlled with a multiscale             
software scheduler, and linked to HPC facilities, assures the usage of the optimal computational              
environment for each specific analysis.  
MuGVRE is presented as an open platform with the aim of growing in functionality, since new                
tools can be easily incorporated by external developers. Hosting at MuGVRE can be an option               
for developers alternative to build a dedicated web site to run their tools.  
MuGVRE was presented to the multiscale genomics community in November 2017, and has             
performed already over 6,500 analysis runs. 
MuGVRE is a unique tool that aims to help researchers in the 3D/4D genomics field to gain an                  
integrated view of discipline, sharing data among the diverse analysis levels and providing a              
complete and integrated view on DNA. We hope that MuGVRE will foster the development,              
deployment and use of new strategies for the analysis of the chromatin structure that were not                
envisioned simply because data was kept in separate silos. 
 
AVAILABILITY 
MuGVRE: https://vre.multiscalegenomics.eu 
General information and documentation: https://www.multiscalegenomics.eu 
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LEGENDS TO FIGURES 
Figure 1. Screenshot of MuGVRE personal workspace 
Figure 2. Sample visualizations at MuGVRE.  
A: Genome browser showing reference sequences, annotations, including a nucleosome          
positioning track (blue marks) (Jbrowse). B: Transcription Factor structure bound to cognate            
DNA fragment (NGL). C. HiC adjacent matrix, combined with genomics annotations, and a 3D              
model of chromatin structure (Tadkit), and D: Coarse-grained model of DNA fiber with several              
attached nucleosomes, from ChromatinDynamics (NGL).  
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ABSTRACT
Molecular dynamics simulation (MD) is, just be-
hind genomics, the bioinformatics tool that gener-
ates the largest amounts of data, and that is us-
ing the largest amount of CPU time in supercom-
puting centres. MD trajectories are obtained after
months of calculations, analysed in situ, and in prac-
tice forgotten. Several projects to generate stable
trajectory databases have been developed for pro-
teins, but no equivalence exists in the nucleic acids
world. We present here a novel database system
to store MD trajectories and analyses of nucleic
acids. The initial data set available consists mainly
of the benchmark of the new molecular dynamics
force-ﬁeld, parmBSC1. It contains 156 simulations,
with over 120 s of total simulation time. A depo-
sition protocol is available to accept the submis-
sion of new trajectory data. The database is based
on the combination of two NoSQL engines, Cassan-
dra for storing trajectories and MongoDB to store
analysis results and simulation metadata. The anal-
yses available include backbone geometries, heli-
cal analysis, NMR observables and a variety of me-
chanical analyses. Individual trajectories and com-
bined meta-trajectories can be downloaded from
the portal. The system is accessible through http:
//mmb.irbbarcelona.org/BIGNASim/. Supplementary
Material is also available on-line at http://mmb.
irbbarcelona.org/BIGNASim/SuppMaterial/.
INTRODUCTION
After almost 40 years since the first biomolecular simula-
tion, molecular dynamics (MD) has become a mature tech-
nique to assess the dynamic properties of macromolecules.
Modern MD simulations are reaching, in a routine man-
ner, the multi-nanosecond and even the microsecond scale,
approaching then the biologically relevant time scale. These
huge trajectory files need to be processed, and ideally stored
for further analysis. However, in practice most of these tra-
jectories are lost after a typically rather superficial analy-
sis. This leads to duplication of efforts, lack of reference
data sets for benchmarking and the impossibility to perform
genome-scale analysis involving hundreds or thousands of
trajectories.
Strategies in building simulation databases
Three large simulation databases have been reported: Dy-
nameomics (1), oriented to the study of protein folding and
stability, reporting over 7000 simulations in the nanosec-
ond range (although only 100 were distributed); MoDEL
(2), aiming to cover a representative subset of the protein
space, with over 1800 10-ns simulations, distributed in a
compressed format; and Dynasome (3), reporting a com-
prehensive collection of protein dynamics properties ob-
tained from over 110 0.1-s simulations, also representa-
tive of the protein space. They had a significant coverage
of the proteome, and involved the generation of Terabytes
of trajectory data. Two of them reported details about the
strategies used to handle data. Dynameomics chose a par-
ticular database engine (MOLAP) (4), with the capability
of being assessable using complex points of view, like time
slice and specific molecular fragments. Although MOLAP
was flexible on the criteria to retrieve a trajectory, its use re-
quired specific software for the analysis. On the other hand,
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MoDEL (2) used a more conservative approach where tra-
jectory data were kept in their original format. This al-
lowed to use existing analysis software. Although the ac-
cess to data was less flexible, MoDEL relied on a special
file system layout to speed up data retrieval. Also, a com-
plete SQL-based metadata storage allowed to define spe-
cific time-slices or molecular fragments, making possible to
pre-calculate, and store, relevant analysis data. Not being
a simulation database per se, more recently, the iBIOMES
project (5,6) reported an infrastructure tomanage and share
distributed simulation data, based in the iRODS framework
(https://irods.org/). In the nucleic acids world, the ABC
consortia recently reported microsecond simulations of all
unique DNA tetramers (7), generating near 10 TB of data.
The project did not report the implementation of any for-
mal database structure, and data are stored in their original
flat files in a series of computers from the European and
American participating groups.
Analysis portals for molecular dynamics simulations
Trajectory analysis is usually done using software provided
together with simulation codes, which is typically refined to
analyse protein dynamics. For nucleic acids, specific soft-
ware, independent from simulation engines, has been de-
veloped and used as de facto standard (8–11). Particularly,
Curves or 3DNA are widely used to obtain helical pa-
rameters, the basis of nucleic acids conformational analy-
sis. Using the experience gained in MoDEL (2) and MD-
Web (12) projects, our group recently developed a new por-
tal, NAFlex (13), which allows a non-experienced user to
setup simulations starting from either DNA sequences, or
3D structures, and providing a wide repertoire of post-
trajectory analysis both general tomacromolecules and spe-
cific of nucleic acids.
We present here BIGNASim, a comprehensive platform
including a database system and analysis portal, aimed to
be a general database for handling nucleic acids simulations.
At its initial stage, the database has been populated with the
trajectories prepared during the development and valida-
tion of the parmBSC1 force-field (14) The database allows
direct access to trajectory data, and contains a complete set
of pre-computed analyses. Additionally, the database is pro-
vided with a flexible NAFlex-based engine allowing users to
perform their own analysis pipelines. BIGNASim accepts
the submission of new trajectory data. A simpler version
of the database managing software and analysis package is
also available for download.
DATABASE DESIGN AND IMPLEMENTATION
BIGNASim (Figure 1) is based on the combination of
twoNoSQL database engines, Cassandra (http://cassandra.
apache.org/) and MongoDB (https://www.mongodb.org),
and an adapted version of the analysis section of our Nu-
cleic AcidsMDportalNAFlex (13). For trajectory datama-
nipulation, the platform uses MDPlus, an in-house python
library that integrates MDAnalysis tools (15) with a devel-
oped Cassandra interface.
The design of the BIGNASim platform has followed a
similar dual approach as done in the case of the MoDEL
project. The main specifications of the design were:
1. Storage, using a consistent structure, of trajectory data,
simulation metadata and analysis results.
2. Retrieval of the trajectory data on the three coordinates:
simulation, time-slice and molecular fragments. Trajec-
tory data should be retrieved in a format that is compat-
ible with the existing analysis software.
3. Storage of analysis and simulation metadata. Database
structure should allow storing any kind of analysis result
and being flexible enough to incorporate new analysis
data without the need of reconfiguration.
The database structure has been divided in two subsys-
tems: (i) the trajectory subsystem, based on Cassandra, and
(ii) the analysis and metadata subsystem, based on Mon-
goDB. These two types of databases show characteristics
that are appropriate for the BIGNASim DB purposes. On
one side, Cassandra is a column-oriented database, espe-
cially efficient when data can be represented in key-value
pairs. The simplicity of trajectory data structure, a uniform
series of Cartesian coordinates that should be retrieved in
well-known groups of data, makes it ideal to be handled by
the Cassandra engine. On the other hand, MongoDB is a
document oriented database, where data should not follow
a rigid schema. MongoDB may store from single values, to
2D or 3D data, or even full length trajectory videos within a
single document. Its flexibility, especially with respect to the
structure of the stored documents, allows the use of a com-
mon data structure both in the database and in the analy-
sis software. The capacity of both systems scales horizon-
tally and they can coexist in the same computer equipment.
Finally, simulation metadata has been placed in the Mon-
goDB database allowing an easier interaction with analysis
data. Indexing coordinates used in both subsystems of the
BIGNASim database are fully consistent, in the way that
analysis and trajectory data match naturally. A detailed de-
scription of the database structure and capabilities can be
found in Supplementary Material.
DATA PORTAL
We have developed a data portal to offer several ways of
accessing the data:
1. Browse and search on the trajectory data set following
a rich set of options, including available metadata, se-
quence, or molecular fragments.
2. Access to simulation details, and quality control of the
trajectories.
3. Access to both standard MD analysis results, and also
nucleic acids specific ones.
4. Access to global meta-simulation analysis results.
5. Possibility of downloading trajectories or meta-
trajectories for further in-house analysis.
6. Possibility of re-analysing trajectory fragments (either
by time slice, or molecular fragment) within the portal.
Searching and browsing the database
Simulations can be located by: (i) sequence, (ii) sequence
fragments and (iii) simulation metadata (Figure 2A). In the
case of sequence search, regular expressions are accepted,
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Figure 1. Global outline of the database platform and data flow.
allowing searching for degenerated sequence strings. Addi-
tionally, sequences corresponding to structures in the PDB
structures can be retrieved and inserted automatically. Sim-
ulations containing defined sequence fragments (i.e. bases,
base-pairs or base-pair steps) can be specifically located
(see examples in Supplementary Material). After selection,
simulations are shown in the browser screen (Figure 2B).
Database browser includes an advanced filtering engine to
make the navigation easier. From this screen, individual or
combined analyses, and also meta-trajectories combining
the selected simulations and fragments, can be obtained.
Once a simulation is selected, its description screen con-
tains four sections (see Supplementary Figure S1): (i) Nu-
cleic acid data. Information about sequence, molecular de-
tails, and links to PDB, andNucleic Acids Database (NDB)
(16), when applicable (Supplementary Figure S1A); (ii)
MD simulation. Information about simulation, trajectory
(video and interactive JSmol, http://wiki.jmol.org/index.
php/JSmol) (Supplementary Figure S1B); (iii) Trajectory
analyses. Access to the available pre-computed analyses
(Supplementary Figure S1C) and (iv) Trajectory selection.
Possibility to extract a particular slice and/or atom selec-
tion of the trajectory (Supplementary Figure S1D). Figure
2C shows a representative screen to access to analysis data
for one, several selected trajectories, or global analysis in-
cluding all database data (each bullet links to the analyses
of the indicated molecular fragment). As an example, Fig-
ure 3 shows details of the four consecutive steps required to
obtain the twist helical parameter analysis of a CG bp-step.
A complete help with tutorials can be found at the BIG-
NASim Web site, and in the Examples of Use (Section 5 in
Supplementary Material).
On-demand trajectories and analysis
The BIGNASim portal allows the user to download
dry/imaged trajectories from the available simulations for
further analysis. Additionally, the Cassandra’s infrastruc-
ture offers the possibility of generating new trajectories
choosing either time-slices, or molecular fragments (see
Supplementary Figure S1D). Those trajectories can be
downloaded for ‘in house’ analysis, but also can be sent to
the NAFlex engine (see Figure 1) accessing to specific nu-
cleic acids oriented analysis. Additionally, meta-trajectories
containing data for the same molecular fragment in differ-
ent simulations can be constructed and analysed in a similar
way (see Example of use in Section 5.3 of Supplementary
Material). This flexibility opens a nearly infinite number of
possibilities to post-analyse the stored simulation data.
Personal workspace. BIGNASim provides a personal
workspace to allow users to manage simulation data. De-
fault, anonymous, users are provided with a temporary
workspace where they can store data downloaded from the
database. The temporary workspace holds data retrieved in
a single session, however, using a specific URL provided in
the download operation, it is accessible for a defined pe-
riod of time. Alternatively, users may register on the system
and get a filesystem-like permanent workspace. In this case,
users will find all downloaded data in a single place. The
same structure can be used to upload data to be submitted
to the database.
Available analysis
BIGNASim includes a variety of analysis, specific suited to
nucleic acids (see Supplementary Table S1 for a complete
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Figure 2. Details of screenshots of the BIGNASim portal. (A) Details of the three search options. (B) Browser table. Column selectors and top search
box allow filtering contents. (C) Portal to available analyses, after trajectory selection. Also available for global database analyses. Each bullet leads to
analyses of the indicated molecular fragment. Number in parentheses indicates the available data items on each option. Full screenshots are available in
the Supplementary Material examples
list). Those include standard Cartesian and helical analyses
(9,12,17), principal component (PCA) (18,19) and helical
stiffness analysis (20,21). The server offers also the possi-
bility to determine stacking and hydrogen bonding interac-
tion energies along the trajectory, as well as NMR observ-
ables. In the case of protein-nucleic acid complexes, analy-
sis are performed on the nucleic acid component, and the
protein component is sent to our flexibility analysis por-
tal, FlexServ (http://mmb.irbbarcelona.org/FlexServ). New
analysis protocols, including specific methods for RNA or
protein-nucleic acid complexes, are expected to be added to
the platform in a near future.
DATA DESCRIPTION AND STATISTICS
BIGNASim has been designed to become a long term
archival platform for Nucleic Acids simulations, and its
content is expected to be in constant growth, incorporating
validated simulations from other groups. Both scientific and
technical quality of the stored datawill be assured through a
series of requirements (see Section 3 in Supplementary Ma-
Downloaded from https://academic.oup.com/nar/article-abstract/44/D1/D272/2503098 by guest on 18 September 2019
D276 Nucleic Acids Research, 2016, Vol. 44, Database issue
Figure 3. Screenshots of the BIGNASim portal. Example of navigation in the analysis structure for obtaining the twist parameter of CG bp-steps. (i)
Selection of series of analysis based on curves. (ii) Selection of helical parameters. (iii) Selection of the twist parameter calculated for CG steps on all
individual frames. Numbers in parentheses indicate the amount of available data items on each option. Raw histogram data are available for downloading.
Full screenshots are available in the Supplementary Material examples.
terial for the procedure and instructions to submit new tra-
jectories to the database). Simulations on BIGNASim are
grouped internally in logical data sets that can be eventu-
ally made public or kept on-hold depending on project’s re-
quirements. Its initial public data set corresponds mainly
to the benchmarking of the parmBSC1 force-field (14). Ta-
ble 1 shows the present global statistics of BIGNASim con-
tents. Detailed statistics are kept updated at the BIGNASim
site. To avoid bandwidth problems the data directly avail-
able from the web portal consist of 5000 frames of dry, im-
aged trajectories. Downloadable trajectories are fully con-
sistent with the pre-calculated analyses available at the web
site. Full trajectories, and direct access to the database are
available on request.
DISCUSSION
Data management is a major concern in modern bioinfor-
matics. Most of the large scale bioinformatics data projects,
usually in the genomics or biomedical field, invest signif-
icant efforts in data organization and provide specialized
structures to this aim (the Data Control Centres). However,
little effort has beenmade on finding similar solutions in the
biosimulation world, where also large volume of data is gen-
erated. This leads to the loss of precious information and to
the continuous recalculation of trajectories that have been
already obtainedmany times before in different laboratories
around the world.
The major issues of making such database open to the
community, in the same way as the Protein Data Bank (22)
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Table 1. Global statistics of BIGNASim
Type of simulation Number of simulations Cumulated simulation time
Total 156 120 s
DNA simulations 136 99 s
RNA simulations 14 15.6 s
Prot-DNA complexes 6 5.5 s
Type of analysed group Number of groups Number of stored data items
Total 12 449 18 092 839
Nucleotides (A, C, T, G) 6 516 9 643 652
Base Pairs (AT/TA, GC/CG) 3 043 4 155 377
Base Pair Steps (XpY) 2 890 4 293 810
Up to date statistics are available at BIGNASim portal.
is used to deposit experimental structures, are the limitation
of the database platforms used (mainly SQLbased systems),
the lack of standards to describe the data and, the lack of
tools to analyse trajectories at a high-throughput regime.
Several initiatives in this direction exist though. In 2013
the European Scalalife project published a white-paper on
Standards for Data Handling, also available at BIGNASim
web site. Later, Cheatham’s group presented a different but
compatible ontology for simulation data (23). The latter on-
tology has a better coverage on the simulation process con-
cepts while the Scalalife document was centred in data de-
scription. In this work, a variant of the Scalalife ontology
has been used, and completed, for the generation of simu-
lation metadata (see Ontology, Section 2 in Supplementary
Material).
Our aim here is to build a generally usable simulation
database that will be specially suited for storage and analy-
sis of nucleic acids trajectories.
The first decisionmade in our design was on the nature of
the database platform. It became clear from previous expe-
riences that traditional SQL based systems were too limited
for two main reasons: the inability to grow indefinitely, and
the need of a rigid schema. Modern NoSQL systems have
solved these two issues: they can scale horizontally and do
not require the previous setting of a data schema.
As noted above, we have chosen Cassandra to store tra-
jectories and MongoDB for analysis and metadata. Both
systems have specific advantages. Cassandra is very efficient
in data retrieval, especially for simple data structures. Data
are stored as raw atom-per-time coordinates, so no spe-
cific format is required. For coordinates I/O, we rely on
MDPlus, an extended version of MDAnalysis (15), which
is compatible with most used trajectory formats. Therefore
our system is able to select the output data format on-the-
fly, and hence to interact with most analysis software. The
Cassandra subsystem allows recovering any set of molec-
ular fragments and time-slices and even generating meta-
trajectories joining together data from several trajectories
sharing a common molecular fragment. This is a particu-
larly interesting feature in the simulation of nucleic acids,
as it is common to analyse a single sequence fragment in
different environments (7,24). On the analysis side, Mon-
goDB was selected due to its flexibility in data represen-
tation. Analysis data can be referred to single snapshots,
or averaged over trajectories, or meta-trajectories; they can
correspond to several types of molecular fragments (single
nucleotides, base pairs, base-pair steps); and can lead to any
data type, from single values to 3D grids. MongoDB offers
a very flexible data layout in a way that any data objects
could be easily mapped. Additionally, its powerful indexing
engine allows searches at any level (see examples of use in
Supplementary Material). MongoDB’s GridFS is used as a
file-system substitute to communicate the Cassandra with
the MongoDB subsystems and to support user workspace.
This provides an increased performance over traditional file
systems. BIGNASim is sharing the server with a complete
replica of the Protein Data Bank, which allows enriching
analyses with experimental data in a transparent manner
(see Use Case 4 in Supplementary Material).
Last, but not least, we cannot ignore that the MD analy-
sis world is in continuous evolution. Our database structure
and analysis portal have been designed to allow the easy
incorporation of new analysis types without the need of re-
configuration, which guarantees the long-term suitability of
our project.
CONCLUSION
We have presented here a complete platform to hold and
analyse nucleic acids simulation data. It is based on two
NoSQL database engines, Cassandra to hold trajectory
data and MongoDB for analyses and metadata. At its ini-
tial release, the database included the complete data set
used for the validation of the new parmBSC1 force-field
(more than 120 s of cumulated trajectory data), but its
structure is open to grow to integrate new simulations and
analysis strategies. The system is not limited in size, as the
database engines used scale horizontally, or complexity, as
MongoDB allows for a fully flexible data schema. Trajec-
tory data can be translated to the desired data format on-
the-fly, using the MDPlus package. Most common analy-
ses (helical parameters, NMR observables, stiffness, hydro-
gen bonding and stacking energies and geometries) are pre-
calculated for the trajectories available, to speed up their re-
trieval, but any of those analyses can be also done inter-
actively using our NAFlex interface, directly connected to
the platform. Additionally, whole trajectories, fragments or
meta-trajectories can be analysed or downloaded for fur-
ther in-house processing. To our knowledge this is the most
ambitious database initiative in the world of nucleic acids
simulations, and we expect that it will set the basis for a
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more general strategy in developing distributed simulation
databases.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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BioExcel Building Blocks, a 
software library for interoperable 
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In the recent years, the improvement of software and hardware performance has made biomolecular 
simulations a mature tool for the study of biological processes. Simulation length and the size and 
complexity of the analyzed systems make simulations both complementary and compatible with other 
bioinformatics disciplines. However, the characteristics of the software packages used for simulation 
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comprehensive exercise to bring biomolecular simulations to the “bioinformatics way of working”. The 
exercise has led to the development of the BioExcel Building Blocks (BioBB) library. BioBB’s are built as 
Python wrappers to provide an interoperable architecture. BioBB’s have been integrated in a chain of 
usual software management tools to generate data ontologies, documentation, installation packages, 
???????????????????????? ???? ?????????????? ???? ??????? ?????????????? ??????????????????? ????
computational environments.
Introduction
Biomolecular simulations have attained in the last years a level of maturity that allows to use them as “compu-
tational microscopes” to gain insight in biological processes. Atomistic simulations extend now to the μs range, 
approaching the time range of biological processes1,2. Coarse-grained simulations can go even further, in the 
length of simulations, and the size of the systems that can be analysed3–6. The traditional scope of simulations has 
overpassed the single protein or small nucleic acid systems to deal with relevant multiprotein and protein-nucleic 
acid complexes, nucleosomes, long segments of RNA, sections of chromatin or even full chromosomes5. This 
scenario envisions now a clear bridge between biomolecular simulations and genomics. Multiscale approaches 
can now bring together, for instance, Chip-seq data with simulation of protein-DNA complexes, or HiC or oligo-
paint FISH experiments with large scale simulations of chromatin fibers5. However, the type of tools, and the way 
they are used differ between genomics and biomolecular simulations. Simulations have been traditionally based 
on a reduced number of well optimized codes run in HPC systems, where they indeed occupy a large amount of 
resources (over 60 M CPU-hours of BSC’s MareNostrum supercomputer were dedicated to biomolecular simula-
tions in 2018). On the other hand, traditional bioinformatics uses many competing tools usually orchestrated in 
complex workflows. Considering data, genomics mobilizes indeed the major amount of it, however, the storage 
of a typical μs-range trajectory on a mid-sized system requires already some hundreds of GB like a human whole 
genome obtained by Next-Generation Sequencing (NGS).
Workflow orchestration is a well-accepted concept in bioinformatics. No single, universal, solution 
exists, and the number of available frameworks to build and run workflows is large (https://github.com/
common-workflow-language/common-workflow-language/wiki/Existing-Workflow-systems). Initiatives in the 
past like myGrid7 and BioMoby8, or more recent initiatives like CWL9, or WDL (https://software.broadinstitute.
org/wdl/), have attempted to define an interoperable ecosystem to run bioinformatics tools, web-services and the 
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workflows made out of them. Managers like Taverna10, Rabix11, Cromwell (https://cromwell.readthedocs.io/en/
stable/), KNIME12 or repositories like myExperiment13 allow to execute or store workflow definitions for further 
re-usage. In this context, the ELIXIR (http://elixir-europe.org) organization is working to put in place recommen-
dations to organize such ecosystem. At the level of registration, bio.tools14 and Fairsharing15 provide repositories 
for tools and standards. Specification languages like openAPI (https://www.openapis.org/), and CWL9 are being 
recommended to document APIs and workflows, respectively. In terms of workflow execution, Galaxy16 appears 
as the most popular framework, although other managers are also commonly used (e.g. Nextflow17, PyCOMPSs18, 
Snakemake)19. To formalize this scenario, the FAIR principles20, initially presented to improve the quality of 
scientific data, are now being extended to research software. The key requirements for that (registries, standards, 
software managers and open repositories) are already available. Several organizations including the Software 
Sustainability Institute (https://www.software.ac.uk/), Research Software Engineers’ associations, or ELIXIR itself 
are participating actively in the discussion.
Bioinformatics initiatives have little application to the simulation world. Simulations themselves are run in 
HPC systems in highly optimized environments. Most of the work, like setting up the simulation, a key step 
to assure the quality of the results21–24, and the analysis of trajectories, is done almost manually. Modelers use 
in-house scripts, typically based on the software included in the simulation packages. In this situation, researchers 
usually limit themselves to a single package for all steps: setup, simulation, and analysis. Therefore, since the pos-
sibility of complementing software functionalities across packages is limited, developers should provide complete 
sets, re-implementing what other packages provide already. Additionally, since data formats are also diverse, data 
conversion modules proliferate, what in turn raises the question of which combinations of tools (although theo-
retically compatible) would give correct scientific answers.
Efforts to automate simulation setup and analysis do exist. Several graphical interfaces have been designed 
to ease the interaction with specific simulation packages25–30. These tools are especially useful for non-experts as 
they simplify the learning process. However, these utilities are still linked to specific simulation packages. One 
of the attempts, by our group, was MDWeb31. This was the first approach to offer a unified workbench allowing 
to setup a protein system for atomistic molecular dynamics simulation, able to work for GROMACS32, NAMD33, 
and Amber34, three of the most popular simulation packages. Remarkably, MDWeb is powered internally by a 
series of web services built within the BioMoby framework and uses a common ontology of data types for the 
three simulation packages (http://mmb.irbbarcelona.org/MDWeb2/help.php?id=ontology). In this sense, this 
attempt, still in use with over 3,000 registered users, was rather unique. MDWeb was extended to the nucleic acids 
world with a nucleic-acids specific analysis portal, NAFlex35. At the large-scale end, systems have been designed 
to manage large scale simulation projects. Copernicus36 combines peer-to-peer communication strategies with a 
simulation specific workflow management system, able to control large simulation sets in a distributed computa-
tional network. The iBIOMES project37,38 reported an infrastructure to manage and share distributed simulation 
data, based in the iRODS framework (https://irods.org/). iBioMES has been used recently to manage nucleosome 
simulation data39, in a clear example for the growing overlap between simulation and genomics. Some simulation 
databases have also been built. Dynameomics40, centered in analysing protein folding and stability, MoDEL22 
offering an initial attempt of covering a significant sample of known protein structures, and BigNASim23, special-
ized in Nucleic Acids. Remarkably, MoDEL and BigNASim provided ontologies for representing simulation data 
(https://mmb.irbbarcelona.org/BIGNASim/help.php?id=onto).
Even though a large set of tools are normally combined, the concept of workflow, as understood in general bio-
informatics, is of limited usage. As said, most systems are setup and analyzed using in-house scripts. Recently, the 
BioExcel Center of Excellence (http://bioexcel.eu) has taken the objective of pushing the concept and usage of work-
flows into the biomolecular research field. In this work, we present a comprehensive exercise joining ELIXIR’s rec-
ommendations and services, FAIR principles, and biomolecular simulations. We have selected the automatic setup 
for molecular dynamics simulations of a protein system including sequence variants, as case for demonstration. The 
aim of the exercise is to assess the feasibility of working according the FAIR principles and ELIXIR’s recommenda-
tions in a field that is considered out of the scope of common bioinformatics. We will present a fully interoperable 
software library (the BioExcel Building Blocks, BioBBs) based mainly on (but not limited to) GROMACS32 software 
components. For the deployment of BioBBs, we have leveraged existing platforms and services commonly used in 
bioinformatics, like BioConda41, BioContainers42 or Galaxy16. Workflows built using components of such library 
have been executed in several complementary computational environments, including personal desktops, virtual-
ized systems, public e-infrastructures, and HPC systems. Besides, the components are documented using CWL and 
openAPI, what opens the possibility of run them in CWL complaint workflow managers.
Results and Discussion
Moving toward  FAIR principles. FAIR principles20 were defined with the aim of improving the quality of 
bioinformatics data repositories. Main principles include (1) Findability: Data should be findable, i.e. identified by 
permanent identifiers and included in searchable registries; (2) Accessibility: Data should be stored in permanent 
repositories and accessible in a machine readable form, (3) Interoperability: Data should use well-documented 
formats and standards to allow to interoperate with complementary datasets; and (4) Reusability: Documentation 
about the conditions and limitations of data reusability should be provided. Adherence to these principles has 
become part of the best-practices in bioinformatics data management and begins to be generally understood 
and accepted by the research community. They cannot be applied blindly to research software, but the general 
guidelines can be adapted.
Findability. A primary requirement for findability in the case of software is the availability of a software registry. 
Traditional software repositories like GitHub (https://github.com), are suitable for such usage although they are 
not usually seen as data resources, and the amount of available scientific metadata is limited. To overcome this 
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limitation, registries with different degrees of acceptance exist (https://www.genscript.com/tools.html; https://
omictools.com/; https://www.fda.gov/ScienceResearch/BioinformaticsTools/default.htm). ELIXIR has pushed its 
own tools registry (bio.tools)14. It includes a large set of metadata that allows to search for tools according to their 
scientific utility, and provides extended metadata regarding publications, documentation and support. It is linked 
to ELIXIR’s software benchmarking platform, openEBench (https://openebench.bsc.es), which in turn provides 
data for technical and scientific quality assessment of bioinformatics applications. One of the most remarkable 
features of bio.tools is the use of an extended ontology (EDAM43) for annotation. EDAM annotations allow to 
classify tools according the type of data they consume or produce and provides a controlled vocabulary to define 
their precise functionality. This information has been used to derive tools’ annotation for CWL, or Galaxy44,45 
automatically. Unfortunately, ontology terms for structural bioinformatics, in general, and biomolecular sim-
ulation specifically, were scarce in EDAM. The generation of ontologies on simulation have been attempted in 
the past22,23, but such ontologies have been seldom used outside the projects that generated them. However, the 
interest for addressing simulation data management has increased recently24.
The first step of this exercise was to essay the registration in bio.tools of tools required for setup and analysis of 
a protein simulation. From this assay, several missing data types, file formats, and functionalities were collected 
(see Supplementary Table S1). We have taken the experience in MDWeb31, MoDEL22, and BigNASim23 ontologies 
to fill the gaps in EDAM. The additions included setup, simulation and analysis operations, specific data types 
like system topology, trajectories, or principal components, and file formats covering the most popular simula-
tion codes (Supplementary Table S1). These new terms have been already included in EDAM v1.22 (https://raw.
githubusercontent.com/edamontology/edamontology/master/EDAM_dev.owl) and will be available for tools 
annotation in short. More than thirty simulation related tools, besides the BioBB library components have been 
registered in bio.tools. To provide an additional means for findability, a BioSchemas – based specification (http://
bioschemas.org/) has been included in the appropriate places of BioBB’s documentation.
A software architecture for interoperability. The recipe for full tool interoperability is theoretically simple: the use of a 
common, universal, data model. Past attempts like myGrid7 and BioMoby8 put foundations to this concept, by building 
a community-based data ontology and suggesting tool developers to stick to it when generating new tools. However, 
this attempt was not successful. The community-based approach made difficult to keep control on the evolution of the 
ontology. Similarly, in Galaxy servers, for instance, system administrators may add ad-hoc types and formats, hence 
contributing to make the scenario even more complex. In summary, attempting to generate a common data model 
for bioinformatics remains as a hard issue. Fortunately, when we focus on specific fields (NGS, array analysis, etc.), the 
options are limited, and de-facto standards do exist (bam, vcf, gff file formats in NGS analysis, for instance). Similarly, 
in biomolecular simulation the limited number of software packages makes the scenario less complicated. In any case, 
however, tool interoperability is an issue; a large set of operations in bioinformatics are, in fact, format conversions, and 
there is no security that an input data file is compatible with a given tool, even though that the format is the correct one.
In this exercise, we have defined a specific software architecture to contribute to the interoperability (Fig. 1). 
We use simple wrappers, written in Python, to encapsulate software components. Wrappers are organized in lay-
ers. The inner layer corresponds to the original tool, unaltered. Command-line tools, web services, software con-
tainers, or even remote calls to HPC systems, can be included here. A second one, the compatibility layer, provides 
the module with a well-defined interface for input, output, configuration, and provenance. It performs internally 
the necessary format conversions at input and output and launches the tool. This interface can be fully docu-
mented and specified using accepted standards like openAPI or CWL and can remain stable even when the asso-
ciated tool needs to be updated. These two-layer wrappers can be already integrated in scripts as Python modules 
or executed as standalone command-line tools. A third layer, the adaptor, may be required for the integration in 
execution engines or e-infrastructures. BioBBs adaptors for Galaxy, PyCOMPSs, and CWL compliant managers 
are provided. Such adaptors can be used as templates to extend the usability of the library to other environments.
This architecture, even though it does not provide a common data model, do provide a uniform and stable 
interface, with enough information to plug the components into interoperable workflows (see below). Besides, 
any updates in the inner software tool would require only to update the wrapper, maintaining compatibility with 
previous versions, workflows, and with the chosen deployment options. Table 1 shows the present list of BioBBs 
with indication of their functionalities and associated tools.
Providing accessibility and enabling (re)usability. In the case of tools, the accessibility requirement is even stricter 
than for data: software not only should be accessible, it needs to be installed and executed. Different execution 
scenarios should be considered in the case of biomolecular simulations. They include personal workstations, 
used mainly for setup and analysis, or HPC systems where simulations are usually obtained. To address this prin-
ciple, BioBB’s use several deployment possibilities. Figure 2 shows a global information flow, and Online-only 
Table 1 summarizes the URLs corresponding to the different BioBB deployment alternatives. The main software 
repository used is available on Github. Information embedded in the code allows to generate (1) documentation 
using the ReadTheDocs platform (https://readthedocs.org/), (2) a JSON schema for library specification using 
openAPI, and (3) a reference CWL specification. To ease the deployment in a complete set of environments we 
have put together several packaging systems and services (Fig. 2). From the code deposited in Github, BioBBs 
have been uploaded to the Python Packaging Index Pypi (https://pypi.org/). Also, BioConda41 packages have been 
prepared. These will allow to handle software dependencies in a transparent way, including the installation of 
the embedded tools. Considering only these two options, the package would be already available for installation 
where command-line is the main execution procedure, like personal workstations, clusters, virtual machines, or 
HPC. Installation can be done both as system-wide Python packages or using Python virtual environments. This 
kind of installation is illustrated by the execution of the lysozyme test (see below) in a Jupyter Notebook (https://
jupyter.org/). Following from BioConda packages, and due to its integration with the BioContainers project42, 
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Docker containers are automatically generated and deposited in the quay.io repository. Offered Docker containers 
provide functionality for either individual packages to be integrated in more complex layouts, or complete work-
flows. Docker containers, in turn, are converted to Singularity containers that can be used in security demanding 
environments like HPC. Containers allow the non-expert user to deploy the software easily. For instance, Docker 
containers have been used to deploy BioBBs in a test Galaxy installation (http://dev.usegalaxy.es). BioBBs, encap-
sulated as Virtual Machines, are also available on BioExcel cloud portal (https://bioexcel.ebi.ac.uk), and EGI’s 
appDB (https://appdb.egi.eu). Table 2 summarizes the recommended installation and execution options for the 
environments tested in the project.
BioBBs are fully open source, distributed under the Apache-2 license. Wrapped applications have their own 
licensing schemes, but for the library provided at present only open source software has been included.
Testing BioBBs in several environments. Setup for simulation for protein variants workflow. To test the feasibility of 
the software architecture, we have chosen a well-known procedure, the setup in standard conditions for molecular 
dynamics simulations of a protein system with sequence variants. We have used two biological systems: Lysozyme 
(PDB id 1AKI)46, and Pyruvate kinase (PDB id 2VGB)47. Lysozyme is a small protein (129 res), which structure 
is available at a high resolution. The second system, Pyruvate kinase is a 200 kDa homo-tetramer, meaning a 
~400,000 atom system after setup. Pyruvate kinase is a well-studied system with relevance in the understanding of 
allosteric regulation, but also of biomedical interest: more than 200 sequence variants related to pathogenic effects 
have been reported48. The test-cases consisted in a standard setup for NPT simulation with explicit solvent of sev-
eral selected variants, followed with 5 ns long simulations, and a simple RMSd comparative analysis (see Method 
section). Supplementary Figs S1 and S2 show a schema of the simulation setup workflow as rendered by CWL 
viewer (https://view.commonwl.org) and Galaxy respectively. We have tested (1) the feasibility of running the 
workflow (including software installation, and workflow execution) in a variety of computational environments 
(Lysozyme test) and (2) its scalability on HPC systems (Pyruvate kinase test). Supplementary Table S3 shows a 
summary of the architectures and the executions performed. Execution times are shown just for illustration pur-
poses and are totally dependent on the hardware used. Since most of the execution time corresponds to the sim-
ulation phases, no significant overhead in using the different execution approaches was detected. Parallelization 
has been carried out at different levels. PyCOMPSs has been used to deal with simulations of different protein 
variants, at a ratio of 1 variant per process. GROMACS parallelization schemes (OpenMP for intra-node par-
allelization and MPI when several nodes were involved) were used in the simulation phase. Linear scaling has 
been observed in all cases (note the similar wall-clock times between the two extreme executions made at BSC’s 
MareNostrum, ranging from 2 variants, 384 cores, to 200 variants, 38,400 cores).
Conclusions
Biomolecular simulations are seldom considered as part of the field known as bioinformatics, even structural bio-
informatics. Reasons for that come not only from the use of a different kind of tools and computational resources, 
but also from the traditional lack of applicability of simulation results to day-to-day biology. In the recent years, 
simulation has attained a significant level of maturity, and simulation results are now compatible with biologically 
Fig. 1 BioExcel building block architecture. BioBB’s structure split in three main layers: The inner layer 
corresponds to the original tool unaltered, the second one, the Python compatibility layer provides a 
standardized interface, the third one, the outer workflow manager adaptation layer translates the Python 
standard interface to each specific WF manager.
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relevant systems and time scales. Biomolecular simulations are already tackling questions that can be relevant for 
genomics, or transcriptomics. However, the isolation of biomolecular simulations in the context of bioinformatics 
has prevented the adoption by this community of normal software trends in bioinformatics, like automatic soft-
ware deployment or the use of workflow managers. We have presented here the exercise of treating biomolecular 
simulations as normal bioinformatics operations. To this end, we have decorated standard simulation operations 
with a series of concepts and procedures, like an initial adherence to FAIR principles, the usage and documenta-
tion of workflows and stable interfaces, and the availability of a variety of deployment options, that are becoming 
routine in bioinformatics. FAIR principles for software have not yet been defined in the way as they exist for data. 
The exercise has led to an approach to the selection of software features (registration, methods of installations and 
deployment, documentation, licenses) that can be considered as an initial approach to them. The main outcome 
of the exercise is a complete software library (the BioBBs) that can be installed, deployed, and used as traditional 
bioinformatics applications, but provides a set of operations related to biomolecular simulations. BioBBs have 
been incorporated to the bioinformatics ecosystem: (1) The necessary new terms have been added to EDAM 
ontology, and tools included in the bio.tools registry. Bio.tools would provide a permanent identifier for them 
and the required metadata to assure their findability; (2) Interoperability has been addressed by the design of 
BioBBs architecture, but also through the use of recommended standards for specification (OpenAPI, CWL); and 
(3) Accessibility and usability have been addressed by using the set of well-known utilities, like Pipy, BioConda, 
BioContainers, or Galaxy, allowing the deployment and test of the library in a variety of alternative environments, 
from personal workstations to HPC.
BioBBs align with a variety of software that focus in similar functionality, however it opens the integration of 
biomolecular simulation operations into a more general bioinformatics landscape using similar, and compatible, 
software management procedures.
Methods
Atomistic simulations. Lysozyme test. Simulation of two sequence variants (Val2Tyr, and Val2Ala) of 
chicken Lysozyme (PDB code 1AKI)46 were prepared as follows. Protein structure was obtained from the Protein 
Data Bank49. Amino acid side chains were modified as appropriate using the biobb_model package. Hydrogen 
atoms were added to the structure using standard ionization at pH 7.0. Protein was placed in a Cubic box of 
explicit water solvent (SPC/E water model)50 with the appropriate size to allow 1 nm from the outermost protein 
atom. Periodic Boundary Conditions were applied. Cl− and Na+ ions were added to reach an ion concentration 
of 0.05 M and neutralize the system. Simulations were run using GROMACS 2018, and the Amber99sb-ILDN 
forcefield51. Temperature was maintained at 300 K and pressure to 1 atm. Setup was completed by 5,000 steps of 
Block group Block Id
Wrapped 
software Functionality description
biobb_io
MmbPdb API Call Downloads a PDB file from the RCSB or MMB REST APIs
MmbPdbVariants API Call Creates a text file containing a list of all the variants mapped to a RSCB PDB code from the corresponding UNIPROT entries.
MmbPdbClusterZip API Call Creates a zip file containing all the PDB files in the given sequence similarity cluster percentage of the given RSCB PDB code
biobb_model
fix_side_chain in house Reconstructs the missing side chains and heavy atoms of the given PDB file
mutate in house Creates a new PDB file performing the mutations given in a list of amino acid mutations to the input PDB file.
biobb_md
Pdb2gmx gmx pdb2gmx Creates a compressed (ZIP) Gromacs topology (TOP and ITP files) from a given PDB file.
Editconf gmx editconf Creates a Gromacs structure file (GRO) adding the information of the solvent box to the input structure file.
Genion gmx genion Creates a new compressed Gromacs topology adding ions until reaching the desired concentration to the input compressed Gromacs topology.
Genrestr gmx genrestr Creates a new Gromacs compressed topology applying the indicated force restrains to the given input compressed topology.
Grompp gmx grompp Creates a Gromacs portable binary run input file (TPR) applying the desired properties from the input compressed Gromacs topology.
Mdrun gmx mdrun Performs molecular dynamics simulations from an input Gromacs TPR file.
Make_ndx gmx make_ndx Creates a Gromacs index file (NDX) from an input selection and an input Gromacs structure file.
Solvate gmx solvate Creates a new compressed Gromacs topology file adding solvent molecules to a given input compressed Gromacs topology file.
Ndx2resttop in house Creates a new Gromacs compressed topology applying the force restrains to the input groups in the input index file to the given input compressed topology.
biobb_analysis
cluster gmx cluster Creates cluster structures from a given input trajectory.
rms gmx rms Performs an RMS analysis of the given input trajectory.
cpptraj cpptraj Performs multiple analysis of a given trajectory.
biobb_common — — BioBB Base structure & common elements
biobb_template — — Generic template to build new blocks
Table 1. List of available BioExcel Building blocks. Blocks are grouped by the type of operation and external tool.
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steepest-descent energy minimization, followed by a 10 ps-long NVT equilibration, and a 10 ps-long NPT equi-
libration runs with a restriction of 1,000 kJ/mol.nm2 put on heavy atoms. Production phase for the test consisted 
in 5 ns of unbiased NPT simulation at 2 fs time step. The LINCS algorithm52 was used to keep covalent bonds at 
their equilibrium distances. Simulation setup and equilibration were done using components of the biobb_md 
package.
Pyruvate kinase test. 200 sequence variants for Human erythrocyte Pyruvate kinase (PDB code 2VGB)47 were 
obtained from UniprotKB53 (biobb_io package). Protein structure was obtained from the Protein Data Bank49. 
All non-protein components of the structure were removed, and protein variants were prepared by modifica-
tion of the appropriate amino acid side chains using biobb_model package. Hydrogen atom were added con-
sidering standard ionization states at pH 7.0. Simulation was done in a truncated octahedron box placed at a 
distance of 1.5 nm from the outermost atom of the protein, using TIP3P water molecules54, and using Periodic 
Boundary Conditions. Ions Cl− and Na+ were added to reach an ion concentration of 0.05 M and neutralize the 
system. The Particle mesh Ewald method55 was used to calculate electrostatic and Van der Waals interactions, 
with 0.12 nm of FF grid spacing and a cut-off distance of 1 nm for both Coulomb and Lennard-Jones interactions. 
The LINCS algorithm52 was used to keep covalent bonds at their equilibrium distances. Simulations were run 
using GROMACS 2018, and the Amber99sb-ILDN forcefield51. Temperature was maintained constant at 300 K 
(except in gradual heating), in two separate baths for the protein and non-protein groups, with the V-rescale 
thermostat56 and a coupling constant of 0.1 ps. Pressure was isotropically maintained at 1 bar in NPT ensembles 
through Parrinello-Rahman coupling57 with a constant of 1 ps, and applying a scaling of the center of mass of the 
reference coordinates with the scaling matrix. Given the size and complexity of the system, the Pyruvate kinase 
equilibration was performed with a more extended procedure: Setup was completed with two 5,000 steps energy 
minimizations, the first with a restrained potential of 500 kJ.mol−1.nm−2 on all heavy atoms except those in the 
side chain of the mutated residue, and the second with all heavy atoms restrained. Systems were then equilibrated 
with the following steps: (1) 100 ps of gradual heating from 0 to 300 K with 1,000 kJ.mol−1.nm−2 of restrained 
Fig. 2 Recommended distribution and deployment flow of the BioBBs. Distribution and packaging tools 
used to facilitate BioBB’s installation and execution in a wide range of platforms: HPC, Cloud computing, user 
workstations and even browser interfaces.
Architecture
Installation alternatives Workflow Execution alternatives
PyPI BioConda VM Container Script CWLtool PyCOMPSs Galaxy
Workstation A R (T) A A R (T) A A
Cloud A A R (T) R R (T) A A
MareNostrum (HPC) A A (T) R A R (T)
Galaxy A R (T) R (T)
Table 2. (A)vailable and (R)ecommended alternatives for Biobb installation and workflow execution. (T)est 
executions performed. Container generic denomination corresponds to Docker containers in the workstation, 
cloud and Galaxy cases and to Singularity containers in the MareNostrum HPC case.
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potential in heavy atoms except for mutated side chains, (2) four 20 ps steps of equilibration with descending 
restrain force constants in the same atoms (from 1,000 to 300 kJ.mol−1.nm−2), (3) two 10 ps steps of NPT equi-
libration with restraints in all backbone atoms (200 and 100 kJ.mol−1.nm−2 respectively) and (4) a 100 ps NPT 
equilibration without restraints. After equilibration, we ran 5 ns of unbiased NPT simulation. Simulation setup 
and equilibration were done using components of the biobb_md package.
Computational systems used. Systems used on Lysozyme test were: Workstation: ThinkStation E30 
(LENOVO). Operating system: Linux Ubuntu 18.04. 8 CPU Intel(R) Xeon(R) CPU E31230 @ 3.20 GHz (1 socket, 
4 cores/socket, 2 threads/core). 16 GB of RAM. Virtual Machine: 12 CPU QEMU Virtual CPU version 2.5+. 24 
GB of RAM. Galaxy: 2 CPU QEMU Virtual CPU version 2.5+. Pyruvate kinase test was performed on BSC’s 
MareNostrum supercomputer using from 2 to 800 nodes of 2x Intel Xeon Platinum 8160 24C at 2.1 GHz, 12 × 8 
GB of RAM. Largest test used 4 nodes per simulation with a total of 38,400 cores.
Data Availability
The test data of each building block is available in the correspondent Github repository, see Online-only Table 1. 
The full data collection on the testing phase for BioBBs is available at ref.58.
Code Availability
BioBB’s source code is available at GitHub. URLs for the code and documentation repositories and the alternative 
installation and execution options are summarized in Online-only Table 1.
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function9, interactions10 or normal localization in the cell11. 
Not surprisingly, a recent analysis of more than 400 proteins 
found that up to 20% showed different localization patterns in 
a comparison between fluorescence-tagged proteins and those 
detected by immunofluorescence methods3.
Here we describe and characterize a set of small protein 
domains, which we term inntags, developed with the goal of 
minimizing the risk of functional and structural interference in 
protein tagging. To identify candidate inntags, we performed a 
search for protein domains that have a known three-dimensional 
(3D) structure and a set of specific properties (Online Methods 
and Supplementary Table 1). These structures were further 
scrutinized with the aid of additional criteria (Online Methods) 
to obtain 12 inntag candidates, which correspond to nine proteins 
from plants and insects, two fimbria-associated bacterial proteins 
and one viral envelope protein (Supplementary Fig. 1a).
Misfolded proteins commonly accumulate as aggregates that 
can be easily observed by microscope as varying types of inclusion 
bodies12. Although most inntag fusions attained expression levels 
similar to that of the GFP control construct, many of them displayed 
different degrees of aggregation (Supplementary Fig. 1b–d), 
and only inntags IT5, IT6 and IT10 produced a diffuse pattern in 
all cells. Thus, we selected these three inntags (Supplementary 
Table 2) to further test their suitability as protein tags.
Despite their small size, the structure of the IT5, IT6 and 
IT10 inntags is based on a packed ?-sheet conformation that, in 
the case of the two smaller domains (IT6 and IT10), is probably 
stabilized by several disulfide bridges (Fig. 1b). Integrity 
and stability of GFP and human cyclin E were unaffected by 
these inntags, and their presence did not modify the intracel-
lular mobility of GFP as deduced by fluorescence loss in photo-
bleaching (FLIP) analysis, thus confirming the absence of stable 
associations of the selected inntags with cytoskeletal or other 
large cellular structures (Supplementary Fig. 2). Finally, as both 
fluorescence and protein levels were not affected by the presence 
of any of the inntags (Supplementary Fig. 2), we conclude that 
the three selected inntags do not grossly affect the folding and 
maturation rates of the fused GFP moiety.
We hypothesize that, given their low disorder propensity, 
inntags IT5, IT6 and IT10 should be less likely to produce 
unwanted effects than unstructured peptides such as HA, Flag and 
MYC, three commonly used protein tags that have much higher 
disorder propensity values (Fig. 1c). Intrinsic protein disorder has 
been associated with deleterious gene-dosage effects13, and gene 
overexpression in budding yeast has proved to be an invaluable 
Inntags: small self-
structured epitopes for 
innocuous protein tagging
Maya V Georgieva1,9, Galal Yahya1,2,9, Laia Codó3,4, 
Raúl Ortiz1, Laura Teixidó5, José Claros6, Ricardo Jara6,  
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Protein tagging is widely used in approaches ranging from 
afﬁnity puriﬁcation to ﬂuorescence-based detection in live 
cells. However, an intrinsic limitation of tagging is that the 
native function of the protein may be compromised or even 
abolished by the presence of the tag. Here we describe and 
characterize a set of small, innocuous protein tags (inntags) 
that we anticipate will ﬁnd application in a variety of 
biological techniques.
Proteins and peptides of various sizes and shapes have been 
used since the early 1980s1 to tag proteins for many different 
purposes, ranging from affinity purification2 to microscopic 
detection in whole organisms3. Whereas large, well-folded tags 
can serve to solubilize proteins, small, unfolded peptide tags 
have become invaluable tools for protein purification as well as 
protein-protein interaction studies. Yet both types of tagging 
strategies run the risk that the native function of the protein 
may be abolished or compromised through interactions with 
the tag. Large self-structured tags are more likely to cause steric 
interference than small tags4. However, as they are intrinsically 
disordered, short peptide tags can adopt a wide variety of con-
formations5, which may facilitate interactions with the target 
protein and have unpredictable and adverse effects at differ-
ent levels (Fig. 1a). First, spurious tag-driven interactions at 
intermediate steps of folding may prevent the target protein 
from reaching its final, mature conformation and favor its 
accumulation in large aggregates6. Second, both the misfolded 
and correctly folded fusion protein may be more susceptible 
to degradation. In this regard, one of the most commonly 
used small tags, HA, contains a cryptic caspase-cleavage site7. 
Finally, if unwanted interactions occur at essential target protein 
domains, the tag may modify the protein’s structure8, proper 
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tool to establish functional relationships and pathways14. Thus, 
we analyzed the fitness effects of these tags when overexpressed 
as fusions with GFP in yeast cells. Because HA, Flag and MYC 
epitopes are routinely used as tandem repeats to improve the 
efficiency of immunodetection, we also analyzed hexameric 
versions of these tags, which have similar polypeptide lengths to 
inntags. Whereas monomeric versions of HA, Flag and MYC did 
not produce noticeable effects, the MYC6 tag caused a twofold 
reduction in growth rate and a tenfold reduction in chronological 
lifespan (Supplementary Fig. 3a). Although the effects were not 
as pronounced, Flag6, HA6, IT5 and IT10 also decreased these 
two cell-fitness parameters, and only IT6 did not cause any effect 
when compared to untagged GFP in these assays.
Cell size is one of the main attributes that determine functional 
efficiency in multicellular organisms and fitness in unicellular 
organisms15. We found that the MYC6 tag clearly dysregulated 
this fitness parameter, causing a nearly twofold increase in critical 
size when overexpressed as a GFP fusion (Fig. 1d). HA6, Flag6, 
IT5 and IT10 also caused an increase in the critical size to differ-
ent extents, but the difference due to IT6 overexpression was not 
significant (P < 0.05). Although the monomeric HA, Flag and 
MYC tags produced only minor effects, these tags produced a clear 
increase in the intrinsic variability of critical size (Supplementary 
Fig. 3b). Notably, IT6 did not alter this physiological parameter.
To further characterize the differential deleterious effects of tags 
on cell fitness we chose MYC6 and IT6 to perform a proteome-wide 
analysis of interactors from yeast cells. A total of 183 proteins 
were identified at a 95% confidence level with complete iTRAQ 
data in all pulldown samples, and an average enrichment ratio was 
obtained to compare the relative levels of each interactor in MYC6 
or IT6 pulldowns relative to those in His6-GFP (Supplementary 
Table 3). Once ribosomal proteins were excluded, the functional 
category among interactors most frequently enriched in the MYC6 
pulldown was related to protein folding (Fig. 1e), with a simulation- 
corrected P value of 0.00031. This set of proteins was not present 
among the enriched interactors of IT6, and no correlation was 
observed when comparing the cellular processes with specific 
interactors of MYC6 and IT6. Notably, proteins belonging to 
the chaperone family were clearly enriched (P = 7.3 × 10−4) in 
MYC6 compared to IT6 pulldowns (Fig. 1f), suggesting that over-
expression of disordered proteins could compromise the efficiency 
of the molecular chaperone network by direct nonproductive 
interactions. Supporting this notion, the presence of MYC6 clearly 
reduced (P = 8.7 × 10−6) the intracellular diffusion coefficient of 
GFP in yeast cells (Fig. 1g).
To enable the use of selected inntags in immunofluorescence 
and immunoprecipitation applications, we expressed and purified 
monomeric IT5 or dimeric IT6, and their corresponding fusions 
to GFP, from Escherichia coli cells (Supplementary Fig. 4) for 
mice immunization, and obtained highly specific monoclonal 
antibodies (Fig. 2a,b). Immunofluorescence analysis showed 
that IT6 was slightly superior to HA6 and IT5, and all other tags 
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Figure 1 | Cell fitness effects and interactome analysis of selected  
inntags and other commonly used tags. (a) Epitope tags may have diverse,  
deleterious structural and functional effects on target proteins. Tags can  
interfere with proper folding of target proteins and cause aggregation or  
degradation of misfolded intermediates or drive spurious conformational  
changes that alter the function or intracellular localization of the target  
protein. (b) Structures of inntags IT5 (PDB 1WHP), IT6 (PDB 1WKX) and  
IT10 (PDB 3BBG) selected by bioinformatics screening. (c) Disorder  
predisposition of tags at the amino acid resolution level. (d) GFP fusions  
to different tags were overexpressed in budding yeast cells to determine  
individual critical volumes at budding (N > 400). Mean values (thick  
vertical lines) and confidence limits (? = 0.05, thin vertical lines) for  
the mean are also shown. (e) iTRAQ analysis of proteins interacting with  
MYC6 and IT6 GO terms and the corresponding uncorrected P values (−log)  
of yeast proteins interacting with MYC6 or IT6 fused to His6-GFP and  
identified by iTRAQ. (f) iTRAQ ratios obtained for MYC6 and IT6 interactors belonging to the family of molecular chaperones (Hsp60, Sse1, Ssa1,  
Ssa2, Ssb2, Ssc1, Sti1, Aha1, Ydj1 and Sis1). Mean enrichment values (thick horizontal lines) relative to untagged GFP and confidence limits  
(? = 0.05, thin horizontal lines) for the mean are also shown. (g) Yeast cells overexpressing GFP fused to MYC6 and IT6 were analyzed by time-lapse 
confocal microscopy under FLIP conditions. Protein mobility mean values (N = 40 cells) and confidence limits for the mean (? = 0.05) are shown.  
r.u., relative units. Comparable quantitative differences were obtained from a replicate experiment (d,g); statistical data were obtained from  
three independent pulldown experiments (e,f ).
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were very inefficient and produced low signal-to-background 
ratios (Fig. 2c). Inntags IT5 and IT6 were also very efficient 
for immunoprecipitation of human and budding yeast proteins 
(Fig. 2d–f) or fusions to GFP (Supplementary Fig. 5a–c). Inntags 
IT5 and IT6 displayed similar immunoprecipitation efficiencies 
to that of monomeric Flag and MYC tags, while monomeric HA 
was very ineffective.
Inntag fusions to paradigmatic proteins that localize to 
different cellular compartments in mouse fibroblasts (Fig. 2g  
and Supplementary Fig. 6) and hippocampal neurons (Fig. 2h) 
displayed the expected intracellular localization and, more 
importantly, we did not observe aggregates or a noticeable 
mislocalized fraction that would suggest anomalous effects 
or interactions.
Cyclin-dependent kinases (CDKs) exert multiple interactions 
(Fig. 3a) to perform a series of exquisitely regulated processes 
that drive the eukaryotic cell cycle16, and modification of these 
interactions has a profound impact on their precise execution. 
None of the tags caused observable effects on levels or integrity of 
the CDK Cdc28 (Supplementary Fig. 7a). However, the Cdc28-
Flag6 fusion caused a dramatic change in both cell size and shape 
(Fig. 3b), indicating important alterations in the morphogenetic 
pathways involving Cdc28 in both G1 and G2 phases. In con-
trast, although the IT5 inntag has a similar length to that of the 
Flag6 tag, it did not affect cell morphology and only produced a 
very mild effect in the mean critical size at the G1/S transition 
compared to Flag6 (Fig. 3c). The HA3 tag did not cause gross 
morphological defects, but it did induce a strong increase in the 
critical size at the G1/S transition (Fig. 3c). A comparable effect 
in the average critical size was produced by a fusion of Cdc28 to 
a much larger GFP tag (Supplementary Fig. 8a). By contrast, 
inntag IT6 did not cause significant (P < 0.05) changes in the 
critical size of budding yeast cells.
Molecular chaperones use energy derived from ATP hydroly-
sis to transmit conformational changes to client proteins, thus 
facilitating their proper folding and promoting assembly or 
disassembly of high-order protein complexes17. Ydj1 is the most 
abundant J-domain chaperone in budding yeast and, besides 
acting in proteome homeostasis, has a key role in releasing the 
G1 cyclin Cln3 from the endoplasmic reticulum to trigger cell-
cycle entry18. As Ydj1 contains a dimerization domain at the 
C terminus (Fig. 3d) that is essential for its function, we used 
C-terminal fusions at the endogenous YDJ1 locus (Supplementary 
Fig. 7b) to perform a comparative analysis of tags on Ydj1 function. 
Similarly to Cdc28, fusion of Ydj1 to the Flag6 tag produced the 
most severe effects, which could be observed even under normal 
conditions of growth at 30 °C (Fig. 3e). Both Flag6 and HA3  
tags produced a clear reduction in growth at high temperature, 
where Ydj1 function becomes particularly essential. By contrast, 
fusion of Ydj1 to inntags IT5 and IT6 produced only very mod-
erate effects on growth at 37 °C (Fig. 3e). Ydj1 is also important 
for coordinating growth and cell cycle entry to set the criti-
cal size18,19 and, consistently with their effects on growth rate, 
both Flag6 and HA3 tags caused a marked increase in cell 
size (Fig. 3f), similar to that produced by a large GFP tag 
(Supplementary Fig. 8b). In contrast, neither IT5 nor IT6 
produced an obvious effect on the critical size.
In summary, monomeric HA, Flag and MYC tags are inefficient 
compared to inntags in critical applications such as immuno-
precipitation and immunofluorescence, and multimeric versions 
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Figure 2 | Comparative analysis of inntags in  
immunofluorescence and immunoprecipitation applications.  
(a) GFP fusions to the different tags were expressed in  
HEK293T cells and analyzed by direct fluorescence (top) or  
immunofluorescence (bottom). A sample of GFP-transfected  
cells is shown. Scale bar, 20 ?m. (b) Quantification of  
immunofluorescence signal-to-background ratios produced  
by various tags in HEK293T cells. Mean values (N > 40) and  
confidence limits for the mean (? = 0.05) are shown.  
(c) Yeast cells expressing GFP fusions to the indicated tags  
were analyzed by immunofluorescence with their respective  
antibodies to obtain signal-to-background ratios. Mean values (N = 100) and confidence limits for the mean (? = 0.05) are shown. (d,e) Total extracts 
(CEs) and immunoprecipitates (IPs) of HEK293T cells expressing cyclin E (d) and budding yeast cells expressing Cdc28 (e) fused to various tags,  
detected with antibodies to cyclin E (CycE) (d) and Cdc28 (e). (f) CEs and IPs of budding yeast cells expressing Tdh1 fused to the indicated tags, 
analyzed by immunoblotting with anti-Tdh1. Untagged Tdh1 is indicated by an asterisk. (g) Inntag IT6 fused to ?−actin (cytoskeleton), STX6 (Golgi), 
HO1 (endoplasmic reticulum), histone H1 (nucleus), HDAC2 (nucleus) or GRB2 (plasma membrane) was expressed in NIH3T3 cells and analyzed  
by immunofluorescence (red) with an antibody to IT6. GRB2 images correspond to mitotic cells, where the cytoplasmic membrane is best seen.  
Hoechst-stained nuclei are also shown (blue). Scale bar, 10 ?m. (h) Left, an inntag IT6 fusion to FMRP, which localizes to synapses, expressed in  
mouse hippocampal neurons and analyzed by immunofluorescence (red). A first-derivative image of cotransfected GFP to enhance somatic and  
neuritic limits is shown as reference. Scale bar, 25 ?m. Middle and right, 5× amplification (middle) and 3D projection of the region outlined at left;  
scale bar, 5 ?m. Comparable quantitative differences were obtained from a replicate experiment (b,c).
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of these tags cause strong deleterious effects in key cell-fitness 
parameters and have profound functional interference effects 
on a CDK and a chaperone, proteins with strong interaction 
requirements. Given their structural and functional innocuity 
and their suitability for in situ analysis, we expect that inntags will 
prove to be valuable tools for studying physical and functional 
interactions of proteins, particularly when single-molecule20  
or high-throughput approaches21 are intended.
METHODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. Addgene: Inntag sequences in plasmid vec-
tor have been deposited under accession numbers 66869, 66870 
and 66871. Leibniz Institute DSMZ: hybridoma data have been 
deposited under accession numbers ACC3234, ACC3242 and 
ACC3236.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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Figure 3 | Functional innocuity tests of 
inntags on proteins with strong interaction 
requirements. (a) Structural representation  
of Cdc28 based on the PDB structure of  
Cdk2 (PDB 1W98) showing major interaction 
interfaces of CDKs with cyclins, Cks1-type 
subunits and ankyrin-containing proteins.  
The cyclin-interacting PSTAIRE helix (blue),  
the T-loop (orange) and key catalytic residues 
(red) are also indicated. (b) Bright-field 
images of budding yeast cells expressing 
endogenous levels of Cdc28 fused to IT5,  
IT6, HA3 or Flag6. A control strain (no tag)  
is shown as reference. Scale bar, 10 ?m.  
(c) Individual critical volumes at budding  
of cells as in b are plotted (N > 200). Mean 
values (thick vertical lines) and confidence 
limits (? = 0.05, thin vertical lines) for  
the mean are also shown. (d) PDB structure  
of the C-terminal Ydj1 dimer (PDB 1XAO).  
(e) Serial dilutions of budding yeast cells  
expressing endogenous levels of Ydj1 fused 
to IT5, IT6, HA3 or Flag6 were plated and 
incubated for growth at the indicated temperatures. A control strain (no tag) is shown as reference. (f) Individual critical volumes at budding of cells 
as in e are plotted (N > 250). Mean values (thick vertical lines) and confidence limits (? = 0.05, thin vertical lines) for the mean are also shown. 
Comparable quantitative differences were obtained from a replicate experiment (c,f). 
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Bioinformatics screening for inntag candidates. The aim of our 
initial bioinformatics screen was to obtain a list of protein domains 
suitable to prepare fusion proteins. Owing to the difficulty of 
predicting antigenicity from pure theoretical approaches, our 
strategy took as starting point more than 2,000 protein families 
reported in VarDB22 and epitopes reported in IEDB23. Protein 
structures containing the 63,424 epitopes listed in IEDB were 
obtained using BLASTP with standard setting against the PDB 
database for protein structures24. Finally, the list was extended 
to include possible homologs using the corresponding PFAM25 
domains. The final list included 3,500 antigenic proteins covering 
1,383 PFAM domains. The initial list was further checked for 
the following properties. First, antigenicity was analyzed by 
BCIPRED26. The method uses a combination of sequence-based 
estimations including hydrophilicity, flexibility, accessibility, 
propensity of ?-turns, antigenic propensity and polarity. Domains 
considered antigenic by at least two of the above criteria were 
accepted. Second, solvent accessibility, distance to epitope of 
N or C terminals and solvent accessibility of epitope, globular 
index, were calculated from the 3D structure using VMD27. 
These properties were used to discard domains where the pre-
dicted epitope was not accessible, binding to epitope would collide 
with the fused protein or terminal structures that could preclude 
a viable fusion construct. Third, functional characterization 
was obtained from Gene Ontology28 and PFAM25 annotations. 
Discarded terms affected to the following categories: Membrane 
related and solubility, activity, binding, polymeric state, and 
protein binding promiscuity.
The screening led to a short list of 226 domains (Supplementary 
Table 1) that was manually curated to further discard specific 
activities or properties that were not annotated in the above 
databases. These structures were further scrutinized to remove 
those annotated as having any enzymatic activity and those that 
bind small cofactors or other proteins already used in molecular 
interaction assays. We also rejected domains that have the ability 
to form stable homopolymers or show known regulatory 
sequences for degradation or localization. Finally, we excluded 
entries belonging to vertebrate organisms.
Disorder propensity was determined at the single–amino acid 
level with the aid of PONDR-FIT, a meta-predictor software that 
combines several individual disorder prediction algorithms29.
Mammalian cell culture, expression vectors and cell analysis. 
NIH3T3 and HEK293T cells were obtained from ATCC and 
maintained for fewer than seven passages in DMEM contain-
ing glutamine, antibiotics and 10% FCS. Cells were periodically 
tested for mycoplasma infection (Minerva BioLabs). Hippocampal 
neurons were obtained from mouse hippocampi and cultured 
in supplemented Neurobasal medium as described30. Synthetic 
DNA encoding inntags was subcloned in a plasmid derived from 
pEGFP-N1 (Clontech) where some of the polylinker sequences had 
been replaced with a T7 promoter, ribosome binding sequences 
for gene expression in E. coli and mammalian cells, and a His6 
peptide for affinity purification. Inntag DNAs can be obtained 
from Addgene. Cells were transfected with Lipofectamine 2000 
(Invitrogen) and analyzed 24 h after transfection. Expression level 
and aggregation index of GFP fusions in HEK293T cells were 
analyzed by epifluorescence microscopy with the aid of ImageJ.
Yeast strains, growth conditions and cell measurements. Yeast 
parental strain CML128 and methods used for chromosomal gene 
transplacement have been described31. Yeast cells were grown 
under exponential conditions for 7–8 generations in SC medium32 
with 2% glucose at 30 °C unless stated otherwise. Cell volume at 
bud emergence was determined from bright-field images with the 
aid of the ImageJ plugin BudJ19 (http://www.ibmb.csic.es/home/
maldea). Cell volume distributions were obtained with the aid of 
a Coulter Counter ZB as described33.
Inntag purification. Expression of His6-tagged inntags and GFP 
fusions was induced in E. coli BL21 (DE3) and cells were induced 
with 0.5 mM IPTG and grown at 25 °C for 18 h at 220 r.p.m. 
Expressed proteins were affinity purified under native conditions 
on Ni-NTA (Qiagen) as directed by the manufacturer.
iTRAQ analysis of the differential interactome of MYC6 and 
IT6. The iTRAQ analysis was done at the BIDMC Proteomics 
Core Center (Harvard University) essentially as described34. 
Ni-NTA beads with either His6-GFP, His6-GFP-MYC6 or His6-
GFP-IT6 were used in interaction assays with yeast cell extracts 
(CML128) as described35. High-salt eluates were digested with 
trypsin, labeled with 8 isobaric tags, pooled and separated by 
2D liquid chromatography into 15 fractions, being each 
fraction analyzed in an 8-plex run using an AB/Sciex 4800 
MALDI-TOF/TOF mass spectrometer. GO analysis was done 
by GO Term Finder (http://www.yeastgenome.org).
Monoclonal antibody production. Female BALB/c mice 
were immunized intraperitoneally with 75 ?g of each inntag, 
emulsified in adjuvant (Stimune Adjuvant; Prionics). 30 and 
60 d later, mice were injected with 75 ?g of each antigen in 
adjuvant. 4 d before the fusion procedure, each mouse received 
an intravenous injection of the same antigen in PBS 20 mM 
phosphate. Splenocytes were fused with the Sp2/0-Ag14 
mouse myeloma cell line36. Hybridoma clones were selected by 
conventional indirect ELISA, and cells from positive wells were 
cloned by limiting dilution. Relevant hybridomas have been 
deposited at the Leibniz Institute DSMZ. Monoclonal antibod-
ies were purified from supernatants by affinity chromatography 
on protein G (HiTrap Protein G Sepharose High Performance; 
GE Healthcare).
Western blotting and immunoprecipitation analysis. Western 
blot analysis31 was performed with antibodies to GFP (mouse 
clones 7.1 and 13.1, Roche), HA (mouse clone 12CA5, Roche), 
Flag (mouse clone M2, Sigma), MYC (mouse clone 9E10, Sigma), 
IT5 (mouse clone R19/8-11/18, AntibodyBcn), IT6 (mouse clone 
R19/4-11/15, AntibodyBcn), cyclin E1 (mouse clone EP435E, 
human specific, Millipore), Cdc28 (rabbit polyclonal, a gift from 
C. Mann), Ydj1 (mouse clone 1G10.H8, Abnova) and tubulin 
(mouse clone B-5-1-2, Sigma). Antibodies were used at a final 
concentration of 2 ng/ml. Solubility of inntag-GFP fusions in 
HEK293T cells was assessed by centrifugation (at 20,800 × g for 
15 min) of cell extracts prepared in lysis buffer (50 mM Tris-HCl 
(pH 8), 150 mM NaCl, 2 mM DTT and protease and phosphatase 
inhibitors). Immunoprecipitation of yeast cell extracts was per-
formed with equal amounts of yeast cells (100 OD600) and 1 ?g of 
the corresponding monoclonal antibodies as described35.
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Immunofluorescence. HEK293T or NIH3T3 cells were quickly 
washed in PBS and fixed in 4% paraformaldehyde and 4% sucrose 
for 30 min at room temperature. Fixed cells were permeabilized 
with 0.1% Triton X-100 in PBS for 5 min at 4 °C and blocked 
with 1% BSA in PBS. Blocking of hippocampal neurons was done 
with 5% NGS in PBS. Yeast cells were fixed and spheroplasted 
as described35. The aforementioned primary antibodies were 
detected with goat Alexa Fluor 568–labeled anti-mouse second-
ary antibodies (Molecular Probes) in blocking solution. Anti-
GFP (mouse clones 7.1 and 13.1, Roche, 10 ng/ml) was used as 
reference for signal and background analysis. Fluorescence loss in 
photobleaching (FLIP) was performed in a Zeiss LSM780 confocal 
microscope. A small circular region of the cytoplasm (3.6 ?m2) 
was repetitively photobleached at full laser power for 3 s at a 
time and, between the bleaching periods, the cell was imaged with 
low intensity light to record fluorescence loss. For quantitative 
analysis, background intensity was subtracted, and intensities 
outside the photobleached area were measured over time and 
normalized using a transfected nonbleached cell. Fluorescence 
correlation spectroscopy (FCS) was performed essentially as 
described37, and correlation data were fitted with the aid of 
QuickFit 3 software (http://www.dkfz.de/Macromol/quickfit/) 
assuming an anomalous mode of diffusion.
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